UniProtAcc	Gene	Mutation	UniProt/Mutation	Gene/Mutation	Type	Note	Evidence	PubMed Ids	Annotation	Comment
O00141	SGK1	T256A	O00141/T256A	SGK1/T256A	MUTAGEN	T->A: Low activity.	ECO:0000269|PubMed:10191262	10191262	decrease	
O00141	SGK1	T256D	O00141/T256D	SGK1/T256D	MUTAGEN	T->D: Low activity.	ECO:0000269|PubMed:10191262	10191262	decrease	
O00141	SGK1	T256E	O00141/T256E	SGK1/T256E	MUTAGEN	T->E: Low activity.	ECO:0000269|PubMed:10191262	10191262	decrease	
O00141	SGK1	Y298A	O00141/Y298A	SGK1/Y298A	MUTAGEN	Y->A: Abolishes interaction with NEDD4 and NEDD4L.	ECO:0000269|PubMed:11696533	11696533	decrease	
O00141	SGK1	S422A	O00141/S422A	SGK1/S422A	MUTAGEN	S->A: Low activity.	ECO:0000269|PubMed:10191262, ECO:0000269|PubMed:11696533, ECO:0000269|PubMed:12911626, ECO:0000269|PubMed:15040001	10191262,11696533,12911626,15040001	decrease	
O00238	BMPR1B	R31C	O00238/R31C	BMPR1B/R31C	VARIANT	R -> C (in AMD3; unknown pathological significance; mouse BMPR1B construct containing this mutation shows reduced GDF5-dependent receptor activation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP:rs745854387)	ECO:0000269|PubMed:26105076	26105076	decrease	
O00238	BMPR1B	R31H	O00238/R31H	BMPR1B/R31H	VARIANT	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs200035802)	ECO:0000269|PubMed:17344846	17344846		
O00238	BMPR1B	C53R	O00238/C53R	BMPR1B/C53R	VARIANT	C -> R (in AMD3; mouse BMPR1B construct containing this mutation shows loss of GDF5-dependent receptor activation, chicken BMPR1B construct containing this mutation does not show reduced chondrocyte differentiation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP:rs863225041)	ECO:0000269|PubMed:24129431	24129431	loss	
O00238	BMPR1B	I200K	O00238/I200K	BMPR1B/I200K	VARIANT	I -> K (in BDA2; in animal models loss of kinase activity and loss of positive regulation of chondrocyte differentiation; dbSNP:rs121434417)	ECO:0000269|PubMed:14523231	14523231	loss	
O00238	BMPR1B	D297N	O00238/D297N	BMPR1B/D297N	VARIANT	D -> N (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O00238	BMPR1B	K325N	O00238/K325N	BMPR1B/K325N	VARIANT	K -> N (in BDA1D; acts in a dominant-negative manner; dbSNP:rs869025614)	ECO:0000269|PubMed:25758993	25758993		
O00238	BMPR1B	R486Q	O00238/R486Q	BMPR1B/R486Q	VARIANT	R -> Q (in brachydactyly type C and BDA2; with also additional features of symphalangism-1; dbSNP:rs121434419)	ECO:0000269|PubMed:16957682	16957682		
O00238	BMPR1B	R486W	O00238/R486W	BMPR1B/R486W	VARIANT	R -> W (in BDA2; in animal models no effect on kinase activity but strongly decreased positive regulation of chondrocyte differentiation; dbSNP:rs121434418)	ECO:0000269|PubMed:14523231	14523231		
O00418	EEF2K	T291M	O00418/T291M	EEF2K/T291M	VARIANT	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs147978363)	ECO:0000269|PubMed:17344846	17344846		
O00418	EEF2K	D609H	O00418/D609H	EEF2K/D609H	VARIANT	D -> H	ECO:0000269|PubMed:17344846	17344846		
O00444	PLK4	D154A	O00444/D154A	PLK4/D154A	MUTAGEN	D->A: Catalytically inactive mutant that causes some centrosome amplification above background levels when overexpressed.	ECO:0000269|PubMed:16244668	16244668	loss	
O00444	PLK4	N669R	O00444/N669R	PLK4/N669R	MUTAGEN	N->R: Does not affect the interaction with TENT5C.	ECO:0000269|PubMed:32433990	32433990		
O00444	PLK4	I670P	O00444/I670P	PLK4/I670P	MUTAGEN	I->P: Decreases substantially the interaction with TENT5C. Does not affect localization to the centrosome. Loss of TENT5C recruitment to the centrosome.	ECO:0000269|PubMed:32433990	32433990		
O14578	CIT	L183F	O14578/L183F	CIT/L183F	VARIANT	L -> F	ECO:0000269|PubMed:17344846	17344846		
O14730	RIOK3	K290A	O14730/K290A	RIOK3/K290A	MUTAGEN	K->A: Decreases autophosphorylation (in vitro); abolishes inhibition of TNF-alpha-induced NF-kappaB activation; no effect on interaction with IRF3; fails to activate IFN-beta promoter and IRF3 phosphorylation.	ECO:0000269|PubMed:19557502, ECO:0000269|PubMed:24807708	19557502,24807708	loss	
O14733	MAP2K7	R162C	O14733/R162C	MAP2K7/R162C	VARIANT	R -> C (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O14733	MAP2K7	R162H	O14733/R162H	MAP2K7/R162H	VARIANT	R -> H (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O14757	CHEK1	K132R	O14757/K132R	CHEK1/K132R	MUTAGEN	K->R: Strong reduction of chromatin-associated CHK1 ubiquitination.	ECO:0000269|PubMed:32357935	32357935	decrease	
O14757	CHEK1	S317A	O14757/S317A	CHEK1/S317A	MUTAGEN	S->A: Abrogates interaction with RAD51; when associated with A-345. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Abrogates nuclear retention upon checkpoint activation. Impairs interaction with FBXO6.	ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856	11390642,12588868,12676583,12676962,15665856	decrease	
O14757	CHEK1	S317E	O14757/S317E	CHEK1/S317E	MUTAGEN	S->E: Enhances interaction with RAD51; when associated with E-345.	ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856	11390642,12588868,12676583,12676962,15665856	increase	
O14757	CHEK1	F344A	O14757/F344A	CHEK1/F344A	MUTAGEN	F->A: Impairs nuclear export.	ECO:0000269|PubMed:12676962	12676962	increase	
O14757	CHEK1	S345A	O14757/S345A	CHEK1/S345A	MUTAGEN	S->A: Abrogates interaction with RAD51; when associated with A-317. Reduces phosphorylation and impairs activation by hydroxyurea and ionizing radiation. Impairs interaction with YWHAZ which is required for nuclear retention after checkpoint activation.	ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:19716789	11390642,12588868,12676583,12676962,15665856,19716789	decrease	
O14757	CHEK1	S345E	O14757/S345E	CHEK1/S345E	MUTAGEN	S->E: Enhances interaction with RAD51; when associated with E-317.	ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:19716789	11390642,12588868,12676583,12676962,15665856,19716789	increase	
O14757	CHEK1	M353A	O14757/M353A	CHEK1/M353A	MUTAGEN	M->A: Impairs nuclear export.	ECO:0000269|PubMed:12676962	12676962	increase	
O14757	CHEK1	S357A	O14757/S357A	CHEK1/S357A	MUTAGEN	S->A: No effect on phosphorylation induced by hydroxyurea.	ECO:0000269|PubMed:11390642	11390642		
O14757	CHEK1	S366A	O14757/S366A	CHEK1/S366A	MUTAGEN	S->A: No effect on phosphorylation induced by hydroxyurea.	ECO:0000269|PubMed:11390642	11390642		
O14757	CHEK1	R372E	O14757/R372E	CHEK1/R372E	MUTAGEN	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-376 and E-379.	ECO:0000269|PubMed:19716789	19716789		
O14757	CHEK1	R376E	O14757/R376E	CHEK1/R376E	MUTAGEN	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-379.	ECO:0000269|PubMed:19716789	19716789		
O14757	CHEK1	R379E	O14757/R379E	CHEK1/R379E	MUTAGEN	R->E: In 3RE mutant. Disrupts the folding and/or conformation, allowing increased accessibility to FBXO6 component of SCF-type E3 ubiquitin ligase complex; when associated with E-372 and E-376.	ECO:0000269|PubMed:19716789	19716789		
O14757	CHEK1	K436R	O14757/K436R	CHEK1/K436R	MUTAGEN	K->R: Enhances stability of the protein, probably by preventing ubiquitination at this site.	ECO:0000269|PubMed:19716789	19716789		inconclusive
O14757	CHEK1	S468A	O14757/S468A	CHEK1/S468A	MUTAGEN	S->A: No effect on phosphorylation induced by hydroxyurea.	ECO:0000269|PubMed:11390642	11390642		
O14874	BCKDK	R224P	O14874/R224P	BCKDK/R224P	VARIANT	R -> P (in BCKDKD; dbSNP:rs147210405)	ECO:0000269|PubMed:22956686	22956686		
O14920	IKBKB	A360S	O14920/A360S	IKBKB/A360S	VARIANT	A -> S (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
O14920	IKBKB	K44A	O14920/K44A	IKBKB/K44A	MUTAGEN	K->A: Loss of kinase activity and no effect on binding to NIK.	ECO:0000269|PubMed:9346484, ECO:0000269|PubMed:9346485	93,464,849,346,485	loss	
O14920	IKBKB	K163R	O14920/K163R	IKBKB/K163R	MUTAGEN	K->R: Monoubiquitinated; when associated with E-177 and E-181.	ECO:0000269|PubMed:19675099	19675099		
O14920	IKBKB	S177E	O14920/S177E	IKBKB/S177E	MUTAGEN	S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-181. Monoubiquitinated; when associated with R-163 and E-181. Strongly promoted NF-kappa-B gene expression; when associated with E-181.	ECO:0000269|PubMed:19675099, ECO:0000269|PubMed:9346484	196,750,999,346,484	activating	
O14920	IKBKB	S181E	O14920/S181E	IKBKB/S181E	MUTAGEN	S->E: Full activation. Interaction with TRIM21 is enhanced; when associated with E-177. Monoubiquitinated; when associated with R-163 and E-177. Strongly promoted NF-kappa-B gene expression; when associated with E-177.	ECO:0000269|PubMed:19675099, ECO:0000269|PubMed:9346484	196,750,999,346,484	activating	
O14920	IKBKB	P191A	O14920/P191A	IKBKB/P191A	MUTAGEN	P->A: Loss of hypoxic inducibility.	ECO:0000269|PubMed:17114296	17114296		inconclusive (tricky one)
O14936	CASK	R28L	O14936/R28L	CASK/R28L	VARIANT	R -> L (in FGS4; does not reveal significant alterations induced by the mutation substitution; causes a partial skipping of exon 2 of the protein; dbSNP:rs137852816)	ECO:0000269|PubMed:19200522	19200522		
O14936	CASK	G96V	O14936/G96V	CASK/G96V	VARIANT	G -> V (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O14936	CASK	Y268H	O14936/Y268H	CASK/Y268H	VARIANT	Y -> H (in MICPCH; dbSNP:rs137852817)	ECO:0000269|PubMed:19377476	19377476		
O14936	CASK	P396S	O14936/P396S	CASK/P396S	VARIANT	P -> S (in MICPCH; dbSNP:rs137852820)	ECO:0000269|PubMed:19377476	19377476		
O14936	CASK	D710G	O14936/D710G	CASK/D710G	VARIANT	D -> G (in MICPCH; dbSNP:rs137852818)	ECO:0000269|PubMed:19377476	19377476		
O14965	AURKA	S155R	O14965/S155R	AURKA/S155R	VARIANT	S -> R (in a colorectal adenocarcinoma sample; somatic mutation; reduces interaction with TPX2)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19801554	17344846,19801554	decrease	
O14965	AURKA	F165A	O14965/F165A	AURKA/F165A	MUTAGEN	F->A: Decreases the interaction with phosphatase type 1 isoforms.	ECO:0000269|PubMed:11551964	11551964		inconclusive (another tricky one; PP1 can do both things... better to ignore this one)
O14965	AURKA	G198N	O14965/G198N	AURKA/G198N	MUTAGEN	G->N: Reduces interaction with TPX2. Reduces kinase activity tenfold. Promotes interaction with the AURKB binding partners INCENP and BIRC5 that are normally not bound by AURKA.	ECO:0000269|PubMed:19357306	19357306	decrease	
O14965	AURKA	R205A	O14965/R205A	AURKA/R205A	MUTAGEN	R->A: Reduces ubiquitination and proteasomal degradation.	ECO:0000269|PubMed:10851084	10851084		inconclusive (but 'increase')
O14965	AURKA	T287A	O14965/T287A	AURKA/T287A	MUTAGEN	T->A: No direct effect on catalytic activity.	ECO:0000269|PubMed:19668197	19668197		
O14965	AURKA	T287E	O14965/T287E	AURKA/T287E	MUTAGEN	T->E: Enhances interaction with TPX2.	ECO:0000269|PubMed:19668197	19668197	activating	
O14965	AURKA	C290A	O14965/C290A	AURKA/C290A	MUTAGEN	C->A: Enhances stability; when associated with A-393.	ECO:0000269|PubMed:27837025	27837025		
O14965	AURKA	Y334A	O14965/Y334A	AURKA/Y334A	MUTAGEN	Y->A: Reduces binding to MYCN.	ECO:0000269|PubMed:27837025	27837025	decrease	
O14965	AURKA	Q335A	O14965/Q335A	AURKA/Q335A	MUTAGEN	Q->A: Reduces binding to MYCN.	ECO:0000269|PubMed:27837025	27837025	decrease	
O14965	AURKA	F346A	O14965/F346A	AURKA/F346A	MUTAGEN	F->A: Decreases the interaction with phosphatase type 1 isoforms.	ECO:0000269|PubMed:11551964	11551964		inconclusive (another tricky one; PP1 can do both things... better to ignore this one)
O14965	AURKA	C393A	O14965/C393A	AURKA/C393A	MUTAGEN	C->A: Enhances stability; when associated with A-290.	ECO:0000269|PubMed:27837025	27837025		
O14976	GAK	G962D	O14976/G962D	GAK/G962D	VARIANT	G -> D (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs773153935)	ECO:0000269|PubMed:17344846	17344846		
O15021	MAST4	Q920R	O15021/Q920R	MAST4/Q920R	VARIANT	Q -> R	ECO:0000269|PubMed:17344846	17344846		
O15021	MAST4	R1954W	O15021/R1954W	MAST4/R1954W	VARIANT	R -> W	ECO:0000269|PubMed:17344846	17344846		
O15021	MAST4	S2290C	O15021/S2290C	MAST4/S2290C	VARIANT	S -> C	ECO:0000269|PubMed:17344846	17344846		
O15021	MAST4	E2467D	O15021/E2467D	MAST4/E2467D	VARIANT	E -> D (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15075	DCLK1	G29C	O15075/G29C	DCLK1/G29C	VARIANT	G -> C (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15075	DCLK1	T46M	O15075/T46M	DCLK1/T46M	VARIANT	T -> M (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15075	DCLK1	R93Q	O15075/R93Q	DCLK1/R93Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1366698690)	ECO:0000269|PubMed:17344846	17344846		
O15075	DCLK1	S291F	O15075/S291F	DCLK1/S291F	VARIANT	S -> F (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15111	CHUK	T179A	O15111/T179A	CHUK/T179A	MUTAGEN	T->A: No change in phosphorylation.	ECO:0000269|PubMed:9520446	9520446		
O15111	CHUK	S180A	O15111/S180A	CHUK/S180A	MUTAGEN	S->A: No change in phosphorylation.	ECO:0000269|PubMed:9520446	9520446		
O15146	MUSK	D38E	O15146/D38E	MUSK/D38E	VARIANT	D -> E (in CMS9; dbSNP:rs775587809)	ECO:0000269|PubMed:24183479	24183479		
O15146	MUSK	P344R	O15146/P344R	MUSK/P344R	VARIANT	P -> R (in CMS9; dbSNP:rs387906803)	ECO:0000269|PubMed:19949040	19949040		
O15146	MUSK	N819S	O15146/N819S	MUSK/N819S	VARIANT	N -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs757577755)	ECO:0000269|PubMed:17344846	17344846		
O15146	MUSK	M835V	O15146/M835V	MUSK/M835V	VARIANT	M -> V (in CMS9; reduces AChR aggregation in developing neuromuscular junction)	ECO:0000269|PubMed:23326516	23326516		
O15146	MUSK	G584D	O15146/G584D	MUSK/G584D	MUTAGEN	G->C,D: Mild decrease in kinase activity.	ECO:0000269|PubMed:25029443	25029443	decrease	
O15146	MUSK	D743N	O15146/D743N	MUSK/D743N	MUTAGEN	D->N: Severe loss of kinase activity.	ECO:0000269|PubMed:25029443	25029443	loss	
O15164	TRIM24	I320T	O15164/I320T	TRIM24/I320T	VARIANT	I -> T (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		NOT A KINASE
O15164	TRIM24	T403N	O15164/T403N	TRIM24/T403N	VARIANT	T -> N (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		NOT A KINASE
O15164	TRIM24	S762N	O15164/S762N	TRIM24/S762N	VARIANT	S -> N	ECO:0000269|PubMed:17344846	17344846		NOT A KINASE
O15164	TRIM24	S768A	O15164/S768A	TRIM24/S768A	MUTAGEN	S->A: Ubiquitination is significantly lower than wild-type.	ECO:0000269|PubMed:24820418	24820418		NOT A KINASE
O15164	TRIM24	D827A	O15164/D827A	TRIM24/D827A	MUTAGEN	D->A: Strongly reduced affinity for histone H3 that is not methylated at 'Lys-4' (H3K4me0).	ECO:0000269|PubMed:21164480	21164480		NOT A KINASE
O15164	TRIM24	C840W	O15164/C840W	TRIM24/C840W	MUTAGEN	C->W: Abolishes interaction with histone H3.	ECO:0000269|PubMed:21164480	21164480		NOT A KINASE
O15197	EPHB6	S170T	O15197/S170T	EPHB6/S170T	VARIANT	S -> T	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	A221V	O15197/A221V	EPHB6/A221V	VARIANT	A -> V	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	P282H	O15197/P282H	EPHB6/P282H	VARIANT	P -> H	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	D360N	O15197/D360N	EPHB6/D360N	VARIANT	D -> N (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O15197	EPHB6	A603P	O15197/A603P	EPHB6/A603P	VARIANT	A -> P (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O15197	EPHB6	R719Q	O15197/R719Q	EPHB6/R719Q	VARIANT	R -> Q (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O15197	EPHB6	P743S	O15197/P743S	EPHB6/P743S	VARIANT	P -> S (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	R813H	O15197/R813H	EPHB6/R813H	VARIANT	R -> H	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	E875K	O15197/E875K	EPHB6/E875K	VARIANT	E -> K (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O15197	EPHB6	D930G	O15197/D930G	EPHB6/D930G	VARIANT	D -> G (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O15197	EPHB6	I993V	O15197/I993V	EPHB6/I993V	VARIANT	I -> V	ECO:0000269|PubMed:17344846	17344846		
O15530	PDPK1	S25A	O15530/S25A	PDPK1/S25A	MUTAGEN	S->A: No effect.	ECO:0000269|PubMed:10455013	10455013		
O15530	PDPK1	S241A	O15530/S241A	PDPK1/S241A	MUTAGEN	S->A: No activation.	ECO:0000269|PubMed:10455013	10455013	loss	
O15530	PDPK1	Y373F	O15530/Y373F	PDPK1/Y373F	MUTAGEN	Y->F: Reduction in basal activity.	ECO:0000269|PubMed:11481331	11481331	decrease	
O15530	PDPK1	Y376F	O15530/Y376F	PDPK1/Y376F	MUTAGEN	Y->F: Reduction in basal activity.	ECO:0000269|PubMed:11481331	11481331	decrease	
O15530	PDPK1	S393A	O15530/S393A	PDPK1/S393A	MUTAGEN	S->A: No effect.	ECO:0000269|PubMed:10455013	10455013		
O15530	PDPK1	S394A	O15530/S394A	PDPK1/S394A	MUTAGEN	S->A: Abolishes phosphorylation by MAP3K5; when associated with A-398.	ECO:0000269|PubMed:22544756	22544756		
O15530	PDPK1	S396A	O15530/S396A	PDPK1/S396A	MUTAGEN	S->A: No effect.	ECO:0000269|PubMed:10455013	10455013		
O15530	PDPK1	S398A	O15530/S398A	PDPK1/S398A	MUTAGEN	S->A: Abolishes phosphorylation by MAP3K5; when associated with A-394.	ECO:0000269|PubMed:22544756	22544756		
O15530	PDPK1	S410A	O15530/S410A	PDPK1/S410A	MUTAGEN	S->A: No effect.	ECO:0000269|PubMed:10455013	10455013		
O15530	PDPK1	R474A	O15530/R474A	PDPK1/R474A	MUTAGEN	R->A: No PDGF-dependent translocation to the membrane.	ECO:0000269|PubMed:9637919	9637919		
O43187	IRAK2	S249L	O43187/S249L	IRAK2/S249L	VARIANT	S -> L (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O43187	IRAK2	P421T	O43187/P421T	IRAK2/P421T	VARIANT	P -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O43283	MAP3K13	P746L	O43283/P746L	MAP3K13/P746L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O43283	MAP3K13	K195A	O43283/K195A	MAP3K13/K195A	MUTAGEN	K->A: Kinase inactive. Fails to activate NF-kappa-B.	ECO:0000269|PubMed:12492477	12492477	loss	
O43293	DAPK3	T299D	O43293/T299D	DAPK3/T299D	MUTAGEN	T->D: Predominantly cytoplasmic localization; phosphomimetic.	ECO:0000269|PubMed:15611134	15611134		
O43293	DAPK3	V427A	O43293/V427A	DAPK3/V427A	MUTAGEN	V->A: Predominantly nuclear localization; when associated with A-434 and A-441.	ECO:0000269|PubMed:15611134	15611134		
O43293	DAPK3	V434A	O43293/V434A	DAPK3/V434A	MUTAGEN	V->A: Predominantly nuclear localization; when associated with A-427 and A-441.	ECO:0000269|PubMed:15611134	15611134		
O43293	DAPK3	L441A	O43293/L441A	DAPK3/L441A	MUTAGEN	L->A: Predominantly nuclear localization; when associated with A-427 and A-434.	ECO:0000269|PubMed:15611134	15611134		
O43318	MAP3K7	E70Q	O43318/E70Q	MAP3K7/E70Q	VARIANT	E -> Q (in FMD2; dbSNP:rs886039231)	ECO:0000269|PubMed:27426733	27426733		
O43318	MAP3K7	V100E	O43318/V100E	MAP3K7/V100E	VARIANT	V -> E (in FMD2; dbSNP:rs886039232)	ECO:0000269|PubMed:27426733	27426733		
O43318	MAP3K7	G110C	O43318/G110C	MAP3K7/G110C	VARIANT	G -> C (in CSCF; dbSNP:rs886039235)	ECO:0000269|PubMed:27426734	27426734		
O43318	MAP3K7	G168R	O43318/G168R	MAP3K7/G168R	VARIANT	G -> R (in FMD2; increases autophosphorylation; no effect on MAPK signaling; no effect on NF-kappa-B signaling; dbSNP:rs886039233)	ECO:0000269|PubMed:27426733	27426733		
O43318	MAP3K7	W241R	O43318/W241R	MAP3K7/W241R	VARIANT	W -> R (in CSCF; dbSNP:rs886039237)	ECO:0000269|PubMed:27426734	27426734		
O43318	MAP3K7	R410Q	O43318/R410Q	MAP3K7/R410Q	VARIANT	R -> Q (found in a consanguineous family with intellectual disability; unknown pathological significance; dbSNP:rs201721045)	ECO:0000269|PubMed:28397838	28397838		
O43318	MAP3K7	K34R	O43318/K34R	MAP3K7/K34R	MUTAGEN	K->R: No effect on ubiquitination.	ECO:0000269|PubMed:29291351	29291351		
O43318	MAP3K7	K158R	O43318/K158R	MAP3K7/K158R	MUTAGEN	K->R: Abolishes ubiquitination.	ECO:0000269|PubMed:29291351	29291351		
O43318	MAP3K7	K209R	O43318/K209R	MAP3K7/K209R	MUTAGEN	K->R: Strongly decreases ubiquitination.	ECO:0000269|PubMed:29291351	29291351		
O43318	MAP3K7	P512R	O43318/P512R	MAP3K7/P512R	MUTAGEN	P->R,A: Enhances autophosphorylation; Alters MAPK signaling.	ECO:0000269|PubMed:27426733	27426733		
O43318	MAP3K7	P512A	O43318/P512A	MAP3K7/P512A	MUTAGEN	P->R,A: Enhances autophosphorylation; Alters MAPK signaling.	ECO:0000269|PubMed:27426733	27426733		
O43353	RIPK2	K47M	O43353/K47M	RIPK2/K47M	MUTAGEN	K->M: Reduces FAS-mediated apoptosis.	ECO:0000269|PubMed:9575181, ECO:0000269|PubMed:9642260	95,751,819,642,260		
O43353	RIPK2	K209R	O43353/K209R	RIPK2/K209R	MUTAGEN	K->R: Complete loss of polyubiquitination.	ECO:0000269|PubMed:18079694	18079694	decrease	
O43353	RIPK2	Q437E	O43353/Q437E	RIPK2/Q437E	MUTAGEN	Q->E: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43353	RIPK2	R444E	O43353/R444E	RIPK2/R444E	MUTAGEN	R->E: Abolishes interaction with NOD1.	ECO:0000269|PubMed:17054981	17054981		
O43353	RIPK2	D467R	O43353/D467R	RIPK2/D467R	MUTAGEN	D->R: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43353	RIPK2	K471E	O43353/K471E	RIPK2/K471E	MUTAGEN	K->E: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43353	RIPK2	Y474F	O43353/Y474F	RIPK2/Y474F	MUTAGEN	Y->F: Decreases interaction with NOD2.	ECO:0000269|PubMed:21123652	21123652		
O43353	RIPK2	R483E	O43353/R483E	RIPK2/R483E	MUTAGEN	R->E: Abolishes interaction with NOD1.	ECO:0000269|PubMed:17054981	17054981		
O43353	RIPK2	R488E	O43353/R488E	RIPK2/R488E	MUTAGEN	R->E: Abolishes interaction with NOD1.	ECO:0000269|PubMed:17054981	17054981		
O43353	RIPK2	I496A	O43353/I496A	RIPK2/I496A	MUTAGEN	I->A: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43353	RIPK2	E500R	O43353/E500R	RIPK2/E500R	MUTAGEN	E->R: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43353	RIPK2	K503R	O43353/K503R	RIPK2/K503R	MUTAGEN	K->R: Abolished ubiquitination by ZNRF4.	ECO:0000269|PubMed:28656966	28656966	increase	
O43353	RIPK2	R528E	O43353/R528E	RIPK2/R528E	MUTAGEN	R->E: Decreased interaction with NGFR.	ECO:0000269|PubMed:26646181	26646181		
O43683	BUB1	E36D	O43683/E36D	BUB1/E36D	VARIANT	E -> D (in colorectal cancer; dbSNP:rs1801328)	ECO:0000269|PubMed:10366450	10366450		
O43683	BUB1	Y259C	O43683/Y259C	BUB1/Y259C	VARIANT	Y -> C (in pancreatic cancer; associated with N-265; failure to rescue the spindle-assembly checkpoint activity as a result of a deficient recruitment of MAD2L1 and BUBR1 to kinetochores; efficient restoration of chromosome congression; reduced binding to BUB3; rescue of the ability of kinetochores to bind SGO1 and CENPF but not MCAK)	ECO:0000269|PubMed:12655561, ECO:0000269|PubMed:19487456	12655561,19487456		
O43683	BUB1	H265N	O43683/H265N	BUB1/H265N	VARIANT	H -> N (in pancreatic cancer; associated with C-259; complete rescue of the spindle-assembly checkpoint activity; increased rate of chromosome congression errors)	ECO:0000269|PubMed:12655561, ECO:0000269|PubMed:19487456	12655561,19487456		
O43683	BUB1	S492Y	O43683/S492Y	BUB1/S492Y	VARIANT	S -> Y (in colorectal cancer; dbSNP:rs121909055)	ECO:0000269|PubMed:9521327	9521327		
O43683	BUB1	P648R	O43683/P648R	BUB1/P648R	VARIANT	P -> R (in colorectal cancer; dbSNP:rs376649190)	ECO:0000269|PubMed:10366450	10366450		
O43683	BUB1	A106D	O43683/A106D	BUB1/A106D	MUTAGEN	A->D,W: Loss of interaction with KNL1.	ECO:0000269|PubMed:17981135	17981135		
O43683	BUB1	A106W	O43683/A106W	BUB1/A106W	MUTAGEN	A->D,W: Loss of interaction with KNL1.	ECO:0000269|PubMed:17981135	17981135		
O43683	BUB1	L122G	O43683/L122G	BUB1/L122G	MUTAGEN	L->G: Loss of interaction with KNL1.	ECO:0000269|PubMed:17981135	17981135		
O43683	BUB1	A130S	O43683/A130S	BUB1/A130S	MUTAGEN	A->S: Partial rescue of the spindle-assembly checkpoint activity. Increased rate of chromosome congression errors. Impaired localization to kinetochores and loss of kinetochore binding of CENPF, SGO1 and BUBR1 but not of MCAK, MAD1L1 or MAD2L1.	ECO:0000269|PubMed:19487456	19487456		
O43683	BUB1	K535A	O43683/K535A	BUB1/K535A	MUTAGEN	K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-536 and A-537.	ECO:0000269|PubMed:17158872	17158872		
O43683	BUB1	E536A	O43683/E536A	BUB1/E536A	MUTAGEN	E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-537.	ECO:0000269|PubMed:17158872	17158872		
O43683	BUB1	N537A	O43683/N537A	BUB1/N537A	MUTAGEN	N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-536.	ECO:0000269|PubMed:17158872	17158872		
O43683	BUB1	T609A	O43683/T609A	BUB1/T609A	MUTAGEN	T->A: Diminished interaction with PLK1.	ECO:0000269|PubMed:16760428	16760428		
O43683	BUB1	K625A	O43683/K625A	BUB1/K625A	MUTAGEN	K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-626 and A-627.	ECO:0000269|PubMed:17158872	17158872		
O43683	BUB1	E626A	O43683/E626A	BUB1/E626A	MUTAGEN	E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-627.	ECO:0000269|PubMed:17158872	17158872		
O43683	BUB1	N627A	O43683/N627A	BUB1/N627A	MUTAGEN	N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-626.	ECO:0000269|PubMed:17158872	17158872		
O43781	DYRK3	M239L	O43781/M239L	DYRK3/M239L	VARIANT	M -> L	ECO:0000269|PubMed:17344846	17344846		
O43781	DYRK3	K238M	O43781/K238M	DYRK3/K238M	MUTAGEN	K->M: Kinase dead; Induces formation of stress granules-like in absence of stress. Impaired dissolution of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material.	ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919, ECO:0000269|PubMed:29973724	23415227,29634919,29973724	loss	
O43781	DYRK3	S350A	O43781/S350A	DYRK3/S350A	MUTAGEN	S->A: Decreased stability of the protein.	ECO:0000269|PubMed:29634919	29634919	decrease	
O43781	DYRK3	S350D	O43781/S350D	DYRK3/S350D	MUTAGEN	S->E,D: Phosphomimetic mutant; increased stability of the protein.	ECO:0000269|PubMed:29634919	29634919	increase	
O60229	KALRN	S196L	O60229/S196L	KALRN/S196L	VARIANT	S -> L	ECO:0000269|PubMed:17344846	17344846		
O60229	KALRN	R213W	O60229/R213W	KALRN/R213W	VARIANT	R -> W (in a colorectal cancer sample; somatic mutation; dbSNP:rs1187034389)	ECO:0000269|PubMed:16959974	16959974		
O60229	KALRN	S1897C	O60229/S1897C	KALRN/S1897C	VARIANT	S -> C (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O60285	NUAK1	S600A	O60285/S600A	NUAK1/S600A	MUTAGEN	S->A: Abrogates phosphorylation by PKB/AKT1. Does not affect ability to induce senescence.	ECO:0000269|PubMed:12409306, ECO:0000269|PubMed:19927127	12409306,19927127	loss	
O60307	MAST3	S101F	O60307/S101F	MAST3/S101F	VARIANT	S -> F (in DEE108; unknown pathological significance)	ECO:0000269|PubMed:35095415	35095415		
O60307	MAST3	S104L	O60307/S104L	MAST3/S104L	VARIANT	S -> L (in DEE108)	ECO:0000269|PubMed:35095415	35095415		
O60307	MAST3	R406P	O60307/R406P	MAST3/R406P	VARIANT	R -> P (in DEE108)	ECO:0000269|PubMed:34185323	34185323		
O60307	MAST3	G510S	O60307/G510S	MAST3/G510S	VARIANT	G -> S (in DEE108)	ECO:0000269|PubMed:34185323	34185323		
O60307	MAST3	G515S	O60307/G515S	MAST3/G515S	VARIANT	G -> S (in DEE108)	ECO:0000269|PubMed:34185323, ECO:0000269|PubMed:35095415	34185323,35095415		
O60307	MAST3	L516P	O60307/L516P	MAST3/L516P	VARIANT	L -> P (in DEE108)	ECO:0000269|PubMed:34185323, ECO:0000269|PubMed:35095415	34185323,35095415		
O60307	MAST3	V551L	O60307/V551L	MAST3/V551L	VARIANT	V -> L (in DEE108; unknown pathological significance)	ECO:0000269|PubMed:34185323	34185323		
O60307	MAST3	F655L	O60307/F655L	MAST3/F655L	VARIANT	F -> L (found in a patient with autism spectrum disorder without history of seizures; unknown pathological significance)	ECO:0000269|PubMed:34185323	34185323		
O60566	BUB1B	M15T	O60566/M15T	BUB1B/M15T	VARIANT	M -> T (in a colorectal cancer cell line; dbSNP:rs1392369693)	ECO:0000269|PubMed:9521327	9521327		
O60566	BUB1B	R36Q	O60566/R36Q	BUB1B/R36Q	VARIANT	R -> Q (in PCS; dbSNP:rs534297115)	ECO:0000269|PubMed:16411201	16411201		
O60566	BUB1B	R550Q	O60566/R550Q	BUB1B/R550Q	VARIANT	R -> Q (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989187)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	R814H	O60566/R814H	BUB1B/R814H	VARIANT	R -> H (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989182)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	L844F	O60566/L844F	BUB1B/L844F	VARIANT	L -> F (in MVA1; associated with H-921; heterozygous compound with nonsense mutation; dbSNP:rs28989181)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	I909T	O60566/I909T	BUB1B/I909T	VARIANT	I -> T (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989184)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	Q921H	O60566/Q921H	BUB1B/Q921H	VARIANT	Q -> H (in MVA1; associated with F-844; heterozygous compound with nonsense mutation; dbSNP:rs28989183)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	L1012P	O60566/L1012P	BUB1B/L1012P	VARIANT	L -> P (in MVA1; heterozygous compound with nonsense mutation; dbSNP:rs28989185)	ECO:0000269|PubMed:15475955	15475955		
O60566	BUB1B	A159W	O60566/A159W	BUB1B/A159W	MUTAGEN	A->W: Loss of interaction with KNL1.	ECO:0000269|PubMed:17981135	17981135		
O60566	BUB1B	F175A	O60566/F175A	BUB1B/F175A	MUTAGEN	F->A: Loss of interaction with KNL1.	ECO:0000269|PubMed:17981135	17981135		
O60566	BUB1B	D579E	O60566/D579E	BUB1B/D579E	MUTAGEN	D->E: Abolishes the cleavage by caspase-3.	ECO:0000269|PubMed:16227576	16227576	increase	
O60566	BUB1B	D610E	O60566/D610E	BUB1B/D610E	MUTAGEN	D->E: Abolishes the cleavage by caspase-3.	ECO:0000269|PubMed:16227576	16227576	increase	
O60566	BUB1B	T620A	O60566/T620A	BUB1B/T620A	MUTAGEN	T->A: Induces chromosome congression defects and mitotic delay.	ECO:0000269|PubMed:17785528	17785528		
O60566	BUB1B	K795A	O60566/K795A	BUB1B/K795A	MUTAGEN	K->A: Does not abolish the capacity to inhibit APC/CDC20.	ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:12925705	11702782,12925705	loss	
O60566	BUB1B	K795R	O60566/K795R	BUB1B/K795R	MUTAGEN	K->R: Inhibits kinase activity.	ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:12925705	11702782,12925705	loss	
O60674	JAK2	K191Q	O60674/K191Q	JAK2/K191Q	VARIANT	K -> Q (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O60674	JAK2	K539L	O60674/K539L	JAK2/K539L	VARIANT	K -> L (in myeloproliferative disorder with erythrocytosis; requires 2 nucleotide substitutions; dbSNP:rs121912473)	ECO:0000269|PubMed:17267906	17267906		
O60674	JAK2	K607N	O60674/K607N	JAK2/K607N	VARIANT	K -> N (in AML; dbSNP:rs121912472)	ECO:0000269|PubMed:16247455	16247455		
O60674	JAK2	V617F	O60674/V617F	JAK2/V617F	VARIANT	V -> F (in PV, THCYT3 and AML; associated with susceptibility to Budd-Chiari syndrome; somatic mutation in a high percentage of patients with essential thrombocythemia or myelofibrosis; leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity; dbSNP:rs77375493)	ECO:0000269|PubMed:15781101, ECO:0000269|PubMed:15793561, ECO:0000269|PubMed:15858187, ECO:0000269|PubMed:16247455, ECO:0000269|PubMed:16325696, ECO:0000269|PubMed:16603627	15781101,15793561,15858187,16247455,16325696,16603627	activating	
O60674	JAK2	V617I	O60674/V617I	JAK2/V617I	VARIANT	V -> I (in THCYT3; dbSNP:rs77375493)	ECO:0000269|PubMed:22397670	22397670		
O60885	BRD4	N140A	O60885/N140A	BRD4/N140A	MUTAGEN	N->A: Abolishes binding to acetylated histones.	ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:23728299	22464331,23728299		
O60885	BRD4	N433A	O60885/N433A	BRD4/N433A	MUTAGEN	N->A: Abolishes binding to acetylated histones.	ECO:0000269|PubMed:22464331	22464331		
O75116	ROCK2	S1194P	O75116/S1194P	ROCK2/S1194P	VARIANT	S -> P (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O75116	ROCK2	D1131A	O75116/D1131A	ROCK2/D1131A	MUTAGEN	D->A: Abolishes cleavage by granzyme B.	ECO:0000269|PubMed:15699075	15699075	decrease	
O75385	ULK1	V290M	O75385/V290M	ULK1/V290M	VARIANT	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs370624303)	ECO:0000269|PubMed:17344846	17344846		
O75385	ULK1	S784C	O75385/S784C	ULK1/S784C	VARIANT	S -> C (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	N244S	O75460/N244S	ERN1/N244S	VARIANT	N -> S (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs1397145500)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	L474R	O75460/L474R	ERN1/L474R	VARIANT	L -> R (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs186305118)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	R635W	O75460/R635W	ERN1/R635W	VARIANT	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs146710304)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	S769F	O75460/S769F	ERN1/S769F	VARIANT	S -> F (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	P830L	O75460/P830L	ERN1/P830L	VARIANT	P -> L (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1279653488)	ECO:0000269|PubMed:17344846	17344846		
O75460	ERN1	Q105E	O75460/Q105E	ERN1/Q105E	MUTAGEN	Q->E: Impaired ability to homodimerize.	ECO:0000269|PubMed:16973740	16973740	decrease	
O75460	ERN1	C109S	O75460/C109S	ERN1/C109S	MUTAGEN	C->S: No effect on dimerization. No effect on interaction with P4HB; when associated with S-148 and S-332.	ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:32149426	12637535,32149426		
O75460	ERN1	D123P	O75460/D123P	ERN1/D123P	MUTAGEN	D->P: Abolishes ability to homodimerize.	ECO:0000269|PubMed:16973740	16973740	loss	
O75460	ERN1	W125A	O75460/W125A	ERN1/W125A	MUTAGEN	W->A: Abolishes ability to homodimerize.	ECO:0000269|PubMed:16973740	16973740	loss	
O75460	ERN1	C148S	O75460/C148S	ERN1/C148S	MUTAGEN	C->S: No effect on dimerization. Weakens dimer; when associated with S-332. Abolishes interaction with PDIA6. Prolonged splicing of XBP1, probably due to prolonged activation of PDIA6. Inhibits formation of oxidized multimeric forms of ERN1 in response to ER stress. No effect on interaction with P4HB; when associated with S-109 and S-332.	ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426	12637535,24508390,32149426		
O75460	ERN1	C332S	O75460/C332S	ERN1/C332S	MUTAGEN	C->S: No effect on dimerization. Weakens dimer; when associated with S-148. No effect on interaction with P4HB; when associated with S-109 and S-148.	ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:32149426	12637535,32149426		
O75582	RPS6KA5	S212A	O75582/S212A	RPS6KA5/S212A	MUTAGEN	S->A: Inactivates the N-terminal kinase domain.	ECO:0000269|PubMed:15568999	15568999	loss	
O75582	RPS6KA5	T700D	O75582/T700D	RPS6KA5/T700D	MUTAGEN	T->A,D: Strongly reduces phosphorylation of T-581 in response to PMA and UV-C.	ECO:0000269|PubMed:17117922	17117922	decrease	
O75676	RPS6KA4	S236L	O75676/S236L	RPS6KA4/S236L	VARIANT	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs746466314)	ECO:0000269|PubMed:17344846	17344846		
O75716	STK16	G2A	O75716/G2A	STK16/G2A	MUTAGEN	G->A: Loss of myristoylation.	ECO:0000269|PubMed:10364453	10364453		
O75716	STK16	C6S	O75716/C6S	STK16/C6S	MUTAGEN	C->S: Loss of palmitoylation.	ECO:0000269|PubMed:10364453	10364453		
O75716	STK16	C8S	O75716/C8S	STK16/C8S	MUTAGEN	C->S: Loss of palmitoylation.	ECO:0000269|PubMed:10364453	10364453		
O75914	PAK3	R67C	O75914/R67C	PAK3/R67C	VARIANT	R -> C (in XLID30; dbSNP:rs121434612)	ECO:0000269|PubMed:10946356	10946356		
O75914	PAK3	A380E	O75914/A380E	PAK3/A380E	VARIANT	A -> E (in XLID30; dbSNP:rs121434613)	ECO:0000269|PubMed:12884430	12884430		
O75914	PAK3	T440S	O75914/T440S	PAK3/T440S	VARIANT	T -> S (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O75962	TRIO	R924S	O75962/R924S	TRIO/R924S	VARIANT	R -> S (in MRD44; unknown pathological significance; dbSNP:rs772072746)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	T1075I	O75962/T1075I	TRIO/T1075I	VARIANT	T -> I (in MRD63; slightly increased occipitofrontal circumference; increased activation of RAC1-mediated signaling; increased lamellipodia formation)	ECO:0000269|PubMed:32109419	32109419	increase	
O75962	TRIO	N1080I	O75962/N1080I	TRIO/N1080I	VARIANT	N -> I (in MRD63; slightly increased occipitofrontal circumference; increased activation of RAC1-mediated signaling; increased neurite outgrowth; dbSNP:rs879255628)	ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:32109419	27418539,32109419	increase	
O75962	TRIO	Y1238H	O75962/Y1238H	TRIO/Y1238H	VARIANT	Y -> H (in MRD44; unknown pathological significance; dbSNP:rs756004023)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	D1368V	O75962/D1368V	TRIO/D1368V	VARIANT	D -> V (found in patient with severe intellectual disability; unknown pathological significance)	ECO:0000269|PubMed:23033978	23033978		
O75962	TRIO	P1461T	O75962/P1461T	TRIO/P1461T	VARIANT	P -> T (in MRD44; no effect on RAC1-mediated signaling; no effect on neurite outgrowth; dbSNP:rs879255627)	ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:32109419	27418539,32109419		
O75962	TRIO	A1922T	O75962/A1922T	TRIO/A1922T	VARIANT	A -> T (in MRD44; unknown pathological significance)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	S1939N	O75962/S1939N	TRIO/S1939N	VARIANT	S -> N (in MRD44; unknown pathological significance)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	V1978M	O75962/V1978M	TRIO/V1978M	VARIANT	V -> M (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O75962	TRIO	L2201V	O75962/L2201V	TRIO/L2201V	VARIANT	L -> V (in MRD44; unknown pathological significance; dbSNP:rs771342869)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	E2247D	O75962/E2247D	TRIO/E2247D	VARIANT	E -> D (in MRD44; unknown pathological significance; dbSNP:rs1258664728)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	T2563M	O75962/T2563M	TRIO/T2563M	VARIANT	T -> M (found in patient with severe intellectual disability; unknown pathological significance; dbSNP:rs751663099)	ECO:0000269|PubMed:23033978	23033978		
O75962	TRIO	R2707Q	O75962/R2707Q	TRIO/R2707Q	VARIANT	R -> Q (in MRD44; unknown pathological significance; dbSNP:rs768858988)	ECO:0000269|PubMed:26721934	26721934		
O75962	TRIO	N1389A	O75962/N1389A	TRIO/N1389A	MUTAGEN	N->A: No change in nucleotide exchange activity.	ECO:0000269|PubMed:9790533	9790533		
O75962	TRIO	K1437A	O75962/K1437A	TRIO/K1437A	MUTAGEN	K->A: No change in nucleotide exchange activity.	ECO:0000269|PubMed:9790533	9790533		
O75962	TRIO	K2917A	O75962/K2917A	TRIO/K2917A	MUTAGEN	K->A: Expected to disrupt kinase activity. Causes reorganization of the actin cytoskeleton in the absence of NGF.	ECO:0000269|PubMed:22155786	22155786	decrease	
O76039-1	CDKL5	G994R	O76039/G994R	CDKL5/G994R	VARIANT	G -> R (in DEE2; unknown pathological significance; dbSNP:rs866859766)	ECO:0000269|PubMed:27864847	27864847		
O76039	CDKL5	A40V	O76039/A40V	CDKL5/A40V	VARIANT	A -> V (in DEE2; causes mislocalization of the protein in the cytoplasm; dbSNP:rs122460159)	ECO:0000269|PubMed:17993579, ECO:0000269|PubMed:18790821	17993579,18790821	decrease	
O76039	CDKL5	I72N	O76039/I72N	CDKL5/I72N	VARIANT	I -> N (in DEE2; dbSNP:rs62641235)	ECO:0000269|PubMed:16015284	16015284		
O76039	CDKL5	I72T	O76039/I72T	CDKL5/I72T	VARIANT	I -> T (in DEE2; dbSNP:rs62641235)	ECO:0000269|PubMed:19241098	19241098		
O76039	CDKL5	H127R	O76039/H127R	CDKL5/H127R	VARIANT	H -> R (in DEE2; dbSNP:rs267608468)	ECO:0000269|PubMed:19241098	19241098		
O76039	CDKL5	H145Y	O76039/H145Y	CDKL5/H145Y	VARIANT	H -> Y (in DEE2; unknown pathological significance)	ECO:0000269|PubMed:23708187	23708187		
O76039	CDKL5	C152F	O76039/C152F	CDKL5/C152F	VARIANT	C -> F (in DEE2; affect activity; causes mislocalization of the protein in the cytoplasm; dbSNP:rs122460157)	ECO:0000269|PubMed:15499549, ECO:0000269|PubMed:16935860	1,549,954,916,935,860	decrease	
O76039	CDKL5	R175S	O76039/R175S	CDKL5/R175S	VARIANT	R -> S (in DEE2; affect activity; does not affect the cellular distribution of the protein; dbSNP:rs61749700)	ECO:0000269|PubMed:15499549, ECO:0000269|PubMed:16935860	1,549,954,916,935,860		inconclusive
O76039	CDKL5	R178P	O76039/R178P	CDKL5/R178P	VARIANT	R -> P (in DEE2; dbSNP:rs267606715)	ECO:0000269|PubMed:18809835	18809835		
O76039	CDKL5	R178Q	O76039/R178Q	CDKL5/R178Q	VARIANT	R -> Q (in DEE2; dbSNP:rs267606715)	ECO:0000269|PubMed:23662938, ECO:0000269|PubMed:23708187, ECO:0000269|PubMed:24564546	23662938,23708187,24564546		
O76039	CDKL5	R178W	O76039/R178W	CDKL5/R178W	VARIANT	R -> W (in DEE2; dbSNP:rs267608493)	ECO:0000269|PubMed:26993267	26993267		
O76039	CDKL5	P180L	O76039/P180L	CDKL5/P180L	VARIANT	P -> L (in DEE2; dbSNP:rs61749704)	ECO:0000269|PubMed:16611748	16611748		
O76039	CDKL5	L182P	O76039/L182P	CDKL5/L182P	VARIANT	L -> P (in DEE2)	ECO:0000269|PubMed:23708187	23708187		
O76039	CDKL5	S196L	O76039/S196L	CDKL5/S196L	VARIANT	S -> L (in DEE2; dbSNP:rs267608501)	ECO:0000269|PubMed:27864847	27864847		
O76039	CDKL5	G207E	O76039/G207E	CDKL5/G207E	VARIANT	G -> E (in DEE2)	ECO:0000269|PubMed:23708187	23708187		
O76039	CDKL5	L220P	O76039/L220P	CDKL5/L220P	VARIANT	L -> P (in DEE2; causes mislocalization of the protein in the cytoplasm; dbSNP:rs267608511)	ECO:0000269|PubMed:17993579, ECO:0000269|PubMed:18790821	17993579,18790821	decrease	
O76039	CDKL5	T288I	O76039/T288I	CDKL5/T288I	VARIANT	T -> I (in DEE2; dbSNP:rs267606713)	ECO:0000269|PubMed:18809835	18809835		
O76039	CDKL5	C291Y	O76039/C291Y	CDKL5/C291Y	VARIANT	C -> Y (in DEE2; dbSNP:rs267606714)	ECO:0000269|PubMed:18809835	18809835		
O76039	CDKL5	N368H	O76039/N368H	CDKL5/N368H	VARIANT	N -> H (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O76039	CDKL5	A374T	O76039/A374T	CDKL5/A374T	VARIANT	A -> T (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O76039	CDKL5	N399T	O76039/N399T	CDKL5/N399T	VARIANT	N -> T (in DEE2; dbSNP:rs267608611)	ECO:0000269|PubMed:19253388	19253388		
O76039	CDKL5	P574Q	O76039/P574Q	CDKL5/P574Q	VARIANT	P -> Q (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs199897804)	ECO:0000269|PubMed:17344846	17344846		
O76039	CDKL5	H581Y	O76039/H581Y	CDKL5/H581Y	VARIANT	H -> Y (in DEE2; unknown pathological significance)	ECO:0000269|PubMed:23708187	23708187		
O76039	CDKL5	P647L	O76039/P647L	CDKL5/P647L	VARIANT	P -> L (probable disease-associated variant found in a patient with autism spectrum disorder)	ECO:0000269|PubMed:25969726	25969726		
O76039	CDKL5	V718M	O76039/V718M	CDKL5/V718M	VARIANT	V -> M (in DEE2; dbSNP:rs267608653)	ECO:0000269|PubMed:18790821, ECO:0000269|PubMed:26993267	18790821,26993267		
O76039	CDKL5	V793A	O76039/V793A	CDKL5/V793A	VARIANT	V -> A (in DEE2; unknown pathological significance; dbSNP:rs62643617)	ECO:0000269|PubMed:16611748	16611748		
O76039	CDKL5	R858C	O76039/R858C	CDKL5/R858C	VARIANT	R -> C (in DEE2; unknown pathological significance; dbSNP:rs773760466)	ECO:0000269|PubMed:23708187	23708187		
O94804	STK10	K277E	O94804/K277E	STK10/K277E	VARIANT	K -> E (in TGCT; somatic mutation; dbSNP:rs757545210)	ECO:0000269|PubMed:16175573, ECO:0000269|PubMed:17344846	16175573,17344846		
O94806	PRKD3	V716M	O94806/V716M	PRKD3/V716M	VARIANT	V -> M (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O94806	PRKD3	T156A	O94806/T156A	PRKD3/T156A	MUTAGEN	T->A: Slight loss in ability to bind DAG and phorbol-ester; when associated with F-158.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	Y158F	O94806/Y158F	PRKD3/Y158F	MUTAGEN	Y->F: Slight loss in ability to bind DAG and phorbol-ester; when associated with A-156.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	P165G	O94806/P165G	PRKD3/P165G	MUTAGEN	P->G: No effect on ability to bind phorbol ester, loss of ability to bind DAG, reduced DAG-induced membrane translocation.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	T166A	O94806/T166A	PRKD3/T166A	MUTAGEN	T->A: Slight loss in ability to bind DAG and phorbol-ester.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	Y170F	O94806/Y170F	PRKD3/Y170F	MUTAGEN	Y->F: Slight loss in ability to bind DAG and phorbol-ester.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	P282G	O94806/P282G	PRKD3/P282G	MUTAGEN	P->G: No effect on ability to bind phorbol ester, increase in ability to bind DAG.	ECO:0000269|PubMed:18076381	18076381		
O94806	PRKD3	I284V	O94806/I284V	PRKD3/I284V	MUTAGEN	I->V: Slight increase in ability to bind DAG, no effect on phorbol-ester binding.				
O94806	PRKD3	K293W	O94806/K293W	PRKD3/K293W	MUTAGEN	K->W: Increased ability to bind DAG, no effect on phorbol-ester binding.	ECO:0000269|PubMed:18076381	18076381		
O94921	CDK14	M432I	O94921/M432I	CDK14/M432I	VARIANT	M -> I (in an ovarian mucinous carcinoma; somatic mutation; dbSNP:rs773301216)	ECO:0000269|PubMed:17344846	17344846		
O95382	MAP3K6	P869T	O95382/P869T	MAP3K6/P869T	VARIANT	P -> T (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
O95382	MAP3K6	S925L	O95382/S925L	MAP3K6/S925L	VARIANT	S -> L (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O95382	MAP3K6	T968I	O95382/T968I	MAP3K6/T968I	VARIANT	T -> I (in an ovarian endometrioid cancer sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O95747	OXSR1	P433S	O95747/P433S	OXSR1/P433S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O95819	MAP4K4	S712T	O95819/S712T	MAP4K4/S712T	VARIANT	S -> T	ECO:0000269|PubMed:17344846	17344846		
O95835	LATS1	M669I	O95835/M669I	LATS1/M669I	VARIANT	M -> I (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1390558952)	ECO:0000269|PubMed:17344846	17344846		
O95835	LATS1	R806P	O95835/R806P	LATS1/R806P	VARIANT	R -> P (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
O95835	LATS1	Y559F	O95835/Y559F	LATS1/Y559F	MUTAGEN	Y->F: Loss of interaction with YAP1.	ECO:0000269|PubMed:18158288	18158288	decrease	
O96017	CHEK2	A17S	O96017/A17S	CHEK2/A17S	VARIANT	A -> S (in an osteogenic sarcoma sample; somatic mutation; might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer; dbSNP:rs137853008)	ECO:0000269|PubMed:11746983	11746983		
O96017	CHEK2	T59K	O96017/T59K	CHEK2/T59K	VARIANT	T -> K (in multiple cancers; dbSNP:rs149991239)	ECO:0000269|PubMed:12052256	12052256		
O96017	CHEK2	E64K	O96017/E64K	CHEK2/E64K	VARIANT	E -> K (in prostate cancer; somatic mutation; dbSNP:rs141568342)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	P85L	O96017/P85L	CHEK2/P85L	VARIANT	P -> L (in an osteogenic sarcoma sample; neutral allele among Ashkenazi Jewish women; dbSNP:rs17883862)	ECO:0000269|PubMed:11746983, ECO:0000269|PubMed:15649950, ECO:0000269|Ref.10	1,174,698,315,649,950		
O96017	CHEK2	R117G	O96017/R117G	CHEK2/R117G	VARIANT	R -> G (in BC; dbSNP:rs28909982)	ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15818573	12454775,12610780,15818573		
O96017	CHEK2	R137Q	O96017/R137Q	CHEK2/R137Q	VARIANT	R -> Q (might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer; dbSNP:rs368570187)	ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:15818573	12454775,15818573		
O96017	CHEK2	R145P	O96017/R145P	CHEK2/R145P	VARIANT	R -> P (in prostate cancer; somatic mutation; dbSNP:rs587781667)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	R145W	O96017/R145W	CHEK2/R145W	VARIANT	R -> W (in colon cancer and LFS2; does not cause protein abrogation in familial colorectal cancer; loss of the ability to interact with and phosphorylate CDC25A and to promote CDC25A degradation in response to ionizing radiation; dbSNP:rs137853007)	ECO:0000269|PubMed:10617473, ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11719428, ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15535844, ECO:0000269|PubMed:15818573	10617473,11298456,11719428,12610780,15535844,15818573	decrease	
O96017	CHEK2	I157T	O96017/I157T	CHEK2/I157T	VARIANT	I -> T (might influence susceptibility to different types of cancer; does not cause protein abrogation in familial colorectal cancer; loss of the ability to interact with and phosphorylate CDC25A and to promote CDC25A degradation in response to ionizing radiation; dbSNP:rs17879961)	ECO:0000269|PubMed:10617473, ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11461078, ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:14612911, ECO:0000269|PubMed:15087378, ECO:0000269|PubMed:15095295, ECO:0000269|PubMed:15239132, ECO:0000269|PubMed:15492928, ECO:0000269|PubMed:15535844, ECO:0000269|PubMed:15810020, ECO:0000269|PubMed:15818573, ECO:0000269|Ref.10	10617473,11298456,11461078,12533788,12610780,14612911,15087378,15095295,15239132,15492928,15535844,15810020,15818573	decrease	
O96017	CHEK2	G167R	O96017/G167R	CHEK2/G167R	VARIANT	G -> R (in prostate cancer; somatic mutation; dbSNP:rs72552322)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	R180C	O96017/R180C	CHEK2/R180C	VARIANT	R -> C (in prostate cancer; somatic mutation; dbSNP:rs77130927)	ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:21618645	12533788,21618645		
O96017	CHEK2	R180H	O96017/R180H	CHEK2/R180H	VARIANT	R -> H (in prostate cancer; somatic mutation; dbSNP:rs137853009)	ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:15818573	12454775,12533788,15818573		
O96017	CHEK2	R181C	O96017/R181C	CHEK2/R181C	VARIANT	R -> C (in prostate cancer; somatic mutation; dbSNP:rs137853010)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	R181H	O96017/R181H	CHEK2/R181H	VARIANT	R -> H (in prostate cancer; somatic mutation; dbSNP:rs121908701)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	E239K	O96017/E239K	CHEK2/E239K	VARIANT	E -> K (in prostate cancer; germline mutation; dbSNP:rs121908702)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	I251F	O96017/I251F	CHEK2/I251F	VARIANT	I -> F (in prostate cancer; unknown pathological significance; dbSNP:rs587780189)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	R318H	O96017/R318H	CHEK2/R318H	VARIANT	R -> H (in prostate cancer; unknown pathological significance; somatic mutation; dbSNP:rs143611747)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	T323P	O96017/T323P	CHEK2/T323P	VARIANT	T -> P (in prostate cancer; somatic mutation; dbSNP:rs750984976)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	Y327C	O96017/Y327C	CHEK2/Y327C	VARIANT	Y -> C (in prostate cancer; unknown pathological significance; somatic mutation; dbSNP:rs587780194)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	Y390C	O96017/Y390C	CHEK2/Y390C	VARIANT	Y -> C (in BC; does not phosphorylate p53/TP53; dbSNP:rs200928781)	ECO:0000269|PubMed:25619829	25619829	loss	
O96017	CHEK2	S428F	O96017/S428F	CHEK2/S428F	VARIANT	S -> F (may increase breast cancer risk; dbSNP:rs137853011)	ECO:0000269|PubMed:15649950	15649950		
O96017	CHEK2	T476K	O96017/T476K	CHEK2/T476K	VARIANT	T -> K (in prostate cancer; somatic mutation)	ECO:0000269|PubMed:12533788	12533788		
O96017	CHEK2	S379A	O96017/S379A	CHEK2/S379A	MUTAGEN	S->A: Abrogates autophosphorylation at Ser-379 and prevents ubiquitination.	ECO:0000269|PubMed:18644861	18644861	decrease	
O96017	CHEK2	S456A	O96017/S456A	CHEK2/S456A	MUTAGEN	S->A: Increased ubiquitination and degradation by the proteasome.	ECO:0000269|PubMed:17715138	17715138		inconclusive
P00519	ABL1	R47G	P00519/R47G	ABL1/R47G	VARIANT	R -> G (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P00519	ABL1	R166K	P00519/R166K	ABL1/R166K	VARIANT	R -> K (in a melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P00519	ABL1	T735A	P00519/T735A	ABL1/T735A	MUTAGEN	T->A: Abolishes phosphorylation. Loss of binding				
P00533	EGFR	E709A	P00533/E709A	EGFR/E709A	VARIANT	E -> A (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517085)	ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793	15623594,16205628,16533793		
P00533	EGFR	E709K	P00533/E709K	EGFR/E709K	VARIANT	E -> K (found in a lung cancer sample; dbSNP:rs727504256)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	G719A	P00533/G719A	EGFR/G719A	VARIANT	G -> A (found in a lung cancer sample; dbSNP:rs121913428)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	G719C	P00533/G719C	EGFR/G719C	VARIANT	G -> C (found in a lung cancer sample; dbSNP:rs28929495)	ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16533793	15623594,16533793		
P00533	EGFR	G719D	P00533/G719D	EGFR/G719D	VARIANT	G -> D (found in a lung cancer sample; dbSNP:rs121913428)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	G724S	P00533/G724S	EGFR/G724S	VARIANT	G -> S (found in a lung cancer sample; dbSNP:rs1051753269)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	E734K	P00533/E734K	EGFR/E734K	VARIANT	E -> K (found in a lung cancer sample; dbSNP:rs121913420)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	L747F	P00533/L747F	EGFR/L747F	VARIANT	L -> F (found in a lung cancer sample)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	R748P	P00533/R748P	EGFR/R748P	VARIANT	R -> P (found in a lung cancer sample)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	V769M	P00533/V769M	EGFR/V769M	VARIANT	V -> M (found in a lung cancer sample; dbSNP:rs147149347)	ECO:0000269|PubMed:15623594	15623594		
P00533	EGFR	Q787R	P00533/Q787R	EGFR/Q787R	VARIANT	Q -> R (found in a lung cancer sample)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	L833V	P00533/L833V	EGFR/L833V	VARIANT	L -> V (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517126)	ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793	15623594,16205628,16533793		
P00533	EGFR	V834L	P00533/V834L	EGFR/V834L	VARIANT	V -> L (found in a lung cancer sample; dbSNP:rs397517127)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	H835L	P00533/H835L	EGFR/H835L	VARIANT	H -> L (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs397517128)	ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628	15623594,16205628		
P00533	EGFR	L838V	P00533/L838V	EGFR/L838V	VARIANT	L -> V (found in a lung cancer sample; more sensitive to gefitinib than wild-type; dbSNP:rs864621996)	ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628	15623594,16205628		
P00533	EGFR	L858M	P00533/L858M	EGFR/L858M	VARIANT	L -> M (found in a lung cancer sample; dbSNP:rs121913443)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	G873E	P00533/G873E	EGFR/G873E	VARIANT	G -> E (found in a lung cancer sample)	ECO:0000269|PubMed:16533793	16533793		
P00533	EGFR	Y275A	P00533/Y275A	EGFR/Y275A	MUTAGEN	Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.	ECO:0000269|PubMed:12297050	12297050		
P00533	EGFR	F287A	P00533/F287A	EGFR/F287A	MUTAGEN	F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.	ECO:0000269|PubMed:12297050	12297050		
P00533	EGFR	R309S	P00533/R309S	EGFR/R309S	MUTAGEN	R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.	ECO:0000269|PubMed:12297050	12297050		
P00533	EGFR	D587A	P00533/D587A	EGFR/D587A	MUTAGEN	D->A: Increased EGF binding; when associated with A-590 and A-609.	ECO:0000269|PubMed:19718021	19718021		
P00533	EGFR	H590A	P00533/H590A	EGFR/H590A	MUTAGEN	H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.	ECO:0000269|PubMed:19718021	19718021		
P00533	EGFR	K609A	P00533/K609A	EGFR/K609A	MUTAGEN	K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.	ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:19718021	12620237,19718021		
P00533	EGFR	L692P	P00533/L692P	EGFR/L692P	MUTAGEN	L->A,P: Strongly reduced phosphorylation.	ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760	1,956,041,719,563,760		inconclusive
P00533	EGFR	K745M	P00533/K745M	EGFR/K745M	MUTAGEN	K->A,M: Abolishes kinase activity.	ECO:0000269|PubMed:19560417	19560417	loss	
P00533	EGFR	Y1016F	P00533/Y1016F	EGFR/Y1016F	MUTAGEN	Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.	ECO:0000269|PubMed:10805725	10805725		
P00533	EGFR	C1049A	P00533/C1049A	EGFR/C1049A	MUTAGEN	C->A: Decreased palmitoylation.	ECO:0000269|PubMed:27153536	27153536		
P00533	EGFR	Q1067G	P00533/Q1067G	EGFR/Q1067G	MUTAGEN	Q->G: No effect on interaction with CBLC.	ECO:0000269|PubMed:22888118	22888118		
P00533	EGFR	R1068G	P00533/R1068G	EGFR/R1068G	MUTAGEN	R->G: Strongly decreases interaction with CBLC.	ECO:0000269|PubMed:22888118	22888118	increase	
P00533	EGFR	Y1069F	P00533/Y1069F	EGFR/Y1069F	MUTAGEN	Y->F: Abolishes interaction with CBLC.	ECO:0000269|PubMed:22888118	22888118	activating	
P00533	EGFR	Y1092F	P00533/Y1092F	EGFR/Y1092F	MUTAGEN	Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.	ECO:0000269|PubMed:10805725	10805725		
P00533	EGFR	Y1110F	P00533/Y1110F	EGFR/Y1110F	MUTAGEN	Y->F: No change in interaction with PIK3C2B.	ECO:0000269|PubMed:10805725	10805725		
P00533	EGFR	C1146A	P00533/C1146A	EGFR/C1146A	MUTAGEN	C->A: Decreased palmitoylation.	ECO:0000269|PubMed:27153536	27153536		
P00533	EGFR	Y1172F	P00533/Y1172F	EGFR/Y1172F	MUTAGEN	Y->F: No change in interaction with PIK3C2B.	ECO:0000269|PubMed:10805725	10805725		
P00533	EGFR	Y1197F	P00533/Y1197F	EGFR/Y1197F	MUTAGEN	Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.	ECO:0000269|PubMed:10805725	10805725		
P00540	MOS	A123T	P00540/A123T	MOS/A123T	VARIANT	A -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P04049	RAF1	R256S	P04049/R256S	RAF1/R256S	VARIANT	R -> S (in NS5; dbSNP:rs397516826)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	S259F	P04049/S259F	RAF1/S259F	VARIANT	S -> F (in NS5; dbSNP:rs397516827)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	T260I	P04049/T260I	RAF1/T260I	VARIANT	T -> I (in hypertrophic cardiomyopathy; unknown pathological significance; dbSNP:rs869025501)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	T260R	P04049/T260R	RAF1/T260R	VARIANT	T -> R (in NS5)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	Q335H	P04049/Q335H	RAF1/Q335H	VARIANT	Q -> H (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P04049	RAF1	D486G	P04049/D486G	RAF1/D486G	VARIANT	D -> G (in NS5; dbSNP:rs397516815)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	T491R	P04049/T491R	RAF1/T491R	VARIANT	T -> R (in NS5; dbSNP:rs80338799)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	S612T	P04049/S612T	RAF1/S612T	VARIANT	S -> T (in NS5; dbSNP:rs1448392469)	ECO:0000269|PubMed:17603483	17603483		
P04049	RAF1	K375W	P04049/K375W	RAF1/K375W	MUTAGEN	K->W: Catalytically inactive.	ECO:0000269|PubMed:20956560	20956560	loss	
P04049	RAF1	T491D	P04049/T491D	RAF1/T491D	MUTAGEN	T->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-494.	ECO:0000269|PubMed:16892053	16892053	activating	
P04049	RAF1	S494D	P04049/S494D	RAF1/S494D	MUTAGEN	S->D: Increased kinase activity but can still be inhibited by PPP5C; when associated with D-491.	ECO:0000269|PubMed:16892053	16892053	activating	
P04626	ERBB2	I654V	P04626/I654V	ERBB2/I654V	VARIANT	I -> V (in allele B3; dbSNP:rs1801201)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8095488	173,448,468,095,488		
P04626	ERBB2	I655V	P04626/I655V	ERBB2/I655V	VARIANT	I -> V (in allele B2 and allele B3; dbSNP:rs1136201)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3	173,448,468,095,488		
P04626	ERBB2	L755P	P04626/L755P	ERBB2/L755P	VARIANT	L -> P (in LNCR; somatic mutation; unknown pathological significance; dbSNP:rs121913469)	ECO:0000269|PubMed:15457249	15457249		
P04626	ERBB2	M774MAYVM	P04626/M774MAYVM	ERBB2/M774MAYVM	VARIANT	M -> MAYVM (in LNCR; somatic mutation; unknown pathological significance)	ECO:0000269|PubMed:15457249	15457249		
P04626	ERBB2	G776S	P04626/G776S	ERBB2/G776S	VARIANT	G -> S (in GASC; somatic mutation; unknown pathological significance; dbSNP:rs28933369)	ECO:0000269|PubMed:15457249, ECO:0000269|PubMed:17344846	15457249,17344846		
P04626	ERBB2	S779SVGS	P04626/S779SVGS	ERBB2/S779SVGS	VARIANT	S -> SVGS (in LNCR; somatic mutation; unknown pathological significance)	ECO:0000269|PubMed:15457249	15457249		
P04626	ERBB2	N857S	P04626/N857S	ERBB2/N857S	VARIANT	N -> S (in OC; somatic mutation; unknown pathological significance; dbSNP:rs28933370)	ECO:0000269|PubMed:15457249, ECO:0000269|PubMed:17344846	15457249,17344846		
P04626	ERBB2	E914K	P04626/E914K	ERBB2/E914K	VARIANT	E -> K (in GLM; somatic mutation; unknown pathological significance; dbSNP:rs28933368)	ECO:0000269|PubMed:15457249	15457249		
P04626	ERBB2	M611A	P04626/M611A	ERBB2/M611A	MUTAGEN	M->A: Prevents synthesis of isoform 2.	ECO:0000269|PubMed:16794579	16794579		
P04626	ERBB2	M687A	P04626/M687A	ERBB2/M687A	MUTAGEN	M->A: Prevents synthesis of isoform 3.	ECO:0000269|PubMed:16794579	16794579		
P04626	ERBB2	M706A	P04626/M706A	ERBB2/M706A	MUTAGEN	M->A: No effect on isoform production.	ECO:0000269|PubMed:16794579	16794579		
P04626	ERBB2	M712A	P04626/M712A	ERBB2/M712A	MUTAGEN	M->A: No effect on isoform production.	ECO:0000269|PubMed:16794579	16794579		
P04629	NTRK1	L93P	P04629/L93P	NTRK1/L93P	VARIANT	L -> P (in CIPA; aberrantly processed; shows diminished autophosphorylation in neuronal cells)	ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935	10982191,11159935	decrease	
P04629	NTRK1	A107V	P04629/A107V	NTRK1/A107V	VARIANT	A -> V (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs540521894)	ECO:0000269|PubMed:17344846	17344846		
P04629	NTRK1	A110D	P04629/A110D	NTRK1/A110D	VARIANT	A -> D (in CIPA)	ECO:0000269|PubMed:28328124	28328124		
P04629	NTRK1	L213P	P04629/L213P	NTRK1/L213P	VARIANT	L -> P (in CIPA; aberrantly processed; shows diminished autophosphorylation in neuronal cells; dbSNP:rs747711259)	ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:11159935	10330344,11159935	decrease	
P04629	NTRK1	Y359C	P04629/Y359C	NTRK1/Y359C	VARIANT	Y -> C (in CIPA; dbSNP:rs121964869)	ECO:0000269|PubMed:11310631	11310631		
P04629	NTRK1	E492K	P04629/E492K	NTRK1/E492K	VARIANT	E -> K (in CIPA; dbSNP:rs144901788)	ECO:0000269|PubMed:22302274	22302274		
P04629	NTRK1	G517E	P04629/G517E	NTRK1/G517E	VARIANT	G -> E (in CIPA; following transfection in neuroblastoma cells and NGF treatment, small decrease in the percentage of cells differentiated into neuronal phenotype, but in differentiated cells, the average neurite length is comparable to wild-type; no effect on N-glycosylation, subcellular location, nor on basal and NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux; dbSNP:rs606231467)	ECO:0000269|PubMed:27676246	27676246		inconclusive
P04629	NTRK1	G522E	P04629/G522E	NTRK1/G522E	VARIANT	G -> E (in CIPA; no effect on N-glycosylation, nor on subcellular location; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	ECO:0000269|PubMed:27676246	27676246	decrease	
P04629	NTRK1	G522R	P04629/G522R	NTRK1/G522R	VARIANT	G -> R (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs1571699266)	ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935	10982191,11159935	decrease	
P04629	NTRK1	I572S	P04629/I572S	NTRK1/I572S	VARIANT	I -> S (in CIPA)	ECO:0000269|PubMed:18077166	18077166		
P04629	NTRK1	M587V	P04629/M587V	NTRK1/M587V	VARIANT	M -> V (in CIPA; dbSNP:rs121964870)	ECO:0000269|PubMed:10233776	10233776		
P04629	NTRK1	R649Q	P04629/R649Q	NTRK1/R649Q	VARIANT	R -> Q (in CIPA; dbSNP:rs786205449)	ECO:0000269|PubMed:28328124	28328124		
P04629	NTRK1	R649W	P04629/R649W	NTRK1/R649W	VARIANT	R -> W (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs369353892)	ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:11159935	10330344,11159935	decrease	
P04629	NTRK1	R654C	P04629/R654C	NTRK1/R654C	VARIANT	R -> C (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs764992664)	ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:22302274	10982191,11159935,22302274	decrease	
P04629	NTRK1	L657P	P04629/L657P	NTRK1/L657P	VARIANT	L -> P (in CIPA; following transfection in neuroblastoma cells and NGF treatment, loss of differentiation into neuronal phenotype; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	ECO:0000269|PubMed:27676246	27676246	decrease	
P04629	NTRK1	D674Y	P04629/D674Y	NTRK1/D674Y	VARIANT	D -> Y (in CIPA; might impair the function of the enzyme without compromising autophosphorylation; dbSNP:rs80356677)	ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:28177573	10982191,11159935,28177573		
P04629	NTRK1	P695L	P04629/P695L	NTRK1/P695L	VARIANT	P -> L (in CIPA; dbSNP:rs121964868)	ECO:0000269|PubMed:10861667	10861667		
P04629	NTRK1	I699T	P04629/I699T	NTRK1/I699T	VARIANT	I -> T (in CIPA; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux)	ECO:0000269|PubMed:27676246	27676246	decrease	
P04629	NTRK1	L700P	P04629/L700P	NTRK1/L700P	VARIANT	L -> P (in CIPA)	ECO:0000269|PubMed:28328124	28328124		
P04629	NTRK1	G714S	P04629/G714S	NTRK1/G714S	VARIANT	G -> S (in CIPA; processed as wild-type but shows significantly diminished autophosphorylation in both neuronal and non-neuronal cells; dbSNP:rs770727871)	ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:11159935	10330344,11159935	decrease	
P04629	NTRK1	L717R	P04629/L717R	NTRK1/L717R	VARIANT	L -> R (in CIPA)	ECO:0000269|PubMed:18077166	18077166		
P04629	NTRK1	C752S	P04629/C752S	NTRK1/C752S	VARIANT	C -> S (in CIPA; unknown pathological significance; following transfection in neuroblastoma cells and NGF treatment, no effect on neurite outgrowth, nor neurite length; no effect on N-glycosylation, subcellular location, basal and NGF-induced autophosphorylation, nor on NGF-stimulated calcium flux)	ECO:0000269|PubMed:27676246	27676246		
P04629	NTRK1	C763S	P04629/C763S	NTRK1/C763S	VARIANT	C -> S (in CIPA; following transfection in neuroblastoma cells and NGF treatment, decreased percentage of cells differentiated into neuronal phenotype and reduced neurite length compared with wild-type; slightly decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal and NGF-induced autophosphorylation; small reduction in NGF-stimulated calcium flux)	ECO:0000269|PubMed:27676246	27676246	decrease	
P04629	NTRK1	R771C	P04629/R771C	NTRK1/R771C	VARIANT	R -> C (in CIPA; partially decreased N-glycosylation; reduced expression at the plasma membrane; reduced basal autophosphorylation and complete loss of NGF-induced autophosphorylation; loss of NGF-stimulated calcium flux; dbSNP:rs1324983370)	ECO:0000269|PubMed:27676246	27676246	decrease	
P04629	NTRK1	Y496F	P04629/Y496F	NTRK1/Y496F	MUTAGEN	Y->F: Loss of interaction with SHC1 and altered phosphorylation of SHC1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-791.	ECO:0000269|PubMed:8155326	8155326		inconclusive
P04629	NTRK1	K544A	P04629/K544A	NTRK1/K544A	MUTAGEN	K->A: No effect on interaction with GGA3.	ECO:0000269|PubMed:26446845	26446845		
P04629	NTRK1	Y791F	P04629/Y791F	NTRK1/Y791F	MUTAGEN	Y->F: Loss of interaction with PLCG1 and altered phosphorylation of PLCG1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-496.	ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326	75,106,978,155,326		inconclusive
P05129	PRKCG	G63R	P05129/G63R	PRKCG/G63R	VARIANT	G -> R (in SCA14)	ECO:0000269|PubMed:29053796	29053796		
P05129	PRKCG	G63V	P05129/G63V	PRKCG/G63V	VARIANT	G -> V (in SCA14; dbSNP:rs386134159)	ECO:0000269|PubMed:29053796	29053796		
P05129	PRKCG	H101Y	P05129/H101Y	PRKCG/H101Y	VARIANT	H -> Y (in SCA14; dbSNP:rs121918511)	ECO:0000269|PubMed:12644968	12644968		
P05129	PRKCG	S119P	P05129/S119P	PRKCG/S119P	VARIANT	S -> P (in SCA14; dbSNP:rs121918512)	ECO:0000269|PubMed:12644968	12644968		
P05129	PRKCG	G128D	P05129/G128D	PRKCG/G128D	VARIANT	G -> D (in SCA14; dbSNP:rs121918513)	ECO:0000269|PubMed:12644968	12644968		
P05129	PRKCG	R141C	P05129/R141C	PRKCG/R141C	VARIANT	R -> C	ECO:0000269|PubMed:9545390	9545390		
P05129	PRKCG	H415Q	P05129/H415Q	PRKCG/H415Q	VARIANT	H -> Q	ECO:0000269|PubMed:9545390	9545390		
P05129	PRKCG	A523D	P05129/A523D	PRKCG/A523D	VARIANT	A -> D	ECO:0000269|PubMed:9545390	9545390		
P05771	PRKCB	V144M	P05771/V144M	PRKCB/V144M	VARIANT	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs764534677)	ECO:0000269|PubMed:17344846	17344846		
P05771	PRKCB	V496M	P05771/V496M	PRKCB/V496M	VARIANT	V -> M (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1466858740)	ECO:0000269|PubMed:17344846	17344846		
P06213	INSR	N42K	P06213/N42K	INSR/N42K	VARIANT	N -> K (in RMS; impairs transport to the plasma membrane and reduces the affinity to bind insulin; dbSNP:rs121913143)	ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819	21,217,342,365,819		
P06213	INSR	V55A	P06213/V55A	INSR/V55A	VARIANT	V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)	ECO:0000269|PubMed:1607067	1607067		
P06213	INSR	I56T	P06213/I56T	INSR/I56T	VARIANT	I -> T (in LEPRCH; abolishes post-translational processing; dbSNP:rs1555689937)	ECO:0000269|PubMed:24498630	24498630	decrease	
P06213	INSR	G58R	P06213/G58R	INSR/G58R	VARIANT	G -> R (in LEPRCH; Helmond; inhibits processing and transport; dbSNP:rs52836744)	ECO:0000269|PubMed:1730625	1730625	decrease	
P06213	INSR	D86G	P06213/D86G	INSR/D86G	VARIANT	D -> G (in IRAN type A)	ECO:0000269|PubMed:9175790	9175790		
P06213	INSR	L89P	P06213/L89P	INSR/L89P	VARIANT	L -> P (in IRAN type A)	ECO:0000269|PubMed:9175790	9175790		
P06213	INSR	R113P	P06213/R113P	INSR/R113P	VARIANT	R -> P (in LEPRCH; Atlanta-1; abolishes insulin binding; dbSNP:rs121913153)	ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:8419945	120,239,898,419,945	loss	
P06213	INSR	A119V	P06213/A119V	INSR/A119V	VARIANT	A -> V (in LEPRCH; markedly impairs insulin binding; dbSNP:rs1347473020)	ECO:0000269|PubMed:12023989	12023989	decrease	
P06213	INSR	L120Q	P06213/L120Q	INSR/L120Q	VARIANT	L -> Q (in LEPRCH; inhibits receptor processing)	ECO:0000269|PubMed:12970295	12970295	decrease	
P06213	INSR	I146M	P06213/I146M	INSR/I146M	VARIANT	I -> M (in LEPRCH; mild; dbSNP:rs121913159)	ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8326490	78,154,428,326,490		
P06213	INSR	V167L	P06213/V167L	INSR/V167L	VARIANT	V -> L (in IRAN type A; dbSNP:rs938519025)	ECO:0000269|PubMed:10733238	10733238		
P06213	INSR	P220L	P06213/P220L	INSR/P220L	VARIANT	P -> L (in Ins resistance; severe; dbSNP:rs749094324)	ECO:0000269|PubMed:8242067	8242067		
P06213	INSR	C228R	P06213/C228R	INSR/C228R	VARIANT	C -> R (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P06213	INSR	H236R	P06213/H236R	INSR/H236R	VARIANT	H -> R (in RMS and LEPRCH; Winnipeg; may impair receptor processing; dbSNP:rs121913145)	ECO:0000269|PubMed:17201797, ECO:0000269|PubMed:2365819	172,017,972,365,819		
P06213	INSR	R256C	P06213/R256C	INSR/R256C	VARIANT	R -> C (in RMS; dbSNP:rs781007453)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	L260P	P06213/L260P	INSR/L260P	VARIANT	L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)	ECO:0000269|PubMed:2479553	2479553		
P06213	INSR	R279C	P06213/R279C	INSR/R279C	VARIANT	R -> C (in IRAN type A; inhibits receptor internalization; dbSNP:rs1568470274)	ECO:0000269|PubMed:12107746	12107746		inconclusive
P06213	INSR	R279H	P06213/R279H	INSR/R279H	VARIANT	R -> H (in IRAN type A; interferes with receptor processing; dbSNP:rs1329693158)	ECO:0000269|PubMed:12970295	12970295		inconclusive
P06213	INSR	C280Y	P06213/C280Y	INSR/C280Y	VARIANT	C -> Y (in IRAN type A)	ECO:0000269|PubMed:11260230	11260230		
P06213	INSR	C286Y	P06213/C286Y	INSR/C286Y	VARIANT	C -> Y (in LEPRCH; abolishes post-translational processing)	ECO:0000269|PubMed:24498630	24498630		
P06213	INSR	C301Y	P06213/C301Y	INSR/C301Y	VARIANT	C -> Y (in LEPRCH)	ECO:0000269|PubMed:9703342	9703342		
P06213	INSR	S350L	P06213/S350L	INSR/S350L	VARIANT	S -> L (in RMS and LEPRCH)	ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:8314008	129,702,958,314,008		
P06213	INSR	G386S	P06213/G386S	INSR/G386S	VARIANT	G -> S (in RMS; may impair receptor processing; dbSNP:rs764221583)	ECO:0000269|PubMed:17201797	17201797		
P06213	INSR	G393R	P06213/G393R	INSR/G393R	VARIANT	G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)	ECO:0000269|PubMed:1607067	1607067		
P06213	INSR	F409V	P06213/F409V	INSR/F409V	VARIANT	F -> V (in IRAN type A; dbSNP:rs121913142)	ECO:0000269|PubMed:8388389	8388389		
P06213	INSR	W439S	P06213/W439S	INSR/W439S	VARIANT	W -> S (in LEPRCH; impairs transport of the receptor to the cell surface; dbSNP:rs121913158)	ECO:0000269|PubMed:8188715	8188715		inconclusive
P06213	INSR	N458D	P06213/N458D	INSR/N458D	VARIANT	N -> D (in LEPRCH; partially inhibits receptor processing and autophosphorylation; strongly impairs ERK phosphorylation; induces wild-type levels of IRS-1 phosphorylation; dbSNP:rs121913160)	ECO:0000269|PubMed:12970295	12970295	decrease	
P06213	INSR	K487E	P06213/K487E	INSR/K487E	VARIANT	K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)	ECO:0000269|PubMed:2834824	2834824		
P06213	INSR	N489D	P06213/N489D	INSR/N489D	VARIANT	N -> D (in IRAN type A; unknown pathological significance; dbSNP:rs1135401742)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	N489S	P06213/N489S	INSR/N489S	VARIANT	N -> S (in IRAN type A; dbSNP:rs121913147)	ECO:0000269|PubMed:2365819	2365819		
P06213	INSR	Q492K	P06213/Q492K	INSR/Q492K	VARIANT	Q -> K	ECO:0000269|PubMed:2859121	2859121		
P06213	INSR	S635L	P06213/S635L	INSR/S635L	VARIANT	S -> L (in RMS; decreases post-translational processing)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	V657F	P06213/V657F	INSR/V657F	VARIANT	V -> F (in LEPRCH; impairs post-translational processing; dbSNP:rs1135401737)	ECO:0000269|PubMed:28765322	28765322	decrease	
P06213	INSR	W659R	P06213/W659R	INSR/W659R	VARIANT	W -> R (in LEPRCH; impairs post-translational processing)	ECO:0000269|PubMed:28765322	28765322	decrease	
P06213	INSR	R762S	P06213/R762S	INSR/R762S	VARIANT	R -> S (in IRAN type A; dbSNP:rs121913138)	ECO:0000269|PubMed:3283938	3283938		
P06213	INSR	Y818C	P06213/Y818C	INSR/Y818C	VARIANT	Y -> C (in LEPRCH; abolishes post-translational processing)	ECO:0000269|PubMed:22768670, ECO:0000269|PubMed:28765322	22768670,28765322	decrease	
P06213	INSR	S835I	P06213/S835I	INSR/S835I	VARIANT	S -> I (in RMS; impairs post-translational processing; dbSNP:rs1135401739)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	A842V	P06213/A842V	INSR/A842V	VARIANT	A -> V (in RMS; decreases post-translational processing; dbSNP:rs1135401738)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	T858A	P06213/T858A	INSR/T858A	VARIANT	T -> A (in T2D; dbSNP:rs182552223)	ECO:0000269|PubMed:7657032	7657032		
P06213	INSR	P874L	P06213/P874L	INSR/P874L	VARIANT	P -> L (in RMS; impairs post-translational processing)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	N878S	P06213/N878S	INSR/N878S	VARIANT	N -> S (in RMS; impairs post-translational processing; dbSNP:rs887190835)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	I925T	P06213/I925T	INSR/I925T	VARIANT	I -> T (in LEPRCH; abolishes post-translational processing; abolishes insulin binding; dbSNP:rs1599881881)	ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:28765322	12023989,28765322	loss	
P06213	INSR	R926W	P06213/R926W	INSR/R926W	VARIANT	R -> W (in LEPRCH; markedly impairs insulin binding;impairs post-translational processing; dbSNP:rs911929963)	ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:28765322	12023989,28765322	decrease	
P06213	INSR	T937M	P06213/T937M	INSR/T937M	VARIANT	T -> M (in LEPRCH; impaired receptor processing; impairs post-translational processing)	ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:9299395	287,653,229,299,395	decrease	
P06213	INSR	P997T	P06213/P997T	INSR/P997T	VARIANT	P -> T (in RMS; reduces insulin binding)	ECO:0000269|PubMed:12023989	12023989		
P06213	INSR	R1020Q	P06213/R1020Q	INSR/R1020Q	VARIANT	R -> Q (in IRAN type A; dbSNP:rs121913148)	ECO:0000269|PubMed:2002058	2002058		
P06213	INSR	I1023F	P06213/I1023F	INSR/I1023F	VARIANT	I -> F	ECO:0000269|PubMed:8890729	8890729		
P06213	INSR	G1035V	P06213/G1035V	INSR/G1035V	VARIANT	G -> V (in IRAN type A; dbSNP:rs121913135)	ECO:0000269|PubMed:2544998	2544998		
P06213	INSR	V1054M	P06213/V1054M	INSR/V1054M	VARIANT	V -> M (in IRAN type A; unknown pathological significance; dbSNP:rs1135401741)	ECO:0000269|PubMed:28765322	28765322		
P06213	INSR	A1055V	P06213/A1055V	INSR/A1055V	VARIANT	A -> V (in IRAN type A; dbSNP:rs1599874183)	ECO:0000269|PubMed:10733238	10733238		
P06213	INSR	A1075D	P06213/A1075D	INSR/A1075D	VARIANT	A -> D (in IRAN type A)	ECO:0000269|PubMed:8243830	8243830		
P06213	INSR	K1095E	P06213/K1095E	INSR/K1095E	VARIANT	K -> E (in a subject with non-insulin dependent diabetes mellitus; dbSNP:rs909008899)	ECO:0000269|PubMed:2040394	2040394		
P06213	INSR	R1119W	P06213/R1119W	INSR/R1119W	VARIANT	R -> W (in LEPRCH; dbSNP:rs1229730671)	ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:9249867	129,702,959,249,867		
P06213	INSR	I1143T	P06213/I1143T	INSR/I1143T	VARIANT	I -> T (in RMS; reduces insulin binding)	ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989	10443650,12023989	decrease	
P06213	INSR	R1158Q	P06213/R1158Q	INSR/R1158Q	VARIANT	R -> Q (in T2D)	ECO:0000269|PubMed:1470163	1470163		
P06213	INSR	R1158W	P06213/R1158W	INSR/R1158W	VARIANT	R -> W (in RMS; abolishes insulin binding; dbSNP:rs111993466)	ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989	10443650,12023989	loss	
P06213	INSR	A1161T	P06213/A1161T	INSR/A1161T	VARIANT	A -> T (in IRAN type A; dbSNP:rs121913139)	ECO:0000269|PubMed:2168397	2168397		
P06213	INSR	A1162E	P06213/A1162E	INSR/A1162E	VARIANT	A -> E (in IRAN type A; impairs proteolytic processing; dbSNP:rs121913154)	ECO:0000269|PubMed:8096518	8096518		
P06213	INSR	M1180I	P06213/M1180I	INSR/M1180I	VARIANT	M -> I (in a patient with insulin resistance; dbSNP:rs121913157)	ECO:0000269|PubMed:1890161	1890161		
P06213	INSR	R1191Q	P06213/R1191Q	INSR/R1191Q	VARIANT	R -> Q (in T2D; dbSNP:rs121913150)	ECO:0000269|PubMed:1607076	1607076		
P06213	INSR	R1201Q	P06213/R1201Q	INSR/R1201Q	VARIANT	R -> Q (in HHF5 and IRAN type A; interferes with kinase activation by insulin; dbSNP:rs121913156)	ECO:0000269|PubMed:15161766, ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049	15161766,8082780,8288049		
P06213	INSR	R1201W	P06213/R1201W	INSR/R1201W	VARIANT	R -> W (in LEPRCH and RMS; reduces insulin binding possibly due to reduced receptor levels on the cell surface; dbSNP:rs1568426700)	ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:9703342	120,239,899,703,342		
P06213	INSR	P1205L	P06213/P1205L	INSR/P1205L	VARIANT	P -> L (in IRAN type A; moderate; dbSNP:rs1295645322)	ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:8314008	15,635,828,314,008		
P06213	INSR	E1206K	P06213/E1206K	INSR/E1206K	VARIANT	E -> K (in LEPRCH)	ECO:0000269|PubMed:9249867	9249867		
P06213	INSR	W1227S	P06213/W1227S	INSR/W1227S	VARIANT	W -> S (in IRAN type A; dbSNP:rs121913140)	ECO:0000269|PubMed:1963473	1963473		
P06213	INSR	R1378Q	P06213/R1378Q	INSR/R1378Q	VARIANT	R -> Q (in IRAN type A; dbSNP:rs52826008)	ECO:0000269|PubMed:8314008	8314008		
P06213	INSR	L991A	P06213/L991A	INSR/L991A	MUTAGEN	L->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	ECO:0000269|PubMed:7559478	7559478		
P06213	INSR	Y992A	P06213/Y992A	INSR/Y992A	MUTAGEN	Y->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	ECO:0000269|PubMed:7559478	7559478		
P06213	INSR	N996A	P06213/N996A	INSR/N996A	MUTAGEN	N->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.	ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478	75,378,497,559,478		
P06213	INSR	P997A	P06213/P997A	INSR/P997A	MUTAGEN	P->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.	ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478	75,378,497,559,478		
P06213	INSR	E998A	P06213/E998A	INSR/E998A	MUTAGEN	E->A: Does not affect interaction with IRS1, SHC1 or PIK3R1.	ECO:0000269|PubMed:7537849	7537849		
P06213	INSR	Y999E	P06213/Y999E	INSR/Y999E	MUTAGEN	Y->E: Abolishes interaction with IRS1 and SHC1.	ECO:0000269|PubMed:2842060, ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:9428692	2842060,7537849,7559478,9428692		
P06213	INSR	Y999F	P06213/Y999F	INSR/Y999F	MUTAGEN	Y->F: Has no effect on insulin-stimulated autophosphorylation, but inhibits the biological activity of the receptor. Abolishes interaction with IRS1 and almost completely prevents interaction with SHC1. Has no effect on interaction with PIK3R1. Abolishes interaction with STAT5B.	ECO:0000269|PubMed:2842060, ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:9428692	2842060,7537849,7559478,9428692	loss	
P06213	INSR	L1000A	P06213/L1000A	INSR/L1000A	MUTAGEN	L->A,R: Severely reduces interaction with SHC1. Has no effect on interaction with IRS1.	ECO:0000269|PubMed:7559478	7559478		
P06213	INSR	L1000R	P06213/L1000R	INSR/L1000R	MUTAGEN	L->A,R: Severely reduces interaction with SHC1. Has no effect on interaction with IRS1.	ECO:0000269|PubMed:7559478	7559478		
P06213	INSR	A1002D	P06213/A1002D	INSR/A1002D	MUTAGEN	A->D: Reduces interaction with IRS1 but has no effect on interaction with SHC1.	ECO:0000269|PubMed:7559478	7559478		
P06213	INSR	K1057A	P06213/K1057A	INSR/K1057A	MUTAGEN	K->A: Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1.	ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849	10803466,3101064,7537849	loss	
P06213	INSR	K1057R	P06213/K1057R	INSR/K1057R	MUTAGEN	K->M,R: Abolishes the kinase activity.	ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849	10803466,3101064,7537849	loss	
P06213	INSR	Y1189F	P06213/Y1189F	INSR/Y1189F	MUTAGEN	Y->F: Reduced interaction with GRB7.	ECO:0000269|PubMed:10803466	10803466		
P06213	INSR	Y1190F	P06213/Y1190F	INSR/Y1190F	MUTAGEN	Y->F: Strongly reduced interaction with GRB7.	ECO:0000269|PubMed:10803466	10803466		
P06239	LCK	V28L	P06239/V28L	LCK/V28L	VARIANT	V -> L (found in leukemia)	ECO:0000269|PubMed:8139546	8139546		
P06239	LCK	P232PQKP	P06239/P232PQKP	LCK/P232PQKP	VARIANT	P -> PQKP (in leukemia)				
P06239	LCK	L341P	P06239/L341P	LCK/L341P	VARIANT	L -> P (in IMD22; dbSNP:rs587777335)	ECO:0000269|PubMed:22985903	22985903		
P06239	LCK	A353V	P06239/A353V	LCK/A353V	VARIANT	A -> V (found in leukemia)	ECO:0000269|PubMed:8139546	8139546		
P06239	LCK	P447L	P06239/P447L	LCK/P447L	VARIANT	P -> L (found in leukemia)	ECO:0000269|PubMed:8139546	8139546		
P06239	LCK	S59E	P06239/S59E	LCK/S59E	MUTAGEN	S->E: Allows interaction with SQSTM1.	ECO:0000269|PubMed:8618896	8618896		
P06239	LCK	R154K	P06239/R154K	LCK/R154K	MUTAGEN	R->K: No effect on interaction with SQSTM1.	ECO:0000269|PubMed:8618896	8618896		
P06241	FYN	V243L	P06241/V243L	FYN/V243L	VARIANT	V -> L (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P06241	FYN	G410R	P06241/G410R	FYN/G410R	VARIANT	G -> R (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P06493	CDK1	Y4D	P06493/Y4D	CDK1/Y4D	MUTAGEN	Y->D,E: Constitutive polyubiquitination.	ECO:0000269|PubMed:20395957	20395957	decrease	
P06493	CDK1	Y4E	P06493/Y4E	CDK1/Y4E	MUTAGEN	Y->D,E: Constitutive polyubiquitination.	ECO:0000269|PubMed:20395957	20395957	decrease	
P07332	FES	R483M	P07332/R483M	FES/R483M	MUTAGEN	R->M: Abolishes pTyr binding. Abolishes association with microtubules. Abolishes autophosphorylation. Reduced kinase activity.	ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18775312	15485904,18775312	decrease	
P07332	FES	R706Q	P07332/R706Q	FES/R706Q	MUTAGEN	R->Q: Negligible effect on autophosphorylation and kinase activity.	ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:16455651	15867340,16455651		neutral?
P07333	CSF1R	G589E	P07333/G589E	CSF1R/G589E	VARIANT	G -> E (in HDLS1; dbSNP:rs281860268)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	H643Q	P07333/H643Q	CSF1R/H643Q	VARIANT	H -> Q (in BANDDOS; dbSNP:rs184499252)	ECO:0000269|PubMed:30982608	30982608		
P07333	CSF1R	C653R	P07333/C653R	CSF1R/C653R	VARIANT	C -> R (in HDLS1; dbSNP:rs690016559)	ECO:0000269|PubMed:24532199	24532199		
P07333	CSF1R	P693H	P07333/P693H	CSF1R/P693H	VARIANT	P -> H (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P07333	CSF1R	A770P	P07333/A770P	CSF1R/A770P	VARIANT	A -> P (in HDLS1; dbSNP:rs281860271)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	D837Y	P07333/D837Y	CSF1R/D837Y	VARIANT	D -> Y (in HDLS1; dbSNP:rs387906662)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	I843F	P07333/I843F	CSF1R/I843F	VARIANT	I -> F (in HDLS1; dbSNP:rs690016558)	ECO:0000269|PubMed:24532199	24532199		
P07333	CSF1R	F849S	P07333/F849S	CSF1R/F849S	VARIANT	F -> S (in HDLS1; dbSNP:rs281860277)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	L868P	P07333/L868P	CSF1R/L868P	VARIANT	L -> P (in HDLS1; dbSNP:rs281860278)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	P878T	P07333/P878T	CSF1R/P878T	VARIANT	P -> T (in HDLS1; dbSNP:rs281860280)	ECO:0000269|PubMed:22197934	22197934		
P07333	CSF1R	I906T	P07333/I906T	CSF1R/I906T	VARIANT	I -> T (in HDLS1; dbSNP:rs690016560)	ECO:0000269|PubMed:24532199	24532199		
P07333	CSF1R	Y708F	P07333/Y708F	CSF1R/Y708F	MUTAGEN	Y->F: Impairs degradation of activated CSF1R.	ECO:0000269|PubMed:10340379	10340379	increase	
P07333	CSF1R	D802V	P07333/D802V	CSF1R/D802V	MUTAGEN	D->V: Constitutive kinase activity. Loss of inhibition by imatinib.	ECO:0000269|PubMed:10340379, ECO:0000269|PubMed:16170366	10340379,16170366	activating	resistance
P07947	YES1	Y426F	P07947/Y426F	YES1/Y426F	MUTAGEN	Y->F: About 50% loss of CSK-mediated inhibition.	ECO:0000269|PubMed:9794236	9794236	increase	
P07948	LYN	D385Y	P07948/D385Y	LYN/D385Y	VARIANT	D -> Y (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P07948	LYN	G2A	P07948/G2A	LYN/G2A	MUTAGEN	G->A: Loss of localization to the cell membrane; when associated with A-3.	ECO:0000269|PubMed:18817770	18817770		
P07948	LYN	C3A	P07948/C3A	LYN/C3A	MUTAGEN	C->A: Loss of localization to the cell membrane; when associated with A-2.	ECO:0000269|PubMed:18817770	18817770		
P07948	LYN	K275A	P07948/K275A	LYN/K275A	MUTAGEN	K->A: Loss of activity and no effect on localization to the cell membrane. Abundant localization in the nucleus; when associated with A-2 and A-3.	ECO:0000269|PubMed:11435302, ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188, ECO:0000269|PubMed:18817770	11435302,11517336,15173188,18817770	loss	
P07948	LYN	K275R	P07948/K275R	LYN/K275R	MUTAGEN	K->L,R: Loss of kinase activity.	ECO:0000269|PubMed:11435302, ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188, ECO:0000269|PubMed:18817770	11435302,11517336,15173188,18817770	loss	
P07948	LYN	D346A	P07948/D346A	LYN/D346A	MUTAGEN	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-353; A-498 and A-499.	ECO:0000269|PubMed:15173188	15173188		
P07948	LYN	E353A	P07948/E353A	LYN/E353A	MUTAGEN	E->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-498 and A-499.	ECO:0000269|PubMed:15173188	15173188		
P07948	LYN	D498A	P07948/D498A	LYN/D498A	MUTAGEN	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-499.	ECO:0000269|PubMed:15173188	15173188		
P07948	LYN	D499A	P07948/D499A	LYN/D499A	MUTAGEN	D->A: Impedes the trafficking from the Golgi apparatus toward the cell membrane; when associated with A-346; A-353 and A-498.	ECO:0000269|PubMed:15173188	15173188		
P07949	RET	P20L	P07949/P20L	RET/P20L	VARIANT	P -> L (in HSCR1; sporadic form)	ECO:0000269|PubMed:7633441	7633441		
P07949	RET	S32L	P07949/S32L	RET/S32L	VARIANT	S -> L (in HSCR1; familial form; dbSNP:rs76764689)	ECO:0000269|PubMed:10618407, ECO:0000269|PubMed:8114939	106,184,078,114,939		
P07949	RET	L40P	P07949/L40P	RET/L40P	VARIANT	L -> P (in HSCR1)	ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:9043870	77,045,579,043,870		
P07949	RET	P64L	P07949/P64L	RET/P64L	VARIANT	P -> L (in HSCR1; familial form; dbSNP:rs77596424)	ECO:0000269|PubMed:8114939	8114939		
P07949	RET	R77C	P07949/R77C	RET/R77C	VARIANT	R -> C (in HSCR1)	ECO:0000269|PubMed:10618407	10618407		
P07949	RET	G93S	P07949/G93S	RET/G93S	VARIANT	G -> S (in HSCR1; unknown pathological significance; dbSNP:rs1477699803)	ECO:0000269|PubMed:7633441	7633441		
P07949	RET	R114C	P07949/R114C	RET/R114C	VARIANT	R -> C (in HSCR1; unknown pathological significance; dbSNP:rs747483905)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	C142S	P07949/C142S	RET/C142S	VARIANT	C -> S (in HSCR1; sporadic form)				
P07949	RET	V145G	P07949/V145G	RET/V145G	VARIANT	V -> G (in HSCR1; also in a colorectal cancer sample; somatic mutation; dbSNP:rs1588863999)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:22174939	16959974,22174939		
P07949	RET	P155L	P07949/P155L	RET/P155L	VARIANT	P -> L (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	C157Y	P07949/C157Y	RET/C157Y	VARIANT	C -> Y (in HSCR1; unknown pathological significance)	ECO:0000269|Ref.63			
P07949	RET	R163Q	P07949/R163Q	RET/R163Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs149403911)	ECO:0000269|PubMed:17344846	17344846		
P07949	RET	F174S	P07949/F174S	RET/F174S	VARIANT	F -> S (in HSCR1; sporadic form)	ECO:0000269|PubMed:9094028	9094028		
P07949	RET	R175P	P07949/R175P	RET/R175P	VARIANT	R -> P (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R180P	P07949/R180P	RET/R180P	VARIANT	R -> P (in HSCR1; sporadic form)	ECO:0000269|PubMed:9090527	9090527		
P07949	RET	C197Y	P07949/C197Y	RET/C197Y	VARIANT	C -> Y (in HSCR1; sporadic form)	ECO:0000269|PubMed:9094028	9094028		
P07949	RET	P198T	P07949/P198T	RET/P198T	VARIANT	P -> T (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs76736111)	ECO:0000269|PubMed:18252215	18252215		
P07949	RET	R231H	P07949/R231H	RET/R231H	VARIANT	R -> H (in HSCR1; familial form; dbSNP:rs79661516)				
P07949	RET	E251K	P07949/E251K	RET/E251K	VARIANT	E -> K (in HSCR1; familial form; dbSNP:rs562449603)				
P07949	RET	T278A	P07949/T278A	RET/T278A	VARIANT	T -> A (in HSCR1; dbSNP:rs541929171)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	T278N	P07949/T278N	RET/T278N	VARIANT	T -> N (found in two patients with Hirschsprung disease; dbSNP:rs35118262)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22174939	17344846,22174939		
P07949	RET	T278P	P07949/T278P	RET/T278P	VARIANT	T -> P (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R287Q	P07949/R287Q	RET/R287Q	VARIANT	R -> Q (in HSCR1; sporadic form; dbSNP:rs1564491460)				
P07949	RET	V292M	P07949/V292M	RET/V292M	VARIANT	V -> M (found in patients with Hirschsprung disease; unknown pathological significance; dbSNP:rs34682185)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22174939	17344846,22174939		
P07949	RET	D300N	P07949/D300N	RET/D300N	VARIANT	D -> N (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R313Q	P07949/R313Q	RET/R313Q	VARIANT	R -> Q (in HSCR1; dbSNP:rs77702891)	ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:9090527	221,749,399,090,527		
P07949	RET	S316I	P07949/S316I	RET/S316I	VARIANT	S -> I (in HSCR1; dbSNP:rs1060499894)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R330Q	P07949/R330Q	RET/R330Q	VARIANT	R -> Q (in HSCR1; dbSNP:rs80236571)	ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:8114939	76,334,418,114,939		
P07949	RET	S339L	P07949/S339L	RET/S339L	VARIANT	S -> L (in HSCR1; dbSNP:rs774829203)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	D353Y	P07949/D353Y	RET/D353Y	VARIANT	D -> Y (in HSCR1; dbSNP:rs1837785429)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	N359K	P07949/N359K	RET/N359K	VARIANT	N -> K (in HSCR1; unknown pathological significance)	ECO:0000269|Ref.63			
P07949	RET	R360Q	P07949/R360Q	RET/R360Q	VARIANT	R -> Q (in HSCR1; dbSNP:rs762472027)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R360W	P07949/R360W	RET/R360W	VARIANT	R -> W (in HSCR1)	ECO:0000269|PubMed:10618407, ECO:0000269|PubMed:16959974	10618407,16959974		
P07949	RET	F393L	P07949/F393L	RET/F393L	VARIANT	F -> L (in HSCR1; familial form; dbSNP:rs78098482)	ECO:0000269|PubMed:8114939	8114939		
P07949	RET	N394H	P07949/N394H	RET/N394H	VARIANT	N -> H (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF)	ECO:0000269|PubMed:18252215	18252215		
P07949	RET	N394K	P07949/N394K	RET/N394K	VARIANT	N -> K (in HSCR1)	ECO:0000269|PubMed:10618407	10618407		
P07949	RET	V397M	P07949/V397M	RET/V397M	VARIANT	V -> M (in HSCR1; dbSNP:rs183729115)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	P399L	P07949/P399L	RET/P399L	VARIANT	P -> L (in HSCR1; sporadic form; dbSNP:rs1554818362)	ECO:0000269|PubMed:7704557	7704557		
P07949	RET	V412M	P07949/V412M	RET/V412M	VARIANT	V -> M (in HSCR1; dbSNP:rs746970700)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	G423R	P07949/G423R	RET/G423R	VARIANT	G -> R (in HSCR1; dbSNP:rs767601598)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	A432E	P07949/A432E	RET/A432E	VARIANT	A -> E (found in a patient with congenital central hypoventilation syndrome; unknown pathological significance; dbSNP:rs552057730)	ECO:0000269|PubMed:14566559	14566559		
P07949	RET	R475Q	P07949/R475Q	RET/R475Q	VARIANT	R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)				
P07949	RET	E480K	P07949/E480K	RET/E480K	VARIANT	E -> K (in HSCR1; dbSNP:rs537874538)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	C531CEEC	P07949/C531CEEC	RET/C531CEEC	VARIANT	C -> CEEC (in MTC; familial form)	ECO:0000269|PubMed:10323403	10323403		
P07949	RET	G593E	P07949/G593E	RET/G593E	VARIANT	G -> E (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P07949	RET	E595Q	P07949/E595Q	RET/E595Q	VARIANT	E -> Q (in HSCR1; dbSNP:rs1483605155)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	C609G	P07949/C609G	RET/C609G	VARIANT	C -> G (in MEN2A; dbSNP:rs77558292)				
P07949	RET	C609R	P07949/C609R	RET/C609R	VARIANT	C -> R (in MEN2A; dbSNP:rs77558292)				
P07949	RET	C609W	P07949/C609W	RET/C609W	VARIANT	C -> W (in HSCR1; familial form; dbSNP:rs377767396)	ECO:0000269|PubMed:7881414	7881414		
P07949	RET	C609Y	P07949/C609Y	RET/C609Y	VARIANT	C -> Y (in MTC, MEN2A and HSCR1; familial and sporadic forms; dbSNP:rs77939446)	ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613, ECO:0000269|Ref.63	7633441,7849720,9384613		
P07949	RET	C611G	P07949/C611G	RET/C611G	VARIANT	C -> G (in MTC; familial form; dbSNP:rs377767391)	ECO:0000269|PubMed:9677065	9677065		
P07949	RET	C611R	P07949/C611R	RET/C611R	VARIANT	C -> R (in MEN2A; dbSNP:rs377767391)				
P07949	RET	C611S	P07949/C611S	RET/C611S	VARIANT	C -> S (in MEN2A; dbSNP:rs377767391)				
P07949	RET	C611W	P07949/C611W	RET/C611W	VARIANT	C -> W (in MEN2A and MTC; familial form; dbSNP:rs80069458)	ECO:0000269|PubMed:8103403	8103403		
P07949	RET	C611Y	P07949/C611Y	RET/C611Y	VARIANT	C -> Y (in MEN2A; dbSNP:rs377767397)				
P07949	RET	C618F	P07949/C618F	RET/C618F	VARIANT	C -> F (in MEN2A and MTC; familial form; dbSNP:rs79781594)				
P07949	RET	C618G	P07949/C618G	RET/C618G	VARIANT	C -> G (in MEN2A; dbSNP:rs76262710)	ECO:0000269|PubMed:8099202	8099202		
P07949	RET	C618R	P07949/C618R	RET/C618R	VARIANT	C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)	ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:9259198	7849720,7881414,7915165,9259198		
P07949	RET	C618S	P07949/C618S	RET/C618S	VARIANT	C -> S (in MEN2A, HSCR1 and MTC; familial and sporadic forms; dbSNP:rs79781594)	ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613	7849720,7860065,7915165,8103403,9384613		
P07949	RET	C618Y	P07949/C618Y	RET/C618Y	VARIANT	C -> Y (in MEN2A and MTC; familial form; dbSNP:rs79781594)				
P07949	RET	C620F	P07949/C620F	RET/C620F	VARIANT	C -> F (in MEN2A and MTC; familial form; dbSNP:rs77503355)	ECO:0000269|PubMed:7915165	7915165		
P07949	RET	C620G	P07949/C620G	RET/C620G	VARIANT	C -> G (in MEN2A and MTC; familial and sporadic forms; dbSNP:rs77316810)				
P07949	RET	C620R	P07949/C620R	RET/C620R	VARIANT	C -> R (in MEN2A, MTC and HSCR1; familial and sporadic forms; dbSNP:rs77316810)	ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9384613, ECO:0000269|Ref.63	7633441,7881414,7915165,8103403,9090527,9384613		
P07949	RET	C620S	P07949/C620S	RET/C620S	VARIANT	C -> S (in MEN2A and MTC; familial form; dbSNP:rs77503355)	ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7860065	78,497,207,860,065		
P07949	RET	C620W	P07949/C620W	RET/C620W	VARIANT	C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)	ECO:0000269|PubMed:9384613	9384613		
P07949	RET	C620Y	P07949/C620Y	RET/C620Y	VARIANT	C -> Y (in MEN2A; dbSNP:rs77503355)	ECO:0000269|PubMed:8103403	8103403		
P07949	RET	Q626K	P07949/Q626K	RET/Q626K	VARIANT	Q -> K (in HSCR1; sporadic form; dbSNP:rs1255575160)	ECO:0000269|PubMed:10090908	10090908		
P07949	RET	C630F	P07949/C630F	RET/C630F	VARIANT	C -> F (in MEN2A and MTC; familial form; dbSNP:rs377767405)				
P07949	RET	C630S	P07949/C630S	RET/C630S	VARIANT	C -> S (in MTC; sporadic form; dbSNP:rs377767405)				
P07949	RET	C630Y	P07949/C630Y	RET/C630Y	VARIANT	C -> Y (in MTC; familial and sporadic forms; dbSNP:rs377767405)				
P07949	RET	D631G	P07949/D631G	RET/D631G	VARIANT	D -> G (in thyroid carcinoma; somatic mutation; dbSNP:rs121913308)				
P07949	RET	C634CHELC	P07949/C634CHELC	RET/C634CHELC	VARIANT	C -> CHELC (in MEN2A)	ECO:0000269|PubMed:9097963	9097963		
P07949	RET	C634F	P07949/C634F	RET/C634F	VARIANT	C -> F (in MEN2A and pheochromocytoma; dbSNP:rs75996173)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202	12000816,7915165,8099202		
P07949	RET	C634G	P07949/C634G	RET/C634G	VARIANT	C -> G (in MEN2A and pheochromocytoma; dbSNP:rs75076352)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202	12000816,7915165,8099202		
P07949	RET	C634R	P07949/C634R	RET/C634R	VARIANT	C -> R (in MEN2A, pheochromocytoma and MTC; familial form; also found as somatic mutation in a sporadic thyroid carcinoma; dbSNP:rs75076352)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403	12000816,7860065,8103403		
P07949	RET	C634S	P07949/C634S	RET/C634S	VARIANT	C -> S (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs75076352)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:8099202	120,008,168,099,202		
P07949	RET	C634W	P07949/C634W	RET/C634W	VARIANT	C -> W (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs77709286)	ECO:0000269|PubMed:12000816	12000816		
P07949	RET	C634Y	P07949/C634Y	RET/C634Y	VARIANT	C -> Y (in MEN2A, pheochromocytoma and MTC; familial form; dbSNP:rs75996173)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202	12000816,7860065,7915165,8099202		
P07949	RET	T636TCRT	P07949/T636TCRT	RET/T636TCRT	VARIANT	T -> TCRT (in MEN2A)	ECO:0000269|PubMed:9452064	9452064		
P07949	RET	A639G	P07949/A639G	RET/A639G	VARIANT	A -> G (in MTC; sporadic form)	ECO:0000269|PubMed:11692159	11692159		
P07949	RET	A640G	P07949/A640G	RET/A640G	VARIANT	A -> G (in MEN2A; dbSNP:rs78935588)	ECO:0000269|PubMed:10522989	10522989		
P07949	RET	A641G	P07949/A641G	RET/A641G	VARIANT	A -> G (in MTC; sporadic form)	ECO:0000269|PubMed:11692159	11692159		
P07949	RET	P679L	P07949/P679L	RET/P679L	VARIANT	P -> L (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	S690P	P07949/S690P	RET/S690P	VARIANT	S -> P (in HSCR1; sporadic form)				
P07949	RET	R694Q	P07949/R694Q	RET/R694Q	VARIANT	R -> Q (in HSCR1; dbSNP:rs141185224)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	E762Q	P07949/E762Q	RET/E762Q	VARIANT	E -> Q (in HSCR1; sporadic form)	ECO:0000269|PubMed:7704557	7704557		
P07949	RET	S765P	P07949/S765P	RET/S765P	VARIANT	S -> P (in HSCR1; dbSNP:rs75075748)	ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870	7704557,8114938,9043870		
P07949	RET	S767R	P07949/S767R	RET/S767R	VARIANT	S -> R (in HSCR1; sporadic form)				
P07949	RET	E768D	P07949/E768D	RET/E768D	VARIANT	E -> D (in MTC; familial and sporadic forms; dbSNP:rs78014899)	ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338	7784092,7845675,8807338		
P07949	RET	N783S	P07949/N783S	RET/N783S	VARIANT	N -> S (in HSCR1; dbSNP:rs587778656)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	L790F	P07949/L790F	RET/L790F	VARIANT	L -> F (in MEN2A and MTC; familial form; dbSNP:rs75030001)	ECO:0000269|PubMed:9506724	9506724		
P07949	RET	Y791F	P07949/Y791F	RET/Y791F	VARIANT	Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; familial form; dbSNP:rs77724903)	ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724	12000816,9090527,9506724		
P07949	RET	V804L	P07949/V804L	RET/V804L	VARIANT	V -> L (in MTC; familial form; dbSNP:rs79658334)	ECO:0000269|PubMed:7784092	7784092		
P07949	RET	V804M	P07949/V804M	RET/V804M	VARIANT	V -> M (in MTC; familial form; dbSNP:rs79658334)	ECO:0000269|PubMed:10826520, ECO:0000269|PubMed:9452077	108,265,209,452,077		
P07949	RET	R813Q	P07949/R813Q	RET/R813Q	VARIANT	R -> Q (in HSCR1; sporadic form; dbSNP:rs1318733775)	ECO:0000269|PubMed:10090908	10090908		
P07949	RET	G830R	P07949/G830R	RET/G830R	VARIANT	G -> R (in HSCR1; dbSNP:rs200127630)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R844L	P07949/R844L	RET/R844L	VARIANT	R -> L (in MTC; familial form; dbSNP:rs55947360)	ECO:0000269|PubMed:10826520, ECO:0000269|PubMed:17344846	10826520,17344846		
P07949	RET	R873Q	P07949/R873Q	RET/R873Q	VARIANT	R -> Q (in HSCR1; sporadic form; dbSNP:rs1451004715)				
P07949	RET	A883F	P07949/A883F	RET/A883F	VARIANT	A -> F (in MEN2B; somatic mutation in sporadic medullary thyroid carcinoma; requires 2 nucleotide substitutions; dbSNP:rs377767429)	ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560	92,946,159,360,560		
P07949	RET	S891A	P07949/S891A	RET/S891A	VARIANT	S -> A (in MTC; familial form; dbSNP:rs75234356)	ECO:0000269|PubMed:9398735	9398735		
P07949	RET	F893L	P07949/F893L	RET/F893L	VARIANT	F -> L (in HSCR1; sporadic form)				
P07949	RET	R897Q	P07949/R897Q	RET/R897Q	VARIANT	R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)	ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:8114938	77,045,578,114,938		
P07949	RET	K907E	P07949/K907E	RET/K907E	VARIANT	K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)				
P07949	RET	K907T	P07949/K907T	RET/K907T	VARIANT	K -> T (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	M918T	P07949/M918T	RET/M918T	VARIANT	M -> T (in MEN2B and MTC; sporadic form; somatic mutation; also found in a patient with renal agenesis; dbSNP:rs74799832)	ECO:0000269|PubMed:18252215, ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338	18252215,7906417,7906866,7911697,8595427,8807338		
P07949	RET	E921K	P07949/E921K	RET/E921K	VARIANT	E -> K (in HSCR1; sporadic form)				
P07949	RET	S922F	P07949/S922F	RET/S922F	VARIANT	S -> F (in MTC; sporadic form; dbSNP:rs377767432)	ECO:0000269|PubMed:11692159	11692159		
P07949	RET	T946M	P07949/T946M	RET/T946M	VARIANT	T -> M (in MEN2B and MTC; familial form)				
P07949	RET	F961L	P07949/F961L	RET/F961L	VARIANT	F -> L (in HSCR1)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	R972G	P07949/R972G	RET/R972G	VARIANT	R -> G (in HSCR1; familial form; dbSNP:rs76534745)	ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:8114938	77,045,578,114,938		
P07949	RET	P973L	P07949/P973L	RET/P973L	VARIANT	P -> L (in HSCR1; familial form)	ECO:0000269|PubMed:7704557	7704557		
P07949	RET	M980T	P07949/M980T	RET/M980T	VARIANT	M -> T (in HSCR1; sporadic form)				
P07949	RET	P1039L	P07949/P1039L	RET/P1039L	VARIANT	P -> L (in HSCR1; dbSNP:rs79853121)	ECO:0000269|PubMed:9497256	9497256		
P07949	RET	P1049L	P07949/P1049L	RET/P1049L	VARIANT	P -> L (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs1490712863)	ECO:0000269|PubMed:18252215	18252215		
P07949	RET	L1052V	P07949/L1052V	RET/L1052V	VARIANT	L -> V (in HSCR1; dbSNP:rs1564501947)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	L1061P	P07949/L1061P	RET/L1061P	VARIANT	L -> P (in HSCR1; dbSNP:rs536486113)	ECO:0000269|PubMed:10484767, ECO:0000269|Ref.63	10484767		
P07949	RET	Y1062C	P07949/Y1062C	RET/Y1062C	VARIANT	Y -> C (in HSCR1; dbSNP:rs587778659)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	M1064T	P07949/M1064T	RET/M1064T	VARIANT	M -> T (in HSCR1; familial form; dbSNP:rs149513065)	ECO:0000269|PubMed:22174939	22174939		
P07949	RET	P1067S	P07949/P1067S	RET/P1067S	VARIANT	P -> S (in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP:rs775583354)	ECO:0000269|PubMed:18252215	18252215		
P07949	RET	F1112Y	P07949/F1112Y	RET/F1112Y	VARIANT	F -> Y (in a bladder transitional cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P07949	RET	D707N	P07949/D707N	RET/D707N	MUTAGEN	D->N: Impaired cleavage by caspase-3 and loss of induced cell death.	ECO:0000269|PubMed:21357690	21357690		
P07949	RET	K758R	P07949/K758R	RET/K758R	MUTAGEN	K->R: Loss of kinase activity. No effect on interaction with and dissociation from CBLC and CD2AP.	ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:21357690	1,875,338,121,357,690	loss	
P08069	IGF1R	V105L	P08069/V105L	IGF1R/V105L	VARIANT	V -> L (in a renal chromophobe sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08069	IGF1R	R739Q	P08069/R739Q	IGF1R/R739Q	VARIANT	R -> Q (in IGF1RES; leads to failure of processing of the IGF1R proreceptor to mature IGF1R; dbSNP:rs121912429)	ECO:0000269|PubMed:15928254	15928254		
P08069	IGF1R	R1337C	P08069/R1337C	IGF1R/R1337C	VARIANT	R -> C (in IGF1RES; unknown pathological significance; significant decrease in IGF1-induced DNA synthesis; significant increase in IGF1-induced AKT1 phosphorylation in patient fibroblasts; dbSNP:rs141802822)	ECO:0000269|PubMed:25040157	25040157		
P08069	IGF1R	A1347V	P08069/A1347V	IGF1R/A1347V	VARIANT	A -> V (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08069	IGF1R	Y980F	P08069/Y980F	IGF1R/Y980F	MUTAGEN	Y->F: Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7541045	104,545,687,541,045	decrease	
P08069	IGF1R	K1033A	P08069/K1033A	IGF1R/K1033A	MUTAGEN	K->A: Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1.	ECO:0000269|PubMed:7541045	7541045	loss	
P08069	IGF1R	Y1280F	P08069/Y1280F	IGF1R/Y1280F	MUTAGEN	Y->F: No effect on GRB10-binding.	ECO:0000269|PubMed:10454568	10454568		
P08069	IGF1R	Y1281F	P08069/Y1281F	IGF1R/Y1281F	MUTAGEN	Y->F: No effect on GRB10-binding.	ECO:0000269|PubMed:10454568	10454568		
P08069	IGF1R	Y1346F	P08069/Y1346F	IGF1R/Y1346F	MUTAGEN	Y->F: Loss of GRB10-binding.	ECO:0000269|PubMed:10454568	10454568		
P08581	MET	H150Y	P08581/H150Y	MET/H150Y	VARIANT	H -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1436957498)	ECO:0000269|PubMed:20949619	20949619		
P08581	MET	E168D	P08581/E168D	MET/E168D	VARIANT	E -> D (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs55985569)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20949619	17344846,20949619		
P08581	MET	N375K	P08581/N375K	MET/N375K	VARIANT	N -> K (found in lung cancer also including cases carrying EGFR mutations; unknown pathological significance; decreased hepatocyte growth factor-activated receptor activity; decreased interaction with HGF; dbSNP:rs776693512)	ECO:0000269|PubMed:28294470	28294470	decrease	
P08581	MET	C385Y	P08581/C385Y	MET/C385Y	VARIANT	C -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs752055485)	ECO:0000269|PubMed:20949619	20949619		
P08581	MET	P773L	P08581/P773L	MET/P773L	VARIANT	P -> L (in gastric cancer; dbSNP:rs771333219)	ECO:0000269|PubMed:12920089	12920089		
P08581	MET	F841V	P08581/F841V	MET/F841V	VARIANT	F -> V (in DFNB97; dbSNP:rs794728016)	ECO:0000269|PubMed:25941349	25941349		
P08581	MET	P991S	P08581/P991S	MET/P991S	VARIANT	P -> S (in gastric cancer; prolonged tyrosine phosphorylation in response to HGF/SF; transforming activity in athymic nude mice; dbSNP:rs768678989)	ECO:0000269|PubMed:11042681	11042681	increase	
P08581	MET	T992I	P08581/T992I	MET/T992I	VARIANT	T -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs56391007)	ECO:0000269|PubMed:11042681, ECO:0000269|PubMed:17053076, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20949619	11042681,17053076,17344846,20949619		
P08581	MET	Y1003S	P08581/Y1003S	MET/Y1003S	VARIANT	Y -> S (probable disease-associated variant found in lesional sample from a patient with sporadically occurring, unilateral osteofibrous dysplasia; somatic mutation; complete loss of ligand-induced CBL-mediated ubiquitination, resulting in protein stabilization)	ECO:0000269|PubMed:12244174	12244174		
P08581	MET	H1094R	P08581/H1094R	MET/H1094R	VARIANT	H -> R (in RCCP; causes malignant transformation in cell lines; dbSNP:rs121913243)	ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9563489	104,339,449,563,489		
P08581	MET	M1131T	P08581/M1131T	MET/M1131T	VARIANT	M -> T (in RCCP; germline mutation; dbSNP:rs121913668)	ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397	104,339,449,140,397		
P08581	MET	T1173I	P08581/T1173I	MET/T1173I	VARIANT	T -> I (in HCC; dbSNP:rs121913675)	ECO:0000269|PubMed:9927037	9927037		
P08581	MET	V1188L	P08581/V1188L	MET/V1188L	VARIANT	V -> L (in RCCP; germline mutation; dbSNP:rs121913669)	ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397	104,339,449,140,397		
P08581	MET	L1195V	P08581/L1195V	MET/L1195V	VARIANT	L -> V (in RCCP; somatic mutation; dbSNP:rs121913673)	ECO:0000269|PubMed:9140397	9140397		
P08581	MET	V1220I	P08581/V1220I	MET/V1220I	VARIANT	V -> I (in RCCP; germline mutation; dbSNP:rs121913670)	ECO:0000269|PubMed:9140397	9140397		
P08581	MET	D1228H	P08581/D1228H	MET/D1228H	VARIANT	D -> H (in RCCP; somatic mutation; dbSNP:rs121913671)	ECO:0000269|PubMed:9140397	9140397		
P08581	MET	D1228N	P08581/D1228N	MET/D1228N	VARIANT	D -> N (in RCCP; germline mutation; dbSNP:rs121913671)	ECO:0000269|PubMed:9140397	9140397		
P08581	MET	Y1230C	P08581/Y1230C	MET/Y1230C	VARIANT	Y -> C (in RCCP; germline mutation; dbSNP:rs121913246)	ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397	104,339,449,140,397		
P08581	MET	Y1230H	P08581/Y1230H	MET/Y1230H	VARIANT	Y -> H (in RCCP; somatic mutation; dbSNP:rs121913247)	ECO:0000269|PubMed:9140397	9140397		
P08581	MET	Y1234C	P08581/Y1234C	MET/Y1234C	VARIANT	Y -> C (in DA11; not phosphorylated in reponse to HGF; severely decreased tyrosin kinase activity; dbSNP:rs1554400286)	ECO:0000269|PubMed:30777867	30777867	decrease	
P08581	MET	K1244R	P08581/K1244R	MET/K1244R	VARIANT	K -> R (in HCC; dbSNP:rs121913677)	ECO:0000269|PubMed:9927037	9927037		
P08581	MET	M1250I	P08581/M1250I	MET/M1250I	VARIANT	M -> I (in HCC; dbSNP:rs121913676)	ECO:0000269|PubMed:9927037	9927037		
P08581	MET	M1250T	P08581/M1250T	MET/M1250T	VARIANT	M -> T (in RCCP; somatic mutation; dbSNP:rs121913245)	ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397	104,339,449,140,397		
P08581	MET	V1294I	P08581/V1294I	MET/V1294I	VARIANT	V -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1263785859)	ECO:0000269|PubMed:20949619	20949619		
P08581	MET	Y1234F	P08581/Y1234F	MET/Y1234F	MUTAGEN	Y->F: Complete loss of kinase activity and of ligand-induced ubiquitination. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1235.	ECO:0000269|PubMed:12244174, ECO:0000269|PubMed:18819921	12244174,18819921		
P08581	MET	Y1235F	P08581/Y1235F	MET/Y1235F	MUTAGEN	Y->F: Complete loss of kinase activity. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1234.	ECO:0000269|PubMed:12244174, ECO:0000269|PubMed:18819921	12244174,18819921		
P08581	MET	Y1313F	P08581/Y1313F	MET/Y1313F	MUTAGEN	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1349, F-1356 and F-1365.	ECO:0000269|PubMed:12244174	12244174		
P08581	MET	Y1349F	P08581/Y1349F	MET/Y1349F	MUTAGEN	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1356 and F-1365.	ECO:0000269|PubMed:12244174	12244174		
P08581	MET	Y1356F	P08581/Y1356F	MET/Y1356F	MUTAGEN	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1365.	ECO:0000269|PubMed:12244174	12244174		
P08581	MET	Y1365F	P08581/Y1365F	MET/Y1365F	MUTAGEN	Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1356.	ECO:0000269|PubMed:12244174	12244174		
P08631	HCK	D399G	P08631/D399G	HCK/D399G	VARIANT	D -> G (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08631	HCK	G3C	P08631/G3C	HCK/G3C	MUTAGEN	G->C: Slight palmitoylation, cytoplasmic and caveolar localization; in isoform 1;.	ECO:0000269|PubMed:11904303, ECO:0000269|PubMed:7791757	119,043,037,791,757		
P08631	HCK	G3S	P08631/G3S	HCK/G3S	MUTAGEN	G->S: Abolishes palmitoylation and localization at the cell membrane.	ECO:0000269|PubMed:11904303, ECO:0000269|PubMed:7791757	119,043,037,791,757		
P08631	HCK	G23A	P08631/G23A	HCK/G23A	MUTAGEN	G->A: Myristoylation and palmitoylation are abolished, leading to entirely cytoplasmic localization; in isoform 2.	ECO:0000269|PubMed:7791757	7791757		
P08631	HCK	C24S	P08631/C24S	HCK/C24S	MUTAGEN	C->S: Palmitoylation is abolished, some cytoplasmic and no calveolar localization; in isoform 2.	ECO:0000269|PubMed:7791757	7791757		
P08922	ROS1	Y419H	P08922/Y419H	ROS1/Y419H	VARIANT	Y -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1444274116)	ECO:0000269|PubMed:17344846	17344846		
P08922	ROS1	Q865H	P08922/Q865H	ROS1/Q865H	VARIANT	Q -> H (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08922	ROS1	K2003R	P08922/K2003R	ROS1/K2003R	VARIANT	K -> R (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08922	ROS1	F2138S	P08922/F2138S	ROS1/F2138S	VARIANT	F -> S (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P08922	ROS1	Y2274F	P08922/Y2274F	ROS1/Y2274F	MUTAGEN	Y->F: Loss of phosphorylation at Y-2274 and loss of interaction with PTPN11.	ECO:0000269|PubMed:12538861	12538861	decrease	
P08922	ROS1	Y2334F	P08922/Y2334F	ROS1/Y2334F	MUTAGEN	Y->F: Loss of phosphorylation at Y-2334 and loss of interaction with PTPN11.	ECO:0000269|PubMed:12538861	12538861	decrease	
P09619	PDGFRB	R561C	P09619/R561C	PDGFRB/R561C	VARIANT	R -> C (in IMF1; dbSNP:rs367543286)	ECO:0000269|PubMed:23731537	23731537		
P09619	PDGFRB	P584R	P09619/P584R	PDGFRB/P584R	VARIANT	P -> R (in KOGS; dbSNP:rs863224946)	ECO:0000269|PubMed:25454926	25454926		
P09619	PDGFRB	Y589H	P09619/Y589H	PDGFRB/Y589H	VARIANT	Y -> H (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P09619	PDGFRB	L658P	P09619/L658P	PDGFRB/L658P	VARIANT	L -> P (in IBGC4; no effect on protein abundance; loss of PDGF beta receptor activity; dbSNP:rs397509381)	ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395	23255827,24065723,26599395	loss	
P09619	PDGFRB	P660T	P09619/P660T	PDGFRB/P660T	VARIANT	P -> T (in IMF1; dbSNP:rs144050370)	ECO:0000269|PubMed:23731542	23731542		
P09619	PDGFRB	T882I	P09619/T882I	PDGFRB/T882I	VARIANT	T -> I (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P09619	PDGFRB	R987W	P09619/R987W	PDGFRB/R987W	VARIANT	R -> W (in IBGC4; decreased protein abundance; no effect on receptor activity; decreased PDGF signaling pathway; dbSNP:rs397509382)	ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395	23255827,24065723,26599395		
P09619	PDGFRB	E1071V	P09619/E1071V	PDGFRB/E1071V	VARIANT	E -> V (in IBGC4; no effect on protein abundance; no effect on receptor activity; decreased PDGF signaling pathway)	ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395	24065723,26599395		
P09619	PDGFRB	Y579F	P09619/Y579F	PDGFRB/Y579F	MUTAGEN	Y->F: Loss of kinase activity; when associated with F-581. Strongly reduces interaction with SRC family kinases. No effect on interaction with GRB10.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7685273	104,545,687,685,273	decrease	
P09619	PDGFRB	Y581F	P09619/Y581F	PDGFRB/Y581F	MUTAGEN	Y->F: Loss of kinase activity; when associated with F-579. No effect on interaction with GRB10.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7685273	104,545,687,685,273	decrease	
P09619	PDGFRB	K634A	P09619/K634A	PDGFRB/K634A	MUTAGEN	K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825	1314164,1846866,20494825	loss	
P09619	PDGFRB	K634R	P09619/K634R	PDGFRB/K634R	MUTAGEN	K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825	1314164,1846866,20494825	loss	
P09619	PDGFRB	Y716F	P09619/Y716F	PDGFRB/Y716F	MUTAGEN	Y->F: No effect neither on interaction with GRB10 and RASA1 nor on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164	104,545,681,314,164		
P09619	PDGFRB	Y740F	P09619/Y740F	PDGFRB/Y740F	MUTAGEN	Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-751. Strongly decreases phosphatidylinositol 3-kinase activity. No effect on interaction with GRB10 and RASA1.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:21679854	10454568,1314164,1375321,21679854		
P09619	PDGFRB	Y751F	P09619/Y751F	PDGFRB/Y751F	MUTAGEN	Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-740. Abolishes phosphatidylinositol 3-kinase activity and interaction with NCK1, and slightly reduces interaction with RASA1. No effect on interaction with GRB10.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:7692233	10454568,1314164,1375321,1653029,21679854,7692233		
P09619	PDGFRB	Y763F	P09619/Y763F	PDGFRB/Y763F	MUTAGEN	Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:1314164	1314164		
P09619	PDGFRB	Y771F	P09619/Y771F	PDGFRB/Y771F	MUTAGEN	Y->F: Loss of interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321	10454568,1314164,1375321		
P09619	PDGFRB	Y775F	P09619/Y775F	PDGFRB/Y775F	MUTAGEN	Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:1314164	1314164		
P09619	PDGFRB	Y778F	P09619/Y778F	PDGFRB/Y778F	MUTAGEN	Y->F: Strongly reduces expression levels.	ECO:0000269|PubMed:1314164	1314164		
P09619	PDGFRB	Y857F	P09619/Y857F	PDGFRB/Y857F	MUTAGEN	Y->F: Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:20494825	10454568,1314164,1653029,20494825	decrease	
P09619	PDGFRB	Y1009F	P09619/Y1009F	PDGFRB/Y1009F	MUTAGEN	Y->F: No effect on interaction with GRB10. Abolishes interaction with PLCG1; when associated with F-1021.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811	10454568,1396585,7691811		
P09619	PDGFRB	Y1021F	P09619/Y1021F	PDGFRB/Y1021F	MUTAGEN	Y->F: Strongly reduces up-regulation of cell proliferation. Abolishes interaction with PLCG1; when associated with F-1009. No effect on interaction with GRB10.	ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:21679854	10454568,1396585,17620338,21679854		
P0C1S8	WEE2	N332K	P0C1S8/N332K	WEE2/N332K	VARIANT	N -> K (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P0C1S8	WEE2	R398H	P0C1S8/R398H	WEE2/R398H	VARIANT	R -> H (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs200610853)	ECO:0000269|PubMed:17344846	17344846		
P10398	ARAF	G331C	P10398/G331C	ARAF/G331C	VARIANT	G -> C (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P10721	KIT	S451C	P10721/S451C	KIT/S451C	VARIANT	S -> C (in MASTC; unknown pathological significance)	ECO:0000269|PubMed:24289326	24289326		
P10721	KIT	A533D	P10721/A533D	KIT/A533D	VARIANT	A -> D (in MASTC; unknown pathological significance; dbSNP:rs753212327)	ECO:0000269|PubMed:15173254	15173254		
P10721	KIT	K550I	P10721/K550I	KIT/K550I	VARIANT	K -> I (in GIST; somatic mutation)	ECO:0000269|PubMed:9438854	9438854		
P10721	KIT	V559A	P10721/V559A	KIT/V559A	VARIANT	V -> A (in GIST; dbSNP:rs121913517)	ECO:0000269|PubMed:11505412	11505412		
P10721	KIT	V559D	P10721/V559D	KIT/V559D	VARIANT	V -> D (in GIST; somatic mutation; dbSNP:rs121913517)	ECO:0000269|PubMed:9438854	9438854		
P10721	KIT	E583K	P10721/E583K	KIT/E583K	VARIANT	E -> K (in PBT; dbSNP:rs121913680)	ECO:0000269|PubMed:1376329	1376329		
P10721	KIT	F584C	P10721/F584C	KIT/F584C	VARIANT	F -> C (in PBT; dbSNP:rs28933371)	ECO:0000269|PubMed:11074500	11074500		
P10721	KIT	F584L	P10721/F584L	KIT/F584L	VARIANT	F -> L (in PBT; dbSNP:rs794726671)	ECO:0000269|PubMed:1370874	1370874		
P10721	KIT	G601R	P10721/G601R	KIT/G601R	VARIANT	G -> R (in PBT)	ECO:0000269|PubMed:11074500	11074500		
P10721	KIT	L656P	P10721/L656P	KIT/L656P	VARIANT	L -> P (in PBT)	ECO:0000269|PubMed:11074500	11074500		
P10721	KIT	G664R	P10721/G664R	KIT/G664R	VARIANT	G -> R (in PBT; dbSNP:rs121913679)	ECO:0000269|PubMed:1717985	1717985		
P10721	KIT	D737N	P10721/D737N	KIT/D737N	VARIANT	D -> N (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs751005114)	ECO:0000269|PubMed:17344846	17344846		
P10721	KIT	R791G	P10721/R791G	KIT/R791G	VARIANT	R -> G (in PBT; dbSNP:rs1722708855)	ECO:0000269|PubMed:7687267	7687267		
P10721	KIT	R796G	P10721/R796G	KIT/R796G	VARIANT	R -> G (in PBT; with sensorineural deafness; dbSNP:rs121913684)	ECO:0000269|PubMed:9450866	9450866		
P10721	KIT	R804W	P10721/R804W	KIT/R804W	VARIANT	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs145602440)	ECO:0000269|PubMed:17344846	17344846		
P10721	KIT	G812V	P10721/G812V	KIT/G812V	VARIANT	G -> V (in PBT)	ECO:0000269|PubMed:7687267	7687267		
P10721	KIT	D816V	P10721/D816V	KIT/D816V	VARIANT	D -> V (in MASTSYS, MASTC and mast cell leukemia; somatic mutation; constitutively activated; loss of interaction with MPDZ; dbSNP:rs121913507)	ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7691885, ECO:0000269|PubMed:9990072	11018522,17595334,19164557,19265199,19865100,21640708,7691885,9990072	activating	
P10721	KIT	D820G	P10721/D820G	KIT/D820G	VARIANT	D -> G (in mast cell disease; systemic; dbSNP:rs121913682)	ECO:0000269|PubMed:9029028	9029028		
P10721	KIT	N822K	P10721/N822K	KIT/N822K	VARIANT	N -> K (in a germ cell tumor of the testis; somatic mutation; dbSNP:rs121913514)	ECO:0000269|PubMed:16175573, ECO:0000269|PubMed:17344846	16175573,17344846		
P10721	KIT	A829P	P10721/A829P	KIT/A829P	VARIANT	A -> P (in a germ cell tumor of the testis; somatic mutation; dbSNP:rs1057519713)	ECO:0000269|PubMed:16175573, ECO:0000269|PubMed:17344846	16175573,17344846		
P10721	KIT	T847P	P10721/T847P	KIT/T847P	VARIANT	T -> P (in PBT; dbSNP:rs121913687)	ECO:0000269|PubMed:9699740	9699740		
P10721	KIT	I571A	P10721/I571A	KIT/I571A	MUTAGEN	I->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-939.	ECO:0000269|PubMed:12444928	12444928		
P10721	KIT	K623M	P10721/K623M	KIT/K623M	MUTAGEN	K->M: Stronger interaction with MPDZ.	ECO:0000269|PubMed:11018522	11018522		
P10721	KIT	S741A	P10721/S741A	KIT/S741A	MUTAGEN	S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-746.	ECO:0000269|PubMed:7539802	7539802		
P10721	KIT	S746A	P10721/S746A	KIT/S746A	MUTAGEN	S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-741.	ECO:0000269|PubMed:7539802	7539802		
P10721	KIT	Y823F	P10721/Y823F	KIT/Y823F	MUTAGEN	Y->F: No decrease in activity. Leads to autophosphorylation at Tyr-900.	ECO:0000269|PubMed:20147452	20147452	activating	
P10721	KIT	L939A	P10721/L939A	KIT/L939A	MUTAGEN	L->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-571.	ECO:0000269|PubMed:12444928	12444928		
P11274	BCR	S400P	P11274/S400P	BCR/S400P	VARIANT	S -> P (in a bladder transitional cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P11274	BCR	E1161K	P11274/E1161K	BCR/E1161K	VARIANT	E -> K	ECO:0000269|PubMed:17344846	17344846		
P11274	BCR	Y177F	P11274/Y177F	BCR/Y177F	MUTAGEN	Y->F: Abolishes interaction with FES and GRB2.	ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:9407116	153,025,869,407,116		
P11274	BCR	R1090A	P11274/R1090A	BCR/R1090A	MUTAGEN	R->A: Loss of GAP activity. Loss of GAP activity; when associated with A-1202.	ECO:0000269|PubMed:17116687	17116687		
P11274	BCR	N1202A	P11274/N1202A	BCR/N1202A	MUTAGEN	N->A: Loss of GAP activity; when associated with A-1090.	ECO:0000269|PubMed:17116687	17116687		
P11274	BCR	V1271A	P11274/V1271A	BCR/V1271A	MUTAGEN	V->A: Reduces interaction with PDZK1. Abolishes interaction with DLG4. No effect on synaptic localization.	ECO:0000269|PubMed:15494376, ECO:0000269|PubMed:20962234	15494376,20962234		
P11309	PIM1	Y53H	P11309/Y53H	PIM1/Y53H	VARIANT	Y -> H (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P11362	FGFR1	W4C	P11362/W4C	FGFR1/W4C	VARIANT	W -> C (in HH2; unknown pathological significance; dbSNP:rs760884357)	ECO:0000269|PubMed:26277103	26277103		
P11362	FGFR1	G48S	P11362/G48S	FGFR1/G48S	VARIANT	G -> S (in HH2; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; dbSNP:rs121909640)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	G70R	P11362/G70R	FGFR1/G70R	VARIANT	G -> R (in HH2; dbSNP:rs140254426)	ECO:0000269|PubMed:25077900	25077900		
P11362	FGFR1	R78C	P11362/R78C	FGFR1/R78C	VARIANT	R -> C (in HH2; dbSNP:rs1554570706)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	S96C	P11362/S96C	FGFR1/S96C	VARIANT	S -> C (in HH2; unknown pathological significance)	ECO:0000269|PubMed:26277103	26277103		
P11362	FGFR1	G97D	P11362/G97D	FGFR1/G97D	VARIANT	G -> D (in HH2)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	Y99C	P11362/Y99C	FGFR1/Y99C	VARIANT	Y -> C (in HH2; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression; dbSNP:rs727505373)	ECO:0000269|PubMed:12627230, ECO:0000269|PubMed:19820032	12627230,19820032		
P11362	FGFR1	C101F	P11362/C101F	FGFR1/C101F	VARIANT	C -> F (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	V102I	P11362/V102I	FGFR1/V102I	VARIANT	V -> I (in HH2; dbSNP:rs55642501)	ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:16764984	15605412,16764984		
P11362	FGFR1	V116I	P11362/V116I	FGFR1/V116I	VARIANT	V -> I (in HH2; dbSNP:rs747842199)	ECO:0000269|PubMed:25077900	25077900		
P11362	FGFR1	N117S	P11362/N117S	FGFR1/N117S	VARIANT	N -> S (in HH2; some patients also carry GNRHR mutations; dbSNP:rs780765366)	ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382	19820032,23643382		
P11362	FGFR1	S125L	P11362/S125L	FGFR1/S125L	VARIANT	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs121913473)	ECO:0000269|PubMed:17344846	17344846		
P11362	FGFR1	D129A	P11362/D129A	FGFR1/D129A	VARIANT	D -> A (in HH2; dbSNP:rs765615419)	ECO:0000269|PubMed:15605412	15605412		
P11362	FGFR1	L165S	P11362/L165S	FGFR1/L165S	VARIANT	L -> S (in HRTFDS; dbSNP:rs397515481)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	A167S	P11362/A167S	FGFR1/A167S	VARIANT	A -> S (in HH2; with cleft palate, corpus callosum agenesis, unilateral deafness and fusion of fourth and fifth metacarpal bones; dbSNP:rs121909630)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	V174A	P11362/V174A	FGFR1/V174A	VARIANT	V -> A (in HH2)	ECO:0000269|PubMed:25077900	25077900		
P11362	FGFR1	C178S	P11362/C178S	FGFR1/C178S	VARIANT	C -> S (in HH2; with severe ear anomalies)	ECO:0000269|PubMed:16757108	16757108		
P11362	FGFR1	L191S	P11362/L191S	FGFR1/L191S	VARIANT	L -> S (in HRTFDS; dbSNP:rs869025669)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	D224H	P11362/D224H	FGFR1/D224H	VARIANT	D -> H (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	Y228D	P11362/Y228D	FGFR1/Y228D	VARIANT	Y -> D (in HH2; some patients also carry KISS1R mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)	ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382	19820032,23643382		
P11362	FGFR1	G237D	P11362/G237D	FGFR1/G237D	VARIANT	G -> D (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	G237S	P11362/G237S	FGFR1/G237S	VARIANT	G -> S (in HH2; with or without anosmia; also found in a family member with isolated anosmia; may impair proper folding; dbSNP:rs121909635)	ECO:0000269|PubMed:16606836	16606836		
P11362	FGFR1	I239T	P11362/I239T	FGFR1/I239T	VARIANT	I -> T (in HH2; some patients also carry PROKR2 and GNRH1 mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)	ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382	19820032,23643382		
P11362	FGFR1	L245P	P11362/L245P	FGFR1/L245P	VARIANT	L -> P (in HH2)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	R250Q	P11362/R250Q	FGFR1/R250Q	VARIANT	R -> Q (in HH2; with or without anosmia; results in Kallmann syndrome in the presence of HS6ST1 mutation TRP-306; reduces receptor affinity for fibroblast growth factor; dbSNP:rs121909645)	ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900	19820032,21700882,23643382,25077900		
P11362	FGFR1	R250W	P11362/R250W	FGFR1/R250W	VARIANT	R -> W (in HH2)	ECO:0000269|PubMed:16882753, ECO:0000269|PubMed:17154279	16882753,17154279		
P11362	FGFR1	P252R	P11362/P252R	FGFR1/P252R	VARIANT	P -> R (in PS and JWS; dbSNP:rs121909627)	ECO:0000269|PubMed:10861678, ECO:0000269|PubMed:7874169	108,616,787,874,169		
P11362	FGFR1	P252T	P11362/P252T	FGFR1/P252T	VARIANT	P -> T (in a lung bronchoalveolar carcinoma sample; somatic mutation; dbSNP:rs121913472)	ECO:0000269|PubMed:17344846	17344846		
P11362	FGFR1	R254Q	P11362/R254Q	FGFR1/R254Q	VARIANT	R -> Q (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	G270D	P11362/G270D	FGFR1/G270D	VARIANT	G -> D (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	V273M	P11362/V273M	FGFR1/V273M	VARIANT	V -> M (in HH2; dbSNP:rs1131691929)	ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:16764984	15605412,16764984		
P11362	FGFR1	E274G	P11362/E274G	FGFR1/E274G	VARIANT	E -> G (in HH2; also found in a family member with isolated anosmia; dbSNP:rs727505369)				
P11362	FGFR1	C277Y	P11362/C277Y	FGFR1/C277Y	VARIANT	C -> Y (in HH2)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	P283R	P11362/P283R	FGFR1/P283R	VARIANT	P -> R (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	I300T	P11362/I300T	FGFR1/I300T	VARIANT	I -> T (in TRIGNO1; dbSNP:rs121909633)	ECO:0000269|PubMed:11173846	11173846		
P11362	FGFR1	N330I	P11362/N330I	FGFR1/N330I	VARIANT	N -> I (in OGD; dbSNP:rs121909632)	ECO:0000269|PubMed:15625620, ECO:0000269|PubMed:16470795	15625620,16470795		
P11362	FGFR1	S332C	P11362/S332C	FGFR1/S332C	VARIANT	S -> C (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	Y339C	P11362/Y339C	FGFR1/Y339C	VARIANT	Y -> C (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	L342S	P11362/L342S	FGFR1/L342S	VARIANT	L -> S (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a splice site mutation in NSMF; dbSNP:rs121909638)	ECO:0000269|PubMed:23643382	23643382		
P11362	FGFR1	A343V	P11362/A343V	FGFR1/A343V	VARIANT	A -> V (in HH2)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	S346C	P11362/S346C	FGFR1/S346C	VARIANT	S -> C (in HH2; also found in a family member with isolated anosmia)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	G348R	P11362/G348R	FGFR1/G348R	VARIANT	G -> R (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a mutation in IL17RD; dbSNP:rs886037634)	ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900	2,364,338,225,077,900		
P11362	FGFR1	P366L	P11362/P366L	FGFR1/P366L	VARIANT	P -> L (in HH2; with or without anosmia; dbSNP:rs121909641)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	Y374C	P11362/Y374C	FGFR1/Y374C	VARIANT	Y -> C (in OGD; elevated basal activity and increased FGF2-mediated activity; dbSNP:rs121909631)	ECO:0000269|PubMed:15625620	15625620	increase	
P11362	FGFR1	C381R	P11362/C381R	FGFR1/C381R	VARIANT	C -> R (in OGD; dbSNP:rs121909634)	ECO:0000269|PubMed:15625620, ECO:0000269|PubMed:16470795	15625620,16470795		
P11362	FGFR1	R470L	P11362/R470L	FGFR1/R470L	VARIANT	R -> L (in HH2; some patients also carry GNRHR mutations; dbSNP:rs121909637)	ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382	19820032,23643382		
P11362	FGFR1	P483T	P11362/P483T	FGFR1/P483T	VARIANT	P -> T (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in SPRY4; dbSNP:rs397515444)	ECO:0000269|PubMed:23643382	23643382		
P11362	FGFR1	G490R	P11362/G490R	FGFR1/G490R	VARIANT	G -> R (in HRTFDS; dbSNP:rs869025670)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	A520T	P11362/A520T	FGFR1/A520T	VARIANT	A -> T (in HH2; dbSNP:rs749758370)	ECO:0000269|PubMed:15605412	15605412		
P11362	FGFR1	I538V	P11362/I538V	FGFR1/I538V	VARIANT	I -> V (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	N546K	P11362/N546K	FGFR1/N546K	VARIANT	N -> K (in ECCL; somatic mutation; activating mutation; strongly increased speed of the first autophosphorylation and loss of the normal sequential order of autophosphorylation; dbSNP:rs779707422)	ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:26942290	1,922,489,726,942,290	activating	
P11362	FGFR1	V561M	P11362/V561M	FGFR1/V561M	VARIANT	V -> M	ECO:0000269|PubMed:26942290	26942290		
P11362	FGFR1	V607M	P11362/V607M	FGFR1/V607M	VARIANT	V -> M (in HH2; with bimanual synkinesis; dbSNP:rs121909629)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	H621R	P11362/H621R	FGFR1/H621R	VARIANT	H -> R (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	R622G	P11362/R622G	FGFR1/R622G	VARIANT	R -> G (in HH2; with severe ear anomalies; dbSNP:rs121909628)	ECO:0000269|PubMed:16757108	16757108		
P11362	FGFR1	R622Q	P11362/R622Q	FGFR1/R622Q	VARIANT	R -> Q (in HH2)	ECO:0000269|PubMed:16757108	16757108		
P11362	FGFR1	D623Y	P11362/D623Y	FGFR1/D623Y	VARIANT	D -> Y (in HRTFDS; dbSNP:rs398122946)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	R627T	P11362/R627T	FGFR1/R627T	VARIANT	R -> T (in HRTFDS; dbSNP:rs869025671)	ECO:0000269|PubMed:24888332	24888332		
P11362	FGFR1	N628K	P11362/N628K	FGFR1/N628K	VARIANT	N -> K (in HRTFDS; dbSNP:rs869025672)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	K656E	P11362/K656E	FGFR1/K656E	VARIANT	K -> E (in ECCL; somatic mutation; dbSNP:rs869320694)	ECO:0000269|PubMed:26942290	26942290		
P11362	FGFR1	V664L	P11362/V664L	FGFR1/V664L	VARIANT	V -> L (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P11362	FGFR1	W666R	P11362/W666R	FGFR1/W666R	VARIANT	W -> R (in HH2; with cleft palate; dbSNP:rs1563433902)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	E670K	P11362/E670K	FGFR1/E670K	VARIANT	E -> K (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in FLRT3; dbSNP:rs397515446)	ECO:0000269|PubMed:23643382	23643382		
P11362	FGFR1	A671P	P11362/A671P	FGFR1/A671P	VARIANT	A -> P (in HH2)	ECO:0000269|PubMed:19820032	19820032		
P11362	FGFR1	S685F	P11362/S685F	FGFR1/S685F	VARIANT	S -> F (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	G687R	P11362/G687R	FGFR1/G687R	VARIANT	G -> R (in HH2; dbSNP:rs727505376)	ECO:0000269|PubMed:15845591, ECO:0000269|PubMed:22927827	15845591,22927827		
P11362	FGFR1	E692G	P11362/E692G	FGFR1/E692G	VARIANT	E -> G (in HH2; phenotype consistent with Kallmann syndrome; the patient also carries a rare variant in DUSP6; dbSNP:rs397515445)	ECO:0000269|PubMed:23643382	23643382		
P11362	FGFR1	I693F	P11362/I693F	FGFR1/I693F	VARIANT	I -> F (in HH2)	ECO:0000269|PubMed:17154279	17154279		
P11362	FGFR1	G703R	P11362/G703R	FGFR1/G703R	VARIANT	G -> R (in HH2)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	G703S	P11362/G703S	FGFR1/G703S	VARIANT	G -> S (in HH2; dbSNP:rs768957161)	ECO:0000269|PubMed:16764984	16764984		
P11362	FGFR1	M719R	P11362/M719R	FGFR1/M719R	VARIANT	M -> R (in HH2)	ECO:0000269|PubMed:12627230	12627230		
P11362	FGFR1	M719V	P11362/M719V	FGFR1/M719V	VARIANT	M -> V (in HH2; unknown pathological significance; dbSNP:rs1085307879)	ECO:0000269|PubMed:26277103	26277103		
P11362	FGFR1	P722H	P11362/P722H	FGFR1/P722H	VARIANT	P -> H (in HH2; associated with K-724; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606805)	ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:23643382	16606836,23643382		
P11362	FGFR1	P722S	P11362/P722S	FGFR1/P722S	VARIANT	P -> S (in HH2; dbSNP:rs121909642)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	N724K	P11362/N724K	FGFR1/N724K	VARIANT	N -> K (in HH2; associated with H-722; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606806)	ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:23643382	16606836,23643382		
P11362	FGFR1	C725Y	P11362/C725Y	FGFR1/C725Y	VARIANT	C -> Y (in HRTFDS; dbSNP:rs398122945)	ECO:0000269|PubMed:23812909	23812909		
P11362	FGFR1	P745S	P11362/P745S	FGFR1/P745S	VARIANT	P -> S (in HH2)	ECO:0000269|PubMed:15001591, ECO:0000269|PubMed:15845591	15001591,15845591		
P11362	FGFR1	D768Y	P11362/D768Y	FGFR1/D768Y	VARIANT	D -> Y (in HH2; the patient also carries a rare variant in FGF8; dbSNP:rs121909644)	ECO:0000269|PubMed:23643382	23643382		
P11362	FGFR1	V795I	P11362/V795I	FGFR1/V795I	VARIANT	V -> I (in HH2; also found in a family member with isolated anosmia; dbSNP:rs781328162)	ECO:0000269|PubMed:16882753	16882753		
P11362	FGFR1	R577E	P11362/R577E	FGFR1/R577E	MUTAGEN	R->E: Strongly reduced autophosphorylation in response to FGF signaling. No effect on in vitro kinase activity.	ECO:0000269|PubMed:20133753	20133753	decrease	
P11362	FGFR1	R609V	P11362/R609V	FGFR1/R609V	MUTAGEN	R->V: Abolishes interaction with PLCG1.				
P11362	FGFR1	Y653F	P11362/Y653F	FGFR1/Y653F	MUTAGEN	Y->F: No effect on kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-654.	ECO:0000269|PubMed:8622701	8622701		
P11362	FGFR1	Y654F	P11362/Y654F	FGFR1/Y654F	MUTAGEN	Y->F: Reduced kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-653.	ECO:0000269|PubMed:8622701	8622701	decrease	
P11362	FGFR1	D755V	P11362/D755V	FGFR1/D755V	MUTAGEN	D->V: Abolishes interaction with PLCG1.				
P11362	FGFR1	Y766F	P11362/Y766F	FGFR1/Y766F	MUTAGEN	Y->F: Abolishes interaction with PLCG1 and SHB. Decreases phosphorylation of FRS2, activation of RAS and			decrease	
P11801	PSKH1	D218A	P11801/D218A	PSKH1/D218A	MUTAGEN	D->A: Loss of autophosphorylation.	ECO:0000269|PubMed:11087665	11087665	decrease	
P11802	CDK4	R24C	P11802/R24C	CDK4/R24C	VARIANT	R -> C (in CMM3; somatic and familial; generates a dominant oncogene resistant to inhibition by p16(INK4a); dbSNP:rs11547328)	ECO:0000269|PubMed:7652577, ECO:0000269|PubMed:8528263	76,525,778,528,263		
P11802	CDK4	R24H	P11802/R24H	CDK4/R24H	VARIANT	R -> H (in CMM3; dbSNP:rs104894340)	ECO:0000269|PubMed:9425228	9425228		
P11802	CDK4	N41S	P11802/N41S	CDK4/N41S	VARIANT	N -> S (in CMM3; sporadic; dbSNP:rs144890720)	ECO:0000269|PubMed:9311594	9311594		
P11802	CDK4	T172A	P11802/T172A	CDK4/T172A	MUTAGEN	T->A: Weak enzyme activity towards RB1, but no effect on binding of CCDN1 nor CCDN3.	ECO:0000269|PubMed:16782892	16782892	decrease	
P11802	CDK4	T172E	P11802/T172E	CDK4/T172E	MUTAGEN	T->E: Retains moderate enzyme activity.	ECO:0000269|PubMed:16782892	16782892		
P11802	CDK4	P173S	P11802/P173S	CDK4/P173S	MUTAGEN	P->S: No effect on in vitro phosphorylation by CDK7. Greatly reduced T-172 phosphorylation and enzyme activity.	ECO:0000269|PubMed:19487459	19487459	decrease	
P12931	SRC	P302E	P12931/P302E	SRC/P302E	MUTAGEN	P->E: Kinase active. Interacts with PDLIM4; when associated with E-307 and F-419.	ECO:0000269|PubMed:19307596	19307596		
P12931	SRC	P307E	P12931/P307E	SRC/P307E	MUTAGEN	P->E: Kinase active. Interacts with PDLIM4; when associated with E-302 and F-419.	ECO:0000269|PubMed:19307596	19307596		
P14616	INSRR	E278Q	P14616/E278Q	INSRR/E278Q	VARIANT	E -> Q (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P14616	INSRR	G1065E	P14616/G1065E	INSRR/G1065E	VARIANT	G -> E (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P15056	BRAF	T241M	P15056/T241M	BRAF/T241M	VARIANT	T -> M (in NS7; dbSNP:rs387906660)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	T241P	P15056/T241P	BRAF/T241P	VARIANT	T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)	ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	18042262,19206169		
P15056	BRAF	T241R	P15056/T241R	BRAF/T241R	VARIANT	T -> R (in NS7; dbSNP:rs387906660)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	T244P	P15056/T244P	BRAF/T244P	VARIANT	T -> P (in CFC1; dbSNP:rs397507465)	ECO:0000269|PubMed:18042262	18042262		
P15056	BRAF	L245F	P15056/L245F	BRAF/L245F	VARIANT	L -> F (in CFC1; dbSNP:rs397507466)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	A246P	P15056/A246P	BRAF/A246P	VARIANT	A -> P (in CFC1; dbSNP:rs180177034)	ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	16474404,18042262,19206169		
P15056	BRAF	Q257R	P15056/Q257R	BRAF/Q257R	VARIANT	Q -> R (in CFC1; dbSNP:rs180177035)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	16439621,16474404,18042262,19206169		
P15056	BRAF	Q262K	P15056/Q262K	BRAF/Q262K	VARIANT	Q -> K (in CFC1; dbSNP:rs397507470)	ECO:0000269|PubMed:18042262	18042262		
P15056	BRAF	E275K	P15056/E275K	BRAF/E275K	VARIANT	E -> K (in CFC1)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	R462I	P15056/R462I	BRAF/R462I	VARIANT	R -> I (in CRC; dbSNP:rs180177032)	ECO:0000269|PubMed:12198537	12198537		
P15056	BRAF	I463S	P15056/I463S	BRAF/I463S	VARIANT	I -> S (in CRC; dbSNP:rs180177033)	ECO:0000269|PubMed:12198537	12198537		
P15056	BRAF	G464E	P15056/G464E	BRAF/G464E	VARIANT	G -> E (in CRC; dbSNP:rs121913348)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:12198537	12068308,12198537		
P15056	BRAF	G466A	P15056/G466A	BRAF/G466A	VARIANT	G -> A (in melanoma; dbSNP:rs121913351)	ECO:0000269|PubMed:12068308	12068308		
P15056	BRAF	G466E	P15056/G466E	BRAF/G466E	VARIANT	G -> E (in melanoma; dbSNP:rs121913351)	ECO:0000269|PubMed:12068308	12068308		
P15056	BRAF	G466V	P15056/G466V	BRAF/G466V	VARIANT	G -> V (in LNCR; dbSNP:rs121913351)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:12460919	12068308,12460919		
P15056	BRAF	S467A	P15056/S467A	BRAF/S467A	VARIANT	S -> A (in CFC1; dbSNP:rs869025606)	ECO:0000269|PubMed:16439621	16439621		
P15056	BRAF	F468S	P15056/F468S	BRAF/F468S	VARIANT	F -> S (in CFC1; dbSNP:rs397507473)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262	16439621,18042262		
P15056	BRAF	G469E	P15056/G469E	BRAF/G469E	VARIANT	G -> E (in CFC1 and colon cancer; dbSNP:rs121913355)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	12068308,16439621,16474404,18042262,19206169		
P15056	BRAF	G469R	P15056/G469R	BRAF/G469R	VARIANT	G -> R (in NHL; dbSNP:rs121913357)	ECO:0000269|PubMed:14612909	14612909		
P15056	BRAF	G469V	P15056/G469V	BRAF/G469V	VARIANT	G -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913355)	ECO:0000269|PubMed:17344846	17344846		
P15056	BRAF	L485F	P15056/L485F	BRAF/L485F	VARIANT	L -> F (in CFC1; dbSNP:rs180177036)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169	16439621,16474404,19206169		
P15056	BRAF	K499E	P15056/K499E	BRAF/K499E	VARIANT	K -> E (in CFC1; dbSNP:rs180177037)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262	16439621,16474404,18042262		
P15056	BRAF	K499N	P15056/K499N	BRAF/K499N	VARIANT	K -> N (in CFC1; dbSNP:rs397507476)	ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	18042262,19206169		
P15056	BRAF	E501G	P15056/E501G	BRAF/E501G	VARIANT	E -> G (in CFC1; dbSNP:rs180177039)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404	16439621,16474404		
P15056	BRAF	E501K	P15056/E501K	BRAF/E501K	VARIANT	E -> K (in CFC1; dbSNP:rs180177038)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169	16439621,16474404,19206169		
P15056	BRAF	L525P	P15056/L525P	BRAF/L525P	VARIANT	L -> P (in CFC1; dbSNP:rs869025340)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	W531C	P15056/W531C	BRAF/W531C	VARIANT	W -> C (in NS7; dbSNP:rs606231228)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	N580D	P15056/N580D	BRAF/N580D	VARIANT	N -> D (in CFC1)	ECO:0000269|PubMed:18042262	18042262		
P15056	BRAF	N581D	P15056/N581D	BRAF/N581D	VARIANT	N -> D (in CFC1; dbSNP:rs180177040)	ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262	16439621,16474404,18042262		
P15056	BRAF	N581S	P15056/N581S	BRAF/N581S	VARIANT	N -> S (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913370)	ECO:0000269|PubMed:17344846	17344846		
P15056	BRAF	E586K	P15056/E586K	BRAF/E586K	VARIANT	E -> K (in ovarian cancer; dbSNP:rs121913340)	ECO:0000269|PubMed:12068308	12068308		
P15056	BRAF	D594G	P15056/D594G	BRAF/D594G	VARIANT	D -> G (in NHL; dbSNP:rs121913338)	ECO:0000269|PubMed:14612909	14612909		
P15056	BRAF	F595L	P15056/F595L	BRAF/F595L	VARIANT	F -> L (in CFC1; also found in colon cancer; dbSNP:rs121913341)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169	12068308,16439621,18042262,19206169		
P15056	BRAF	G596R	P15056/G596R	BRAF/G596R	VARIANT	G -> R (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs121913361)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:17344846	12068308,17344846		
P15056	BRAF	G596V	P15056/G596V	BRAF/G596V	VARIANT	G -> V (in CFC1; dbSNP:rs397507483)	ECO:0000269|PubMed:16439621	16439621		
P15056	BRAF	L597R	P15056/L597R	BRAF/L597R	VARIANT	L -> R (in LNCR; also found in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs121913366)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846	12068308,12460919,17344846		
P15056	BRAF	T599R	P15056/T599R	BRAF/T599R	VARIANT	T -> R (in CFC1; dbSNP:rs121913375)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	V600D	P15056/V600D	BRAF/V600D	VARIANT	V -> D (in a melanoma cell line; requires 2 nucleotide substitutions; dbSNP:rs121913377)	ECO:0000269|PubMed:12068308	12068308		
P15056	BRAF	V600E	P15056/V600E	BRAF/V600E	VARIANT	V -> E (in CRC; also found in sarcoma, metastatic melanoma, ovarian serous carcinoma, pilocytic astrocytoma; somatic mutation; most common mutation; constitutive and elevated kinase activity; efficiently induces cell transformation; suppression of mutation in melanoma causes growth arrest and promotes apoptosis; loss of regulation by PMRT5; dbSNP:rs113488022)	ECO:0000269|PubMed:12068308, ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24455489	12068308,12198537,14500344,16959974,17344846,21917714,23263490,24455489	activating	
P15056	BRAF	K601E	P15056/K601E	BRAF/K601E	VARIANT	K -> E (in CRC; dbSNP:rs121913364)	ECO:0000269|PubMed:12198537	12198537		
P15056	BRAF	K601Q	P15056/K601Q	BRAF/K601Q	VARIANT	K -> Q (in CFC1; dbSNP:rs121913364)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	D638E	P15056/D638E	BRAF/D638E	VARIANT	D -> E (in CFC1; dbSNP:rs180177042)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	Q709R	P15056/Q709R	BRAF/Q709R	VARIANT	Q -> R (in CFC1; dbSNP:rs397507486)	ECO:0000269|PubMed:19206169	19206169		
P15056	BRAF	M53D	P15056/M53D	BRAF/M53D	MUTAGEN	M->D: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1.	ECO:0000269|PubMed:29433126	29433126	decrease	
P15056	BRAF	K88E	P15056/K88E	BRAF/K88E	MUTAGEN	K->E: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1.	ECO:0000269|PubMed:29433126	29433126	decrease	
P15056	BRAF	R509H	P15056/R509H	BRAF/R509H	MUTAGEN	R->H: Loss of MAP2K1-mediated-BRAF-KSR1 dimerization.	ECO:0000269|PubMed:29433126	29433126	loss	
P15056	BRAF	K578R	P15056/K578R	BRAF/K578R	MUTAGEN	K->R: Blocks EGF-induced ubiquitination and ERK activation.	ECO:0000269|PubMed:23907581	23907581	loss	
P15056	BRAF	I666R	P15056/I666R	BRAF/I666R	MUTAGEN	I->R: No effect on MAP2K1-mediated-BRAF-KSR1 dimerization, however loss of BRAF-mediated phosphorylation of MAP2K1.	ECO:0000269|PubMed:29433126	29433126	decrease	
P15735	PHKG2	V106E	P15735/V106E	PHKG2/V106E	VARIANT	V -> E (in GSD9C; dbSNP:rs137853589)	ECO:0000269|PubMed:8896567	8896567		
P15735	PHKG2	E157K	P15735/E157K	PHKG2/E157K	VARIANT	E -> K (in GSD9C; dbSNP:rs752961445)	ECO:0000269|PubMed:12930917	12930917		
P15735	PHKG2	G189E	P15735/G189E	PHKG2/G189E	VARIANT	G -> E (in GSD9C; dbSNP:rs137853588)	ECO:0000269|PubMed:8896567	8896567		
P15735	PHKG2	D215N	P15735/D215N	PHKG2/D215N	VARIANT	D -> N (in GSD9C; dbSNP:rs767427889)	ECO:0000269|PubMed:12930917	12930917		
P16066	NPR1	F270C	P16066/F270C	NPR1/F270C	VARIANT	F -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P16234	PDGFRA	R481G	P16234/R481G	PDGFRA/R481G	VARIANT	R -> G (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	ECO:0000269|PubMed:21224473	21224473		
P16234	PDGFRA	L507P	P16234/L507P	PDGFRA/L507P	VARIANT	L -> P (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	ECO:0000269|PubMed:21224473	21224473		
P16234	PDGFRA	I562M	P16234/I562M	PDGFRA/I562M	VARIANT	I -> M (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	ECO:0000269|PubMed:21224473	21224473		
P16234	PDGFRA	H570R	P16234/H570R	PDGFRA/H570R	VARIANT	H -> R (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	ECO:0000269|PubMed:21224473	21224473		
P16234	PDGFRA	P653L	P16234/P653L	PDGFRA/P653L	VARIANT	P -> L (in GISTPS; unknown pathological significance)	ECO:0000269|PubMed:25975287	25975287		
P16234	PDGFRA	L705P	P16234/L705P	PDGFRA/L705P	VARIANT	L -> P (in a hypereosinophilic syndrome sample; does not lead to constitutive kinase activation)	ECO:0000269|PubMed:21224473	21224473		
P16234	PDGFRA	G829R	P16234/G829R	PDGFRA/G829R	VARIANT	G -> R (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P16234	PDGFRA	D846Y	P16234/D846Y	PDGFRA/D846Y	VARIANT	D -> Y (in GISTPS; unknown pathological significance; dbSNP:rs121908588)	ECO:0000269|PubMed:14699510	14699510		
P16234	PDGFRA	Y849C	P16234/Y849C	PDGFRA/Y849C	VARIANT	Y -> C (in GIST)	ECO:0000269|PubMed:15928335	15928335		
P16234	PDGFRA	E996K	P16234/E996K	PDGFRA/E996K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs779173667)	ECO:0000269|PubMed:17344846	17344846		
P16234	PDGFRA	D1071N	P16234/D1071N	PDGFRA/D1071N	VARIANT	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs376544204)	ECO:0000269|PubMed:17344846	17344846		
P16234	PDGFRA	Y572F	P16234/Y572F	PDGFRA/Y572F	MUTAGEN	Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-574.	ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:14644164	10734113,14644164		
P16234	PDGFRA	Y574F	P16234/Y574F	PDGFRA/Y574F	MUTAGEN	Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-572.	ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:14644164	10734113,14644164		
P16234	PDGFRA	Y720F	P16234/Y720F	PDGFRA/Y720F	MUTAGEN	Y->F: Strongly reduced interaction with PTPN11 and GRB2.	ECO:0000269|PubMed:8943348	8943348		
P16234	PDGFRA	Y731F	P16234/Y731F	PDGFRA/Y731F	MUTAGEN	Y->F: No effect on autophosphorylation and phosphorylation of PLCG1. Abolishes activation of phosphatidylinositol 3-kinase.	ECO:0000269|PubMed:1646396	1646396	decrease	
P16234	PDGFRA	Y742F	P16234/Y742F	PDGFRA/Y742F	MUTAGEN	Y->F: No effect on autophosphorylation and phosphorylation of PLCG1. Abolishes activation of phosphatidylinositol 3-kinase.	ECO:0000269|PubMed:1646396	1646396	decrease	
P16234	PDGFRA	Y762F	P16234/Y762F	PDGFRA/Y762F	MUTAGEN	Y->F: Abolishes interaction with CRK.	ECO:0000269|PubMed:10733900	10733900		
P16591	FER	E404Q	P16591/E404Q	FER/E404Q	VARIANT	E -> Q (in an ovarian Endometrioid carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P16591	FER	W460C	P16591/W460C	FER/W460C	VARIANT	W -> C (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P17252	PRKCA	P98S	P17252/P98S	PRKCA/P98S	VARIANT	P -> S (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P17252	PRKCA	D467N	P17252/D467N	PRKCA/D467N	VARIANT	D -> N (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P17612	PRKACA	G137R	P17612/G137R	PRKACA/G137R	VARIANT	G -> R (in CAFD1; decreased interaction with regulatory subunit PRKAR2B)	ECO:0000269|PubMed:33058759	33058759		
P17612	PRKACA	K48R	P17612/K48R	PRKACA/K48R	MUTAGEN	K->R: Enhanced basal kinase activity; when associated with Q-96, L-121, A-124, K-182 and A-184.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	L96Q	P17612/L96Q	PRKACA/L96Q	MUTAGEN	L->Q: Enhanced basal kinase activity; when associated with R-48, L-121, A-124, K-182 and A-184.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	M121L	P17612/M121L	PRKACA/M121L	MUTAGEN	M->L: Enhanced basal kinase activity; when associated with R-48, Q-96, A-124, K-182 and A-184.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	V124A	P17612/V124A	PRKACA/V124A	MUTAGEN	V->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, K-182 and A-184.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	Q182K	P17612/Q182K	PRKACA/Q182K	MUTAGEN	Q->K: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and A-184.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	T184A	P17612/T184A	PRKACA/T184A	MUTAGEN	T->A: Enhanced basal kinase activity; when associated with R-48, Q-96, L-121, A-124 and K-182.	ECO:0000269|PubMed:21774789	21774789		
P17612	PRKACA	R195A	P17612/R195A	PRKACA/R195A	MUTAGEN	R->A: No phosphorylation.	ECO:0000269|PubMed:12372837	12372837	decrease	
P17612	PRKACA	G201A	P17612/G201A	PRKACA/G201A	MUTAGEN	G->A: No phosphorylation.	ECO:0000269|PubMed:12372837	12372837	loss	
P17612	PRKACA	T202A	P17612/T202A	PRKACA/T202A	MUTAGEN	T->A: No phosphorylation.	ECO:0000269|PubMed:12372837	12372837	loss	
P17612	PRKACA	Y205A	P17612/Y205A	PRKACA/Y205A	MUTAGEN	Y->A: Loss of allosteric regulation.	ECO:0000269|PubMed:18178622	18178622	decrease	
P17948	FLT1	L422I	P17948/L422I	FLT1/L422I	VARIANT	L -> I (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P17948	FLT1	R781Q	P17948/R781Q	FLT1/R781Q	VARIANT	R -> Q (in a glioma low grade oligodendroglioma sample; somatic mutation; dbSNP:rs553261958)	ECO:0000269|PubMed:17344846	17344846		
P17948	FLT1	L1061V	P17948/L1061V	FLT1/L1061V	VARIANT	L -> V (in a bladder transitional cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P17948	FLT1	V767A	P17948/V767A	FLT1/V767A	MUTAGEN	V->A: Abolishes proteolytic cleavage by PSEN1.	ECO:0000269|PubMed:22016384	22016384		
P17948	FLT1	K861M	P17948/K861M	FLT1/K861M	MUTAGEN	K->M: Abolishes enzyme activity. Abolishes interaction with PLCG.	ECO:0000269|PubMed:9299537	9299537	loss	
P17948	FLT1	Y1169F	P17948/Y1169F	FLT1/Y1169F	MUTAGEN	Y->F: Loss of phosphorylation site. Abolishes interaction with PLCG.	ECO:0000269|PubMed:9299537	9299537		
P17948	FLT1	Y1213F	P17948/Y1213F	FLT1/Y1213F	MUTAGEN	Y->F: Loss of phosphorylation site. Abolishes interaction with PIK3R1.	ECO:0000269|PubMed:9722576	9722576		
P17948	FLT1	Y1333F	P17948/Y1333F	FLT1/Y1333F	MUTAGEN	Y->F: Loss of phosphorylation site. Abolishes interaction with CBL.	ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:9722576	150,015,539,722,576		
P19525	EIF2AK2	M11L	P19525/M11L	EIF2AK2/M11L	VARIANT	M -> L (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	ECO:0000269|PubMed:32197074	32197074	decrease	
P19525	EIF2AK2	N32S	P19525/N32S	EIF2AK2/N32S	VARIANT	N -> S (in LEUDEN; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	S97F	P19525/S97F	EIF2AK2/S97F	VARIANT	S -> F (in LEUDEN; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	A109S	P19525/A109S	EIF2AK2/A109S	VARIANT	A -> S (in LEUDEN; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	A109V	P19525/A109V	EIF2AK2/A109V	VARIANT	A -> V (in LEUDEN; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	L114Q	P19525/L114Q	EIF2AK2/L114Q	VARIANT	L -> Q (found in a patient with dysmorphic facies, syndactyly, congenital microcephaly and global developmental delay; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	Y133F	P19525/Y133F	EIF2AK2/Y133F	VARIANT	Y -> F (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	ECO:0000269|PubMed:32197074	32197074	decrease	
P19525	EIF2AK2	G138A	P19525/G138A	EIF2AK2/G138A	VARIANT	G -> A (in DYT33; unknown pathological significance)	ECO:0000269|PubMed:33236446	33236446		
P19525	EIF2AK2	G325S	P19525/G325S	EIF2AK2/G325S	VARIANT	G -> S (in LEUDEN; unknown pathological significance)	ECO:0000269|PubMed:32197074	32197074		
P19525	EIF2AK2	L439V	P19525/L439V	EIF2AK2/L439V	VARIANT	L -> V (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P19525	EIF2AK2	S461C	P19525/S461C	EIF2AK2/S461C	VARIANT	S -> C (in LEUDEN; unknown pathological significance; reduced phosphorylation of eukaryotic translation initiation factor 2-alpha in patient cells)	ECO:0000269|PubMed:32197074	32197074	decrease	
P19525	EIF2AK2	K60A	P19525/K60A	EIF2AK2/K60A	MUTAGEN	K->A: Impairs dsRNA binding but not dimerization or activity.	ECO:0000269|PubMed:11337501	11337501		
P19525	EIF2AK2	S83A	P19525/S83A	EIF2AK2/S83A	MUTAGEN	S->A: No effect on enzymatic activity; when associated with A-88; A-89 and A-90.	ECO:0000269|PubMed:11152499	11152499		
P19525	EIF2AK2	T88A	P19525/T88A	EIF2AK2/T88A	MUTAGEN	T->A: No effect on enzymatic activity; when associated with A-83; A-89 and A-90.	ECO:0000269|PubMed:11152499	11152499		
P19525	EIF2AK2	T89A	P19525/T89A	EIF2AK2/T89A	MUTAGEN	T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-90.	ECO:0000269|PubMed:11152499	11152499		
P19525	EIF2AK2	T90A	P19525/T90A	EIF2AK2/T90A	MUTAGEN	T->A: No effect on enzymatic activity; when associated with A-83; A-88 and A-89.	ECO:0000269|PubMed:11152499	11152499		
P19525	EIF2AK2	S242A	P19525/S242A	EIF2AK2/S242A	MUTAGEN	S->A: Moderate loss of activity; when associated with A-255 and A-258.	ECO:0000269|PubMed:11152499	11152499		
P19525	EIF2AK2	T255A	P19525/T255A	EIF2AK2/T255A	MUTAGEN	T->A: Moderate loss of activity; when associated with A-242 and A-255.	ECO:0000269|PubMed:11152499	11152499		
P20594	NPR2	P32T	P20594/P32T	NPR2/P32T	VARIANT	P -> T (in AMD1; dbSNP:rs28931581)	ECO:0000269|PubMed:15146390	15146390		
P20594	NPR2	S76P	P20594/S76P	NPR2/S76P	VARIANT	S -> P (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; loss of localization to the plasma membrane; dbSNP:rs796065355)	ECO:0000269|PubMed:24001744	24001744	loss	
P20594	NPR2	R110C	P20594/R110C	NPR2/R110C	VARIANT	R -> C (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; retained in the endoplasmic reticulum; dbSNP:rs758478717)	ECO:0000269|PubMed:24471569	24471569	loss	
P20594	NPR2	D176E	P20594/D176E	NPR2/D176E	VARIANT	D -> E (in AMD1; dbSNP:rs28929479)	ECO:0000269|PubMed:15146390	15146390		
P20594	NPR2	V187I	P20594/V187I	NPR2/V187I	VARIANT	V -> I (does not affect C-type natriuretic peptide-induced signaling; dbSNP:rs768423636)	ECO:0000269|PubMed:24471569	24471569		
P20594	NPR2	R263P	P20594/R263P	NPR2/R263P	VARIANT	R -> P (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; loss of localization to the plasma membrane; dbSNP:rs139036657)	ECO:0000269|PubMed:24001744	24001744	loss	
P20594	NPR2	Y338C	P20594/Y338C	NPR2/Y338C	VARIANT	Y -> C (in AMD1; dbSNP:rs1828087195)	ECO:0000269|PubMed:15146390	15146390		
P20594	NPR2	A409T	P20594/A409T	NPR2/A409T	VARIANT	A -> T (in AMD1)	ECO:0000269|PubMed:15146390	15146390		
P20594	NPR2	Q417E	P20594/Q417E	NPR2/Q417E	VARIANT	Q -> E (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; no effect on cell surface expression; dbSNP:rs796065356)	ECO:0000269|PubMed:24471569	24471569	loss	
P20594	NPR2	A488P	P20594/A488P	NPR2/A488P	VARIANT	A -> P (in ECDM; mutant and wild-type alleles have similar expression levels; the mutation results in increased guanylate cyclase activity; dbSNP:rs587777597)	ECO:0000269|PubMed:24259409	24259409		inconclusive
P20594	NPR2	R655C	P20594/R655C	NPR2/R655C	VARIANT	R -> C (in ECDM; the mutation results in increased guanylate cyclase activity; dbSNP:rs587777596)	ECO:0000269|PubMed:24057292	24057292		inconclusive
P20594	NPR2	L658F	P20594/L658F	NPR2/L658F	VARIANT	L -> F (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; loss of natriuretic peptide receptor activity; dominant negative effect; dbSNP:rs1314542724)	ECO:0000269|PubMed:17652215, ECO:0000269|PubMed:26980729	17652215,26980729	decrease	
P20594	NPR2	Y708C	P20594/Y708C	NPR2/Y708C	VARIANT	Y -> C (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; dbSNP:rs1305337032)	ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:26980729	15146390,26980729		
P20594	NPR2	R776W	P20594/R776W	NPR2/R776W	VARIANT	R -> W (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity; dbSNP:rs1303913631)	ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:26980729	15146390,26980729		
P20594	NPR2	R819C	P20594/R819C	NPR2/R819C	VARIANT	R -> C (in SNSK; loss of C-type natriuretic peptide-induced signaling; dominant negative effect; no effect on cell surface expression; dbSNP:rs766256429)	ECO:0000269|PubMed:24001744	24001744	decrease	
P20594	NPR2	V882M	P20594/V882M	NPR2/V882M	VARIANT	V -> M (in ECDM; the mutation results in higher guanylate cyclase activity; causes a 15-fold increase in basal Vmax; has higher affinity for GTP than wild-type in the presence of NPPC; might lead to a structural change that locks the enzyme in a conformation mimicking the ATP-bound state)	ECO:0000269|PubMed:22870295, ECO:0000269|PubMed:23827346	22870295,23827346		inconclusive
P20594	NPR2	R957C	P20594/R957C	NPR2/R957C	VARIANT	R -> C (in AMD1; dbSNP:rs370158184)	ECO:0000269|PubMed:15146390	15146390		
P20594	NPR2	G959A	P20594/G959A	NPR2/G959A	VARIANT	G -> A (in AMD1; no effect on subcellular location; changed glycosylation; no effect on C-type natriuretic peptide binding; decreased guanylate cyclase activity)	ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:26980729	15146390,26980729		inconclusive
P20594	NPR2	N24D	P20594/N24D	NPR2/N24D	MUTAGEN	N->D,Q: Decreased glycosylation. Decreased guanylate cyclase activity.	ECO:0000269|PubMed:26980729	26980729		inconclusive
P20594	NPR2	N24Q	P20594/N24Q	NPR2/N24Q	MUTAGEN	N->D,Q: Decreased glycosylation. Decreased guanylate cyclase activity.	ECO:0000269|PubMed:26980729	26980729		inconclusive
P20794	MAK	G27R	P20794/G27R	MAK/G27R	VARIANT	G -> R (in RP62; dbSNP:rs754916169)	ECO:0000269|PubMed:21835304	21835304		
P20794	MAK	R166H	P20794/R166H	MAK/R166H	VARIANT	R -> H (in RP62; dbSNP:rs387906648)	ECO:0000269|PubMed:21835304	21835304		
P20794	MAK	I181T	P20794/I181T	MAK/I181T	VARIANT	I -> T (in RP62; dbSNP:rs750559316)	ECO:0000269|PubMed:21835304	21835304		
P20794	MAK	R272P	P20794/R272P	MAK/R272P	VARIANT	R -> P (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P20794	MAK	Y159F	P20794/Y159F	MAK/Y159F	MUTAGEN	Y->F: Abolishes autophosphorylation and impairs kinase activity.	ECO:0000269|PubMed:21986944	21986944	loss	
P21127	CDK11B	V452A	P21127/V452A	CDK11B/V452A	VARIANT	V -> A	ECO:0000269|PubMed:17344846	17344846		
P21127	CDK11B	I463V	P21127/I463V	CDK11B/I463V	VARIANT	I -> V	ECO:0000269|PubMed:17344846	17344846		
P21127	CDK11B	G506S	P21127/G506S	CDK11B/G506S	VARIANT	G -> S	ECO:0000269|PubMed:17344846	17344846		
P21675	TAF1	G453D	P21675/G453D	TAF1/G453D	VARIANT	G -> D (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21675	TAF1	N472D	P21675/N472D	TAF1/N472D	VARIANT	N -> D (found in a patient with X-linked intellectual disability; unknown pathological significance; dbSNP:rs200177996)	ECO:0000269|PubMed:25644381	25644381		
P21675	TAF1	P575S	P21675/P575S	TAF1/P575S	VARIANT	P -> S (in MRXS33; dbSNP:rs864321630)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	E651K	P21675/E651K	TAF1/E651K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21675	TAF1	M691I	P21675/M691I	TAF1/M691I	VARIANT	M -> I (in a lung bronchoalveolar carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21675	TAF1	C786R	P21675/C786R	TAF1/C786R	VARIANT	C -> R (in MRXS33; dbSNP:rs864321628)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	D955H	P21675/D955H	TAF1/D955H	VARIANT	D -> H (in MRXS33; dbSNP:rs864321631)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	R1169C	P21675/R1169C	TAF1/R1169C	VARIANT	R -> C (found in a patient with X-linked intellectual disability; unknown pathological significance; dbSNP:rs1569301036)	ECO:0000269|PubMed:25644381	25644381		
P21675	TAF1	R1225W	P21675/R1225W	TAF1/R1225W	VARIANT	R -> W (in MRXS33; dbSNP:rs864321629)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	I1316T	P21675/I1316T	TAF1/I1316T	VARIANT	I -> T (in MRXS33; dbSNP:rs864321627)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	R1431H	P21675/R1431H	TAF1/R1431H	VARIANT	R -> H (in MRXS33; unknown pathological significance)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	N1496H	P21675/N1496H	TAF1/N1496H	VARIANT	N -> H (in MRXS33; unknown pathological significance)	ECO:0000269|PubMed:26637982	26637982		
P21675	TAF1	D145A	P21675/D145A	TAF1/D145A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-147; A-149; A-150; A-152 and A-154.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	D147A	P21675/D147A	TAF1/D147A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-145; A-149; A-150; A-152 and A-154.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	E149A	P21675/E149A	TAF1/E149A	MUTAGEN	E->A: Reduces kinase activity; when associated with A-145; A-147; A-150; A-152 and A-154.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	D150A	P21675/D150A	TAF1/D150A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-152 and A-154.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	D152A	P21675/D152A	TAF1/D152A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-150 and A-154.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	K154A	P21675/K154A	TAF1/K154A	MUTAGEN	K->A: Reduces kinase activity; when associated with A-145; A-147; A-149; A-150 and A-152.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	C305A	P21675/C305A	TAF1/C305A	MUTAGEN	C->A: Reduces kinase activity; when associated with A-307; A-308; A-309 and A-310.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	S307A	P21675/S307A	TAF1/S307A	MUTAGEN	S->A: Reduces kinase activity; when associated with A-305; A-308; A-309 and A-310.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	D308A	P21675/D308A	TAF1/D308A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-305; A-307; A-309 and A-310.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	D309A	P21675/D309A	TAF1/D309A	MUTAGEN	D->A: Reduces kinase activity; when associated with A-305; A-307; A-308 and A-310.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	E310A	P21675/E310A	TAF1/E310A	MUTAGEN	E->A: Reduces kinase activity; when associated with A-305; A-307; A-308 and A-309.	ECO:0000269|PubMed:9660973	9660973		
P21675	TAF1	E721Q	P21675/E721Q	TAF1/E721Q	MUTAGEN	E->Q: 25% decrease in histone acetylation.	ECO:0000269|PubMed:15870300	15870300	decrease	
P21709	EPHA1	E703K	P21709/E703K	EPHA1/E703K	VARIANT	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21802	FGFR2	Y105C	P21802/Y105C	FGFR2/Y105C	VARIANT	Y -> C (in CS; dbSNP:rs1434545235)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8946174	117,818,728,946,174		
P21802	FGFR2	A172F	P21802/A172F	FGFR2/A172F	VARIANT	A -> F (in PS; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:11781872	11781872		
P21802	FGFR2	R203C	P21802/R203C	FGFR2/R203C	VARIANT	R -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
P21802	FGFR2	S252F	P21802/S252F	FGFR2/S252F	VARIANT	S -> F (in APRS; requires 2 nucleotide substitutions; dbSNP:rs121918498)	ECO:0000269|PubMed:9002682	9002682		
P21802	FGFR2	S252W	P21802/S252W	FGFR2/S252W	VARIANT	S -> W (in APRS and PS; common mutation; dbSNP:rs79184941)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057, ECO:0000269|PubMed:9719378	11781872,15190072,7668257,7719344,9452027,9677057,9719378		
P21802	FGFR2	P253R	P21802/P253R	FGFR2/P253R	VARIANT	P -> R (in APRS; common mutation; dbSNP:rs77543610)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057	11781872,7668257,7719344,9452027,9677057		
P21802	FGFR2	P263L	P21802/P263L	FGFR2/P263L	VARIANT	P -> L (in CS; dbSNP:rs779326224)	ECO:0000269|PubMed:11173845	11173845		
P21802	FGFR2	S267P	P21802/S267P	FGFR2/S267P	VARIANT	S -> P (in CS; dbSNP:rs121918505)	ECO:0000269|PubMed:11781872	11781872		
P21802	FGFR2	T268TG	P21802/T268TG	FGFR2/T268TG	VARIANT	T -> TG (in CS)	ECO:0000269|PubMed:8644708	8644708		
P21802	FGFR2	G272V	P21802/G272V	FGFR2/G272V	VARIANT	G -> V (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21802	FGFR2	F276V	P21802/F276V	FGFR2/F276V	VARIANT	F -> V (in CS; dbSNP:rs1057519036)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:9521581	11173845,11781872,9521581		
P21802	FGFR2	C278Y	P21802/C278Y	FGFR2/C278Y	VARIANT	C -> Y (in CS; dbSNP:rs776587763)	ECO:0000269|PubMed:11173845	11173845		
P21802	FGFR2	Y281C	P21802/Y281C	FGFR2/Y281C	VARIANT	Y -> C (in CS; dbSNP:rs1057519038)	ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872	11380921,11781872		
P21802	FGFR2	D283N	P21802/D283N	FGFR2/D283N	VARIANT	D -> N (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21802	FGFR2	I288S	P21802/I288S	FGFR2/I288S	VARIANT	I -> S (in CS)	ECO:0000269|PubMed:11173845	11173845		
P21802	FGFR2	Q289P	P21802/Q289P	FGFR2/Q289P	VARIANT	Q -> P (in CS and JWS; dbSNP:rs121918497)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:8644708	11173845,11380921,11781872,7581378,8644708		
P21802	FGFR2	W290C	P21802/W290C	FGFR2/W290C	VARIANT	W -> C (in PS; severe; also in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs121918499)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9150725	11781872,17344846,9150725		
P21802	FGFR2	W290G	P21802/W290G	FGFR2/W290G	VARIANT	W -> G (in CS; dbSNP:rs121918501)	ECO:0000269|PubMed:8528214	8528214		
P21802	FGFR2	W290R	P21802/W290R	FGFR2/W290R	VARIANT	W -> R (in CS; dbSNP:rs121918501)				
P21802	FGFR2	K292E	P21802/K292E	FGFR2/K292E	VARIANT	K -> E (in CS; dbSNP:rs121918500)	ECO:0000269|PubMed:9152842	9152842		
P21802	FGFR2	Y301C	P21802/Y301C	FGFR2/Y301C	VARIANT	Y -> C (in CS; dbSNP:rs1554930684)	ECO:0000269|PubMed:9521581	9521581		
P21802	FGFR2	A314S	P21802/A314S	FGFR2/A314S	VARIANT	A -> S (in craniosynostosis; dbSNP:rs1358919643)	ECO:0000269|PubMed:9521581	9521581		
P21802	FGFR2	A315S	P21802/A315S	FGFR2/A315S	VARIANT	A -> S (in a non-syndromic craniosynostosis patient with abnormal intrauterine history; confers predisposition to craniosynostosis; dbSNP:rs121918504)	ECO:0000269|PubMed:10951518, ECO:0000269|PubMed:11781872	10951518,11781872		
P21802	FGFR2	D321A	P21802/D321A	FGFR2/D321A	VARIANT	D -> A (in PS; dbSNP:rs121918510)	ECO:0000269|PubMed:7719333	7719333		
P21802	FGFR2	Y328C	P21802/Y328C	FGFR2/Y328C	VARIANT	Y -> C (in CS; dbSNP:rs121918493)	ECO:0000269|PubMed:7874170	7874170		
P21802	FGFR2	N331I	P21802/N331I	FGFR2/N331I	VARIANT	N -> I (in CS)	ECO:0000269|PubMed:8956050	8956050		
P21802	FGFR2	A337ANA	P21802/A337ANA	FGFR2/A337ANA	VARIANT	A -> ANA (in CS)				
P21802	FGFR2	A337P	P21802/A337P	FGFR2/A337P	VARIANT	A -> P (in CS; dbSNP:rs387906676)	ECO:0000269|PubMed:9677057	9677057		
P21802	FGFR2	G338E	P21802/G338E	FGFR2/G338E	VARIANT	G -> E (in CS; dbSNP:rs1057519044)	ECO:0000269|PubMed:8946174	8946174		
P21802	FGFR2	G338R	P21802/G338R	FGFR2/G338R	VARIANT	G -> R (in CS; dbSNP:rs1057519043)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:9677057	11781872,7581378,9677057		
P21802	FGFR2	Y340C	P21802/Y340C	FGFR2/Y340C	VARIANT	Y -> C (in PS; dbSNP:rs1554928884)	ECO:0000269|PubMed:10394936, ECO:0000269|PubMed:11781872	10394936,11781872		
P21802	FGFR2	Y340H	P21802/Y340H	FGFR2/Y340H	VARIANT	Y -> H (in CS; dbSNP:rs121918489)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7987400	117,818,727,987,400		
P21802	FGFR2	T341P	P21802/T341P	FGFR2/T341P	VARIANT	T -> P (in PS and CS; dbSNP:rs121918495)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345	11173845,11781872,7719345		
P21802	FGFR2	C342F	P21802/C342F	FGFR2/C342F	VARIANT	C -> F (in CS; dbSNP:rs121918487)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057	11781872,8644708,9677057		
P21802	FGFR2	C342G	P21802/C342G	FGFR2/C342G	VARIANT	C -> G (in PS; dbSNP:rs121918488)	ECO:0000269|PubMed:10394936	10394936		
P21802	FGFR2	C342R	P21802/C342R	FGFR2/C342R	VARIANT	C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)	ECO:0000269|PubMed:10633130, ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345, ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057	10633130,11173845,11380921,11781872,7719345,7987400,8528214,8644708,9677057		
P21802	FGFR2	C342S	P21802/C342S	FGFR2/C342S	VARIANT	C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)	ECO:0000269|PubMed:10633130, ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, ECO:0000269|Ref.10	10633130,11173845,11781872,7581378,7987400,8644708,9385368		
P21802	FGFR2	C342W	P21802/C342W	FGFR2/C342W	VARIANT	C -> W (in CS; dbSNP:rs121918496)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8528214	11173845,11781872,8528214		
P21802	FGFR2	C342Y	P21802/C342Y	FGFR2/C342Y	VARIANT	C -> Y (in CS and PS; dbSNP:rs121918487)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7719345, ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057	11173845,11380921,11781872,7581378,7719345,7987400,8644708,9677057		
P21802	FGFR2	A344G	P21802/A344G	FGFR2/A344G	VARIANT	A -> G (in CS and JWS; dbSNP:rs121918492)	ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7874170	75,813,787,874,170		
P21802	FGFR2	A344P	P21802/A344P	FGFR2/A344P	VARIANT	A -> P (in CS and PS)	ECO:0000269|PubMed:8644708	8644708		
P21802	FGFR2	S347C	P21802/S347C	FGFR2/S347C	VARIANT	S -> C (in CS; dbSNP:rs121918494)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7874170	117,818,727,874,170		
P21802	FGFR2	S351C	P21802/S351C	FGFR2/S351C	VARIANT	S -> C (in CS, PS and ABS2; dbSNP:rs121918502)	ECO:0000269|PubMed:10633130, ECO:0000269|PubMed:8946174, ECO:0000269|PubMed:9693549	10633130,8946174,9693549		
P21802	FGFR2	S354C	P21802/S354C	FGFR2/S354C	VARIANT	S -> C (in CS; dbSNP:rs121918490)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214	11173845,11781872,7581378,7987400,8528214		
P21802	FGFR2	S354Y	P21802/S354Y	FGFR2/S354Y	VARIANT	S -> Y (in CS)	ECO:0000269|PubMed:11173845	11173845		
P21802	FGFR2	V359F	P21802/V359F	FGFR2/V359F	VARIANT	V -> F (in CS and PS)	ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:8644708	111,738,458,644,708		
P21802	FGFR2	A362S	P21802/A362S	FGFR2/A362S	VARIANT	A -> S (in CS)	ECO:0000269|PubMed:10574673	10574673		
P21802	FGFR2	S372C	P21802/S372C	FGFR2/S372C	VARIANT	S -> C (in BSTVS; dbSNP:rs121913477)	ECO:0000269|PubMed:8696350	8696350		
P21802	FGFR2	Y375C	P21802/Y375C	FGFR2/Y375C	VARIANT	Y -> C (in PS and BSTVS; dbSNP:rs121913478)	ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350	11781872,12000365,8696350		
P21802	FGFR2	Y381D	P21802/Y381D	FGFR2/Y381D	VARIANT	Y -> D (in BBDS1; dbSNP:rs387906678)	ECO:0000269|PubMed:22387015	22387015		
P21802	FGFR2	G384R	P21802/G384R	FGFR2/G384R	VARIANT	G -> R (in CS; dbSNP:rs1554927408)	ECO:0000269|PubMed:8946174	8946174		
P21802	FGFR2	R612T	P21802/R612T	FGFR2/R612T	VARIANT	R -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P21802	FGFR2	G613R	P21802/G613R	FGFR2/G613R	VARIANT	G -> R	ECO:0000269|PubMed:10626794, ECO:0000269|PubMed:1309608	106,267,941,309,608		
P21802	FGFR2	A648T	P21802/A648T	FGFR2/A648T	VARIANT	A -> T (in LADD1; dbSNP:rs121918508)	ECO:0000269|PubMed:16501574	16501574		
P21802	FGFR2	G663E	P21802/G663E	FGFR2/G663E	VARIANT	G -> E (in PS)	ECO:0000269|PubMed:11781872	11781872		
P21802	FGFR2	R678G	P21802/R678G	FGFR2/R678G	VARIANT	R -> G (in CS; dbSNP:rs1845559552)	ECO:0000269|PubMed:11781872	11781872		
P21802	FGFR2	N265Q	P21802/N265Q	FGFR2/N265Q	MUTAGEN	N->Q: Reduced N-glycosylation. Reduced expression at the cell surface.	ECO:0000269|PubMed:16844695	16844695		decrease
P21860	ERBB3	V104M	P21860/V104M	ERBB3/V104M	VARIANT	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1057519893)	ECO:0000269|PubMed:17344846	17344846		
P21860	ERBB3	T873S	P21860/T873S	ERBB3/T873S	VARIANT	T -> S (in VSCN1; unknown pathological significance; some decrease in ERBB2 phosphorylation upon NG1 treatment, compared to wild-type; does not affect the subcellular localization at the cell membrane)	ECO:0000269|PubMed:33497358	33497358	decrease	
P21860	ERBB3	Q932R	P21860/Q932R	ERBB3/Q932R	VARIANT	Q -> R (in VSCN1; unknown pathological significance; some decrease in ERBB2 phosphorylation upon NG1 treatment, compared to wild-type; does not affect the subcellular localization at the cell membrane)	ECO:0000269|PubMed:33497358	33497358	decrease	
P22455	FGFR4	G388R	P22455/G388R	FGFR4/G388R	VARIANT	G -> R (in cancer cells, may be associated with accelerated disease progression and increased tumor cell motility, possibly due to increased stability of the protease MMP14; leads to phosphorylation at residue Y-390, resulting in prolonged FGFR4 activity; increases interaction with STAT3, resulting in STAT3 phosphorylation and signaling activation.; dbSNP:rs351855)	ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254, ECO:0000269|PubMed:26675719, ECO:0000269|Ref.7	18670643,18756523,20876804,21349172,21882254,26675719	increase	
P22455	FGFR4	V550M	P22455/V550M	FGFR4/V550M	VARIANT	V -> M (in breast pleomorphic lobular sample; somatic mutation; dbSNP:rs774571806)	ECO:0000269|PubMed:17344846	17344846		
P22455	FGFR4	P712T	P22455/P712T	FGFR4/P712T	VARIANT	P -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P22455	FGFR4	S772N	P22455/S772N	FGFR4/S772N	VARIANT	S -> N (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P22455	FGFR4	Y754F	P22455/Y754F	FGFR4/Y754F	MUTAGEN	Y->F: Loss of interaction with PLCG1.	ECO:0000269|PubMed:7518429	7518429	decrease	PLCG1 is one, but not the only interaction partner of FGFR4 (as per Uniprot). Hard to argue as "loss" type.
P22607	FGFR3	T79S	P22607/T79S	FGFR3/T79S	VARIANT	T -> S (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P22607	FGFR3	C228R	P22607/C228R	FGFR3/C228R	VARIANT	C -> R (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P22607	FGFR3	S249C	P22607/S249C	FGFR3/S249C	VARIANT	S -> C (in KERSEB, BLC, cervical cancer and TD1; dbSNP:rs121913483)	ECO:0000269|PubMed:10360402, ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844	10360402,10471491,15772091,8589699,8845844		
P22607	FGFR3	P250R	P22607/P250R	FGFR3/P250R	VARIANT	P -> R (in MNKS; also some individuals with autosomal dominant congenital sensorineural deafness without craniosynostosis; dbSNP:rs4647924)	ECO:0000269|PubMed:11746040, ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9525367, ECO:0000269|PubMed:9950359	11746040,9042914,9525367,9950359		
P22607	FGFR3	E322K	P22607/E322K	FGFR3/E322K	VARIANT	E -> K (in colorectal cancer; dbSNP:rs121913111)	ECO:0000269|PubMed:11325814	11325814		
P22607	FGFR3	T338M	P22607/T338M	FGFR3/T338M	VARIANT	T -> M	ECO:0000269|PubMed:17344846	17344846		
P22607	FGFR3	G370C	P22607/G370C	FGFR3/G370C	VARIANT	G -> C (in KERSEB, BLC, keratinocytic non-epidermolytic nevus and TD1; dbSNP:rs121913479)	ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094, ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9790257	10471491,15772091,16841094,8845844,9790257		
P22607	FGFR3	S371C	P22607/S371C	FGFR3/S371C	VARIANT	S -> C (in KERSEB and TD1; dbSNP:rs121913484)	ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:7773297	157,720,917,773,297		
P22607	FGFR3	G375C	P22607/G375C	FGFR3/G375C	VARIANT	G -> C (in ACH; dbSNP:rs75790268)	ECO:0000269|PubMed:7758520	7758520		
P22607	FGFR3	A391E	P22607/A391E	FGFR3/A391E	VARIANT	A -> E (in CAN; dbSNP:rs28931615)	ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034	179,355,057,493,034		
P22607	FGFR3	D513N	P22607/D513N	FGFR3/D513N	VARIANT	D -> N (in LADD2; unknown pathological significance; dbSNP:rs121913112)	ECO:0000269|PubMed:16501574	16501574		
P22607	FGFR3	I538V	P22607/I538V	FGFR3/I538V	VARIANT	I -> V (in hypochondroplasia; dbSNP:rs80053154)	ECO:0000269|PubMed:10215410	10215410		
P22607	FGFR3	N540K	P22607/N540K	FGFR3/N540K	VARIANT	N -> K (in hypochondroplasia; dbSNP:rs28933068)	ECO:0000269|PubMed:7670477	7670477		
P22607	FGFR3	N540S	P22607/N540S	FGFR3/N540S	VARIANT	N -> S (in hypochondroplasia; mild; dbSNP:rs77722678)	ECO:0000269|PubMed:10777366, ECO:0000269|PubMed:12707965	10777366,12707965		
P22607	FGFR3	N540T	P22607/N540T	FGFR3/N540T	VARIANT	N -> T (in hypochondroplasia; dbSNP:rs77722678)	ECO:0000269|PubMed:9452043	9452043		
P22607	FGFR3	R621H	P22607/R621H	FGFR3/R621H	VARIANT	R -> H (in CATSHLS; dbSNP:rs121913113)	ECO:0000269|PubMed:17033969	17033969		
P22607	FGFR3	D646N	P22607/D646N	FGFR3/D646N	VARIANT	D -> N	ECO:0000269|PubMed:17344846	17344846		
P22607	FGFR3	K650M	P22607/K650M	FGFR3/K650M	VARIANT	K -> M (in KERSEB, ACH, TD1 and SADDAN; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs121913105)	ECO:0000269|PubMed:10053006, ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:9207791	10053006,10671061,15772091,17509076,17561467,9207791	activating	
P22607	FGFR3	K650Q	P22607/K650Q	FGFR3/K650Q	VARIANT	K -> Q (in hypochondroplasia and BLC; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations; constitutively activated kinase; dbSNP:rs78311289)	ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:11314002, ECO:0000269|PubMed:8754806	11055896,11314002,8754806	activating	
P22607	FGFR3	Y577F	P22607/Y577F	FGFR3/Y577F	MUTAGEN	Y->F: Minor effect on kinase activity.	ECO:0000269|PubMed:11294897	11294897	increase	
P22607	FGFR3	Y760F	P22607/Y760F	FGFR3/Y760F	MUTAGEN	Y->F: Minor effect on kinase activity.	ECO:0000269|PubMed:11294897	11294897	increase	
P22607	FGFR3	Y770F	P22607/Y770F	FGFR3/Y770F	MUTAGEN	Y->F: Minor effect on kinase activity. Increased mitogen activity.	ECO:0000269|PubMed:11294897	11294897	increase	
P22694	PRKACB	S54L	P22694/S54L	PRKACB/S54L	VARIANT	S -> L (in CAFD2; dbSNP:rs1663748771)	ECO:0000269|PubMed:33058759	33058759		
P22694	PRKACB	H88N	P22694/H88N	PRKACB/H88N	VARIANT	H -> N (in CAFD2)	ECO:0000269|PubMed:33058759	33058759		
P22694	PRKACB	H88R	P22694/H88R	PRKACB/H88R	VARIANT	H -> R (in CAFD2; increased sensitivity to cAMP activation; dbSNP:rs768056300)	ECO:0000269|PubMed:33058759	33058759	increase	
P22694	PRKACB	G235R	P22694/G235R	PRKACB/G235R	VARIANT	G -> R (in CAFD2; increased sensitivity to cAMP activation; decreased interaction with regulatory subunits PRKAR1A and PRKAR2B)	ECO:0000269|PubMed:33058759	33058759	increase	
P23443	RPS6KB1	M225I	P23443/M225I	RPS6KB1/M225I	VARIANT	M -> I	ECO:0000269|PubMed:17344846	17344846		
P23443	RPS6KB1	W276C	P23443/W276C	RPS6KB1/W276C	VARIANT	W -> C	ECO:0000269|PubMed:17344846	17344846		
P23443	RPS6KB1	G289E	P23443/G289E	RPS6KB1/G289E	VARIANT	G -> E (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P23443	RPS6KB1	S398A	P23443/S398A	RPS6KB1/S398A	VARIANT	S -> A	ECO:0000269|PubMed:17344846	17344846		
P23443	RPS6KB1	T412E	P23443/T412E	RPS6KB1/T412E	MUTAGEN	T->E: Mimics phosphorylation. Facilitates phosphorylation of T-252 by PDPK1; when associated with E-434; E-441; E-444 and E-447. Mimics phosphorylation. No effect on interaction with PDPK1 and phosphorylation of T-252. Impairs association with the eIF3 complex.	ECO:0000269|PubMed:16286006, ECO:0000269|PubMed:19570988, ECO:0000269|PubMed:9445476	16286006,19570988,9445476	increase	
P23443	RPS6KB1	S434E	P23443/S434E	RPS6KB1/S434E	MUTAGEN	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-441; E-444 and E-447.	ECO:0000269|PubMed:9445476	9445476		
P23443	RPS6KB1	S441E	P23443/S441E	RPS6KB1/S441E	MUTAGEN	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-444 and E-447.	ECO:0000269|PubMed:9445476	9445476		
P23443	RPS6KB1	T444E	P23443/T444E	RPS6KB1/T444E	MUTAGEN	T->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-441 and E-447.	ECO:0000269|PubMed:9445476	9445476		
P23443	RPS6KB1	S447E	P23443/S447E	RPS6KB1/S447E	MUTAGEN	S->E: Facilitates phosphorylation of T-252 by PDPK1; when associated with E-412; E-434; E-441 and E-444.	ECO:0000269|PubMed:9445476	9445476		
P23458	JAK1	S703I	P23458/S703I	JAK1/S703I	VARIANT	S -> I (in AIIDE; increased activation of protein kinase activity; constitutive gain of function through the transactivation of associated JAK kinases; increased receptor signaling pathway via JAK-STAT)	ECO:0000269|PubMed:32750333	32750333	increase	
P24723	PRKCH	V374I	P24723/V374I	PRKCH/V374I	VARIANT	V -> I (associated with susceptibility to ischemic stroke; increases autophosphorylation and kinase activity; dbSNP:rs2230500)	ECO:0000269|PubMed:17206144, ECO:0000269|PubMed:17344846	17206144,17344846	increase	
P24723	PRKCH	T575A	P24723/T575A	PRKCH/T575A	VARIANT	T -> A (in a aLLTEL/AML1+ sample; somatic mutation; dbSNP:rs1378993559)	ECO:0000269|PubMed:17344846	17344846		
P24723	PRKCH	T594I	P24723/T594I	PRKCH/T594I	VARIANT	T -> I (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P24941	CDK2	P45L	P24941/P45L	CDK2/P45L	VARIANT	P -> L (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25092	GUCY2C	G61R	P25092/G61R	GUCY2C/G61R	VARIANT	G -> R (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25092	GUCY2C	D387G	P25092/D387G	GUCY2C/D387G	VARIANT	D -> G (in MECIL; activation of guanylate cyclase activity is 60% lower than in wild-type; dbSNP:rs587776905)	ECO:0000269|PubMed:22521417	22521417	decrease	
P25098	GRK2	R578Q	P25098/R578Q	GRK2/R578Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25098	GRK2	D3K	P25098/D3K	GRK2/D3K	MUTAGEN	D->K: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin. 60% reduction in phosphorylation of beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	ECO:0000269|PubMed:19715378	19715378	decrease	
P25098	GRK2	L4A	P25098/L4A	GRK2/L4A	MUTAGEN	L->A: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin. 90% reduction in phosphorylation of beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	ECO:0000269|PubMed:19715378	19715378	decrease	
P25098	GRK2	D10A	P25098/D10A	GRK2/D10A	MUTAGEN	D->A: 95% reduction in phosphorylation of G-protein coupled receptor rhodopsin and beta-2 adrenergic receptor ADRB2. Does not affect binding to ADRB2. Not activated by receptor binding. No effect on phosphorylation of the non-receptor substrate tubulin.	ECO:0000269|PubMed:19715378	19715378	decrease	
P25440	BRD2	G30E	P25440/G30E	BRD2/G30E	VARIANT	G -> E (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25440	BRD2	R558G	P25440/R558G	BRD2/R558G	VARIANT	R -> G (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25440	BRD2	P714L	P25440/P714L	BRD2/P714L	VARIANT	P -> L (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P25440	BRD2	Q78A	P25440/Q78A	BRD2/Q78A	MUTAGEN	Q->A: Loss of homodimerization.	ECO:0000269|PubMed:17148447	17148447	loss	
P25440	BRD2	Y153K	P25440/Y153K	BRD2/Y153K	MUTAGEN	Y->K: Loss of homodimerization.	ECO:0000269|PubMed:17148447	17148447	loss	
P25440	BRD2	I154A	P25440/I154A	BRD2/I154A	MUTAGEN	I->A: Partial loss of homodimerization; when associated with A-182.	ECO:0000269|PubMed:17148447	17148447		
P25440	BRD2	E170A	P25440/E170A	BRD2/E170A	MUTAGEN	E->A: Loss of homodimerization.	ECO:0000269|PubMed:17148447	17148447	loss	
P25440	BRD2	L174E	P25440/L174E	BRD2/L174E	MUTAGEN	L->E: Loss of homodimerization.	ECO:0000269|PubMed:17148447	17148447	loss	
P25440	BRD2	V177E	P25440/V177E	BRD2/V177E	MUTAGEN	V->E: Loss of homodimerization.	ECO:0000269|PubMed:17148447	17148447	loss	
P25440	BRD2	Q182A	P25440/Q182A	BRD2/Q182A	MUTAGEN	Q->A: Partial loss of homodimerization; when associated with A-154.	ECO:0000269|PubMed:17148447	17148447		
P27037	ACVR2A	D306N	P27037/D306N	ACVR2A/D306N	VARIANT	D -> N (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs764255410)	ECO:0000269|PubMed:17344846	17344846		
P27037	ACVR2A	A367T	P27037/A367T	ACVR2A/A367T	VARIANT	A -> T (found in a clear cell renal carcinoma case; somatic mutation)	ECO:0000269|PubMed:21248752	21248752		
P27361	MAPK3	K168R	P27361/K168R	MAPK3/K168R	MUTAGEN	K->R: Complete loss of ubiquitination by TRIM15; when associated with R-302.	ECO:0000269|PubMed:34497368	34497368		
P27361	MAPK3	K302R	P27361/K302R	MAPK3/K302R	MUTAGEN	K->R: Complete loss of ubiquitination by TRIM15; when associated with R-168.	ECO:0000269|PubMed:34497368	34497368		
P27448	MARK3	V429A	P27448/V429A	MARK3/V429A	VARIANT	V -> A	ECO:0000269|PubMed:17344846	17344846		
P27448	MARK3	R570G	P27448/R570G	MARK3/R570G	VARIANT	R -> G (in VIPB; dbSNP:rs376395495)	ECO:0000269|PubMed:29771303	29771303		
P27448	MARK3	T211A	P27448/T211A	MARK3/T211A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
P28482	MAPK1	I74N	P28482/I74N	MAPK1/I74N	VARIANT	I -> N (in NS13; results in increased MAPK signaling; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	ECO:0000269|PubMed:32721402	32721402	increase	
P28482	MAPK1	H80Y	P28482/H80Y	MAPK1/H80Y	VARIANT	H -> Y (in NS13; results in increased MAPK signaling; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	ECO:0000269|PubMed:32721402	32721402	increase	
P28482	MAPK1	A174V	P28482/A174V	MAPK1/A174V	VARIANT	A -> V (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	ECO:0000269|PubMed:32721402	32721402	increase	
P28482	MAPK1	D318G	P28482/D318G	MAPK1/D318G	VARIANT	D -> G (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	ECO:0000269|PubMed:32721402	32721402	increase	
P28482	MAPK1	D318N	P28482/D318N	MAPK1/D318N	VARIANT	D->N: Inhibits interaction with MAP2K1 but not with TPR; when associated with N-321.	ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19494114	18794356,19494114		
P28482	MAPK1	E322Q	P28482/E322Q	MAPK1/E322Q	VARIANT	E -> Q (in NS13)	ECO:0000269|PubMed:32721402	32721402		
P28482	MAPK1	P323R	P28482/P323R	MAPK1/P323R	VARIANT	P -> R (in NS13; results in increased MAPK signaling; increased translocation to the nucleus; reduced interaction wth DUSP6; no effect on interaction with MAP2K1)	ECO:0000269|PubMed:32721402	32721402	increase	
P28482	MAPK1	K54R	P28482/K54R	MAPK1/K54R	MUTAGEN	K->R: Does not inhibit interaction with MAP2K1.	ECO:0000269|PubMed:18794356	18794356		
P28482	MAPK1	T185A	P28482/T185A	MAPK1/T185A	MUTAGEN	T->A: Inhibits interaction with TPR; when associated with A-187.	ECO:0000269|PubMed:18794356	18794356		
P28482	MAPK1	Y187A	P28482/Y187A	MAPK1/Y187A	MUTAGEN	Y->A: Inhibits interaction with TPR; when associated with A-185.	ECO:0000269|PubMed:18794356	18794356		
P28482	MAPK1	L234A	P28482/L234A	MAPK1/L234A	MUTAGEN	L->A: Inhibits interaction with TPR.	ECO:0000269|PubMed:18794356	18794356		decrease; MAPK1 phosphorylates TPR normally
P28482	MAPK1	D318A	P28482/D318A	MAPK1/D318A	MUTAGEN	D->A: Loss of dephosphorylation by PTPRJ.	ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19494114	18794356,19494114	increase	
P28482	MAPK1	D321N	P28482/D321N	MAPK1/D321N	MUTAGEN	D->N: Inhibits interaction with MAP2K1 but not with TPR; when associated with N-318.	ECO:0000269|PubMed:18794356	18794356		
P29317	EPHA2	G777S	P29317/G777S	EPHA2/G777S	VARIANT	G -> S (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs922655349)	ECO:0000269|PubMed:17344846	17344846		
P29317	EPHA2	T940I	P29317/T940I	EPHA2/T940I	VARIANT	T -> I (in CTRCT6; reduced protein stability and reduced ability to stimulate cell migration in absence of its ephrin ligand; dbSNP:rs137853200)	ECO:0000269|PubMed:19306328, ECO:0000269|PubMed:22570727	19306328,22570727		decrease
P29317	EPHA2	G948W	P29317/G948W	EPHA2/G948W	VARIANT	G -> W (in CTRCT6; reduced protein stability and reduced ability to stimulate cell migration in absence of its ephrin ligand; dbSNP:rs137853199)	ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:22570727	19005574,22570727		decrease
P29317	EPHA2	R103E	P29317/R103E	EPHA2/R103E	MUTAGEN	R->E: Significantly reduced response to EFNA1.	ECO:0000269|PubMed:19525919	19525919	decrease	
P29317	EPHA2	D739N	P29317/D739N	EPHA2/D739N	MUTAGEN	D->N: Increases serum-induced chemotaxis. Loss of EFNA1-dependent regulation of cell migration.	ECO:0000269|PubMed:19573808	19573808	increase	
P29317	EPHA2	S897D	P29317/S897D	EPHA2/S897D	MUTAGEN	S->A,D: Loss of serum-induced phosphorylation by PKB. Loss of serum-induced chemotaxis.	ECO:0000269|PubMed:19573808	19573808	loss	
P29320	EPHA3	T37K	P29320/T37K	EPHA3/T37K	VARIANT	T -> K (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P29320	EPHA3	N85S	P29320/N85S	EPHA3/N85S	VARIANT	N -> S (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P29320	EPHA3	K207N	P29320/K207N	EPHA3/K207N	VARIANT	K -> N (in a pancreatic ductal adenocarcinoma sample; somatic mutation; dbSNP:rs200567888)	ECO:0000269|PubMed:20838624	20838624		
P29320	EPHA3	S229Y	P29320/S229Y	EPHA3/S229Y	VARIANT	S -> Y (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29320	EPHA3	S449F	P29320/S449F	EPHA3/S449F	VARIANT	S -> F (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29320	EPHA3	G518L	P29320/G518L	EPHA3/G518L	VARIANT	G -> L (in a lung squamous cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:17344846	17344846		
P29320	EPHA3	I621L	P29320/I621L	EPHA3/I621L	VARIANT	I -> L (in a colorectal cancer sample; somatic mutation; dbSNP:rs1414714315)	ECO:0000269|PubMed:16959974	16959974		
P29320	EPHA3	T660K	P29320/T660K	EPHA3/T660K	VARIANT	T -> K (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:16941478	16941478		
P29320	EPHA3	G766E	P29320/G766E	EPHA3/G766E	VARIANT	G -> E (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29320	EPHA3	D806N	P29320/D806N	EPHA3/D806N	VARIANT	D -> N (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P29320	EPHA3	T933M	P29320/T933M	EPHA3/T933M	VARIANT	T -> M (in a lung carcinoma sample; somatic mutation; dbSNP:rs372594677)	ECO:0000269|PubMed:16941478	16941478		
P29320	EPHA3	Y596F	P29320/Y596F	EPHA3/Y596F	MUTAGEN	Y->F: 10-fold suppression of kinase activity; when associated with F-602. Full kinase activity; when associated with F-602 and F-742. Full kinase activity; when associated with F-602 and A-768.	ECO:0000269|PubMed:18547520	18547520		
P29320	EPHA3	Y602F	P29320/Y602F	EPHA3/Y602F	MUTAGEN	Y->F: 10-fold suppression of kinase activity; when associated with F-596. Full kinase activity; when associated with F-596 and F-742. Full kinase activity; when associated with F-596 and A-768.	ECO:0000269|PubMed:18547520	18547520		
P29320	EPHA3	Y742F	P29320/Y742F	EPHA3/Y742F	MUTAGEN	Y->F: Full kinase activity; when associated with F-596 and F-602.	ECO:0000269|PubMed:18547520	18547520		
P29320	EPHA3	S768A	P29320/S768A	EPHA3/S768A	MUTAGEN	S->A: Full kinase activity; when associated with F-596 and F-602.	ECO:0000269|PubMed:18547520	18547520		
P29322	EPHA8	N123K	P29322/N123K	EPHA8/N123K	VARIANT	N -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29322	EPHA8	R179C	P29322/R179C	EPHA8/R179C	VARIANT	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1557556639)	ECO:0000269|PubMed:17344846	17344846		
P29322	EPHA8	R198L	P29322/R198L	EPHA8/R198L	VARIANT	R -> L (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29322	EPHA8	P860L	P29322/P860L	EPHA8/P860L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29323	EPHB2	R199H	P29323/R199H	EPHB2/R199H	VARIANT	R -> H (in prostate cancer; dbSNP:rs201754821)	ECO:0000269|PubMed:15300251	15300251		
P29323	EPHB2	A279S	P29323/A279S	EPHB2/A279S	VARIANT	A -> S (in prostate cancer; dbSNP:rs35882952)	ECO:0000269|PubMed:15300251, ECO:0000269|PubMed:16155194, ECO:0000269|PubMed:17344846	15300251,16155194,17344846		
P29323	EPHB2	C289G	P29323/C289G	EPHB2/C289G	VARIANT	C -> G	ECO:0000269|PubMed:17344846	17344846		
P29323	EPHB2	V650A	P29323/V650A	EPHB2/V650A	VARIANT	V -> A (in prostate cancer; dbSNP:rs142173175)	ECO:0000269|PubMed:16155194	16155194		
P29323	EPHB2	H679N	P29323/H679N	EPHB2/H679N	VARIANT	H -> N (in prostate cancer)	ECO:0000269|PubMed:15300251	15300251		
P29323	EPHB2	R745C	P29323/R745C	EPHB2/R745C	VARIANT	R -> C (in BDPLT22; dbSNP:rs761749948)	ECO:0000269|PubMed:30213874	30213874		
P29323	EPHB2	M883V	P29323/M883V	EPHB2/M883V	VARIANT	M -> V (in prostate cancer; dbSNP:rs372653137)	ECO:0000269|PubMed:16155194	16155194		
P29323	EPHB2	I909M	P29323/I909M	EPHB2/I909M	VARIANT	I -> M (in prostate cancer)	ECO:0000269|PubMed:15300251	15300251		
P29323	EPHB2	K787R	P29323/K787R	EPHB2/K787R	MUTAGEN	K->R: No loss of ubiquitination by RNF186.	ECO:0000269|PubMed:33280498	33280498		
P29323	EPHB2	K891R	P29323/K891R	EPHB2/K891R	MUTAGEN	K->R: Complete loss of ubiquitination by RNF186.	ECO:0000269|PubMed:33280498	33280498		increase
P29376	LTK	R241A	P29376/R241A	LTK/R241A	MUTAGEN	R->A: Abolished homodimerization following interaction with ALKAL1.	ECO:0000269|PubMed:34646012	34646012	loss	
P29376	LTK	Y753F	P29376/Y753F	LTK/Y753F	MUTAGEN	Y->F: Abolishes interaction with PI3-kinase subunit p85, impairs PI3 kinase activity and leads to apoptosis (demonstrated with chimeric EGFR-LTK).	ECO:0000269|PubMed:9223670	9223670	loss	
P29597	TYK2	H732R	P29597/H732R	TYK2/H732R	VARIANT	H -> R (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P29597	TYK2	Y1054F	P29597/Y1054F	TYK2/Y1054F	MUTAGEN	Y->F: Reduces basal catalytic activity and abolishes IFN-dependent activation.	ECO:0000269|PubMed:8702790	8702790	decrease	
P29597	TYK2	Y1055F	P29597/Y1055F	TYK2/Y1055F	MUTAGEN	Y->F: Reduces basal catalytic activity and abolishes IFN-dependent activation.	ECO:0000269|PubMed:8702790	8702790	decrease	
P29597	TYK2	Y1145F	P29597/Y1145F	TYK2/Y1145F	MUTAGEN	Y->F: Does not affect phosphorylation state and enzymatic activity.	ECO:0000269|PubMed:8702790	8702790		
P29597	TYK2	Y1176F	P29597/Y1176F	TYK2/Y1176F	MUTAGEN	Y->F: Does not affect phosphorylation state and enzymatic activity.	ECO:0000269|PubMed:8702790	8702790		
P30291	WEE1	S53A	P30291/S53A	WEE1/S53A	MUTAGEN	S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-123.	ECO:0000269|PubMed:15070733	15070733		
P30291	WEE1	S123A	P30291/S123A	WEE1/S123A	MUTAGEN	S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-53.	ECO:0000269|PubMed:15070733	15070733		
P30530	AXL	R295W	P30530/R295W	AXL/R295W	VARIANT	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs751738506)	ECO:0000269|PubMed:17344846	17344846		
P30530	AXL	R499C	P30530/R499C	AXL/R499C	VARIANT	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs747576071)	ECO:0000269|PubMed:17344846	17344846		
P30530	AXL	E63R	P30530/E63R	AXL/E63R	MUTAGEN	E->R: Slightly reduced affinity for GAS6.	ECO:0000269|PubMed:16362042	16362042	decrease	
P30530	AXL	E66R	P30530/E66R	AXL/E66R	MUTAGEN	E->R: Reduced affinity for GAS6.	ECO:0000269|PubMed:16362042	16362042	decrease	
P30530	AXL	T84R	P30530/T84R	AXL/T84R	MUTAGEN	T->R: Reduced affinity for GAS6.	ECO:0000269|PubMed:16362042	16362042	decrease	
P30530	AXL	K567M	P30530/K567M	AXL/K567M	MUTAGEN	K->M: Catalytically inactive mutant.	ECO:0000269|PubMed:28076778	28076778	loss	
P31749	AKT1	R25C	P31749/R25C	AKT1/R25C	VARIANT	R->A,C: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	ECO:0000269|PubMed:12176338	12176338	decrease	
P31749	AKT1	T435P	P31749/T435P	AKT1/T435P	VARIANT	T -> P (in CWS6; dbSNP:rs397514645)	ECO:0000269|PubMed:23246288	23246288		
P31749	AKT1	K8R	P31749/K8R	AKT1/K8R	MUTAGEN	K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation as well as IGF1-induced membrane recruitment. Decrease in ubiquitination and phosphorylation at T-308 as well as impaired association with the membrane; when associated with K-17.	ECO:0000269|PubMed:19713527	19713527		
P31749	AKT1	K14A	P31749/K14A	AKT1/K14A	MUTAGEN	K->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285	12176338,19713527,21775285	decrease	
P31749	AKT1	K14R	P31749/K14R	AKT1/K14R	MUTAGEN	K->R: Substantial reduction of ubiquitination, phosphorylation at T-308 and S-473, AKT activation, loss of binding to PIP3 as well as IGF1-induced membrane recruitment.	ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285	12176338,19713527,21775285	decrease	
P31749	AKT1	K20Q	P31749/K20Q	AKT1/K20Q	MUTAGEN	K->Q: Substantial reduction of phosphorylation at T-308 and S-473, reduced AKT activation, and reduced binding to PIP3 as well as IGF1-induced membrane recruitment. Loss of membrane localization; when associated with K-17.	ECO:0000269|PubMed:21775285	21775285		
P31749	AKT1	K20R	P31749/K20R	AKT1/K20R	MUTAGEN	K->R: Slight increase of phosphorylation at T-308 and S-473.	ECO:0000269|PubMed:21775285	21775285	increase	
P31749	AKT1	R25A	P31749/R25A	AKT1/R25A	MUTAGEN	R->A,C: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	ECO:0000269|PubMed:12176338	12176338	decrease	
P31749	AKT1	R86A	P31749/R86A	AKT1/R86A	MUTAGEN	R->A: Impairs interaction with PtdIns(3,4,5)P3 and PtdIns(3,4)P2.	ECO:0000269|PubMed:12176338	12176338	decrease	
P31749	AKT1	Y176F	P31749/Y176F	AKT1/Y176F	MUTAGEN	Y->F: Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.	ECO:0000269|PubMed:20333297	20333297	decrease	
P31749	AKT1	T305A	P31749/T305A	AKT1/T305A	MUTAGEN	T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-312.	ECO:0000269|PubMed:22629392	22629392	increase	
P31749	AKT1	T308D	P31749/T308D	AKT1/T308D	MUTAGEN	T->D: 5-fold activation and 18-fold activation; when associated with D-473.	ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:8978681	122,443,018,978,681		
P31749	AKT1	T312A	P31749/T312A	AKT1/T312A	MUTAGEN	T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc levels even more; when associated with A-305.	ECO:0000269|PubMed:22629392	22629392	increase	
P31749	AKT1	S473D	P31749/S473D	AKT1/S473D	MUTAGEN	S->D: 7-fold activation and 25-fold activation; when associated with D-308.	ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:8978681	122,443,018,978,681		
P31749	AKT1	Y474F	P31749/Y474F	AKT1/Y474F	MUTAGEN	Y->F: 55% inhibition of activation.	ECO:0000269|PubMed:12149249	12149249	decrease	
P31751	AKT2	E17K	P31751/E17K	AKT2/E17K	VARIANT	E -> K (in HIHGHH; exhibits plasma membrane localization in serum-starved cells and produced inappropriate tonic nuclear exclusion of FOXO1 in preadipocytes; dbSNP:rs387906659)	ECO:0000269|PubMed:21979934	21979934	activating	
P31751	AKT2	R274H	P31751/R274H	AKT2/R274H	VARIANT	R -> H (in T2D; associated with typical metabolic dyslipidemia with elevated fastin triglyceride, high VLDL triglyceride/cholesterol ratios, low HDL cholesterol levels and high small dense LDL levels; de novo lipogenesis and liver fat are also significantly elevated in this subject; dbSNP:rs121434593)	ECO:0000269|PubMed:15166380, ECO:0000269|PubMed:19164855	15166380,19164855	increase	
P31751	AKT2	T309A	P31751/T309A	AKT2/T309A	MUTAGEN	T->A: Impairs interaction with TTC3; when associated with A-474.	ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950	1,589,045,020,059,950		
P31751	AKT2	T309E	P31751/T309E	AKT2/T309E	MUTAGEN	T->E: Constitutively active; when associated with D-474.	ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950	1,589,045,020,059,950		
P31751	AKT2	S474A	P31751/S474A	AKT2/S474A	MUTAGEN	S->A: Impairs interaction with TTC3; when associated with A-309.	ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950	1,589,045,020,059,950		
P31751	AKT2	S474D	P31751/S474D	AKT2/S474D	MUTAGEN	S->D: Constitutively active; when associated with E-309.	ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950	1,589,045,020,059,950		
P32298	GRK4	L425P	P32298/L425P	GRK4/L425P	VARIANT	L -> P	ECO:0000269|PubMed:17344846	17344846		
P34925	RYK	V243I	P34925/V243I	RYK/V243I	VARIANT	V -> I (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs746238409)	ECO:0000269|PubMed:17344846	17344846		
P34925	RYK	K364A	P34925/K364A	RYK/K364A	MUTAGEN	K->A: No induction of the MAPK pathway.	ECO:0000269|PubMed:10454588	10454588		
P34925	RYK	N484F	P34925/N484F	RYK/N484F	MUTAGEN	N->F: Gain of an autophosphorylation activity. Gain of an autophosphorylation activity; when associated with A-359. Gain of an autophosphorylation activity; when associated with G-334 and G-482.	ECO:0000269|PubMed:10454588	10454588	increase	
P34925	RYK	A485G	P34925/A485G	RYK/A485G	MUTAGEN	A->G: Gain of an autophosphorylation activity. Gain of an autophosphorylation activity; when associated with G-334 and F-481.	ECO:0000269|PubMed:10454588	10454588	increase	
P34947	GRK5	Q41L	P34947/Q41L	GRK5/Q41L	VARIANT	Q -> L (exerts a protective effect in heart failure and ischemia; dbSNP:rs2230345)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18425130	1,734,484,618,425,130		
P34947	GRK5	D163E	P34947/D163E	GRK5/D163E	VARIANT	D -> E (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P34947	GRK5	K215R	P34947/K215R	GRK5/K215R	MUTAGEN	K->R: Failed to phosphorylate p53/TP53.	ECO:0000269|PubMed:20124405	20124405	decrease	
P34947	GRK5	R388A	P34947/R388A	GRK5/R388A	MUTAGEN	R->A: Nuclear exclusion; when associated with A-389; A-391; A-393 and A-394.	ECO:0000269|PubMed:15542828	15542828		
P34947	GRK5	K389A	P34947/K389A	GRK5/K389A	MUTAGEN	K->A: Nuclear exclusion; when associated with A-388; A-391; A-393 and A-394.	ECO:0000269|PubMed:15542828	15542828		
P34947	GRK5	K391A	P34947/K391A	GRK5/K391A	MUTAGEN	K->A: Nuclear exclusion; when associated with A-388; A-389; A-393 and A-394.	ECO:0000269|PubMed:15542828	15542828		
P34947	GRK5	K393A	P34947/K393A	GRK5/K393A	MUTAGEN	K->A: Nuclear exclusion; when associated with A-388; A-389; A-391 and A-394.	ECO:0000269|PubMed:15542828	15542828		
P34947	GRK5	R394A	P34947/R394A	GRK5/R394A	MUTAGEN	R->A: Nuclear exclusion; when associated with A-388; A-389; A-391 and A-393.	ECO:0000269|PubMed:15542828	15542828		
P34947	GRK5	S484A	P34947/S484A	GRK5/S484A	MUTAGEN	S->A: 15-20 fold defects in kinase activity; when associated with A-485.	ECO:0000269|PubMed:8144599	8144599		
P34947	GRK5	T485A	P34947/T485A	GRK5/T485A	MUTAGEN	T->A: 15-20 fold defects in kinase activity; when associated with A-484.	ECO:0000269|PubMed:8144599	8144599		
P34947	GRK5	L550A	P34947/L550A	GRK5/L550A	MUTAGEN	L->A: No detectable plasma membrane localization; when associated with A-551; A-554; and A-555.	ECO:0000269|PubMed:14976207	14976207		
P34947	GRK5	L551A	P34947/L551A	GRK5/L551A	MUTAGEN	L->A: No detectable plasma membrane localization; when associated with A-550; A-554; and A-555.	ECO:0000269|PubMed:14976207	14976207		
P34947	GRK5	L554A	P34947/L554A	GRK5/L554A	MUTAGEN	L->A: No detectable plasma membrane localization; when associated with A-550; A-551; and A-555.	ECO:0000269|PubMed:14976207	14976207		
P34947	GRK5	F555A	P34947/F555A	GRK5/F555A	MUTAGEN	F->A: No detectable plasma membrane localization; when associated with A-550; A-551; and A-554.	ECO:0000269|PubMed:14976207	14976207		
P35590	TIE1	R481C	P35590/R481C	TIE1/R481C	VARIANT	R -> C (in LMPHM11; unknown pathological significance; dbSNP:rs139244400)	ECO:0000269|PubMed:32947856	32947856		
P35590	TIE1	E1061K	P35590/E1061K	TIE1/E1061K	VARIANT	E -> K (in LMPHM11; unknown pathological significance; dbSNP:rs760492428)	ECO:0000269|PubMed:32947856	32947856		
P35590	TIE1	R1109H	P35590/R1109H	TIE1/R1109H	VARIANT	R -> H (in LMPHM11; unknown pathological significance; dbSNP:rs34993202)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:32947856	17344846,32947856		
P35626	GRK3	R104K	P35626/R104K	GRK3/R104K	VARIANT	R -> K (in a lung bronchoalveolar carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P35916	FLT4	R378C	P35916/R378C	FLT4/R378C	VARIANT	R -> C (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs372947534)	ECO:0000269|PubMed:17344846	17344846		
P35916	FLT4	V878M	P35916/V878M	FLT4/V878M	VARIANT	V -> M (in LMPHM1; dbSNP:rs121909654)	ECO:0000269|PubMed:16965327	16965327		
P35916	FLT4	P954S	P35916/P954S	FLT4/P954S	VARIANT	P -> S (in HCI; dbSNP:rs34255532)	ECO:0000269|PubMed:11807987	11807987		
P35916	FLT4	T1010I	P35916/T1010I	FLT4/T1010I	VARIANT	T -> I (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P35916	FLT4	Q1020L	P35916/Q1020L	FLT4/Q1020L	VARIANT	Q -> L (in LMPHM1)	ECO:0000269|PubMed:17458866	17458866		
P35916	FLT4	H1035Q	P35916/H1035Q	FLT4/H1035Q	VARIANT	H -> Q (probable disease-associated variant found in sporadic congenital lymphedema; de novo mutation)	ECO:0000269|PubMed:16965327	16965327		
P35916	FLT4	I1086T	P35916/I1086T	FLT4/I1086T	VARIANT	I -> T (in LMPHM1; dbSNP:rs121909655)	ECO:0000269|PubMed:16965327	16965327		
P35916	FLT4	E1106K	P35916/E1106K	FLT4/E1106K	VARIANT	E -> K (in LMPHM1; dbSNP:rs121909656)	ECO:0000269|PubMed:16924388	16924388		
P35916	FLT4	P1137S	P35916/P1137S	FLT4/P1137S	VARIANT	P -> S (in HCI)	ECO:0000269|PubMed:11807987	11807987		
P35916	FLT4	L1173V	P35916/L1173V	FLT4/L1173V	VARIANT	L -> V (in CHTD7; unknown pathological significance)	ECO:0000269|PubMed:30232381	30232381		
P35916	FLT4	S1235C	P35916/S1235C	FLT4/S1235C	VARIANT	S -> C (in LMPHM1; recessive form)	ECO:0000269|PubMed:26091405	26091405		
P35916	FLT4	T446E	P35916/T446E	FLT4/T446E	MUTAGEN	T->E: Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516 and A-737.	ECO:0000269|PubMed:23878260	23878260		
P35916	FLT4	K516A	P35916/K516A	FLT4/K516A	MUTAGEN	K->A: Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-737.	ECO:0000269|PubMed:23878260	23878260		
P35916	FLT4	R737A	P35916/R737A	FLT4/R737A	MUTAGEN	R->A: Decreases autophosphorylation on tyrosine residues upon ligand binding. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-516.	ECO:0000269|PubMed:23878260	23878260		
P35916	FLT4	Y1063F	P35916/Y1063F	FLT4/Y1063F	MUTAGEN	Y->F: Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration.	ECO:0000269|PubMed:16076871, ECO:0000269|PubMed:20431062	16076871,20431062		
P35916	FLT4	Y1265F	P35916/Y1265F	FLT4/Y1265F	MUTAGEN	Y->F: Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration.	ECO:0000269|PubMed:12881528	12881528		
P35968	KDR	Q2R	P35968/Q2R	KDR/Q2R	VARIANT	Q -> R (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P35968	KDR	A248G	P35968/A248G	KDR/A248G	VARIANT	A -> G (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P35968	KDR	R275L	P35968/R275L	KDR/R275L	VARIANT	R -> L (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P35968	KDR	C482R	P35968/C482R	KDR/C482R	VARIANT	C -> R (in HCI; associated with disease susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced and KDR activity is increased compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation predicts to result in loss-of-function and disruption of the normal association of these molecules; dbSNP:rs34231037)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18931684	17344846,18931684	decrease	
P35968	KDR	G873R	P35968/G873R	KDR/G873R	VARIANT	G -> R (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P35968	KDR	P1147S	P35968/P1147S	KDR/P1147S	VARIANT	P -> S (in HCI; somatic mutation; dbSNP:rs121917766)	ECO:0000269|PubMed:11807987	11807987		
P35968	KDR	Y801F	P35968/Y801F	KDR/Y801F	MUTAGEN	Y->F: Abolishes stimulation of nitric oxide synthesis.	ECO:0000269|PubMed:17303569	17303569	loss	
P35968	KDR	Y951F	P35968/Y951F	KDR/Y951F	MUTAGEN	Y->F: Abolishes reorganization of the actin cytoskeleton and cell migration in response to VEGFA.	ECO:0000269|PubMed:15962004	15962004	loss	
P35968	KDR	Y1054F	P35968/Y1054F	KDR/Y1054F	MUTAGEN	Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1059.	ECO:0000269|PubMed:10102632	10102632		
P35968	KDR	Y1059F	P35968/Y1059F	KDR/Y1059F	MUTAGEN	Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1054.	ECO:0000269|PubMed:10102632	10102632		
P36507	MAP2K2	F57C	P36507/F57C	MAP2K2/F57C	VARIANT	F -> C (in CFC4; dbSNP:rs121434497)	ECO:0000269|PubMed:16439621	16439621		
P36507	MAP2K2	F57V	P36507/F57V	MAP2K2/F57V	VARIANT	F -> V (in CFC4; dbSNP:rs121434498)	ECO:0000269|PubMed:18042262	18042262		
P36507	MAP2K2	Y134H	P36507/Y134H	MAP2K2/Y134H	VARIANT	Y -> H (in CFC4; dbSNP:rs121434499)	ECO:0000269|PubMed:18042262	18042262		
P36888	FLT3	I836M	P36888/I836M	FLT3/I836M	VARIANT	I -> M (in acute lymphoblastic leukemia patients; somatic mutation; dbSNP:rs121913232)	ECO:0000269|PubMed:14504097	14504097		
P36888	FLT3	Y589F	P36888/Y589F	FLT3/Y589F	MUTAGEN	Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A.	ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679	16627759,16684964,9737679	decrease	
P36888	FLT3	Y591F	P36888/Y591F	FLT3/Y591F	MUTAGEN	Y->F: No significant effect on tyrosine phosphorylation. Abolishes activation of STAT5A.	ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:9737679	166,277,599,737,679	decrease	
P36888	FLT3	Y599F	P36888/Y599F	FLT3/Y599F	MUTAGEN	Y->F: Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2.	ECO:0000269|PubMed:16684964	16684964	decrease	
P36894	BMPR1A	F58Y	P36894/F58Y	BMPR1A/F58Y	VARIANT	F -> Y (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P36894	BMPR1A	Y62D	P36894/Y62D	BMPR1A/Y62D	VARIANT	Y -> D (in JPS)	ECO:0000269|PubMed:12417513	12417513		
P36894	BMPR1A	C82Y	P36894/C82Y	BMPR1A/C82Y	VARIANT	C -> Y (in JPS)	ECO:0000269|PubMed:12417513	12417513		
P36894	BMPR1A	C124R	P36894/C124R	BMPR1A/C124R	VARIANT	C -> R (in JPS; dbSNP:rs199476087)	ECO:0000269|PubMed:11536076	11536076		
P36894	BMPR1A	C130R	P36894/C130R	BMPR1A/C130R	VARIANT	C -> R (in JPS; dbSNP:rs1131691168)	ECO:0000269|PubMed:12136244	12136244		
P36894	BMPR1A	A338D	P36894/A338D	BMPR1A/A338D	VARIANT	A -> D (in JPS; dbSNP:rs199476086)	ECO:0000269|PubMed:11536076	11536076		
P36894	BMPR1A	C376Y	P36894/C376Y	BMPR1A/C376Y	VARIANT	C -> Y (in JPS; dbSNP:rs199476088)	ECO:0000269|PubMed:11536076	11536076		
P36894	BMPR1A	R443C	P36894/R443C	BMPR1A/R443C	VARIANT	R -> C (in JPS; dbSNP:rs35619497)	ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:17344846	12417513,17344846		
P36894	BMPR1A	M460T	P36894/M460T	BMPR1A/M460T	VARIANT	M -> T (found in a patient with tubular adenoma and rectal neuroendocrine tumor; unknown pathological significance; dbSNP:rs758309022)	ECO:0000269|PubMed:25860647	25860647		
P36894	BMPR1A	M470T	P36894/M470T	BMPR1A/M470T	VARIANT	M -> T (in JPS; dbSNP:rs199476089)	ECO:0000269|PubMed:12630959	12630959		
P36894	BMPR1A	R486Q	P36894/R486Q	BMPR1A/R486Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs752802257)	ECO:0000269|PubMed:17344846	17344846		
P36896	ACVR1B	I70A	P36896/I70A	ACVR1B/I70A	MUTAGEN	I->A: Decreases binding to activin.	ECO:0000269|PubMed:12665502	12665502	decrease	
P36896	ACVR1B	L75A	P36896/L75A	ACVR1B/L75A	MUTAGEN	L->A: Decreases binding to activin.	ECO:0000269|PubMed:12665502	12665502	decrease	
P36896	ACVR1B	P77A	P36896/P77A	ACVR1B/P77A	MUTAGEN	P->A: Decreases binding to activin.	ECO:0000269|PubMed:12665502	12665502	decrease	
P36897	TGFBR1	A26AA	P36897/A26AA	TGFBR1/A26AA	VARIANT	A -> AA (in allele TGFBR1*10A)	ECO:0000269|PubMed:9661882	9661882		
P36897	TGFBR1	C41Y	P36897/C41Y	TGFBR1/C41Y	VARIANT	C -> Y (in MSSE; hypomorphic variant)	ECO:0000269|PubMed:21358634	21358634		
P36897	TGFBR1	N45S	P36897/N45S	TGFBR1/N45S	VARIANT	N -> S (in MSSE; hypomorphic variant; dbSNP:rs387906696)	ECO:0000269|PubMed:21358634	21358634		
P36897	TGFBR1	G52R	P36897/G52R	TGFBR1/G52R	VARIANT	G -> R (in MSSE; hypomorphic variant; dbSNP:rs587776865)	ECO:0000269|PubMed:21358634	21358634		
P36897	TGFBR1	P83L	P36897/P83L	TGFBR1/P83L	VARIANT	P -> L (in MSSE; hypomorphic variant; dbSNP:rs757374917)	ECO:0000269|PubMed:21358634	21358634		
P36897	TGFBR1	T200I	P36897/T200I	TGFBR1/T200I	VARIANT	T -> I (in LDS1; dbSNP:rs121918712)	ECO:0000269|PubMed:15731757	15731757		
P36897	TGFBR1	K232E	P36897/K232E	TGFBR1/K232E	VARIANT	K -> E (in LDS1)	ECO:0000269|PubMed:16928994	16928994		
P36897	TGFBR1	S241L	P36897/S241L	TGFBR1/S241L	VARIANT	S -> L (in LDS1; dbSNP:rs111854391)	ECO:0000269|PubMed:16596670, ECO:0000269|PubMed:16791849	16596670,16791849		
P36897	TGFBR1	D266Y	P36897/D266Y	TGFBR1/D266Y	VARIANT	D -> Y (in LDS1)	ECO:0000269|PubMed:22113417	22113417		
P36897	TGFBR1	N267H	P36897/N267H	TGFBR1/N267H	VARIANT	N -> H (in a patient with Marfan syndrome)	ECO:0000269|PubMed:16791849	16791849		
P36897	TGFBR1	M318R	P36897/M318R	TGFBR1/M318R	VARIANT	M -> R (in LDS1; dbSNP:rs121918710)	ECO:0000269|PubMed:15731757	15731757		
P36897	TGFBR1	D351G	P36897/D351G	TGFBR1/D351G	VARIANT	D -> G (in LDS1)	ECO:0000269|PubMed:19883511	19883511		
P36897	TGFBR1	T375R	P36897/T375R	TGFBR1/T375R	VARIANT	T -> R (in LDS1; dbSNP:rs1827743139)	ECO:0000269|PubMed:22113417	22113417		
P36897	TGFBR1	D400G	P36897/D400G	TGFBR1/D400G	VARIANT	D -> G (in LDS1; dbSNP:rs121918711)	ECO:0000269|PubMed:15731757	15731757		
P36897	TGFBR1	R487P	P36897/R487P	TGFBR1/R487P	VARIANT	R -> P (in LDS1; dbSNP:rs113605875)	ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16928994	15731757,16928994		
P36897	TGFBR1	R487Q	P36897/R487Q	TGFBR1/R487Q	VARIANT	R -> Q (in LDS1; dbSNP:rs113605875)	ECO:0000269|PubMed:16791849, ECO:0000269|PubMed:16928994, ECO:0000269|PubMed:22113417	16791849,16928994,22113417		
P36897	TGFBR1	R487W	P36897/R487W	TGFBR1/R487W	VARIANT	R -> W (in LDS1; dbSNP:rs111426349)	ECO:0000269|PubMed:16928994	16928994		
P36897	TGFBR1	S187A	P36897/S187A	TGFBR1/S187A	MUTAGEN	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-189 and A-191.	ECO:0000269|PubMed:7774578	7774578		
P36897	TGFBR1	S189A	P36897/S189A	TGFBR1/S189A	MUTAGEN	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-191.	ECO:0000269|PubMed:7774578	7774578		
P36897	TGFBR1	S191A	P36897/S191A	TGFBR1/S191A	MUTAGEN	S->A: Loss of threonine phosphorylation, reduced phosphorylation on serine residues and loss of response to TGF-beta; when associated with 185-VV-186; A-187 and A-189.	ECO:0000269|PubMed:7774578	7774578		
P36897	TGFBR1	L193G	P36897/L193G	TGFBR1/L193G	MUTAGEN	L->G: Loss of interaction with FKBP1A.	ECO:0000269|PubMed:9233797	9233797	decrease	
P36897	TGFBR1	P194K	P36897/P194K	TGFBR1/P194K	MUTAGEN	P->K: Loss of interaction with FKBP1A.	ECO:0000269|PubMed:9233797	9233797	decrease	
P36897	TGFBR1	T200D	P36897/T200D	TGFBR1/T200D	MUTAGEN	T->D: Loss of response to TGF-beta.	ECO:0000269|PubMed:7774578	7774578	decrease	
P37023	ACVRL1	K8N	P37023/K8N	ACVRL1/K8N	VARIANT	K -> N	ECO:0000269|PubMed:24936649	24936649		
P37023	ACVRL1	P30S	P37023/P30S	ACVRL1/P30S	VARIANT	P -> S (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance; dbSNP:rs149664056)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	C34Y	P37023/C34Y	ACVRL1/C34Y	VARIANT	C -> Y (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	S38C	P37023/S38C	ACVRL1/S38C	VARIANT	S -> C	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	G48R	P37023/G48R	ACVRL1/G48R	VARIANT	G -> R (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	W50C	P37023/W50C	ACVRL1/W50C	VARIANT	W -> C (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs121909285)	ECO:0000269|PubMed:10767348, ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:9245985	10767348,14684682,9245985		
P37023	ACVRL1	W50G	P37023/W50G	ACVRL1/W50G	VARIANT	W -> G (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	C51Y	P37023/C51Y	ACVRL1/C51Y	VARIANT	C -> Y (in HHT2; dbSNP:rs863223409)	ECO:0000269|PubMed:10694922	10694922		
P37023	ACVRL1	T52A	P37023/T52A	ACVRL1/T52A	VARIANT	T -> A (in HHT2; dbSNP:rs1131691346)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	E59V	P37023/E59V	ACVRL1/E59V	VARIANT	E -> V (found in a patient with pulmonary arterial hypertension; unknown pathological significance; dbSNP:rs1466116430)	ECO:0000269|PubMed:24936649	24936649		
P37023	ACVRL1	H66P	P37023/H66P	ACVRL1/H66P	VARIANT	H -> P (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	R67Q	P37023/R67Q	ACVRL1/R67Q	VARIANT	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs863223414)	ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:9245985	146,846,829,245,985		
P37023	ACVRL1	R67W	P37023/R67W	ACVRL1/R67W	VARIANT	R -> W (in HHT2; dbSNP:rs1085307405)	ECO:0000269|PubMed:15712270	15712270		
P37023	ACVRL1	C69R	P37023/C69R	ACVRL1/C69R	VARIANT	C -> R (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	C77W	P37023/C77W	ACVRL1/C77W	VARIANT	C -> W (in HHT2; retained in the endoplasmic reticulum)	ECO:0000269|PubMed:10694922, ECO:0000269|PubMed:14684682	10694922,14684682		
P37023	ACVRL1	N96D	P37023/N96D	ACVRL1/N96D	VARIANT	N -> D (in HHT2)	ECO:0000269|PubMed:10694922	10694922		
P37023	ACVRL1	N96S	P37023/N96S	ACVRL1/N96S	VARIANT	N -> S (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	E111D	P37023/E111D	ACVRL1/E111D	VARIANT	E -> D (no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs1481094868)	ECO:0000269|PubMed:26176610	26176610		Neutral
P37023	ACVRL1	L138P	P37023/L138P	ACVRL1/L138P	VARIANT	L -> P	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	E159V	P37023/E159V	ACVRL1/E159V	VARIANT	E -> V (found in a patient with pulmonary arterial hypertension; unknown pathological significance)	ECO:0000269|PubMed:24936649	24936649		
P37023	ACVRL1	D176Y	P37023/D176Y	ACVRL1/D176Y	VARIANT	D -> Y (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	D179A	P37023/D179A	ACVRL1/D179A	VARIANT	D -> A (in HHT2; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs753792569)	ECO:0000269|PubMed:14684682	14684682		
P37023	ACVRL1	T197I	P37023/T197I	ACVRL1/T197I	VARIANT	T -> I (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	E215K	P37023/E215K	ACVRL1/E215K	VARIANT	E -> K (in HHT2; dbSNP:rs754283265)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	W217G	P37023/W217G	ACVRL1/W217G	VARIANT	W -> G (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	G219D	P37023/G219D	ACVRL1/G219D	VARIANT	G -> D (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	G223R	P37023/G223R	ACVRL1/G223R	VARIANT	G -> R (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	S225C	P37023/S225C	ACVRL1/S225C	VARIANT	S -> C (found in a patient with pulmonary arterial hypertension; unknown pathological significance)	ECO:0000269|PubMed:24936649	24936649		
P37023	ACVRL1	V226E	P37023/V226E	ACVRL1/V226E	VARIANT	V -> E (in HHT2; dbSNP:rs1565593639)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	K229R	P37023/K229R	ACVRL1/K229R	VARIANT	K -> R (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	S233L	P37023/S233L	ACVRL1/S233L	VARIANT	S -> L (in HHT2; dbSNP:rs762773076)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	Q237K	P37023/Q237K	ACVRL1/Q237K	VARIANT	Q -> K (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	I245V	P37023/I245V	ACVRL1/I245V	VARIANT	I -> V (in HHT2; no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; affects splicing by inducing the creation of a new donor splice site and the loss of the 3' end of exon 6)	ECO:0000269|PubMed:26176610	26176610		
P37023	ACVRL1	I260L	P37023/I260L	ACVRL1/I260L	VARIANT	I -> L (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	T265P	P37023/T265P	ACVRL1/T265P	VARIANT	T -> P (in HHT2; dbSNP:rs1592223978)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	T277K	P37023/T277K	ACVRL1/T277K	VARIANT	T -> K (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	H280R	P37023/H280R	ACVRL1/H280R	VARIANT	H -> R (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	L285F	P37023/L285F	ACVRL1/L285F	VARIANT	L -> F (in HHT2; dbSNP:rs1085307410)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	L289P	P37023/L289P	ACVRL1/L289P	VARIANT	L -> P (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	L294R	P37023/L294R	ACVRL1/L294R	VARIANT	L -> R (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	H328Q	P37023/H328Q	ACVRL1/H328Q	VARIANT	H -> Q (in HHT2; dbSNP:rs1565594410)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	S333I	P37023/S333I	ACVRL1/S333I	VARIANT	S -> I (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs863223413)	ECO:0000269|PubMed:10767348, ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:9245985	10767348,14684682,9245985		
P37023	ACVRL1	N335H	P37023/N335H	ACVRL1/N335H	VARIANT	N -> H (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	L337P	P37023/L337P	ACVRL1/L337P	VARIANT	L -> P (in HHT2; dbSNP:rs1592224349)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	C344R	P37023/C344R	ACVRL1/C344R	VARIANT	C -> R (in HHT2; dbSNP:rs1592224412)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	C344Y	P37023/C344Y	ACVRL1/C344Y	VARIANT	C -> Y (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs28936688)	ECO:0000269|PubMed:10767348, ECO:0000269|PubMed:14684682	10767348,14684682		
P37023	ACVRL1	A347D	P37023/A347D	ACVRL1/A347D	VARIANT	A -> D (in HHT2)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	A347P	P37023/A347P	ACVRL1/A347P	VARIANT	A -> P (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	R374Q	P37023/R374Q	ACVRL1/R374Q	VARIANT	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs1060503248)	ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15024723	14684682,15024723		
P37023	ACVRL1	R374W	P37023/R374W	ACVRL1/R374W	VARIANT	R -> W (in HHT2; dbSNP:rs28936401)	ECO:0000269|PubMed:11170071, ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:9245985	11170071,14684682,15712270,9245985		
P37023	ACVRL1	M376R	P37023/M376R	ACVRL1/M376R	VARIANT	M -> R (in HHT2; dbSNP:rs28936399)	ECO:0000269|PubMed:8640225	8640225		
P37023	ACVRL1	M376V	P37023/M376V	ACVRL1/M376V	VARIANT	M -> V (in HHT2; dbSNP:rs1555153277)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	P378L	P37023/P378L	ACVRL1/P378L	VARIANT	P -> L (in HHT2; retained in the endoplasmic reticulum)	ECO:0000269|PubMed:14684682	14684682		
P37023	ACVRL1	T396A	P37023/T396A	ACVRL1/T396A	VARIANT	T -> A (found in patients with pulmonary arterial hypertension; unknown pathological significance)	ECO:0000269|PubMed:24936649	24936649		
P37023	ACVRL1	D397G	P37023/D397G	ACVRL1/D397G	VARIANT	D -> G (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	I398N	P37023/I398N	ACVRL1/I398N	VARIANT	I -> N (in HHT2; dbSNP:rs121909286)	ECO:0000269|PubMed:11170071	11170071		
P37023	ACVRL1	W399S	P37023/W399S	ACVRL1/W399S	VARIANT	W -> S (in HHT2; dbSNP:rs121909289)	ECO:0000269|PubMed:14684682	14684682		
P37023	ACVRL1	A400T	P37023/A400T	ACVRL1/A400T	VARIANT	A -> T (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	L403P	P37023/L403P	ACVRL1/L403P	VARIANT	L -> P (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	E407D	P37023/E407D	ACVRL1/E407D	VARIANT	E -> D (in HHT2; dbSNP:rs1565595129)	ECO:0000269|PubMed:10767348, ECO:0000269|PubMed:15712270	1,076,734,815,712,270		
P37023	ACVRL1	R411P	P37023/R411P	ACVRL1/R411P	VARIANT	R -> P (in HHT2; dbSNP:rs121909284)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	R411Q	P37023/R411Q	ACVRL1/R411Q	VARIANT	R -> Q (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs121909284)	ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:8640225	14684682,15024723,8640225		
P37023	ACVRL1	G416S	P37023/G416S	ACVRL1/G416S	VARIANT	G -> S (in HHT2)	ECO:0000269|PubMed:16525724	16525724		
P37023	ACVRL1	I417F	P37023/I417F	ACVRL1/I417F	VARIANT	I -> F (no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs141653630)	ECO:0000269|PubMed:26176610	26176610		
P37023	ACVRL1	P424R	P37023/P424R	ACVRL1/P424R	VARIANT	P -> R (in HHT2; dbSNP:rs1940906429)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	P424T	P37023/P424T	ACVRL1/P424T	VARIANT	P -> T (in HHT2; dbSNP:rs1085307419)	ECO:0000269|PubMed:9245985	9245985		
P37023	ACVRL1	F425L	P37023/F425L	ACVRL1/F425L	VARIANT	F -> L (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	F425V	P37023/F425V	ACVRL1/F425V	VARIANT	F -> V (in HHT2)	ECO:0000269|PubMed:15712270	15712270		
P37023	ACVRL1	Y426C	P37023/Y426C	ACVRL1/Y426C	VARIANT	Y -> C (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	P433R	P37023/P433R	ACVRL1/P433R	VARIANT	P -> R (in HHT2)	ECO:0000269|PubMed:16752392	16752392		
P37023	ACVRL1	V441M	P37023/V441M	ACVRL1/V441M	VARIANT	V -> M (in HHT2; retained in the endoplasmic reticulum; dbSNP:rs1565596498)	ECO:0000269|PubMed:26176610	26176610		
P37023	ACVRL1	C443Y	P37023/C443Y	ACVRL1/C443Y	VARIANT	C -> Y (in HHT2; retained in the endoplasmic reticulum)	ECO:0000269|PubMed:26176610	26176610		
P37023	ACVRL1	P449S	P37023/P449S	ACVRL1/P449S	VARIANT	P -> S (in HHT2; dbSNP:rs1940908457)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	R479L	P37023/R479L	ACVRL1/R479L	VARIANT	R -> L (in HHT2)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	R479P	P37023/R479P	ACVRL1/R479P	VARIANT	R -> P (in HHT2; dbSNP:rs1085307426)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	A482V	P37023/A482V	ACVRL1/A482V	VARIANT	A -> V (in HHT2; dbSNP:rs139142865)	ECO:0000269|PubMed:15024723	15024723		
P37023	ACVRL1	R484W	P37023/R484W	ACVRL1/R484W	VARIANT	R -> W (in HHT2; dbSNP:rs121909288)	ECO:0000269|PubMed:11484689, ECO:0000269|PubMed:15024723	11484689,15024723		
P37023	ACVRL1	K486E	P37023/K486E	ACVRL1/K486E	VARIANT	K -> E (found in a patient with hereditary hemorrhagic talagiectasia; unknown pathological significance; dbSNP:rs113700354)	ECO:0000269|PubMed:20414677	20414677		
P37023	ACVRL1	K487T	P37023/K487T	ACVRL1/K487T	VARIANT	K -> T (in HHT2; mutant protein is capable of targeting the cell surface appropriately; dbSNP:rs1085307428)	ECO:0000269|PubMed:14684682	14684682		
P37173	TGFBR2	C61R	P37173/C61R	TGFBR2/C61R	VARIANT	C -> R (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P37173	TGFBR2	I73V	P37173/I73V	TGFBR2/I73V	VARIANT	I -> V (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P37173	TGFBR2	R190H	P37173/R190H	TGFBR2/R190H	VARIANT	R -> H (in LDS2; dbSNP:rs780542125)	ECO:0000269|PubMed:19533785	19533785		
P37173	TGFBR2	D247V	P37173/D247V	TGFBR2/D247V	VARIANT	D -> V (in LDS2; dbSNP:rs761231369)	ECO:0000269|PubMed:19533785	19533785		
P37173	TGFBR2	Q306HE	P37173/Q306HE	TGFBR2/Q306HE	VARIANT	Q -> HE (in LDS2)	ECO:0000269|PubMed:22113417	22113417		
P37173	TGFBR2	L308P	P37173/L308P	TGFBR2/L308P	VARIANT	L -> P (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs28934568)	ECO:0000269|PubMed:15235604, ECO:0000269|PubMed:20358619	15235604,20358619	decrease	
P37173	TGFBR2	T315M	P37173/T315M	TGFBR2/T315M	VARIANT	T -> M (in HNPCC6; dbSNP:rs34833812)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9590282	173,448,469,590,282		
P37173	TGFBR2	T325P	P37173/T325P	TGFBR2/T325P	VARIANT	T -> P (in LDS2)	ECO:0000269|PubMed:19533785	19533785		
P37173	TGFBR2	H328Y	P37173/H328Y	TGFBR2/H328Y	VARIANT	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P37173	TGFBR2	Y336N	P37173/Y336N	TGFBR2/Y336N	VARIANT	Y -> N (in LDS2; dbSNP:rs104893812)	ECO:0000269|PubMed:15731757	15731757		
P37173	TGFBR2	A355P	P37173/A355P	TGFBR2/A355P	VARIANT	A -> P (in LDS2; dbSNP:rs104893813)	ECO:0000269|PubMed:15731757	15731757		
P37173	TGFBR2	G357R	P37173/G357R	TGFBR2/G357R	VARIANT	G -> R (in LDS2)	ECO:0000269|PubMed:19533785	19533785		
P37173	TGFBR2	G357W	P37173/G357W	TGFBR2/G357W	VARIANT	G -> W (in LDS2; dbSNP:rs104893814)	ECO:0000269|PubMed:15731757	15731757		
P37173	TGFBR2	H377R	P37173/H377R	TGFBR2/H377R	VARIANT	H -> R (in LDS2; dbSNP:rs1553630274)	ECO:0000269|PubMed:22113417	22113417		
P37173	TGFBR2	V387M	P37173/V387M	TGFBR2/V387M	VARIANT	V -> M (in a breast tumor; dbSNP:rs35766612)	ECO:0000269|PubMed:11212236, ECO:0000269|PubMed:17344846	11212236,17344846		
P37173	TGFBR2	N435S	P37173/N435S	TGFBR2/N435S	VARIANT	N -> S (in a breast tumor; signaling of TGF-beta significantly inhibited)	ECO:0000269|PubMed:11212236	11212236	decrease	
P37173	TGFBR2	D446N	P37173/D446N	TGFBR2/D446N	VARIANT	D -> N (in LDS2; dbSNP:rs886039551)	ECO:0000269|PubMed:16251899	16251899	decrease	
P37173	TGFBR2	V447A	P37173/V447A	TGFBR2/V447A	VARIANT	V -> A (in a breast tumor; signaling of TGF-beta significantly inhibited)	ECO:0000269|PubMed:11212236	11212236	decrease	
P37173	TGFBR2	S449F	P37173/S449F	TGFBR2/S449F	VARIANT	S -> F (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs104893807)	ECO:0000269|PubMed:15235604, ECO:0000269|PubMed:22113417	15235604,22113417	decrease	
P37173	TGFBR2	L452M	P37173/L452M	TGFBR2/L452M	VARIANT	L -> M (in a breast tumor; signaling of TGF-beta significantly inhibited)	ECO:0000269|PubMed:11212236	11212236	decrease	
P37173	TGFBR2	M457K	P37173/M457K	TGFBR2/M457K	VARIANT	M -> K (in LDS2)	ECO:0000269|PubMed:20101701	20101701		
P37173	TGFBR2	R460C	P37173/R460C	TGFBR2/R460C	VARIANT	R -> C (in LDS2; dbSNP:rs104893811)	ECO:0000269|PubMed:16027248	16027248		
P37173	TGFBR2	R460H	P37173/R460H	TGFBR2/R460H	VARIANT	R -> H (in LDS2; dbSNP:rs104893816)	ECO:0000269|PubMed:16027248	16027248		
P37173	TGFBR2	N490S	P37173/N490S	TGFBR2/N490S	VARIANT	N -> S (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P37173	TGFBR2	G509V	P37173/G509V	TGFBR2/G509V	VARIANT	G -> V (in LDS2; dbSNP:rs863223853)	ECO:0000269|PubMed:21949523	21949523		
P37173	TGFBR2	I510F	P37173/I510F	TGFBR2/I510F	VARIANT	I -> F (in LDS2)	ECO:0000269|PubMed:21949523	21949523		
P37173	TGFBR2	I510S	P37173/I510S	TGFBR2/I510S	VARIANT	I -> S (in LDS2)	ECO:0000269|PubMed:19883511	19883511		
P37173	TGFBR2	C514R	P37173/C514R	TGFBR2/C514R	VARIANT	C -> R (in LDS2; dbSNP:rs193922664)	ECO:0000269|PubMed:22113417	22113417		
P37173	TGFBR2	W521R	P37173/W521R	TGFBR2/W521R	VARIANT	W -> R (in LDS2; dbSNP:rs1575166666)	ECO:0000269|PubMed:20358619	20358619		
P37173	TGFBR2	E526Q	P37173/E526Q	TGFBR2/E526Q	VARIANT	E -> Q (in esophageal cancer; dbSNP:rs121918714)	ECO:0000269|PubMed:10789724	10789724		
P37173	TGFBR2	R528C	P37173/R528C	TGFBR2/R528C	VARIANT	R -> C (in LDS2; dbSNP:rs104893810)	ECO:0000269|PubMed:15731757	15731757		
P37173	TGFBR2	R528H	P37173/R528H	TGFBR2/R528H	VARIANT	R -> H (in LDS2; dbSNP:rs104893815)	ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16959974	15731757,16959974		
P37173	TGFBR2	T530I	P37173/T530I	TGFBR2/T530I	VARIANT	T -> I (in LDS2)	ECO:0000269|PubMed:19533785	19533785		
P37173	TGFBR2	R537C	P37173/R537C	TGFBR2/R537C	VARIANT	R -> C (in LDS2; has a negative effect on TGF-beta signaling; dbSNP:rs104893809)	ECO:0000269|PubMed:15235604	15235604	decrease	
P41240	CSK	P45L	P41240/P45L	CSK/P45L	VARIANT	P -> L	ECO:0000269|PubMed:17344846	17344846		
P41279	MAP3K8	T290A	P41279/T290A	MAP3K8/T290A	MUTAGEN	T->A: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. Loss of IL1-stimulated MEK phosphorylation activity but not of IL1-stimulated autophosphorylation activity. No effect on KSR2 binding.	ECO:0000269|PubMed:15466476	15466476	loss	
P41279	MAP3K8	T290D	P41279/T290D	MAP3K8/T290D	MUTAGEN	T->D: Impaired MEK phosphorylation and autophosphorylation activities. No effect on KSR2 binding.	ECO:0000269|PubMed:15466476	15466476	decrease	
P41279	MAP3K8	T290E	P41279/T290E	MAP3K8/T290E	MUTAGEN	T->E: Loss of MEK phosphorylation activity and almost abolished autophosphorylation activity. No effect on KSR2 binding.	ECO:0000269|PubMed:15466476	15466476	decrease	
P41743	PRKCI	P118L	P41743/P118L	PRKCI/P118L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P41743	PRKCI	K29A	P41743/K29A	PRKCI/K29A	MUTAGEN	K->A: No effect on interaction with SQSTM1.	ECO:0000269|PubMed:15143057	15143057		
P41743	PRKCI	D72A	P41743/D72A	PRKCI/D72A	MUTAGEN	D->A: Loss of interaction with ECT2, PARD6A and with SQSTM1.	ECO:0000269|PubMed:15143057, ECO:0000269|PubMed:15590654, ECO:0000269|PubMed:19617897	15143057,15590654,19617897	decrease	
P41743	PRKCI	E85A	P41743/E85A	PRKCI/E85A	MUTAGEN	E->A: Slight decrease of interaction with PARD6A. Loss of interaction with PARD6A; when associated with A-91.	ECO:0000269|PubMed:15590654	15590654		
P41743	PRKCI	R91A	P41743/R91A	PRKCI/R91A	MUTAGEN	R->A: Slight decrease of interaction with PARD6A. Loss of interaction with PARD6A; when associated with A-85.	ECO:0000269|PubMed:15590654	15590654		
P41743	PRKCI	Y265F	P41743/Y265F	PRKCI/Y265F	MUTAGEN	Y->F: No effect on the SRC-mediated phosphorylation state. No effect on SRC-induced enzyme activity. Little effect on TRAF6-mediated activation of NF-kappa-B. Decreased binding to KPNB1/importin-beta.	ECO:0000269|PubMed:11713277, ECO:0000269|PubMed:11891849	11713277,11891849		
P41743	PRKCI	K274R	P41743/K274R	PRKCI/K274R	MUTAGEN	K->R: No effect on activity.	ECO:0000269|PubMed:10906326	10906326		
P41743	PRKCI	Y280F	P41743/Y280F	PRKCI/Y280F	MUTAGEN	Y->F: No effect on the SRC-mediated phosphorylation state. No effect on SRC-induced enzyme activity. No effect on TRAF6-mediated activation of NF-kappa-B.	ECO:0000269|PubMed:11713277	11713277		
P41743	PRKCI	Y334F	P41743/Y334F	PRKCI/Y334F	MUTAGEN	Y->F: No effect on the SRC-mediated phosphorylation state. Significant reduction of SRC-induced enzyme activity. Greatly reduced TRAF6-mediated activation of NF-kappa-B. Reduces NGF-dependent cell survival.	ECO:0000269|PubMed:11713277	11713277		
P42345	MTOR	A8S	P42345/A8S	MTOR/A8S	VARIANT	A -> S (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42345	MTOR	M135T	P42345/M135T	MTOR/M135T	VARIANT	M -> T (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42345	MTOR	R624H	P42345/R624H	MTOR/R624H	VARIANT	R -> H (in FCORD2; somatic mutation; unknown pathological significance; dbSNP:rs913197212)	ECO:0000269|PubMed:25799227	25799227		
P42345	MTOR	D1376E	P42345/D1376E	MTOR/D1376E	VARIANT	D -> E (found in a patient with focal epilepsy; unknown pathological significance; dbSNP:rs975577894)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	Y1450D	P42345/Y1450D	MTOR/Y1450D	VARIANT	Y -> D (in FCORD2; somatic mutation)	ECO:0000269|PubMed:25799227	25799227		
P42345	MTOR	W1456G	P42345/W1456G	MTOR/W1456G	VARIANT	W -> G (in FCORD2; somatic mutation; dbSNP:rs1085307114)	ECO:0000269|PubMed:25878179	25878179		
P42345	MTOR	A1459S	P42345/A1459S	MTOR/A1459S	VARIANT	A -> S (in FCORD2; somatic mutation)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	W1490R	P42345/W1490R	MTOR/W1490R	VARIANT	W -> R (in SKS)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	M1595I	P42345/M1595I	MTOR/M1595I	VARIANT	M -> I (in SKS; dbSNP:rs869312671)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	R1709H	P42345/R1709H	MTOR/R1709H	VARIANT	R -> H (in FCORD2; somatic mutation; unknown pathological significance; dbSNP:rs587777895)	ECO:0000269|PubMed:25799227	25799227		
P42345	MTOR	A1832T	P42345/A1832T	MTOR/A1832T	VARIANT	A -> T (in SKS; dbSNP:rs369088781)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	F1888C	P42345/F1888C	MTOR/F1888C	VARIANT	F -> C (in SKS; dbSNP:rs869312666)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	T1977K	P42345/T1977K	MTOR/T1977K	VARIANT	T -> K (in FCORD2; somatic mutation; dbSNP:rs587777893)	ECO:0000269|PubMed:25799227	25799227		
P42345	MTOR	M2011V	P42345/M2011V	MTOR/M2011V	VARIANT	M -> V (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42345	MTOR	R2193C	P42345/R2193C	MTOR/R2193C	VARIANT	R -> C (in FCORD2; somatic mutation)	ECO:0000269|PubMed:25799227	25799227		
P42345	MTOR	L2220F	P42345/L2220F	MTOR/L2220F	VARIANT	L -> F (found in a renal cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:21248752	21248752		
P42345	MTOR	M2327I	P42345/M2327I	MTOR/M2327I	VARIANT	M -> I (in SKS; dbSNP:rs878855328)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	V2406A	P42345/V2406A	MTOR/V2406A	VARIANT	V -> A (found in a renal cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:21248752	21248752		
P42345	MTOR	P2476L	P42345/P2476L	MTOR/P2476L	VARIANT	P -> L (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42345	MTOR	I2501V	P42345/I2501V	MTOR/I2501V	VARIANT	I -> V (found in a patient with non-lesional nocturnal frontal epilepsy; unknown pathological significance; dbSNP:rs968817513)	ECO:0000269|PubMed:27830187	27830187		
P42345	MTOR	S2159A	P42345/S2159A	MTOR/S2159A	MUTAGEN	S->A: Reduces mTORC1-associated S-2481 autophosphorylation; when associated with A-2164.	ECO:0000269|PubMed:21576368	21576368		
P42345	MTOR	S2159D	P42345/S2159D	MTOR/S2159D	MUTAGEN	S->D: Stronger phosphorylation of RPS6KB1; when associated with E-2164.	ECO:0000269|PubMed:21576368	21576368		
P42345	MTOR	T2164A	P42345/T2164A	MTOR/T2164A	MUTAGEN	T->A: Reduces mTORC1-associated S-2481 autophosphorylation; when associated with A-2159.	ECO:0000269|PubMed:21576368	21576368		
P42345	MTOR	T2164E	P42345/T2164E	MTOR/T2164E	MUTAGEN	T->E: Stronger phosphorylation of RPS6KB1; when associated with D-2159.	ECO:0000269|PubMed:21576368	21576368		
P42345	MTOR	D2357E	P42345/D2357E	MTOR/D2357E	MUTAGEN	D->E: Kinase-dead mutant, loss of interaction with TM4SF5 and loss of lysosome membrane localization; when associated with I-2364.	ECO:0000269|PubMed:30956113	30956113		
P42345	MTOR	V2364I	P42345/V2364I	MTOR/V2364I	MUTAGEN	V->I: Kinase-dead mutant, loss of interaction with TM4SF5 and loss of lysosome membrane localization; when associated with E-2357.	ECO:0000269|PubMed:30956113	30956113		
P42679	MATK	A354T	P42679/A354T	MATK/A354T	VARIANT	A -> T (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42679	MATK	R503Q	P42679/R503Q	MATK/R503Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs778726488)	ECO:0000269|PubMed:17344846	17344846		
P42680	TEC	R563K	P42680/R563K	TEC/R563K	VARIANT	R -> K (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P42681	TXK	Y91A	P42681/Y91A	TXK/Y91A	MUTAGEN	Y->A: Reduces expression levels if IFN-gamma.	ECO:0000269|PubMed:12081135	12081135		decrease
P42684	ABL2	E99Q	P42684/E99Q	ABL2/E99Q	VARIANT	E -> Q (somatic mutation in a breast cancer sample)	ECO:0000269|PubMed:17344846	17344846		
P42684	ABL2	R519I	P42684/R519I	ABL2/R519I	VARIANT	R -> I (somatic mutation in a lung squamous cell carcinoma)	ECO:0000269|PubMed:17344846	17344846		
P43250	GRK6	R31Q	P43250/R31Q	GRK6/R31Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs141014084)	ECO:0000269|PubMed:17344846	17344846		
P43250	GRK6	I275M	P43250/I275M	GRK6/I275M	VARIANT	I -> M (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P43250	GRK6	I6A	P43250/I6A	GRK6/I6A	MUTAGEN	I->A: 12-13 fold defects in kinase activity; 180-fold defects in kinase activity; when associated with A-7.	ECO:0000269|PubMed:20729810	20729810		
P43250	GRK6	V7A	P43250/V7A	GRK6/V7A	MUTAGEN	V->A: 12-13 fold defects in kinase activity; 180-fold defects in kinase activity; when associated with A-6.	ECO:0000269|PubMed:20729810	20729810		
P43250	GRK6	N9A	P43250/N9A	GRK6/N9A	MUTAGEN	N->A: 140-fold defects in kinase activity.	ECO:0000269|PubMed:20729810	20729810	loss	How little % do we need to call it a loss rather than decrease? Surely 140fold is enough to be called loss
P43250	GRK6	L12A	P43250/L12A	GRK6/L12A	MUTAGEN	L->A: 1100-fold defects in kinase activity.	ECO:0000269|PubMed:20729810	20729810	loss	
P43250	GRK6	C561S	P43250/C561S	GRK6/C561S	MUTAGEN	C->S: Abolishes palmitoylation; when associated with S-562 and S-565.	ECO:0000269|PubMed:7961702	7961702		
P43250	GRK6	C562S	P43250/C562S	GRK6/C562S	MUTAGEN	C->S: Abolishes palmitoylation; when associated with S-561 and S-565.	ECO:0000269|PubMed:7961702	7961702		
P43250	GRK6	C565S	P43250/C565S	GRK6/C565S	MUTAGEN	C->S: Abolishes palmitoylation; when associated with S-561 and S-562.	ECO:0000269|PubMed:7961702	7961702		
P43403	ZAP70	R192W	P43403/R192W	ZAP70/R192W	VARIANT	R -> W (in ADMIO2; decreases interaction with phosphorylated CD247; decreases ZAP70 phosphorylation; no effect on subcellular localization of CD69 at the cell surface; dbSNP:rs199840952)	ECO:0000269|PubMed:26783323	26783323	decrease	
P43403	ZAP70	L337R	P43403/L337R	ZAP70/L337R	VARIANT	L -> R (in IMD48; dbSNP:rs1254428002)	ECO:0000269|PubMed:18509675	18509675		
P43403	ZAP70	R360P	P43403/R360P	ZAP70/R360P	VARIANT	R -> P (in ADMIO2; no effect on interaction with phosphorylated CD247; increases TCR-induced Y-319 and Y-493 phosphorylation of ZAP70 and phosphorylation of LAT and LCP2; increases subcellular localization of CD69 at the cell surface; weakly decreases autoinhibition conformation; dbSNP:rs869025224)	ECO:0000269|PubMed:26783323	26783323	increase	
P43403	ZAP70	G448E	P43403/G448E	ZAP70/G448E	VARIANT	G -> E (in a head and neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P43403	ZAP70	R465C	P43403/R465C	ZAP70/R465C	VARIANT	R -> C (in IMD48; dbSNP:rs113994174)	ECO:0000269|PubMed:11123350	11123350		
P43403	ZAP70	R465H	P43403/R465H	ZAP70/R465H	VARIANT	R -> H (in IMD48; dbSNP:rs137853201)	ECO:0000269|PubMed:11412303	11412303		
P43403	ZAP70	A507V	P43403/A507V	ZAP70/A507V	VARIANT	A -> V (in IMD48)	ECO:0000269|PubMed:18509675	18509675		
P43403	ZAP70	S518R	P43403/S518R	ZAP70/S518R	VARIANT	S -> R (in IMD48; dbSNP:rs104893674)	ECO:0000269|PubMed:8202713	8202713		
P43403	ZAP70	K541KLEQ	P43403/K541KLEQ	ZAP70/K541KLEQ	VARIANT	K -> KLEQ (in IMD48)	ECO:0000269|PubMed:8124727	8124727		
P43403	ZAP70	C564R	P43403/C564R	ZAP70/C564R	VARIANT	C -> R (in IMD48)	ECO:0000269|PubMed:18509675	18509675		
P43403	ZAP70	R37K	P43403/R37K	ZAP70/R37K	MUTAGEN	R->K: Decreases interaction with phosphorylated CD247; when associated with K-190.	ECO:0000269|PubMed:26783323	26783323		
P43403	ZAP70	R190K	P43403/R190K	ZAP70/R190K	MUTAGEN	R->K: Decreases interaction with phosphorylated CD247; when associated with K-37.	ECO:0000269|PubMed:26783323	26783323		
P43403	ZAP70	K304R	P43403/K304R	ZAP70/K304R	MUTAGEN	K->R: No effect on ubiquitination.	ECO:0000269|PubMed:26903241	26903241		
P43403	ZAP70	Y315A	P43403/Y315A	ZAP70/Y315A	MUTAGEN	Y->A: Increased constitutive kinase activity; when associated with F-319.	ECO:0000269|PubMed:10037717, ECO:0000269|PubMed:11828374, ECO:0000269|PubMed:17512407, ECO:0000269|PubMed:9151714	10037717,11828374,17512407,9151714		
P43403	ZAP70	Y315F	P43403/Y315F	ZAP70/Y315F	MUTAGEN	Y->F: Increased constitutive kinase activity; when associated with F-319. About 75% loss of CD247/CD3Z-binding in stimulated TCR and complete loss of VAV1 interaction.	ECO:0000269|PubMed:10037717, ECO:0000269|PubMed:11828374, ECO:0000269|PubMed:17512407, ECO:0000269|PubMed:9151714	10037717,11828374,17512407,9151714		
P43403	ZAP70	Y319A	P43403/Y319A	ZAP70/Y319A	MUTAGEN	Y->A: Increased constitutive kinase activity; when associated with F-315.	ECO:0000269|PubMed:10037717, ECO:0000269|PubMed:17512407	10037717,17512407		
P43403	ZAP70	Y319F	P43403/Y319F	ZAP70/Y319F	MUTAGEN	Y->F: Increased constitutive kinase activity; when associated with F-315. About 80% loss of TCR-induced NFAT activation.	ECO:0000269|PubMed:10037717, ECO:0000269|PubMed:17512407	10037717,17512407		
P43403	ZAP70	K538R	P43403/K538R	ZAP70/K538R	MUTAGEN	K->R: No effect on ubiquitination.	ECO:0000269|PubMed:26903241	26903241		
P43403	ZAP70	K544R	P43403/K544R	ZAP70/K544R	MUTAGEN	K->R: Strongly decreased ubiquitination.	ECO:0000269|PubMed:26903241	26903241		increase
P43405	SYK	S297A	P43405/S297A	SYK/S297A	MUTAGEN	S->A: Abolishes YWHAG binding.	ECO:0000269|PubMed:21469132	21469132	decrease	
P43405	SYK	Y630F	P43405/Y630F	SYK/Y630F	MUTAGEN	Y->F: Loss of interaction with BLNK.	ECO:0000269|PubMed:18369315	18369315	decrease	
P45983	MAPK8	G171S	P45983/G171S	MAPK8/G171S	VARIANT	G -> S (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45983	MAPK8	G177R	P45983/G177R	MAPK8/G177R	VARIANT	G -> R (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45983	MAPK8	T183A	P45983/T183A	MAPK8/T183A	MUTAGEN	T->A: Phosphorylation blocked.	ECO:0000269|PubMed:7839144	7839144	decrease	
P45983	MAPK8	Y185F	P45983/Y185F	MAPK8/Y185F	MUTAGEN	Y->F: Phosphorylation blocked.	ECO:0000269|PubMed:7839144	7839144	decrease	
P45984	MAPK9	V13M	P45984/V13M	MAPK9/V13M	VARIANT	V -> M (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45984	MAPK9	K56N	P45984/K56N	MAPK9/K56N	VARIANT	K -> N (in a head & Neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45985	MAP2K4	Q142L	P45985/Q142L	MAP2K4/Q142L	VARIANT	Q -> L (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45985	MAP2K4	R154W	P45985/R154W	MAP2K4/R154W	VARIANT	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1567657403)	ECO:0000269|PubMed:17344846	17344846		
P45985	MAP2K4	N234I	P45985/N234I	MAP2K4/N234I	VARIANT	N -> I (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45985	MAP2K4	S251N	P45985/S251N	MAP2K4/S251N	VARIANT	S -> N (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P45985	MAP2K4	A279T	P45985/A279T	MAP2K4/A279T	VARIANT	A -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs753665559)	ECO:0000269|PubMed:17344846	17344846		
P46734	MAP2K3	R26T	P46734/R26T	MAP2K3/R26T	VARIANT	R -> T	ECO:0000269|PubMed:17344846	17344846		
P46734	MAP2K3	R175W	P46734/R175W	MAP2K3/R175W	VARIANT	R -> W (in colon cancer; dbSNP:rs1339756947)	ECO:0000269|PubMed:11414763	11414763		
P46734	MAP2K3	L215V	P46734/L215V	MAP2K3/L215V	VARIANT	L -> V (in colon cancer; dbSNP:rs989026404)	ECO:0000269|PubMed:11414763	11414763		
P46734	MAP2K3	S218A	P46734/S218A	MAP2K3/S218A	MUTAGEN	S->A: Inactivation.	ECO:0000269|PubMed:8622669	8622669	loss	
P46734	MAP2K3	T222A	P46734/T222A	MAP2K3/T222A	MUTAGEN	T->A: Inactivation.	ECO:0000269|PubMed:8622669	8622669	loss	
P48729	CSNK1A1	D297H	P48729/D297H	CSNK1A1/D297H	VARIANT	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P48730	CSNK1D	S97C	P48730/S97C	CSNK1D/S97C	VARIANT	S -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
P49137	MAPKAPK2	T222E	P49137/T222E	MAPKAPK2/T222E	MUTAGEN	T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-334.	ECO:0000269|PubMed:14517288, ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784	14517288,15014438,8846784		
P49137	MAPKAPK2	T334E	P49137/T334E	MAPKAPK2/T334E	MUTAGEN	T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-222.	ECO:0000269|PubMed:14517288, ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784	14517288,15014438,8846784		
P49336	CDK8	F97L	P49336/F97L	CDK8/F97L	VARIANT	F -> L (in IDDHBA; unknown pathological significance)	ECO:0000269|PubMed:30905399	30905399		
P49336	CDK8	D189N	P49336/D189N	CDK8/D189N	VARIANT	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P49336	CDK8	R424C	P49336/R424C	CDK8/R424C	VARIANT	R -> C (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P49336	CDK8	D173A	P49336/D173A	CDK8/D173A	MUTAGEN	D->A: Abrogates kinase activity and TFIIH-dependent transcriptional repression.	ECO:0000269|PubMed:10993082, ECO:0000269|PubMed:30905399	10993082,30905399	loss	
P49674	CSNK1E	R256L	P49674/R256L	CSNK1E/R256L	VARIANT	R -> L (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P49841	GSK3B	R96A	P49841/R96A	GSK3B/R96A	MUTAGEN	R->A: Prevents the phosphorylation of phosphate-primed glycogen synthase.	ECO:0000269|PubMed:11430833	11430833	loss	GSK3B is constitutively active
P49842	STK19	V134Y	P49842/V134Y	STK19/V134Y	MUTAGEN	V->Y: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30712867	30712867	decrease	
P49842	STK19	L139V	P49842/L139V	STK19/L139V	MUTAGEN	L->V: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30712867	30712867	decrease	
P50613	CDK7	G163A	P50613/G163A	CDK7/G163A	VARIANT	G -> A	ECO:0000269|Ref.6			
P50613	CDK7	K41M	P50613/K41M	CDK7/K41M	MUTAGEN	K->M: No effect on interaction with HINT1.	ECO:0000269|PubMed:10958787	10958787		
P50613	CDK7	F91G	P50613/F91G	CDK7/F91G	MUTAGEN	F->G: Enhanced capacity to bind ATP analogs.	ECO:0000269|PubMed:16327805	16327805		inconclusive
P50613	CDK7	S164A	P50613/S164A	CDK7/S164A	MUTAGEN	S->A: No mitotic repression of transcriptional activity of the reconstituted TFIIH complex.	ECO:0000269|PubMed:9832506	9832506		
P50613	CDK7	T170E	P50613/T170E	CDK7/T170E	MUTAGEN	T->E: No effect on interaction with HINT1.	ECO:0000269|PubMed:10958787	10958787		
P50750	CDK9	R225C	P50750/R225C	CDK9/R225C	VARIANT	R -> C (found in patients with global developmental delay and epilepsy with history of choanal atresia; unknown pathological significance; dbSNP:rs767418586)	ECO:0000269|PubMed:30237576	30237576		
P50750	CDK9	G231A	P50750/G231A	CDK9/G231A	VARIANT	G -> A	ECO:0000269|PubMed:10903437, ECO:0000269|PubMed:7695608	109,034,377,695,608		
P50750	CDK9	D167N	P50750/D167N	CDK9/D167N	MUTAGEN	D->N: Abrogates kinase activity.	ECO:0000269|PubMed:10958691, ECO:0000269|PubMed:11145967	10958691,11145967	loss	
P50750	CDK9	T186A	P50750/T186A	CDK9/T186A	MUTAGEN	T->A: Abrogates autophosphorylation; no effect on kinase activity, but impaired CTD phosphorylation.	ECO:0000269|PubMed:11145967, ECO:0000269|PubMed:18566585, ECO:0000269|PubMed:21448926	11145967,18566585,21448926	decrease	
P51451	BLK	A71T	P51451/A71T	BLK/A71T	VARIANT	A -> T (associated with MODY11; reduces the enhancing effect of BLK on insulin secretion; reduces the inducing effect of BLK on the expression of PDX1 and NKX6-1; found as somatic mutation in a colorectal adenocarcinoma sample; dbSNP:rs55758736)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19667185	17344846,19667185	decrease	
P51617	IRAK1	V412M	P51617/V412M	IRAK1/V412M	VARIANT	V -> M (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51617	IRAK1	Q421H	P51617/Q421H	IRAK1/Q421H	VARIANT	Q -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51617	IRAK1	S690G	P51617/S690G	IRAK1/S690G	VARIANT	S -> G (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51812	RPS6KA3	G75V	P51812/G75V	RPS6KA3/G75V	VARIANT	G -> V (in CLS; dbSNP:rs122454124)	ECO:0000269|PubMed:8955270	8955270		
P51812	RPS6KA3	V82F	P51812/V82F	RPS6KA3/V82F	VARIANT	V -> F (in CLS; dbSNP:rs122454126)	ECO:0000269|PubMed:9837815	9837815		
P51812	RPS6KA3	R114W	P51812/R114W	RPS6KA3/R114W	VARIANT	R -> W (in CLS; dbSNP:rs122454127)	ECO:0000269|PubMed:10094187	10094187		
P51812	RPS6KA3	T115S	P51812/T115S	RPS6KA3/T115S	VARIANT	T -> S (in XLID19; dbSNP:rs387906703)	ECO:0000269|PubMed:17100996	17100996		
P51812	RPS6KA3	H127Q	P51812/H127Q	RPS6KA3/H127Q	VARIANT	H -> Q (in CLS)	ECO:0000269|PubMed:9837815	9837815		
P51812	RPS6KA3	D154Y	P51812/D154Y	RPS6KA3/D154Y	VARIANT	D -> Y (in CLS)	ECO:0000269|PubMed:9837815	9837815		
P51812	RPS6KA3	I189K	P51812/I189K	RPS6KA3/I189K	VARIANT	I -> K (in CLS; dbSNP:rs122454130)	ECO:0000269|PubMed:10528858	10528858		
P51812	RPS6KA3	A225V	P51812/A225V	RPS6KA3/A225V	VARIANT	A -> V (in CLS; dbSNP:rs879027948)	ECO:0000269|PubMed:9837815	9837815		
P51812	RPS6KA3	S227A	P51812/S227A	RPS6KA3/S227A	VARIANT	S -> A (in CLS; dbSNP:rs122454125)	ECO:0000269|PubMed:8955270	8955270		
P51812	RPS6KA3	F268S	P51812/F268S	RPS6KA3/F268S	VARIANT	F -> S (in CLS; dbSNP:rs122454131)	ECO:0000269|PubMed:14986828	14986828		
P51812	RPS6KA3	I416V	P51812/I416V	RPS6KA3/I416V	VARIANT	I -> V (in a breast cancer sample; somatic mutation; dbSNP:rs148050184)	ECO:0000269|PubMed:16959974	16959974		
P51812	RPS6KA3	G431D	P51812/G431D	RPS6KA3/G431D	VARIANT	G -> D (in CLS)	ECO:0000269|PubMed:9837815	9837815		
P51812	RPS6KA3	Y483C	P51812/Y483C	RPS6KA3/Y483C	VARIANT	Y -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1271090915)	ECO:0000269|PubMed:17344846	17344846		
P51812	RPS6KA3	L608F	P51812/L608F	RPS6KA3/L608F	VARIANT	L -> F (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51812	RPS6KA3	R729Q	P51812/R729Q	RPS6KA3/R729Q	VARIANT	R -> Q (in CLS; dbSNP:rs28935171)	ECO:0000269|PubMed:10094187	10094187		
P51813	BMX	R670W	P51813/R670W	BMX/R670W	VARIANT	R -> W (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs1029888196)	ECO:0000269|PubMed:17344846	17344846		
P51817	PRKX	H93Q	P51817/H93Q	PRKX/H93Q	MUTAGEN	H->Q: Constitutive kinase activity; when associated with R-202.	ECO:0000269|PubMed:16236808	16236808		
P51817	PRKX	W202R	P51817/W202R	PRKX/W202R	MUTAGEN	W->R: Constitutive kinase activity; when associated with Q-93.	ECO:0000269|PubMed:16236808	16236808		
P51817	PRKX	R283L	P51817/R283L	PRKX/R283L	MUTAGEN	R->L: Increases the affinity for PRKAR2A and PRKAR2B.	ECO:0000269|PubMed:20819953	20819953	increase	
P51841	GUCY2F	R10P	P51841/R10P	GUCY2F/R10P	VARIANT	R -> P (in a breast cancer sample; somatic mutation; dbSNP:rs755991142)	ECO:0000269|PubMed:16959974	16959974		
P51841	GUCY2F	G568D	P51841/G568D	GUCY2F/G568D	VARIANT	G -> D (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs779221554)	ECO:0000269|PubMed:17344846	17344846		
P51841	GUCY2F	K1052R	P51841/K1052R	GUCY2F/K1052R	VARIANT	K -> R (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51841	GUCY2F	E1055D	P51841/E1055D	GUCY2F/E1055D	VARIANT	E -> D (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P51955	NEK2	T170A	P51955/T170A	NEK2/T170A	MUTAGEN	T->A: No effect on kinase activity.	ECO:0000269|PubMed:17197699	17197699		
P51955	NEK2	S171A	P51955/S171A	NEK2/S171A	MUTAGEN	S->A: No effect on kinase activity.	ECO:0000269|PubMed:17197699	17197699		
P51957	NEK4	R777K	P51957/R777K	NEK4/R777K	VARIANT	R -> K (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P52333	JAK3	Y100C	P52333/Y100C	JAK3/Y100C	VARIANT	Y -> C (in T(-)B(+)NK(-) SCID; dbSNP:rs137852624)	ECO:0000269|PubMed:7659163	7659163		
P52333	JAK3	P151R	P52333/P151R	JAK3/P151R	VARIANT	P -> R (in T(-)B(+)NK(-) SCID; likely benign variant; dbSNP:rs55778349)	ECO:0000269|PubMed:10982185, ECO:0000269|PubMed:17344846	10982185,17344846		
P52333	JAK3	D169E	P52333/D169E	JAK3/D169E	VARIANT	D -> E (in T(-)B(+)NK(-) SCID; dbSNP:rs147181709)	ECO:0000269|PubMed:14615376	14615376		
P52333	JAK3	E481G	P52333/E481G	JAK3/E481G	VARIANT	E -> G (in T(-)B(+)NK(-) SCID)	ECO:0000269|PubMed:9354668	9354668		
P52333	JAK3	L527P	P52333/L527P	JAK3/L527P	VARIANT	L -> P (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P52333	JAK3	R582W	P52333/R582W	JAK3/R582W	VARIANT	R -> W (in T(-)B(+)NK(-) SCID; dbSNP:rs193922361)	ECO:0000269|PubMed:9753072	9753072		
P52333	JAK3	G589S	P52333/G589S	JAK3/G589S	VARIANT	G -> S (in T(-)B(+)NK(-) SCID; dbSNP:rs886039394)	ECO:0000269|PubMed:14615376	14615376		
P52333	JAK3	L910S	P52333/L910S	JAK3/L910S	VARIANT	L -> S (in T(-)B(+)NK(-) SCID)	ECO:0000269|PubMed:10982185	10982185		
P52564	MAP2K6	S207A	P52564/S207A	MAP2K6/S207A	MUTAGEN	S->A: Inactivation.			loss	
P52564	MAP2K6	T211A	P52564/T211A	MAP2K6/T211A	MUTAGEN	T->A: Inactivation.			loss	
P53350	PLK1	R12L	P53350/R12L	PLK1/R12L	VARIANT	R -> L (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P53350	PLK1	C67V	P53350/C67V	PLK1/C67V	MUTAGEN	C->V: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with G-130.	ECO:0000269|PubMed:19468302	19468302		
P53350	PLK1	K82M	P53350/K82M	PLK1/K82M	MUTAGEN	K->M: Loss of kinase activity. No effect on S-phase progression.	ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:18174154, ECO:0000269|PubMed:24018379	12207013,12447691,18174154,24018379	loss	
P53350	PLK1	K82R	P53350/K82R	PLK1/K82R	MUTAGEN	K->R: Loss of kinase activity. No effect on RIOK2-binding.	ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488, ECO:0000269|PubMed:21880710	18615013,19160488,21880710	loss	
P53350	PLK1	L130G	P53350/L130G	PLK1/L130G	MUTAGEN	L->G: In analog-sensitive mutant; enlarged catalytic pocket to accommodate purine analogs; when associated with V-67.	ECO:0000269|PubMed:19468302	19468302		
P53350	PLK1	S137A	P53350/S137A	PLK1/S137A	MUTAGEN	S->A: No change in activity. Increases activity and restores recovery after DNA damage checkpoint; when associated with D-210.	ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:18615013	12207013,18615013		
P53350	PLK1	D194A	P53350/D194A	PLK1/D194A	MUTAGEN	D->A: Does not interfere with FRY-binding.	ECO:0000269|PubMed:22753416	22753416		
P53350	PLK1	T210V	P53350/T210V	PLK1/T210V	MUTAGEN	T->V: Reduced catalytic activity, but no effect on affinity for ATP.	ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553, ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488	12207013,12447691,17461553,18615013,19160488	decrease	
P53350	PLK1	R337A	P53350/R337A	PLK1/R337A	MUTAGEN	R->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-340.	ECO:0000269|PubMed:14734534, ECO:0000269|PubMed:18662541	14734534,18662541		
P53350	PLK1	L340A	P53350/L340A	PLK1/L340A	MUTAGEN	L->A: Interferes with ubiquitination and subsequent proteasomal degradation in anaphase; when associated with A-337.	ECO:0000269|PubMed:14734534, ECO:0000269|PubMed:18662541	14734534,18662541		
P53350	PLK1	W414F	P53350/W414F	PLK1/W414F	MUTAGEN	W->F: No effect on centrosomal localization, nor on S-phase progression; when asscociated with A-427. Loss of centrosomal localization and of S-phase progression; when associated with A- 415 and A-427.	ECO:0000269|PubMed:24018379	24018379		
P53350	PLK1	V415A	P53350/V415A	PLK1/V415A	MUTAGEN	V->A: Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-427.	ECO:0000269|PubMed:24018379	24018379		
P53350	PLK1	L427A	P53350/L427A	PLK1/L427A	MUTAGEN	L->A: No effect on centrosomal localization, nor on S-phase progression; when associated with A-414. Loss of centrosomal localization and of S-phase progression; when associated with A- 414 and A-415.	ECO:0000269|PubMed:24018379	24018379		
P53350	PLK1	H538A	P53350/H538A	PLK1/H538A	MUTAGEN	H->A: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with M-540.	ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:18477460, ECO:0000269|PubMed:19468302	14532005,16760428,18477460,19468302		
P53350	PLK1	K540M	P53350/K540M	PLK1/K540M	MUTAGEN	K->M: In pincer mutant; loss of centrosomal location and decreased interaction with phosphorylated CDC25C and BUB1; when associated with A-538.	ECO:0000269|PubMed:14532005, ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:18477460, ECO:0000269|PubMed:19468302	14532005,16760428,18477460,19468302		
P53355	DAPK1	A461S	P53355/A461S	DAPK1/A461S	VARIANT	A -> S	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	S519A	P53355/S519A	DAPK1/S519A	VARIANT	S -> A	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	M941T	P53355/M941T	DAPK1/M941T	VARIANT	M -> T	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	R977W	P53355/R977W	DAPK1/R977W	VARIANT	R -> W	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	K978N	P53355/K978N	DAPK1/K978N	VARIANT	K -> N	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	Y993C	P53355/Y993C	DAPK1/Y993C	VARIANT	Y -> C	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	D994E	P53355/D994E	DAPK1/D994E	VARIANT	D -> E	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	E1005Q	P53355/E1005Q	DAPK1/E1005Q	VARIANT	E -> Q	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	D1007Y	P53355/D1007Y	DAPK1/D1007Y	VARIANT	D -> Y	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	L1008P	P53355/L1008P	DAPK1/L1008P	VARIANT	L -> P	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	T1018A	P53355/T1018A	DAPK1/T1018A	VARIANT	T -> A	ECO:0000269|PubMed:17344846	17344846		
P53355	DAPK1	S289E	P53355/S289E	DAPK1/S289E	MUTAGEN	S->E: Reduction in proapoptotic activity.			decrease	
P53355	DAPK1	S308A	P53355/S308A	DAPK1/S308A	MUTAGEN	S->A: Elevated Ca(2+)-calmodulin binding and Ca(2+)-calmodulin-independent kinase activity. Increases apoptotic activity.	ECO:0000269|PubMed:11579085	11579085	increase	
P53355	DAPK1	S313A	P53355/S313A	DAPK1/S313A	MUTAGEN	S->A: Minimal effect on activity.	ECO:0000269|PubMed:11579085	11579085		
P53667	LIMK1	C84S	P53667/C84S	LIMK1/C84S	MUTAGEN	C->S: Enhances actin aggregation.	ECO:0000269|PubMed:10196227	10196227	increase	
P53667	LIMK1	D460N	P53667/D460N	LIMK1/D460N	MUTAGEN	D->N,A: Abrogates kinase activity.	ECO:0000269|PubMed:10196227, ECO:0000269|PubMed:22328514	10196227,22328514	loss	
P53667	LIMK1	D460A	P53667/D460A	LIMK1/D460A	MUTAGEN	D->N,A: Abrogates kinase activity.	ECO:0000269|PubMed:10196227, ECO:0000269|PubMed:22328514	10196227,22328514	loss	
P53671	LIMK2	D451A	P53671/D451A	LIMK2/D451A	MUTAGEN	D->A: Abrogates kinase activity.	ECO:0000269|PubMed:22328514	22328514	loss	
P53778	MAPK12	F330S	P53778/F330S	MAPK12/F330S	MUTAGEN	F->S: No effect.	ECO:0000269|PubMed:15284239	15284239		
P53779	MAPK10	C462S	P53779/C462S	MAPK10/C462S	MUTAGEN	C->S: Loss of palmitoylation.	ECO:0000269|PubMed:21941371	21941371	loss	
P53779	MAPK10	C463S	P53779/C463S	MAPK10/C463S	MUTAGEN	C->S: Loss of palmitoylation.	ECO:0000269|PubMed:21941371	21941371	loss	
P54646	PRKAA2	P371T	P54646/P371T	PRKAA2/P371T	VARIANT	P -> T (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
P54646	PRKAA2	R407Q	P54646/R407Q	PRKAA2/R407Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54646	PRKAA2	S523G	P54646/S523G	PRKAA2/S523G	VARIANT	S -> G (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
P54646	PRKAA2	T172D	P54646/T172D	PRKAA2/T172D	MUTAGEN	T->D: Phosphomimetic mutant.				
P54753	EPHB3	R168L	P54753/R168L	EPHB3/R168L	VARIANT	R -> L (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54753	EPHB3	R724W	P54753/R724W	EPHB3/R724W	VARIANT	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs371378866)	ECO:0000269|PubMed:17344846	17344846		
P54753	EPHB3	Y614F	P54753/Y614F	EPHB3/Y614F	MUTAGEN	Y->F: Partial loss of phosphorylation and loss of interaction with SH2-containing proteins.	ECO:0000269|PubMed:9674711	9674711		
P54756	EPHA5	R417Q	P54756/R417Q	EPHA5/R417Q	VARIANT	R -> Q (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs199614818)	ECO:0000269|PubMed:17344846	17344846		
P54756	EPHA5	E503K	P54756/E503K	EPHA5/E503K	VARIANT	E -> K (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54756	EPHA5	G582E	P54756/G582E	EPHA5/G582E	VARIANT	G -> E (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1057520012)	ECO:0000269|PubMed:17344846	17344846		
P54756	EPHA5	T856I	P54756/T856I	EPHA5/T856I	VARIANT	T -> I (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54756	EPHA5	N1032S	P54756/N1032S	EPHA5/N1032S	VARIANT	N -> S (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54760	EPHB4	E59K	P54760/E59K	EPHB4/E59K	VARIANT	E -> K (in CMAVM2; unknown pathological significance; dbSNP:rs1584667224)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	R74P	P54760/R74P	EPHB4/R74P	VARIANT	R -> P (in CMAVM2; unknown pathological significance; dbSNP:rs61735971)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	C107R	P54760/C107R	EPHB4/C107R	VARIANT	C -> R (in CMAVM2; unknown pathological significance; dbSNP:rs1562974383)	ECO:0000269|PubMed:29444212	29444212		
P54760	EPHB4	L187P	P54760/L187P	EPHB4/L187P	VARIANT	L -> P (in CMAVM2; unknown pathological significance; dbSNP:rs1584666053)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	C268R	P54760/C268R	EPHB4/C268R	VARIANT	C -> R (in CMAVM2; unknown pathological significance; dbSNP:rs201816920)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	P346L	P54760/P346L	EPHB4/P346L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267601191)	ECO:0000269|PubMed:17344846	17344846		
P54760	EPHB4	V469G	P54760/V469G	EPHB4/V469G	VARIANT	V -> G (in CMAVM2; unknown pathological significance; dbSNP:rs1584662591)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	A509G	P54760/A509G	EPHB4/A509G	VARIANT	A -> G (does not affect tyrosine phosphorylation; does not affect interaction with RASA1; dbSNP:rs146937374)	ECO:0000269|PubMed:30578106	30578106		
P54760	EPHB4	G516R	P54760/G516R	EPHB4/G516R	VARIANT	G -> R (in CMAVM2; unknown pathological significance; dbSNP:rs776305185)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	R656W	P54760/R656W	EPHB4/R656W	VARIANT	R -> W (in CMAVM2; unknown pathological significance; dbSNP:rs745584371)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	A725T	P54760/A725T	EPHB4/A725T	VARIANT	A -> T (in CMAVM2; unknown pathological significance; dbSNP:rs1159930961)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	N745D	P54760/N745D	EPHB4/N745D	VARIANT	N -> D (in CMAVM2; dbSNP:rs1584654433)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	P789R	P54760/P789R	EPHB4/P789R	VARIANT	P -> R (in CMAVM2; unknown pathological significance; dbSNP:rs753075600)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	P789S	P54760/P789S	EPHB4/P789S	VARIANT	P -> S (in CMAVM2; unknown pathological significance; dbSNP:rs1417508111)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	D802G	P54760/D802G	EPHB4/D802G	VARIANT	D -> G (in CMAVM2; dbSNP:rs776410552)	ECO:0000269|PubMed:28730721	28730721		
P54760	EPHB4	G807R	P54760/G807R	EPHB4/G807R	VARIANT	G -> R (in CMAVM2; unknown pathological significance; dbSNP:rs1330628156)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	P820L	P54760/P820L	EPHB4/P820L	VARIANT	P -> L (in CMAVM2; unknown pathological significance; dbSNP:rs1584653650)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	P820T	P54760/P820T	EPHB4/P820T	VARIANT	P -> T (in CMAVM2; unknown pathological significance; dbSNP:rs1584653653)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	C856Y	P54760/C856Y	EPHB4/C856Y	VARIANT	C -> Y (in CMAVM2; dbSNP:rs1584653005)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	F867L	P54760/F867L	EPHB4/F867L	VARIANT	F -> L (in CMAVM2; loss of tyrosine phosphorylation; loss of interaction with RASA1; dbSNP:rs1584652949)	ECO:0000269|PubMed:30578106	30578106	decrease	
P54760	EPHB4	V870E	P54760/V870E	EPHB4/V870E	VARIANT	V -> E (in CMAVM2; unknown pathological significance; dbSNP:rs1584652920)	ECO:0000269|PubMed:29444212	29444212		
P54760	EPHB4	L874P	P54760/L874P	EPHB4/L874P	VARIANT	L -> P (in CMAVM2; unknown pathological significance; dbSNP:rs1584652900)	ECO:0000269|PubMed:28687708	28687708		
P54760	EPHB4	R889W	P54760/R889W	EPHB4/R889W	VARIANT	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs762016655)	ECO:0000269|PubMed:17344846	17344846		
P54760	EPHB4	L95R	P54760/L95R	EPHB4/L95R	MUTAGEN	L->R: Reduces binding affinity for EFNB2.	ECO:0000269|PubMed:16867992	16867992	decrease	
P54762	EPHB1	S707T	P54762/S707T	EPHB1/S707T	VARIANT	S -> T (in an ovarian undifferentiated carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54762	EPHB1	I719V	P54762/I719V	EPHB1/I719V	VARIANT	I -> V (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P54762	EPHB1	R743Q	P54762/R743Q	EPHB1/R743Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1338928289)	ECO:0000269|PubMed:17344846	17344846		
P54762	EPHB1	Y594F	P54762/Y594F	EPHB1/Y594F	MUTAGEN	Y->F: Loss of interaction with NCK1.	ECO:0000269|PubMed:9430661	9430661	decrease	
P54762	EPHB1	Y600F	P54762/Y600F	EPHB1/Y600F	MUTAGEN	Y->F: Loss of interaction with SHC1 and SRC.	ECO:0000269|PubMed:12925710	12925710	decrease	
P54762	EPHB1	Y778F	P54762/Y778F	EPHB1/Y778F	MUTAGEN	Y->F: Loss of interaction with SHC1.	ECO:0000269|PubMed:12925710	12925710	decrease	
P54762	EPHB1	Y928F	P54762/Y928F	EPHB1/Y928F	MUTAGEN	Y->F: Disrupts binding with the GRB10 SH2 domain, providing evidence for phosphorylation. Disrupts interaction with GRB7 and ACP1.	ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9499402	12223469,8798570,9499402	decrease	
P54764	EPHA4	G370E	P54764/G370E	EPHA4/G370E	VARIANT	G -> E (in a bladder carcinoma NOS sample; somatic mutation; dbSNP:rs756952113)	ECO:0000269|PubMed:17344846	17344846		
P54764	EPHA4	S399F	P54764/S399F	EPHA4/S399F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation; dbSNP:rs868224085)	ECO:0000269|PubMed:17344846	17344846		
P54764	EPHA4	Q40A	P54764/Q40A	EPHA4/Q40A	MUTAGEN	Q->A: 10-fold reduced affinity for EFNB2; when associated with A-42.	ECO:0000269|PubMed:19875447	19875447		
P54764	EPHA4	E42A	P54764/E42A	EPHA4/E42A	MUTAGEN	E->A: 10-fold reduced affinity for EFNB2; when associated with A-40.	ECO:0000269|PubMed:19875447	19875447		
P57059	SIK1	G211S	P57059/G211S	SIK1/G211S	VARIANT	G -> S (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P57059	SIK1	P287T	P57059/P287T	SIK1/P287T	VARIANT	P -> T (in DEE30; no change in subcellular location; dbSNP:rs786205159)	ECO:0000269|PubMed:25839329	25839329		
P57059	SIK1	S411C	P57059/S411C	SIK1/S411C	VARIANT	S -> C (in DEE30; no change in subcellular location)	ECO:0000269|PubMed:25839329	25839329		
P57059	SIK1	G469D	P57059/G469D	SIK1/G469D	VARIANT	G -> D (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P57059	SIK1	G636S	P57059/G636S	SIK1/G636S	VARIANT	G -> S (in DEE30; no change in subcellular location; dbSNP:rs786205163)	ECO:0000269|PubMed:25839329	25839329		
P57059	SIK1	S186D	P57059/S186D	SIK1/S186D	MUTAGEN	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	ECO:0000269|PubMed:18348280	18348280		
P57059	SIK1	S186C	P57059/S186C	SIK1/S186C	MUTAGEN	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	ECO:0000269|PubMed:18348280	18348280		
P57059	SIK1	S186G	P57059/S186G	SIK1/S186G	MUTAGEN	S->A,D,C,G: Impaired autophosphorylation and kinase activity.	ECO:0000269|PubMed:18348280	18348280		
P57059	SIK1	S186T	P57059/S186T	SIK1/S186T	MUTAGEN	S->T: Does not autophosphorylation and kinase activity.	ECO:0000269|PubMed:18348280	18348280	decrease	
P57059	SIK1	T473A	P57059/T473A	SIK1/T473A	MUTAGEN	T->A: Reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity. Resistant to inhibition by cAMP signaling and, thus, still able to inhibit TORC activity; when associated with A-575.	ECO:0000269|PubMed:29211348	29211348		
P57059	SIK1	T473E	P57059/T473E	SIK1/T473E	MUTAGEN	T->E: Reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity.	ECO:0000269|PubMed:29211348	29211348	decrease	
P57059	SIK1	S575A	P57059/S575A	SIK1/S575A	MUTAGEN	S->A: Loss of interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit			decrease	
P57078	RIPK4	I81N	P57078/I81N	RIPK4/I81N	VARIANT	I -> N (in BPS; dbSNP:rs387906922)	ECO:0000269|PubMed:22197488	22197488		
P57078	RIPK4	G163D	P57078/G163D	RIPK4/G163D	VARIANT	G -> D (in CHANDS; unknown pathological significance; dbSNP:rs764278537)	ECO:0000269|PubMed:23610050	23610050		
P57078	RIPK4	P189L	P57078/P189L	RIPK4/P189L	VARIANT	P -> L (in BPS; unknown pathological significance)	ECO:0000269|PubMed:25691407	25691407		
P57078	RIPK4	E284K	P57078/E284K	RIPK4/E284K	VARIANT	E -> K (in CHANDS; unknown pathological significance)	ECO:0000269|PubMed:26129644	26129644		
P57078	RIPK4	A496P	P57078/A496P	RIPK4/A496P	VARIANT	A -> P (in BPS; unknown pathological significance)	ECO:0000269|PubMed:25691407	25691407		
P57078	RIPK4	R666H	P57078/R666H	RIPK4/R666H	VARIANT	R -> H (in BPS; unknown pathological significance; dbSNP:rs763794698)	ECO:0000269|PubMed:25691407	25691407		
P68400	CSNK2A1	R47Q	P68400/R47Q	CSNK2A1/R47Q	VARIANT	R -> Q (in OCNDS; dbSNP:rs869312845)	ECO:0000269|PubMed:27048600	27048600		
P68400	CSNK2A1	Y50S	P68400/Y50S	CSNK2A1/Y50S	VARIANT	Y -> S (in OCNDS; dbSNP:rs869312849)	ECO:0000269|PubMed:27048600	27048600		
P68400	CSNK2A1	D175G	P68400/D175G	CSNK2A1/D175G	VARIANT	D -> G (in OCNDS; dbSNP:rs869312848)	ECO:0000269|PubMed:27048600	27048600		
P68400	CSNK2A1	K198R	P68400/K198R	CSNK2A1/K198R	VARIANT	K -> R (in OCNDS; dbSNP:rs869312840)	ECO:0000269|PubMed:27048600	27048600		
P78362	SRPK2	G243D	P78362/G243D	SRPK2/G243D	VARIANT	G -> D (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	K263N	P78527/K263N	PRKDC/K263N	VARIANT	K -> N (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs758032015)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	G500S	P78527/G500S	PRKDC/G500S	VARIANT	G -> S (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	R1136H	P78527/R1136H	PRKDC/R1136H	VARIANT	R -> H (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs781401034)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	L1279F	P78527/L1279F	PRKDC/L1279F	VARIANT	L -> F	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	R1447M	P78527/R1447M	PRKDC/R1447M	VARIANT	R -> M (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	A1680V	P78527/A1680V	PRKDC/A1680V	VARIANT	A -> V (in a metastatic melanoma sample; somatic mutation; dbSNP:rs55735910)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	S2810N	P78527/S2810N	PRKDC/S2810N	VARIANT	S -> N (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	G2941A	P78527/G2941A	PRKDC/G2941A	VARIANT	G -> A (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P78527	PRKDC	L3062R	P78527/L3062R	PRKDC/L3062R	VARIANT	L -> R (in IMD26; shows increased long palindromic (P)-nucleotide stretches in the immunoglobulin coding joints indicating a defect in hairpin opening and insufficient DCLRE1C activation; dbSNP:rs587777685)	ECO:0000269|PubMed:19075392	19075392		
P78527	PRKDC	L1510P	P78527/L1510P	PRKDC/L1510P	MUTAGEN	L->P: Loss of interaction with C1D.	ECO:0000269|PubMed:9679063	9679063	decrease	
P78527	PRKDC	T2609A	P78527/T2609A	PRKDC/T2609A	MUTAGEN	T->A: Leads to radiation sensitivity and impaired				
P78527	PRKDC	S2612A	P78527/S2612A	PRKDC/S2612A	MUTAGEN	S->A: Reduced phosphorylation; when associated with A-2609.				
P78527	PRKDC	T2638A	P78527/T2638A	PRKDC/T2638A	MUTAGEN	T->A: Alleviates phosphorylation, leaves a fully active enzyme with compromised cellular resistance to ionizing radiation without affecting DNA end joining; when associated with A-2647.	ECO:0000269|PubMed:12649176	12649176		
P78527	PRKDC	T2647A	P78527/T2647A	PRKDC/T2647A	MUTAGEN	T->A: Alleviates phosphorylation, leaves a fully active enzyme with compromised cellular resistance to ionizing radiation without affecting DNA end joining; when associated with A-2638.	ECO:0000269|PubMed:12649176	12649176		
P80192	MAP3K9	A246V	P80192/A246V	MAP3K9/A246V	VARIANT	A -> V (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
P80192	MAP3K9	R467C	P80192/R467C	MAP3K9/R467C	VARIANT	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs773256562)	ECO:0000269|PubMed:17344846	17344846		
P80192	MAP3K9	T305A	P80192/T305A	MAP3K9/T305A	MUTAGEN	T->A: Little effect on threonine phosphorylation. Mildly impairs JNK activation.	ECO:0000269|PubMed:15610029	15610029	decrease	
Q00526	CDK3	S106N	Q00526/S106N	CDK3/S106N	VARIANT	S -> N (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q00534	CDK6	A197T	Q00534/A197T	CDK6/A197T	VARIANT	A -> T (in MCPH12; dbSNP:rs606231255)	ECO:0000269|PubMed:23918663	23918663		
Q00534	CDK6	P199L	Q00534/P199L	CDK6/P199L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q00535	CDK5	S159A	Q00535/S159A	CDK5/S159A	MUTAGEN	S->A: No phenotype.	ECO:0000269|PubMed:11583627	11583627		
Q00535	CDK5	S159T	Q00535/S159T	CDK5/S159T	MUTAGEN	S->T: Impaired p35/p25 (CDK5R1) binding.	ECO:0000269|PubMed:11583627	11583627	decrease	
Q00536	CDK16	S119A	Q00536/S119A	CDK16/S119A	MUTAGEN	S->A: Strongly reduces interaction with CCNY.	ECO:0000269|PubMed:22184064	22184064	decrease	
Q00536	CDK16	S153A	Q00536/S153A	CDK16/S153A	MUTAGEN	S->A: Constitutively activated, due to loss of an inhibitory phosphorylation site. Increases interaction with CCNY.	ECO:0000269|PubMed:22184064, ECO:0000269|PubMed:22798068	22184064,22798068	activating	
Q00536	CDK16	S153D	Q00536/S153D	CDK16/S153D	MUTAGEN	S->D: Abolishes interaction with CCNY.	ECO:0000269|PubMed:22184064, ECO:0000269|PubMed:22798068	22184064,22798068	decrease	
Q00537	CDK17	T214I	Q00537/T214I	CDK17/T214I	VARIANT	T -> I (found in a renal cell carcinoma sample; somatic mutation; dbSNP:rs764448325)	ECO:0000269|PubMed:21248752	21248752		
Q01973	ROR1	G144E	Q01973/G144E	ROR1/G144E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q01973	ROR1	F150L	Q01973/F150L	ROR1/F150L	VARIANT	F -> L (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q01973	ROR1	I301V	Q01973/I301V	ROR1/I301V	VARIANT	I -> V (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q01973	ROR1	E562D	Q01973/E562D	ROR1/E562D	VARIANT	E -> D (in a breast cancer sample; somatic mutation; dbSNP:rs760789417)	ECO:0000269|PubMed:16959974	16959974		
Q01973	ROR1	R567I	Q01973/R567I	ROR1/R567I	VARIANT	R -> I (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q01973	ROR1	R736T	Q01973/R736T	ROR1/R736T	VARIANT	R -> T (in DFNB108; impairs plasma membrane location; abolishes downstream NFkB activation; dbSNP:rs1553163562)	ECO:0000269|PubMed:27162350	27162350		
Q01973	ROR1	S776N	Q01973/S776N	ROR1/S776N	VARIANT	S -> N (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q01973	ROR1	C482G	Q01973/C482G	ROR1/C482G	MUTAGEN	C->G: No effect on kinase activity.	ECO:0000269|PubMed:25029443	25029443		
Q01974	ROR2	C182Y	Q01974/C182Y	ROR2/C182Y	VARIANT	C -> Y (in RRS1)	ECO:0000269|PubMed:10932187	10932187		
Q01974	ROR2	R184C	Q01974/R184C	ROR2/R184C	VARIANT	R -> C (in RRS1; dbSNP:rs121909084)	ECO:0000269|PubMed:10932186	10932186		
Q01974	ROR2	R189W	Q01974/R189W	ROR2/R189W	VARIANT	R -> W (in RRS1; dbSNP:rs199975149)	ECO:0000269|PubMed:10932186	10932186		
Q01974	ROR2	R366W	Q01974/R366W	ROR2/R366W	VARIANT	R -> W (in RRS1)	ECO:0000269|PubMed:10932186	10932186		
Q01974	ROR2	V542M	Q01974/V542M	ROR2/V542M	VARIANT	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs140213020)	ECO:0000269|PubMed:17344846	17344846		
Q01974	ROR2	N620K	Q01974/N620K	ROR2/N620K	VARIANT	N -> K (in RRS1)	ECO:0000269|PubMed:10932186	10932186		
Q02156	PRKCE	E143K	Q02156/E143K	PRKCE/E143K	VARIANT	E -> K (in a colorectal cancer sample; somatic mutation; dbSNP:rs772834505)	ECO:0000269|PubMed:16959974	16959974		
Q02156	PRKCE	T566E	Q02156/T566E	PRKCE/T566E	MUTAGEN	T->E: No effect on S-729 phosphorylation.	ECO:0000269|PubMed:11964154	11964154		
Q02156	PRKCE	T710E	Q02156/T710E	PRKCE/T710E	MUTAGEN	T->E: No effect on activity; no effect on S-729 phosphorylation.	ECO:0000269|PubMed:11964154	11964154		
Q02156	PRKCE	S729A	Q02156/S729A	PRKCE/S729A	MUTAGEN	S->A: Enhances T-566 dephosphorylation.	ECO:0000269|PubMed:11964154	11964154	decrease	
Q02750	MAP2K1	F53S	Q02750/F53S	MAP2K1/F53S	VARIANT	F -> S (in CFC3; dbSNP:rs121908594)	ECO:0000269|PubMed:16439621	16439621		
Q02750	MAP2K1	Q56P	Q02750/Q56P	MAP2K1/Q56P	VARIANT	Q -> P (in MEL; somatic mutation; dbSNP:rs1057519729)	ECO:0000269|PubMed:29643386	29643386		
Q02750	MAP2K1	K57E	Q02750/K57E	MAP2K1/K57E	VARIANT	K -> E (in MEL; somatic mutation; dbSNP:rs397516790)	ECO:0000269|PubMed:29643386	29643386		
Q02750	MAP2K1	G128V	Q02750/G128V	MAP2K1/G128V	VARIANT	G -> V (in CFC3; dbSNP:rs121908596)	ECO:0000269|PubMed:18042262	18042262		
Q02750	MAP2K1	Y130C	Q02750/Y130C	MAP2K1/Y130C	VARIANT	Y -> C (in CFC3; dbSNP:rs121908595)	ECO:0000269|PubMed:16439621	16439621		
Q02750	MAP2K1	K97R	Q02750/K97R	MAP2K1/K97R	MUTAGEN	K->R: Loss of catalytic activity. No effect on BRAF-KSR1 or BRAF-KSR2 dimerization.	ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:8131746	294,331,268,131,746	loss	
Q02750	MAP2K1	S150A	Q02750/S150A	MAP2K1/S150A	MUTAGEN	S->A: No loss of activity.	ECO:0000269|PubMed:8131746	8131746		
Q02750	MAP2K1	S212A	Q02750/S212A	MAP2K1/S212A	MUTAGEN	S->A: No loss of activity.	ECO:0000269|PubMed:8131746	8131746		
Q02750	MAP2K1	S218A	Q02750/S218A	MAP2K1/S218A	MUTAGEN	S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-222.	ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:8131746	294,331,268,131,746		
Q02750	MAP2K1	S218D	Q02750/S218D	MAP2K1/S218D	MUTAGEN	S->D: No effect on BRAF-KSR1 dimerization; when associated with D-222.	ECO:0000269|PubMed:29433126	29433126		
Q02750	MAP2K1	M219W	Q02750/M219W	MAP2K1/M219W	MUTAGEN	M->W: Increases interaction with KSR1 and BRAF; when associated with L-220.	ECO:0000269|PubMed:29433126	29433126		
Q02750	MAP2K1	A220L	Q02750/A220L	MAP2K1/A220L	MUTAGEN	A->L: Increases interaction with KSR1 and BRAF; when associated with w-219.	ECO:0000269|PubMed:29433126	29433126		
Q02750	MAP2K1	S222A	Q02750/S222A	MAP2K1/S222A	MUTAGEN	S->A: Loss of catalytic activity. No effect on BRAF-KSR1 dimerization; when associated with A-218.	ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:8131746	294,331,268,131,746		
Q02750	MAP2K1	S222D	Q02750/S222D	MAP2K1/S222D	MUTAGEN	S->D: No effect on BRAF-KSR1 dimerization; when associated with D-218.	ECO:0000269|PubMed:29433126	29433126		
Q02750	MAP2K1	F311S	Q02750/F311S	MAP2K1/F311S	MUTAGEN	F->S: Loss of interaction with BRAF and KSR1. Loss of BRAF-KSR1 dimerization.	ECO:0000269|PubMed:29433126	29433126	decrease	
Q02763	TEK	K117N	Q02763/K117N	TEK/K117N	VARIANT	K -> N (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
Q02763	TEK	C233Y	Q02763/C233Y	TEK/C233Y	VARIANT	C -> Y (in GLC3E; enhanced proteasomal degradation)	ECO:0000269|PubMed:27270174	27270174		
Q02763	TEK	K294N	Q02763/K294N	TEK/K294N	VARIANT	K -> N (in GLC3E; unknown pathological significance; 10-fold decrease of Tyr-1102 phosphorylation; no effect on membrane location; dbSNP:rs146169480)	ECO:0000269|PubMed:27270174	27270174		decrease
Q02763	TEK	Y611C	Q02763/Y611C	TEK/Y611C	VARIANT	Y -> C (in GLC3E; reduced response to ligand; loss of ligand-induced phosphorylation; no effect on basal membrane location; dbSNP:rs1306527531)	ECO:0000269|PubMed:27270174	27270174	loss	
Q02763	TEK	P883A	Q02763/P883A	TEK/P883A	VARIANT	P -> A (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1490428165)	ECO:0000269|PubMed:17344846	17344846		
Q02763	TEK	Y897F	Q02763/Y897F	TEK/Y897F	VARIANT	Y -> F (found in a patient with multiple sporadic venous malformations; increased ligand-independent autophosphorylation; the hyperphosphorylation increases when associated with Leu-915)	ECO:0000269|PubMed:19079259	19079259		
Q02763	TEK	R915L	Q02763/R915L	TEK/R915L	VARIANT	R -> L (found in a patient with multiple sporadic venous malformations; increased ligand-independent autophosphorylation; the autophosphorylation increases when associated with Phe-897)	ECO:0000269|PubMed:19079259	19079259		
Q02763	TEK	A1124V	Q02763/A1124V	TEK/A1124V	VARIANT	A -> V (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q02763	TEK	Y1102F	Q02763/Y1102F	TEK/Y1102F	MUTAGEN	Y->F: Abolishes interaction with SHC1.	ECO:0000269|PubMed:14665640	14665640	decrease	
Q02779	MAP3K10	G107E	Q02779/G107E	MAP3K10/G107E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q02846	GUCY2D	A52S	Q02846/A52S	GUCY2D/A52S	VARIANT	A -> S (in LCA1; unknown pathological significance; dbSNP:rs61749665)	ECO:0000269|PubMed:21602930, ECO:0000269|PubMed:8944027	216,029,308,944,027		
Q02846	GUCY2D	T55M	Q02846/T55M	GUCY2D/T55M	VARIANT	T -> M (in LCA1; dbSNP:rs201414567)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	E103V	Q02846/E103V	GUCY2D/E103V	VARIANT	E -> V (in LCA1)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	C105Y	Q02846/C105Y	GUCY2D/C105Y	VARIANT	C -> Y (in LCA1; does not affect basal guanylate cyclase activity; reduces GUCA1A-induced guanylate cyclase activity; dbSNP:rs61749669)	ECO:0000269|PubMed:11035546, ECO:0000269|PubMed:15123990	1,103,554,615,123,990		decrease
Q02846	GUCY2D	T312M	Q02846/T312M	GUCY2D/T312M	VARIANT	T -> M (in LCA1; dbSNP:rs61749673)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	L325P	Q02846/L325P	GUCY2D/L325P	VARIANT	L -> P (in LCA1; does not affect basal guanylate cyclase activity; reduces GUCA1A-induced guanylate cyclase activity; dbSNP:rs61749675)	ECO:0000269|PubMed:11035546, ECO:0000269|PubMed:15123990	1,103,554,615,123,990		decrease
Q02846	GUCY2D	L325R	Q02846/L325R	GUCY2D/L325R	VARIANT	L -> R (found in a patient with LCA1)	ECO:0000269|PubMed:17724218	17724218		
Q02846	GUCY2D	A362S	Q02846/A362S	GUCY2D/A362S	VARIANT	A -> S (in LCA1; dbSNP:rs61749677)				
Q02846	GUCY2D	G431D	Q02846/G431D	GUCY2D/G431D	VARIANT	G -> D (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1451501407)	ECO:0000269|PubMed:17344846	17344846		
Q02846	GUCY2D	R438C	Q02846/R438C	GUCY2D/R438C	VARIANT	R -> C (in LCA1; dbSNP:rs565948960)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	I573V	Q02846/I573V	GUCY2D/I573V	VARIANT	I -> V (in LCA1; dbSNP:rs61749756)				
Q02846	GUCY2D	W640L	Q02846/W640L	GUCY2D/W640L	VARIANT	W -> L (in LCA1)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	R660Q	Q02846/R660Q	GUCY2D/R660Q	VARIANT	R -> Q (in LCA1; dbSNP:rs61750162)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	P701S	Q02846/P701S	GUCY2D/P701S	VARIANT	P -> S (at homozygosity may be associated with Leber congenital amaurosis in some populations; dbSNP:rs34598902)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:17724218, ECO:0000269|PubMed:21602930	17344846,17724218,21602930		
Q02846	GUCY2D	A710V	Q02846/A710V	GUCY2D/A710V	VARIANT	A -> V (in LCA1; loss of basal and GUCA1A-induced guanylate cyclase activity; does not affect endoplasmic reticulum membrane localization; dbSNP:rs781725943)	ECO:0000269|PubMed:27475985, ECO:0000269|PubMed:30319355	27475985,30319355	loss	
Q02846	GUCY2D	D728H	Q02846/D728H	GUCY2D/D728H	VARIANT	D -> H (in LCA1)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	I734A	Q02846/I734A	GUCY2D/I734A	VARIANT	I -> A (in LCA1; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	R768W	Q02846/R768W	GUCY2D/R768W	VARIANT	R -> W (in LCA1 and CSNB1I; dbSNP:rs61750168)	ECO:0000269|PubMed:17724218, ECO:0000269|PubMed:21602930, ECO:0000269|PubMed:29559409	17724218,21602930,29559409		
Q02846	GUCY2D	M784R	Q02846/M784R	GUCY2D/M784R	VARIANT	M -> R (in LCA1; dbSNP:rs375010731)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	R795Q	Q02846/R795Q	GUCY2D/R795Q	VARIANT	R -> Q (in LCA1; dbSNP:rs61750171)	ECO:0000269|PubMed:17724218	17724218		
Q02846	GUCY2D	E837D	Q02846/E837D	GUCY2D/E837D	VARIANT	E -> D (in CORD6; dbSNP:rs28933695)	ECO:0000269|PubMed:9618177	9618177		
Q02846	GUCY2D	R838C	Q02846/R838C	GUCY2D/R838C	VARIANT	R -> C (in CORD6; dbSNP:rs61750172)	ECO:0000269|PubMed:12552567, ECO:0000269|PubMed:18487367, ECO:0000269|PubMed:25515582, ECO:0000269|PubMed:9618177	12552567,18487367,25515582,9618177		
Q02846	GUCY2D	R838G	Q02846/R838G	GUCY2D/R838G	VARIANT	R -> G (in CORD6)	ECO:0000269|PubMed:18487367	18487367		
Q02846	GUCY2D	R838H	Q02846/R838H	GUCY2D/R838H	VARIANT	R -> H (in CORD6; dbSNP:rs61750173)	ECO:0000269|PubMed:12552567, ECO:0000269|PubMed:18487367, ECO:0000269|PubMed:22194653, ECO:0000269|PubMed:24480840	12552567,18487367,22194653,24480840		
Q02846	GUCY2D	R838P	Q02846/R838P	GUCY2D/R838P	VARIANT	R -> P (in CORD6; dbSNP:rs61750173)	ECO:0000269|PubMed:21552474	21552474		
Q02846	GUCY2D	E841K	Q02846/E841K	GUCY2D/E841K	VARIANT	E -> K (in CORD6; decreases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1341592819)	ECO:0000269|PubMed:25515582, ECO:0000269|PubMed:30319355	25515582,30319355		decrease
Q02846	GUCY2D	K846N	Q02846/K846N	GUCY2D/K846N	VARIANT	K -> N (in CORD6; decreases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1598150539)	ECO:0000269|PubMed:25515582, ECO:0000269|PubMed:30319355	25515582,30319355		decrease
Q02846	GUCY2D	T849A	Q02846/T849A	GUCY2D/T849A	VARIANT	T -> A (in CORD6)	ECO:0000269|PubMed:23734073	23734073		
Q02846	GUCY2D	P858S	Q02846/P858S	GUCY2D/P858S	VARIANT	P -> S (in LCA1; severely impairs basal and GUCA1A-induced guanylate cyclase activity; dbSNP:rs61750176)	ECO:0000269|PubMed:11035546, ECO:0000269|PubMed:15123990	1,103,554,615,123,990		decrease
Q02846	GUCY2D	P873R	Q02846/P873R	GUCY2D/P873R	VARIANT	P -> R (in CORD6; loss basal and GUCA1A-induced guanylate cyclase activity; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1567961680)	ECO:0000269|PubMed:30319355	30319355	loss	
Q02846	GUCY2D	V902L	Q02846/V902L	GUCY2D/V902L	VARIANT	V -> L (in LCA1; increases basal and GUCA1A-induced guanylate cyclase activity; inhibition by RD3 is less effective; does not affect endoplasmic reticulum membrane localization; dbSNP:rs1598150793)	ECO:0000269|PubMed:30319355	30319355	increase	
Q02846	GUCY2D	V933A	Q02846/V933A	GUCY2D/V933A	VARIANT	V -> A (in CACD1; unknown pathological significance; dbSNP:rs1567961904)	ECO:0000269|PubMed:22695961	22695961		
Q02846	GUCY2D	I949T	Q02846/I949T	GUCY2D/I949T	VARIANT	I -> T (in CORD6; dbSNP:rs267606857)	ECO:0000269|PubMed:20517349	20517349		
Q02846	GUCY2D	L954P	Q02846/L954P	GUCY2D/L954P	VARIANT	L -> P (in LCA1; severely impairs basal and GUCA1A induced guanylate cyclase; dbSNP:rs61750182)	ECO:0000269|PubMed:12365911, ECO:0000269|PubMed:15123990	1,236,591,115,123,990		
Q02846	GUCY2D	S1007L	Q02846/S1007L	GUCY2D/S1007L	VARIANT	S -> L (in LCA1)	ECO:0000269|PubMed:21602930	21602930		
Q02846	GUCY2D	I1027IGI	Q02846/I1027IGI	GUCY2D/I1027IGI	VARIANT	I -> IGI (in LCA1)				
Q02846	GUCY2D	R822P	Q02846/R822P	GUCY2D/R822P	MUTAGEN	R->P: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.	ECO:0000269|PubMed:26100624	26100624	decrease	
Q02846	GUCY2D	M823R	Q02846/M823R	GUCY2D/M823R	MUTAGEN	M->R: Fails to become activated by GUCA1A and by GUCA1B. Does not affect the binding to RP3.	ECO:0000269|PubMed:26100624	26100624	decrease	
Q02846	GUCY2D	E925K	Q02846/E925K	GUCY2D/E925K	MUTAGEN	E->K: Changes the substrate specificity from GTP to ATP.	ECO:0000269|PubMed:9600905	9600905		
Q02846	GUCY2D	C997D	Q02846/C997D	GUCY2D/C997D	MUTAGEN	C->D: Changes the substrate specificity from GTP to ATP.	ECO:0000269|PubMed:9600905	9600905		
Q04759	PRKCQ	K240N	Q04759/K240N	PRKCQ/K240N	VARIANT	K -> N (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q04759	PRKCQ	Y90F	Q04759/Y90F	PRKCQ/Y90F	MUTAGEN	Y->F: Loss of function in T-cells proliferation. No effect on kinase activity.	ECO:0000269|PubMed:10652356	10652356		loss
Q04759	PRKCQ	T219A	Q04759/T219A	PRKCQ/T219A	MUTAGEN	T->A: Loss of transactivation of the IL2 promoter and translocation to the plasma membrane. No effect on kinase activity.	ECO:0000269|PubMed:16252004	16252004		
Q04759	PRKCQ	K409E	Q04759/K409E	PRKCQ/K409E	MUTAGEN	K->A,E: Loss of kinase activity.	ECO:0000269|PubMed:10652356	10652356	loss	
Q04771	ACVR1	P115S	Q04771/P115S	ACVR1/P115S	VARIANT	P -> S (in a melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q04771	ACVR1	R202I	Q04771/R202I	ACVR1/R202I	VARIANT	R -> I (in FOP; with some atypical features; dbSNP:rs387906591)	ECO:0000269|PubMed:19330033	19330033		
Q04771	ACVR1	R206H	Q04771/R206H	ACVR1/R206H	VARIANT	R -> H (in FOP; dbSNP:rs121912678)	ECO:0000269|PubMed:16642017, ECO:0000269|PubMed:19085907	16642017,19085907		
Q04771	ACVR1	Q207E	Q04771/Q207E	ACVR1/Q207E	VARIANT	Q -> E (in FOP; with some atypical features)	ECO:0000269|PubMed:19085907	19085907		
Q04771	ACVR1	G328E	Q04771/G328E	ACVR1/G328E	VARIANT	G -> E (in FOP; variant phenotype; dbSNP:rs387906589)	ECO:0000269|PubMed:19085907, ECO:0000269|PubMed:19330033	19085907,19330033		
Q04771	ACVR1	G328R	Q04771/G328R	ACVR1/G328R	VARIANT	G -> R (in FOP; variant phenotype; dbSNP:rs387906588)	ECO:0000269|PubMed:19085907	19085907		
Q04771	ACVR1	G328W	Q04771/G328W	ACVR1/G328W	VARIANT	G -> W (in FOP; variant phenotype; dbSNP:rs387906588)	ECO:0000269|PubMed:19085907	19085907		
Q04771	ACVR1	G356D	Q04771/G356D	ACVR1/G356D	VARIANT	G -> D (in FOP; variant phenotype; dbSNP:rs121912679)	ECO:0000269|PubMed:19085907	19085907		
Q04771	ACVR1	R375P	Q04771/R375P	ACVR1/R375P	VARIANT	R -> P (in FOP; variant phenotype; dbSNP:rs387906590)	ECO:0000269|PubMed:19085907	19085907		
Q04771	ACVR1	T203V	Q04771/T203V	ACVR1/T203V	MUTAGEN	T->V: Almost complete loss of alcaline phosphatase induction; in association with A-325.	ECO:0000269|PubMed:25354296	25354296		
Q04771	ACVR1	Q207D	Q04771/Q207D	ACVR1/Q207D	MUTAGEN	Q->D: Strong induction of SMAD1 phosphorylation.	ECO:0000269|PubMed:9748228	9748228	increase	
Q04771	ACVR1	G325A	Q04771/G325A	ACVR1/G325A	MUTAGEN	G->A: Almost complete loss of alcaline phosphatase induction; in association with V-203.	ECO:0000269|PubMed:25354296	25354296		
Q04912	MST1R	R306H	Q04912/R306H	MST1R/R306H	VARIANT	R -> H (in NPCA3; dbSNP:rs200046052)	ECO:0000269|PubMed:26951679	26951679		
Q04912	MST1R	A327T	Q04912/A327T	MST1R/A327T	VARIANT	A -> T (in NPCA3; unknown pathological significance; dbSNP:rs200757776)	ECO:0000269|PubMed:26951679	26951679		
Q04912	MST1R	V670G	Q04912/V670G	MST1R/V670G	VARIANT	V -> G (in NPCA3; unknown pathological significance; dbSNP:rs201024956)	ECO:0000269|PubMed:26951679	26951679		
Q04912	MST1R	A973T	Q04912/A973T	MST1R/A973T	VARIANT	A -> T (in NPCA3; unknown pathological significance; dbSNP:rs773053723)	ECO:0000269|PubMed:26951679	26951679		
Q05397	PTK2	H292P	Q05397/H292P	PTK2/H292P	VARIANT	H -> P	ECO:0000269|PubMed:17344846	17344846		
Q05397	PTK2	H292Q	Q05397/H292Q	PTK2/H292Q	VARIANT	H -> Q	ECO:0000269|PubMed:17344846	17344846		
Q05397	PTK2	V793A	Q05397/V793A	PTK2/V793A	VARIANT	V -> A (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q05397	PTK2	D1030E	Q05397/D1030E	PTK2/D1030E	VARIANT	D -> E	ECO:0000269|PubMed:17344846	17344846		
Q05397	PTK2	K1044E	Q05397/K1044E	PTK2/K1044E	VARIANT	K -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q05397	PTK2	Y397F	Q05397/Y397F	PTK2/Y397F	MUTAGEN	Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC and activation of BMX. Reduces phosphorylation of NEDD9.	ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:9360983	113,318,709,360,983	decrease	
Q05397	PTK2	V928G	Q05397/V928G	PTK2/V928G	MUTAGEN	V->G: Loss of interaction with TGFB1I1.	ECO:0000269|PubMed:9756887	9756887	decrease	
Q05397	PTK2	L1034S	Q05397/L1034S	PTK2/L1034S	MUTAGEN	L->S: Loss of interaction with TGFB1I1.	ECO:0000269|PubMed:9756887	9756887	decrease	
Q05513	PRKCZ	S514F	Q05513/S514F	PRKCZ/S514F	VARIANT	S -> F (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q05513	PRKCZ	R519C	Q05513/R519C	PRKCZ/R519C	VARIANT	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs376894109)	ECO:0000269|PubMed:17344846	17344846		
Q05513	PRKCZ	K19A	Q05513/K19A	PRKCZ/K19A	MUTAGEN	K->A: No effect on interaction with SQSTM1 and PARD6B.	ECO:0000269|PubMed:12887891	12887891		
Q05513	PRKCZ	D62A	Q05513/D62A	PRKCZ/D62A	MUTAGEN	D->A: Loss of interaction with SQSTM1 and PARD6B.	ECO:0000269|PubMed:12887891	12887891	decrease	
Q05513	PRKCZ	D66A	Q05513/D66A	PRKCZ/D66A	MUTAGEN	D->A: Loss of interaction with SQSTM1 and PARD6B.	ECO:0000269|PubMed:12887891	12887891	decrease	
Q05655	PRKCD	M494V	Q05655/M494V	PRKCD/M494V	VARIANT	M -> V	ECO:0000269|PubMed:7988719	7988719		
Q05655	PRKCD	V593M	Q05655/V593M	PRKCD/V593M	VARIANT	V -> M	ECO:0000269|PubMed:8357834	8357834		
Q05655	PRKCD	T507A	Q05655/T507A	PRKCD/T507A	MUTAGEN	T->A: No effect on kinase activity.	ECO:0000269|PubMed:11772397	11772397		
Q05823	RNASEL	D541E	Q05823/D541E	RNASEL/D541E	VARIANT	D -> E (no change in enzymatic activity; dbSNP:rs627928)	ECO:0000269|PubMed:11799394, ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, ECO:0000269|PubMed:17344846	11799394,11941539,12415269,17344846		
Q05823	RNASEL	K240N	Q05823/K240N	RNASEL/K240N	MUTAGEN	K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-274.	ECO:0000269|PubMed:7680958	7680958		
Q05823	RNASEL	K274N	Q05823/K274N	RNASEL/K274N	MUTAGEN	K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-240.	ECO:0000269|PubMed:7680958	7680958		
Q06187	BTK	L11P	Q06187/L11P	BTK/L11P	VARIANT	L -> P (in XLA; dbSNP:rs1603020228)				
Q06187	BTK	K12R	Q06187/K12R	BTK/K12R	VARIANT	K -> R (in XLA)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	S14F	Q06187/S14F	BTK/S14F	VARIANT	S -> F (in XLA; dbSNP:rs1057520682)				
Q06187	BTK	K19E	Q06187/K19E	BTK/K19E	VARIANT	K -> E (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	F25S	Q06187/F25S	BTK/F25S	VARIANT	F -> S (in XLA)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	K27R	Q06187/K27R	BTK/K27R	VARIANT	K -> R (in XLA)				
Q06187	BTK	R28C	Q06187/R28C	BTK/R28C	VARIANT	R -> C (in XLA; no effect on phosphorylation of GTF2I)				
Q06187	BTK	R28H	Q06187/R28H	BTK/R28H	VARIANT	R -> H (in XLA; moderate; dbSNP:rs128620185)	ECO:0000269|PubMed:7849721, ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:9445504	7849721,8162018,9445504		
Q06187	BTK	R28P	Q06187/R28P	BTK/R28P	VARIANT	R -> P (in XLA)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	T33P	Q06187/T33P	BTK/T33P	VARIANT	T -> P (in XLA; severe; dbSNP:rs128620189)	ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7849721	76,334,297,849,721		
Q06187	BTK	Y39S	Q06187/Y39S	BTK/Y39S	VARIANT	Y -> S (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	Y40C	Q06187/Y40C	BTK/Y40C	VARIANT	Y -> C (in XLA; dbSNP:rs1555980875)				
Q06187	BTK	Y40N	Q06187/Y40N	BTK/Y40N	VARIANT	Y -> N (in XLA)				
Q06187	BTK	I61N	Q06187/I61N	BTK/I61N	VARIANT	I -> N (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	V64D	Q06187/V64D	BTK/V64D	VARIANT	V -> D (in XLA)				
Q06187	BTK	V64F	Q06187/V64F	BTK/V64F	VARIANT	V -> F (in XLA)	ECO:0000269|PubMed:7849006	7849006		
Q06187	BTK	Q103QSVFSSTR	Q06187/Q103QSVFSSTR	BTK/Q103QSVFSSTR	VARIANT	Q -> QSVFSSTR (in XLA)				
Q06187	BTK	V113D	Q06187/V113D	BTK/V113D	VARIANT	V -> D (in XLA; dbSNP:rs128621190)	ECO:0000269|PubMed:7849697	7849697		
Q06187	BTK	S115F	Q06187/S115F	BTK/S115F	VARIANT	S -> F (in XLA)				
Q06187	BTK	T117P	Q06187/T117P	BTK/T117P	VARIANT	T -> P (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	Q127H	Q06187/Q127H	BTK/Q127H	VARIANT	Q -> H (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	C154S	Q06187/C154S	BTK/C154S	VARIANT	C -> S (in XLA)	ECO:0000269|PubMed:9280283	9280283		
Q06187	BTK	C155G	Q06187/C155G	BTK/C155G	VARIANT	C -> G (in XLA)				
Q06187	BTK	C155R	Q06187/C155R	BTK/C155R	VARIANT	C -> R (in XLA)	ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504	92,802,839,445,504		
Q06187	BTK	T184P	Q06187/T184P	BTK/T184P	VARIANT	T -> P (in XLA)				
Q06187	BTK	P190K	Q06187/P190K	BTK/P190K	VARIANT	P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:17344846	17344846		
Q06187	BTK	R288Q	Q06187/R288Q	BTK/R288Q	VARIANT	R -> Q (in XLA; dbSNP:rs1555978277)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	R288W	Q06187/R288W	BTK/R288W	VARIANT	R -> W (in XLA; dbSNP:rs128621194)	ECO:0000269|PubMed:7711734, ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8834236	7711734,8162018,8162056,8834236		
Q06187	BTK	L295P	Q06187/L295P	BTK/L295P	VARIANT	L -> P (in XLA)	ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:9445504	87,231,289,445,504		
Q06187	BTK	G302E	Q06187/G302E	BTK/G302E	VARIANT	G -> E (in XLA)	ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:8695804	76,271,838,695,804		
Q06187	BTK	G302R	Q06187/G302R	BTK/G302R	VARIANT	G -> R (in XLA)				
Q06187	BTK	R307T	Q06187/R307T	BTK/R307T	VARIANT	R -> T (in XLA)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	D308E	Q06187/D308E	BTK/D308E	VARIANT	D -> E (in XLA)				
Q06187	BTK	V319A	Q06187/V319A	BTK/V319A	VARIANT	V -> A (in XLA; moderate)				
Q06187	BTK	Y334S	Q06187/Y334S	BTK/Y334S	VARIANT	Y -> S (in XLA; dbSNP:rs128621196)	ECO:0000269|PubMed:7880320	7880320		
Q06187	BTK	L358F	Q06187/L358F	BTK/L358F	VARIANT	L -> F (in XLA)	ECO:0000269|PubMed:7897635	7897635		
Q06187	BTK	Y361C	Q06187/Y361C	BTK/Y361C	VARIANT	Y -> C (in XLA; mild; dbSNP:rs28935478)	ECO:0000269|PubMed:7849697	7849697		
Q06187	BTK	H362Q	Q06187/H362Q	BTK/H362Q	VARIANT	H -> Q (in XLA)				
Q06187	BTK	H364P	Q06187/H364P	BTK/H364P	VARIANT	H -> P (in XLA)				
Q06187	BTK	N365Y	Q06187/N365Y	BTK/N365Y	VARIANT	N -> Y (in XLA)				
Q06187	BTK	S366F	Q06187/S366F	BTK/S366F	VARIANT	S -> F (in XLA)				
Q06187	BTK	L369F	Q06187/L369F	BTK/L369F	VARIANT	L -> F (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	I370M	Q06187/I370M	BTK/I370M	VARIANT	I -> M (in XLA)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	R372G	Q06187/R372G	BTK/R372G	VARIANT	R -> G (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	L408P	Q06187/L408P	BTK/L408P	VARIANT	L -> P (in XLA; moderate; dbSNP:rs128621198)	ECO:0000269|PubMed:7849721	7849721		
Q06187	BTK	G414R	Q06187/G414R	BTK/G414R	VARIANT	G -> R (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	Y418H	Q06187/Y418H	BTK/Y418H	VARIANT	Y -> H (in XLA; dbSNP:rs144079566)				
Q06187	BTK	I429N	Q06187/I429N	BTK/I429N	VARIANT	I -> N (in XLA)	ECO:0000269|PubMed:8634718	8634718		
Q06187	BTK	K430R	Q06187/K430R	BTK/K430R	VARIANT	K -> R (in XLA)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	E445D	Q06187/E445D	BTK/E445D	VARIANT	E -> D (in XLA)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	G462D	Q06187/G462D	BTK/G462D	VARIANT	G -> D (in XLA)				
Q06187	BTK	G462V	Q06187/G462V	BTK/G462V	VARIANT	G -> V (in XLA)				
Q06187	BTK	Y476D	Q06187/Y476D	BTK/Y476D	VARIANT	Y -> D (in XLA)	ECO:0000269|PubMed:7627183	7627183		
Q06187	BTK	M477R	Q06187/M477R	BTK/M477R	VARIANT	M -> R (in XLA)	ECO:0000269|PubMed:8634718	8634718		
Q06187	BTK	C481S	Q06187/C481S	BTK/C481S	VARIANT	C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826)	ECO:0000269|PubMed:24869597, ECO:0000269|PubMed:24869598, ECO:0000269|PubMed:25189416	24869597,24869598,25189416		RESISTANCE
Q06187	BTK	C502F	Q06187/C502F	BTK/C502F	VARIANT	C -> F (in XLA)				
Q06187	BTK	C502W	Q06187/C502W	BTK/C502W	VARIANT	C -> W (in XLA; dbSNP:rs41310709)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	C506R	Q06187/C506R	BTK/C506R	VARIANT	C -> R (in XLA; dbSNP:rs128621200)	ECO:0000269|PubMed:7880320	7880320		
Q06187	BTK	C506Y	Q06187/C506Y	BTK/C506Y	VARIANT	C -> Y (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	A508D	Q06187/A508D	BTK/A508D	VARIANT	A -> D (in XLA)				
Q06187	BTK	M509I	Q06187/M509I	BTK/M509I	VARIANT	M -> I (in XLA)				
Q06187	BTK	M509V	Q06187/M509V	BTK/M509V	VARIANT	M -> V (in XLA)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	L512P	Q06187/L512P	BTK/L512P	VARIANT	L -> P (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	L512Q	Q06187/L512Q	BTK/L512Q	VARIANT	L -> Q (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	L518R	Q06187/L518R	BTK/L518R	VARIANT	L -> R (in XLA)				
Q06187	BTK	R520Q	Q06187/R520Q	BTK/R520Q	VARIANT	R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202)	ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7880320	7633429,7809124,7849697,7880320	loss	
Q06187	BTK	D521G	Q06187/D521G	BTK/D521G	VARIANT	D -> G (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	D521H	Q06187/D521H	BTK/D521H	VARIANT	D -> H (in XLA; severe)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	D521N	Q06187/D521N	BTK/D521N	VARIANT	D -> N (in XLA; severe)				
Q06187	BTK	A523E	Q06187/A523E	BTK/A523E	VARIANT	A -> E (in XLA)				
Q06187	BTK	R525G	Q06187/R525G	BTK/R525G	VARIANT	R -> G (in XLA; dbSNP:rs886041149)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	R525P	Q06187/R525P	BTK/R525P	VARIANT	R -> P (in XLA)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	R525Q	Q06187/R525Q	BTK/R525Q	VARIANT	R -> Q (in XLA; severe; disturbs ATP-binding; dbSNP:rs128620183)	ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:9445504	78,091,249,445,504	decrease	
Q06187	BTK	N526K	Q06187/N526K	BTK/N526K	VARIANT	N -> K (in XLA; dbSNP:rs1569291237)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	V535F	Q06187/V535F	BTK/V535F	VARIANT	V -> F (in XLA)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	L542P	Q06187/L542P	BTK/L542P	VARIANT	L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203)	ECO:0000269|PubMed:7849697	7849697		
Q06187	BTK	R544G	Q06187/R544G	BTK/R544G	VARIANT	R -> G (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	R544K	Q06187/R544K	BTK/R544K	VARIANT	R -> K (in XLA)	ECO:0000269|PubMed:8834236	8834236		
Q06187	BTK	F559S	Q06187/F559S	BTK/F559S	VARIANT	F -> S (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	R562P	Q06187/R562P	BTK/R562P	VARIANT	R -> P (in XLA; dbSNP:rs104894770)	ECO:0000269|PubMed:10678660, ECO:0000269|PubMed:7809124	106,786,607,809,124		
Q06187	BTK	R562W	Q06187/R562W	BTK/R562W	VARIANT	R -> W (in XLA; dbSNP:rs128621204)	ECO:0000269|PubMed:7711734, ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:9445504	7711734,7849697,7880320,9445504		
Q06187	BTK	W563L	Q06187/W563L	BTK/W563L	VARIANT	W -> L (in XLA; dbSNP:rs1555977474)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	E567K	Q06187/E567K	BTK/E567K	VARIANT	E -> K (in XLA; severe)	ECO:0000269|PubMed:7633420	7633420		
Q06187	BTK	S578Y	Q06187/S578Y	BTK/S578Y	VARIANT	S -> Y (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	W581R	Q06187/W581R	BTK/W581R	VARIANT	W -> R (in XLA; dbSNP:rs128621205)				
Q06187	BTK	A582V	Q06187/A582V	BTK/A582V	VARIANT	A -> V (in XLA)	ECO:0000269|PubMed:7711734, ECO:0000269|PubMed:7809124	77,117,347,809,124		
Q06187	BTK	F583S	Q06187/F583S	BTK/F583S	VARIANT	F -> S (in XLA)				
Q06187	BTK	M587L	Q06187/M587L	BTK/M587L	VARIANT	M -> L (in XLA; mild; dbSNP:rs1603001822)	ECO:0000269|PubMed:7633420	7633420		
Q06187	BTK	E589D	Q06187/E589D	BTK/E589D	VARIANT	E -> D (in XLA)				
Q06187	BTK	E589G	Q06187/E589G	BTK/E589G	VARIANT	E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206)	ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849721	78,091,247,849,721	decrease	
Q06187	BTK	E589K	Q06187/E589K	BTK/E589K	VARIANT	E -> K (in XLA)	ECO:0000269|PubMed:10612838	10612838		
Q06187	BTK	S592P	Q06187/S592P	BTK/S592P	VARIANT	S -> P (in XLA; dbSNP:rs1603001783)	ECO:0000269|PubMed:8834236	8834236		
Q06187	BTK	G594E	Q06187/G594E	BTK/G594E	VARIANT	G -> E (in XLA; mild; interferes with substrate binding)	ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:9445504	78,091,249,445,504	decrease	
Q06187	BTK	G594R	Q06187/G594R	BTK/G594R	VARIANT	G -> R (in XLA; dbSNP:rs1555977339)	ECO:0000269|PubMed:7711734	7711734		
Q06187	BTK	Y598C	Q06187/Y598C	BTK/Y598C	VARIANT	Y -> C (in XLA)				
Q06187	BTK	A607D	Q06187/A607D	BTK/A607D	VARIANT	A -> D (in XLA; mild; dbSNP:rs128621208)	ECO:0000269|PubMed:8162056	8162056		
Q06187	BTK	G613D	Q06187/G613D	BTK/G613D	VARIANT	G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209)	ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849721	78,091,247,849,721	decrease	
Q06187	BTK	P619A	Q06187/P619A	BTK/P619A	VARIANT	P -> A (in XLA)				
Q06187	BTK	P619S	Q06187/P619S	BTK/P619S	VARIANT	P -> S (in XLA)				
Q06187	BTK	P619T	Q06187/P619T	BTK/P619T	VARIANT	P -> T (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	A622P	Q06187/A622P	BTK/A622P	VARIANT	A -> P (in XLA)	ECO:0000269|PubMed:9545398	9545398		
Q06187	BTK	V626G	Q06187/V626G	BTK/V626G	VARIANT	V -> G (in XLA)	ECO:0000269|PubMed:9445504	9445504		
Q06187	BTK	M630I	Q06187/M630I	BTK/M630I	VARIANT	M -> I				
Q06187	BTK	M630K	Q06187/M630K	BTK/M630K	VARIANT	M -> K (in XLA; dbSNP:rs128621210)	ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7880320	78,496,977,880,320		
Q06187	BTK	M630T	Q06187/M630T	BTK/M630T	VARIANT	M -> T (in XLA)				
Q06187	BTK	C633Y	Q06187/C633Y	BTK/C633Y	VARIANT	C -> Y (in XLA)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	R641C	Q06187/R641C	BTK/R641C	VARIANT	R -> C (in XLA)	ECO:0000269|PubMed:7633429	7633429		
Q06187	BTK	R641H	Q06187/R641H	BTK/R641H	VARIANT	R -> H (in XLA; severe)	ECO:0000269|PubMed:7633420, ECO:0000269|PubMed:9445504	76,334,209,445,504		
Q06187	BTK	F644L	Q06187/F644L	BTK/F644L	VARIANT	F -> L (in XLA)				
Q06187	BTK	F644S	Q06187/F644S	BTK/F644S	VARIANT	F -> S (in XLA)	ECO:0000269|PubMed:8695804	8695804		
Q06187	BTK	L647P	Q06187/L647P	BTK/L647P	VARIANT	L -> P (in XLA)				
Q06187	BTK	L652P	Q06187/L652P	BTK/L652P	VARIANT	L -> P (in XLA; dbSNP:rs128622212)	ECO:0000269|PubMed:7849697	7849697		
Q06187	BTK	E41K	Q06187/E41K	BTK/E41K	MUTAGEN	E->K: No effect on phosphorylation of GTF2I.	ECO:0000269|PubMed:9012831	9012831		
Q06187	BTK	P189A	Q06187/P189A	BTK/P189A	MUTAGEN	P->A: No effect on phosphorylation of GTF2I.	ECO:0000269|PubMed:9012831	9012831		
Q06187	BTK	W251L	Q06187/W251L	BTK/W251L	MUTAGEN	W->L: No effect on phosphorylation of GTF2I.	ECO:0000269|PubMed:9012831	9012831		
Q06187	BTK	Y617E	Q06187/Y617E	BTK/Y617E	MUTAGEN	Y->E: Defective in mediating calcium response.	ECO:0000269|PubMed:15375214	15375214	decrease	
Q06418	TYRO3	A831T	Q06418/A831T	TYRO3/A831T	VARIANT	A -> T	ECO:0000269|PubMed:17344846	17344846		
Q06418	TYRO3	I99R	Q06418/I99R	TYRO3/I99R	MUTAGEN	I->R: Abolishes dimerization.	ECO:0000269|PubMed:14623883	14623883	loss	
Q07912	TNK2	R34L	Q07912/R34L	TNK2/R34L	VARIANT	R -> L (in a lung adenocarcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates; no effect on subcellular localization to perinuclear region)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20110370	1,734,484,620,110,370	increase	
Q07912	TNK2	R99Q	Q07912/R99Q	TNK2/R99Q	VARIANT	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on subcellular localization to perinuclear region; dbSNP:rs113498671)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20110370	1,734,484,620,110,370	increase	
Q07912	TNK2	E346K	Q07912/E346K	TNK2/E346K	VARIANT	E -> K (in an ovarian endometrioid cancer sample; somatic mutation; undergoes autoactivation and causes phosphorylation on Y-284 leading to activation of AKT1; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on catalytic activity itself as the purified kinase domain has activity in vitro comparable to wild-type protein; no effect on subcellular localization to perinuclear region; dbSNP:rs970946035)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297	17344846,20110370,20333297	increase	
Q07912	TNK2	M409I	Q07912/M409I	TNK2/M409I	VARIANT	M -> I (in a gastric adenocarcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on subcellular localization to perinuclear region)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:20110370	1,734,484,620,110,370	increase	
Q07912	TNK2	V638M	Q07912/V638M	TNK2/V638M	VARIANT	V -> M (found in patients with childhood-onset epilepsy; unknown pathological significance; loss of interaction with NEDD4 and NEDD4L; increased protein abundance; dbSNP:rs201407161)	ECO:0000269|PubMed:23686771	23686771	increase	
Q07912	TNK2	L120Q	Q07912/L120Q	TNK2/L120Q	MUTAGEN	L->Q: No effect on autophosphorylation at Y-284.	ECO:0000269|PubMed:20110370	20110370		
Q07912	TNK2	L197Q	Q07912/L197Q	TNK2/L197Q	MUTAGEN	L->Q: No effect on autophosphorylation at Y-284.	ECO:0000269|PubMed:20110370	20110370		
Q08345	DDR1	S496A	Q08345/S496A	DDR1/S496A	VARIANT	S -> A (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q08345	DDR1	R105A	Q08345/R105A	DDR1/R105A	MUTAGEN	R->A: Inhibits collagen-induced phosphorylation.	ECO:0000269|PubMed:24509848	24509848	decrease	
Q08345	DDR1	N211Q	Q08345/N211Q	DDR1/N211Q	MUTAGEN	N->Q: Sustained phosphorylation regardless of collagen presence, collagen addition does not alter significantly the levels of constitutive phosphorylation. Located intracellularly and at the cell surface. Displays a reduced rate of receptor internalization, which is not altered in the presence of collagen. Able to bind collagen as wild-type. Exhibits enhanced collagen-independent receptor dimerization. Complete loss of the collagen-independent constitutive activation; when associated with A-655.	ECO:0000269|PubMed:24509848	24509848		
Q08345	DDR1	N260Q	Q08345/N260Q	DDR1/N260Q	MUTAGEN	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	ECO:0000269|PubMed:24509848	24509848	decrease	
Q08345	DDR1	N371Q	Q08345/N371Q	DDR1/N371Q	MUTAGEN	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	ECO:0000269|PubMed:24509848	24509848	decrease	
Q08345	DDR1	T379A	Q08345/T379A	DDR1/T379A	MUTAGEN	T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-393.	ECO:0000269|PubMed:24509848	24509848		
Q08345	DDR1	T393A	Q08345/T393A	DDR1/T393A	MUTAGEN	T->A: Phosphorylates in response to collagen, but at lower levels compared to wild-type. Phosphorylates in response to collagen, but at lower levels compared to wild-type; when associated with A-379.	ECO:0000269|PubMed:24509848	24509848		
Q08345	DDR1	N394Q	Q08345/N394Q	DDR1/N394Q	MUTAGEN	N->Q: Phosphorylates in response to collagen, but at lower levels compared to wild-type. No activation in the absence of collagen.	ECO:0000269|PubMed:24509848	24509848	decrease	
Q08345	DDR1	K655A	Q08345/K655A	DDR1/K655A	MUTAGEN	K->A: Loss of kinase activity. Complete loss of the collagen-independent constitutive activation; when associated with Q-211.	ECO:0000269|PubMed:24509848	24509848		
Q08345	DDR1	G707A	Q08345/G707A	DDR1/G707A	MUTAGEN	G->A: Confers over 20-fold resistance to the ability of an inhibitor to inhibit autophosphorylation.	ECO:0000269|PubMed:23899692	23899692	increase	RESISTANCE
Q08345	DDR1	Y740F	Q08345/Y740F	DDR1/Y740F	MUTAGEN	Y->F: Abolishes interaction with PTPN11.	ECO:0000269|PubMed:16337946	16337946	decrease	
Q08881	ITK	R19K	Q08881/R19K	ITK/R19K	VARIANT	R -> K (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q08881	ITK	P23L	Q08881/P23L	ITK/P23L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q08881	ITK	R335W	Q08881/R335W	ITK/R335W	VARIANT	R -> W (in LPFS1; shows nearly undetectable mutant				
Q08881	ITK	R451Q	Q08881/R451Q	ITK/R451Q	VARIANT	R -> Q (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs779372373)	ECO:0000269|PubMed:17344846	17344846		
Q08881	ITK	P288G	Q08881/P288G	ITK/P288G	MUTAGEN	P->G: Complete loss of interaction with PPIA/CYPA.	ECO:0000269|PubMed:15308100	15308100	decrease	
Q09013	DMPK	L428V	Q09013/L428V	DMPK/L428V	VARIANT	L -> V (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q12852	MAP3K12	E409K	Q12852/E409K	MAP3K12/E409K	VARIANT	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q12866	MERTK	F214V	Q12866/F214V	MERTK/F214V	VARIANT	F -> V (found in a patient with Leber congenital amaurosis; dbSNP:rs1475870132)	ECO:0000269|PubMed:21602930	21602930		
Q12866	MERTK	A446G	Q12866/A446G	MERTK/A446G	VARIANT	A -> G (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q12866	MERTK	E540K	Q12866/E540K	MERTK/E540K	VARIANT	E -> K (in RP38; dbSNP:rs113485015)	ECO:0000269|PubMed:11062461	11062461		
Q12866	MERTK	S661C	Q12866/S661C	MERTK/S661C	VARIANT	S -> C (in RP38)	ECO:0000269|PubMed:11062461	11062461		
Q12866	MERTK	A708S	Q12866/A708S	MERTK/A708S	VARIANT	A -> S (in a head & Neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q12866	MERTK	I871T	Q12866/I871T	MERTK/I871T	VARIANT	I -> T (in RP38; dbSNP:rs377341255)	ECO:0000269|PubMed:11062461	11062461		
Q12866	MERTK	I871V	Q12866/I871V	MERTK/I871V	VARIANT	I -> V	ECO:0000269|PubMed:11062461	11062461		
Q12866	MERTK	P958L	Q12866/P958L	MERTK/P958L	VARIANT	P -> L (found in a patient with Leber congenital amaurosis; dbSNP:rs201460398)	ECO:0000269|PubMed:21602930	21602930		
Q12979	ABR	R683A	Q12979/R683A	ABR/R683A	MUTAGEN	R->A: Reduces GAP activity. Loss of GAP activity; when associated with A-795.	ECO:0000269|PubMed:17116687	17116687		
Q12979	ABR	N795A	Q12979/N795A	ABR/N795A	MUTAGEN	N->A: Loss of GAP activity; when associated with A-683.	ECO:0000269|PubMed:17116687	17116687		
Q12979	ABR	V859A	Q12979/V859A	ABR/V859A	MUTAGEN	V->A: Abolishes interaction with DLG4. No effect on synaptic localization.	ECO:0000269|PubMed:20962234	20962234	decrease	
Q13043	STK4	T175A	Q13043/T175A	STK4/T175A	MUTAGEN	T->A: No effect on activity.	ECO:0000269|PubMed:15109305	15109305		
Q13043	STK4	T177A	Q13043/T177A	STK4/T177A	MUTAGEN	T->A: No effect on activity.	ECO:0000269|PubMed:15109305	15109305		
Q13043	STK4	D326N	Q13043/D326N	STK4/D326N	MUTAGEN	D->N: Resistant to proteolytic cleavage by caspase during apoptosis; when associated with N-349.	ECO:0000269|PubMed:11278283	11278283		
Q13043	STK4	D349N	Q13043/D349N	STK4/D349N	MUTAGEN	D->N: Resistant to proteolytic cleavage by caspase during apoptosis; when associated with N-326.	ECO:0000269|PubMed:11278283	11278283		
Q13131	PRKAA1	Q16R	Q13131/Q16R	PRKAA1/Q16R	VARIANT	Q -> R (in a breast cancer sample; somatic mutation; dbSNP:rs928784854)	ECO:0000269|PubMed:16959974	16959974		
Q13131	PRKAA1	V307Q	Q13131/V307Q	PRKAA1/V307Q	MUTAGEN	V->G,Q: Activates the kinase activity.	ECO:0000269|PubMed:17088252	17088252	increase	
Q13153	PAK1	Y131C	Q13153/Y131C	PAK1/Y131C	VARIANT	Y -> C (in IDDMSSD; gain of function; enhanced PAK1 kinase activity and significantly reduced homodimerization; dbSNP:rs1565638316)	ECO:0000269|PubMed:30290153	30290153	increase	
Q13153	PAK1	Y429C	Q13153/Y429C	PAK1/Y429C	VARIANT	Y -> C (in IDDMSSD; gain-of-function; enhanced PAK1 kinase activity and significantly reduced homodimerization; dbSNP:rs1565583382)	ECO:0000269|PubMed:30290153	30290153	increase	
Q13153	PAK1	H83L	Q13153/H83L	PAK1/H83L	MUTAGEN	H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-86.	ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:9774440	105,518,099,774,440		
Q13153	PAK1	H86L	Q13153/H86L	PAK1/H86L	MUTAGEN	H->L: Abolishes interaction with CDC42, leading to strongly decreased activity; when associated with L-83.	ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:9774440	105,518,099,774,440		
Q13153	PAK1	K299R	Q13153/K299R	PAK1/K299R	MUTAGEN	K->R: Strongly decreases activity. Abolishes kinase activity; when associated with N-389.	ECO:0000269|PubMed:22153498	22153498		
Q13153	PAK1	D389N	Q13153/D389N	PAK1/D389N	MUTAGEN	D->N: Abolishes kinase activity; when associated with R-299.	ECO:0000269|PubMed:22153498	22153498		
Q13163	MAP2K5	K195M	Q13163/K195M	MAP2K5/K195M	MUTAGEN	K->M: Inactivation.	ECO:0000269|PubMed:7759517	7759517	loss	
Q13163	MAP2K5	S311A	Q13163/S311A	MAP2K5/S311A	MUTAGEN	S->A: Inactivation.	ECO:0000269|PubMed:7759517	7759517	loss	
Q13163	MAP2K5	T315A	Q13163/T315A	MAP2K5/T315A	MUTAGEN	T->A: Inactivation.	ECO:0000269|PubMed:7759517	7759517	loss	
Q13164	MAPK7	R535H	Q13164/R535H	MAPK7/R535H	VARIANT	R -> H	ECO:0000269|PubMed:17344846	17344846		
Q13177	PAK2	E435K	Q13177/E435K	PAK2/E435K	VARIANT	E -> K (in KNO2; loss of protein serine/threonine kinase activity)	ECO:0000269|PubMed:33693784	33693784	loss	
Q13177	PAK2	D212N	Q13177/D212N	PAK2/D212N	MUTAGEN	D->N: Inhibits caspase-mediated cleavage.	ECO:0000269|PubMed:9171063	9171063		
Q13177	PAK2	G213A	Q13177/G213A	PAK2/G213A	MUTAGEN	G->A: Abolishes myristoylation of PAK-2p34 and membrane location.	ECO:0000269|PubMed:16617111	16617111		
Q13188	STK3	V60L	Q13188/V60L	STK3/V60L	VARIANT	V -> L (in an ovarian clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13188	STK3	D322N	Q13188/D322N	STK3/D322N	MUTAGEN	D->N: Resistant to proteolytic cleavage.	ECO:0000269|PubMed:11278283	11278283		
Q13233	MAP3K1	S92N	Q13233/S92N	MAP3K1/S92N	VARIANT	S -> N	ECO:0000269|PubMed:17344846	17344846		
Q13233	MAP3K1	V211VIQ	Q13233/V211VIQ	MAP3K1/V211VIQ	VARIANT	V -> VIQ (in SRXY6)				
Q13233	MAP3K1	C443S	Q13233/C443S	MAP3K1/C443S	VARIANT	C -> S	ECO:0000269|PubMed:17344846	17344846		
Q13233	MAP3K1	G616R	Q13233/G616R	MAP3K1/G616R	VARIANT	G -> R (in SRXY6; unknown pathological significance; dbSNP:rs143853590)	ECO:0000269|PubMed:21129722	21129722		
Q13237	PRKG2	W716R	Q13237/W716R	PRKG2/W716R	VARIANT	W -> R (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13237	PRKG2	D412A	Q13237/D412A	PRKG2/D412A	MUTAGEN	D->A: Reduces cGMP binding affinity; when associated with A-415.	ECO:0000269|PubMed:26769964	26769964		
Q13237	PRKG2	R415A	Q13237/R415A	PRKG2/R415A	MUTAGEN	R->A: Reduces cGMP binding affinity; when associated with A-412.	ECO:0000269|PubMed:26769964	26769964		
Q13263	TRIM28	C65A	Q13263/C65A	TRIM28/C65A	MUTAGEN	C->A: Reduces nuclear localization activity of ZNF268; when associated with A-68.	ECO:0000269|PubMed:23665872	23665872		
Q13263	TRIM28	C68A	Q13263/C68A	TRIM28/C68A	MUTAGEN	C->A: Reduces nuclear localization activity of ZNF268; when associated with A-65.	ECO:0000269|PubMed:23665872	23665872		
Q13263	TRIM28	L306P	Q13263/L306P	TRIM28/L306P	MUTAGEN	L->P: Disrupts the interaction with ZNF350 and amost completely relieves the transcription repressive effect of sumoylated TRIM28.	ECO:0000269|PubMed:17942393	17942393		
Q13263	TRIM28	K366G	Q13263/K366G	TRIM28/K366G	MUTAGEN	K->G: Greatly reduced interaction with PPP1CA.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	I368G	Q13263/I368G	TRIM28/I368G	MUTAGEN	I->G: Increased interaction with PPP1CA. Greatly decreased phosphorylation on S-824.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	F370A	Q13263/F370A	TRIM28/F370A	MUTAGEN	F->A: Some reduction in interaction with PPP1CA.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	F370G	Q13263/F370G	TRIM28/F370G	MUTAGEN	F->G: Some reduction in interaction with PPP1CA.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	S440A	Q13263/S440A	TRIM28/S440A	MUTAGEN	S->A: No effect on interaction with PPP1CA nor on sumoylation levels. Decreased sumoylation levels; when associated with D-501 and D-824.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	V488E	Q13263/V488E	TRIM28/V488E	MUTAGEN	V->E: Abolishes interaction with CBX5; when associated with E-490.	ECO:0000269|PubMed:20562864	20562864		
Q13263	TRIM28	L490E	Q13263/L490E	TRIM28/L490E	MUTAGEN	L->E: Abolishes interaction with CBX5; when associated with E-488.	ECO:0000269|PubMed:20562864	20562864		
Q13263	TRIM28	S501A	Q13263/S501A	TRIM28/S501A	MUTAGEN	S->A: No effect on interaction with PPP1CA nor on sumoylation levels. Decreased sumoylation levels; when associated with D-440 and D-824.	ECO:0000269|PubMed:20424263	20424263		
Q13263	TRIM28	K554R	Q13263/K554R	TRIM28/K554R	MUTAGEN	K->R: Moderately reduces sumoylation and repression. Abolishes both sumoylation and repression; when associated with R-575. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-779 and R-804.	ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607	17079232,17942393,18082607		
Q13263	TRIM28	K575R	Q13263/K575R	TRIM28/K575R	MUTAGEN	K->R: Modestly reduced sumoylation and repression. Abolishes both sumoylation and repression; when associated with R-554.	ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:18082607	17079232,18082607		
Q13263	TRIM28	C651A	Q13263/C651A	TRIM28/C651A	MUTAGEN	C->A: Complete loss of the PHD finger-mediated stimulatory effect on sumoylation. Loss of binding UBE2I.	ECO:0000269|PubMed:18082607, ECO:0000269|PubMed:18488044	18082607,18488044		
Q13263	TRIM28	L653A	Q13263/L653A	TRIM28/L653A	MUTAGEN	L->A: Greatly reduced sumoylation. Little further effect on sumoylation; when associated with A-668 and/or A-709.	ECO:0000269|PubMed:18488044	18488044		
Q13263	TRIM28	L668A	Q13263/L668A	TRIM28/L668A	MUTAGEN	L->A: Little effect on sumoylation. Little further effect on sumoylation; when associated with A-653 and/or A-709.	ECO:0000269|PubMed:18488044	18488044		
Q13263	TRIM28	K676R	Q13263/K676R	TRIM28/K676R	MUTAGEN	K->R: Modestly reduces sumoylation and repression.	ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:18082607	17079232,18082607		
Q13263	TRIM28	L709A	Q13263/L709A	TRIM28/L709A	MUTAGEN	L->A: Greatly reduced sumoylation. Little further effect on sumoylation; when associated with A-653 and/or A-668.	ECO:0000269|PubMed:18488044	18488044		
Q13263	TRIM28	K750R	Q13263/K750R	TRIM28/K750R	MUTAGEN	K->R: Some reduced sumoylation and repression.	ECO:0000269|PubMed:18082607	18082607		
Q13263	TRIM28	K779R	Q13263/K779R	TRIM28/K779R	MUTAGEN	K->R: Abolishes both sumoylation and repression; when associated with R-804. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-554 and R-804.	ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607	17079232,17942393,18082607		
Q13263	TRIM28	K804R	Q13263/K804R	TRIM28/K804R	MUTAGEN	K->R: Abolishes both sumoylation and repression; when associated with R-779. Relieves the repressor activity on Dox-induced GADD45A transcription and 2-fold increase in phosphorylation at Ser-824; when associated with R-554 and R-779.	ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607	17079232,17942393,18082607		
Q13263	TRIM28	S824A	Q13263/S824A	TRIM28/S824A	MUTAGEN	S->A: Suppresses Dox-induced CDKN1A/p21 promoter activation. No effect on sumoylation levels. Decreased sumoylation levels; when associated with D-440 and D-501.	ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:20424263	17942393,20424263		
Q13263	TRIM28	S824D	Q13263/S824D	TRIM28/S824D	MUTAGEN	S->D: Enhances Dox-induced CDKN1A/p21 promoter activation. Decreased sumoylation with or without Dox-treatment.	ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:20424263	17942393,20424263		
Q13308	PTK7	A933V	Q13308/A933V	PTK7/A933V	VARIANT	A -> V (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		Inactive domain
Q13308	PTK7	L622D	Q13308/L622D	PTK7/L622D	MUTAGEN	L->D: Prevents proteolysis by MMP14.	ECO:0000269|PubMed:20837484	20837484		Inactive domain
Q13308	PTK7	M641R	Q13308/M641R	PTK7/M641R	MUTAGEN	M->R: No impact on proteolysis by MMP14.	ECO:0000269|PubMed:20837484	20837484		Inactive domain
Q13308	PTK7	M701D	Q13308/M701D	PTK7/M701D	MUTAGEN	M->D: No impact on proteolysis by MMP14.	ECO:0000269|PubMed:20837484	20837484		Inactive domain
Q13315	ATM	R23Q	Q13315/R23Q	ATM/R23Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs587779858)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	R45W	Q13315/R45W	ATM/R45W	VARIANT	R -> W (found in a patient with breast cancer; unknown pathological significance; dbSNP:rs3218684)	ECO:0000269|PubMed:11897822	11897822		
Q13315	ATM	S49C	Q13315/S49C	ATM/S49C	VARIANT	S -> C (in AT; increases protein abundance; dbSNP:rs1800054)	ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333	10425038,10534763,10873394,11897822,17344846,18384426,8665503,8797579,9887333		
Q13315	ATM	I68V	Q13315/I68V	ATM/I68V	VARIANT	I -> V (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	K224E	Q13315/K224E	ATM/K224E	VARIANT	K -> E (in AT; unknown pathological significance; dbSNP:rs145053092)	ECO:0000269|PubMed:10817650	10817650		
Q13315	ATM	P292L	Q13315/P292L	ATM/P292L	VARIANT	P -> L (in AT; associated with lymphoma; decrease phosphorylation of target proteins; increases protein abundance; dbSNP:rs747727055)	ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314	10873394,19431188,9463314		
Q13315	ATM	Y332C	Q13315/Y332C	ATM/Y332C	VARIANT	Y -> C (in B-cell chronic lymphocytic leukemia)	ECO:0000269|PubMed:9892178	9892178		
Q13315	ATM	R337C	Q13315/R337C	ATM/R337C	VARIANT	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs138398778)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	R337H	Q13315/R337H	ATM/R337H	VARIANT	R -> H (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs202160435)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	V341I	Q13315/V341I	ATM/V341I	VARIANT	V -> I (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	A350T	Q13315/A350T	ATM/A350T	VARIANT	A -> T (in B-cell chronic lymphocytic leukemia; dbSNP:rs371713984)	ECO:0000269|PubMed:10023947	10023947		
Q13315	ATM	I352T	Q13315/I352T	ATM/I352T	VARIANT	I -> T (in B-cell chronic lymphocytic leukemia; dbSNP:rs369203092)	ECO:0000269|PubMed:10023947	10023947		
Q13315	ATM	C540Y	Q13315/C540Y	ATM/C540Y	VARIANT	C -> Y (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	L546V	Q13315/L546V	ATM/L546V	VARIANT	L -> V (no effect on phosphorylation of target proteins; dbSNP:rs2227924)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19431188	17344846,19431188		
Q13315	ATM	F570S	Q13315/F570S	ATM/F570S	VARIANT	F -> S (in AT; dbSNP:rs777301065)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	P597L	Q13315/P597L	ATM/P597L	VARIANT	P -> L (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	D661A	Q13315/D661A	ATM/D661A	VARIANT	D -> A (found in a patient with familial breast cancer; unknown pathological significance)	ECO:0000269|PubMed:28202063	28202063		
Q13315	ATM	E699G	Q13315/E699G	ATM/E699G	VARIANT	E -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	S759G	Q13315/S759G	ATM/S759G	VARIANT	S -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	N768D	Q13315/N768D	ATM/N768D	VARIANT	N -> D (in AT)	ECO:0000269|PubMed:9463314	9463314		
Q13315	ATM	R785C	Q13315/R785C	ATM/R785C	VARIANT	R -> C (in AT; dbSNP:rs587778065)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	N813S	Q13315/N813S	ATM/N813S	VARIANT	N -> S (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	E848Q	Q13315/E848Q	ATM/E848Q	VARIANT	E -> Q (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs879254046)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	A869G	Q13315/A869G	ATM/A869G	VARIANT	A -> G (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	F897I	Q13315/F897I	ATM/F897I	VARIANT	F -> I (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	R924W	Q13315/R924W	ATM/R924W	VARIANT	R -> W (found in a patient with familial breast cancer; unknown pathological significance; dbSNP:rs55723361)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063	17344846,28202063		
Q13315	ATM	L950R	Q13315/L950R	ATM/L950R	VARIANT	L -> R (in AT; dbSNP:rs786203054)				
Q13315	ATM	L1001Q	Q13315/L1001Q	ATM/L1001Q	VARIANT	L -> Q (in AT; associated with T-cell acute lymphoblastic leukemia)	ECO:0000269|PubMed:9463314	9463314		
Q13315	ATM	M1040V	Q13315/M1040V	ATM/M1040V	VARIANT	M -> V (found in B-cell non-Hodgkin lymphoma; unknown pathological significance; dbSNP:rs3092857)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	P1054R	Q13315/P1054R	ATM/P1054R	VARIANT	P -> R (in AT, B-cell chronic lymphocytic leukemia, breast cancer patients and familial cancer patients; no effect on phosphorylation of target proteins; dbSNP:rs1800057)	ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333	10023947,10217116,17344846,18384426,19431188,28202063,8665503,8797579,9043869,9792409,9887333		
Q13315	ATM	H1082L	Q13315/H1082L	ATM/H1082L	VARIANT	H -> L (in AT; unknown pathological significance)	ECO:0000269|PubMed:10873394	10873394		
Q13315	ATM	E1091D	Q13315/E1091D	ATM/E1091D	VARIANT	E -> D (in AT)	ECO:0000269|PubMed:9792409	9792409		
Q13315	ATM	S1179F	Q13315/S1179F	ATM/S1179F	VARIANT	S -> F (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	L1255V	Q13315/L1255V	ATM/L1255V	VARIANT	L -> V (found in a patient with early-onset breast cancer; unknown pathological significance)	ECO:0000269|PubMed:18384426	18384426		
Q13315	ATM	L1322I	Q13315/L1322I	ATM/L1322I	VARIANT	L -> I (no effect on phosphorylation of target proteins; dbSNP:rs144535256)	ECO:0000269|PubMed:19431188	19431188		
Q13315	ATM	I1407T	Q13315/I1407T	ATM/I1407T	VARIANT	I -> T (in T-prolymphocytic leukemia; dbSNP:rs1234250980)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	L1420P	Q13315/L1420P	ATM/L1420P	VARIANT	L -> P (in AT)	ECO:0000269|PubMed:10817650	10817650		
Q13315	ATM	F1463S	Q13315/F1463S	ATM/F1463S	VARIANT	F -> S (found in B-cell non-Hodgkin lymphoma; unknown pathological significance)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	I1469M	Q13315/I1469M	ATM/I1469M	VARIANT	I -> M (in a renal papillary cancer sample; somatic mutation; dbSNP:rs775047783)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	H1474D	Q13315/H1474D	ATM/H1474D	VARIANT	H -> D (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	L1488V	Q13315/L1488V	ATM/L1488V	VARIANT	L -> V (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	P1566R	Q13315/P1566R	ATM/P1566R	VARIANT	P -> R (in AT)	ECO:0000269|PubMed:9792409	9792409		
Q13315	ATM	D1682H	Q13315/D1682H	ATM/D1682H	VARIANT	D -> H (in T-prolymphocytic leukemia; dbSNP:rs121434217)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	S1691R	Q13315/S1691R	ATM/S1691R	VARIANT	S -> R (in AT, B-cell chronic lymphocytic leukemia and familial cancer patients; no effect on phosphorylation of target proteins; dbSNP:rs1800059)	ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178	19431188,28202063,8797579,9463314,9892178		
Q13315	ATM	N1739T	Q13315/N1739T	ATM/N1739T	VARIANT	N -> T (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	T1743I	Q13315/T1743I	ATM/T1743I	VARIANT	T -> I (in AT; associated with preleukemic T-cell proliferation; decreased phosphorylation of target proteins; dbSNP:rs587779844)	ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314	194,311,889,463,314		
Q13315	ATM	D1853V	Q13315/D1853V	ATM/D1853V	VARIANT	D -> V (might contribute to B-cell chronic lymphocytic leukemia; dbSNP:rs1801673)	ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, ECO:0000269|PubMed:9887333	10397742,10817650,17344846,28202063,9872980,9887333		
Q13315	ATM	L1910H	Q13315/L1910H	ATM/L1910H	VARIANT	L -> H (in T-prolymphocytic leukemia)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	V1913G	Q13315/V1913G	ATM/V1913G	VARIANT	V -> G (in AT; dbSNP:rs1060501688)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	M1916I	Q13315/M1916I	ATM/M1916I	VARIANT	M -> I (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	A1945T	Q13315/A1945T	ATM/A1945T	VARIANT	A -> T (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	T1953R	Q13315/T1953R	ATM/T1953R	VARIANT	T -> R (in B-cell chronic lymphocytic leukemia)	ECO:0000269|PubMed:10397742	10397742		
Q13315	ATM	Y1961C	Q13315/Y1961C	ATM/Y1961C	VARIANT	Y -> C (found in a patient with familial pancreatic cancer; also found in a lung adenocarcinoma sample; unknown pathological significance; decreased phosphorylation of target proteins; dbSNP:rs56399311)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808	17344846,19431188,28726808		
Q13315	ATM	E1991D	Q13315/E1991D	ATM/E1991D	VARIANT	E -> D (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs587782274)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	D2016G	Q13315/D2016G	ATM/D2016G	VARIANT	D -> G (in AT; unknown pathological significance; dbSNP:rs587781302)	ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:9887333	104,250,389,887,333		
Q13315	ATM	G2063E	Q13315/G2063E	ATM/G2063E	VARIANT	G -> E (in AT; unknown pathological significance; reduces protein abundance; dbSNP:rs866290641)	ECO:0000269|PubMed:10873394	10873394		
Q13315	ATM	A2067D	Q13315/A2067D	ATM/A2067D	VARIANT	A -> D (in AT; dbSNP:rs397514577)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	R2105T	Q13315/R2105T	ATM/R2105T	VARIANT	R -> T (found in a patient with early-onset breast cancer; unknown pathological significance)	ECO:0000269|PubMed:18384426	18384426		
Q13315	ATM	E2139G	Q13315/E2139G	ATM/E2139G	VARIANT	E -> G (in T-prolymphocytic leukemia; somatic mutation)	ECO:0000269|PubMed:9488043	9488043		
Q13315	ATM	E2164K	Q13315/E2164K	ATM/E2164K	VARIANT	E -> K (in T-prolymphocytic leukemia; dbSNP:rs1317619286)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	S2218C	Q13315/S2218C	ATM/S2218C	VARIANT	S -> C (in AT)	ECO:0000269|PubMed:10817650	10817650		
Q13315	ATM	R2227C	Q13315/R2227C	ATM/R2227C	VARIANT	R -> C (in AT; unknown pathological significance; reduces protein abundance; dbSNP:rs564652222)	ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9887333	108,733,949,887,333		
Q13315	ATM	A2274T	Q13315/A2274T	ATM/A2274T	VARIANT	A -> T (in B-cell chronic lymphocytic leukemia; unknown pathological significance; no effect on phosphorylation of target proteins; dbSNP:rs567060474)	ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:19431188	10023947,19431188		
Q13315	ATM	G2287A	Q13315/G2287A	ATM/G2287A	VARIANT	G -> A (found in a patient with familial pancreatic cancer; unknown pathological significance; dbSNP:rs1800061)	ECO:0000269|PubMed:28726808, ECO:0000269|PubMed:8665503	287,268,088,665,503		
Q13315	ATM	L2307F	Q13315/L2307F	ATM/L2307F	VARIANT	L -> F (found in patients with familial pancreatic cancer; also found in a lung adenocarcinoma sample; unknown pathological significance; dbSNP:rs56009889)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28726808	17344846,28726808		
Q13315	ATM	I2356F	Q13315/I2356F	ATM/I2356F	VARIANT	I -> F (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs876658517)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	T2396S	Q13315/T2396S	ATM/T2396S	VARIANT	T -> S (in T-prolymphocytic leukemia; also found in a patient with early-onset breast cancer; unknown pathological significance; dbSNP:rs370559102)	ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:9288106	183,844,269,288,106		
Q13315	ATM	S2408L	Q13315/S2408L	ATM/S2408L	VARIANT	S -> L (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs730881315)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	K2418KK	Q13315/K2418KK	ATM/K2418KK	VARIANT	K -> KK (in mantle cell lymphoma)	ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620	1,039,774,210,706,620		
Q13315	ATM	A2420P	Q13315/A2420P	ATM/A2420P	VARIANT	A -> P (in B-cell chronic lymphocytic leukemia)	ECO:0000269|PubMed:10397742	10397742		
Q13315	ATM	E2423G	Q13315/E2423G	ATM/E2423G	VARIANT	E -> G (in mantle cell lymphoma; dbSNP:rs121434221)	ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620	1,039,774,210,706,620		
Q13315	ATM	V2424G	Q13315/V2424G	ATM/V2424G	VARIANT	V -> G (in AT; also found in B-cell chronic lymphocytic leukemia and T-prolymphocytic leukemia; may be associated with increased risk for breast cancer; decreased phosphorylation of target proteins; dbSNP:rs28904921)	ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178	19431188,8755918,9288106,9463314,9892178		
Q13315	ATM	Q2442P	Q13315/Q2442P	ATM/Q2442P	VARIANT	Q -> P (in T-prolymphocytic leukemia; also in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9288106	173,448,469,288,106		
Q13315	ATM	R2443Q	Q13315/R2443Q	ATM/R2443Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs587782310)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	C2464R	Q13315/C2464R	ATM/C2464R	VARIANT	C -> R (found in patients with familial pancreatic cancer; also found in a small cell lung cancer sample; unknown pathological significance; dbSNP:rs55801750)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28726808	17344846,28726808		
Q13315	ATM	Y2470D	Q13315/Y2470D	ATM/Y2470D	VARIANT	Y -> D (in AT; dbSNP:rs876659365)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	R2486G	Q13315/R2486G	ATM/R2486G	VARIANT	R -> G (in T-prolymphocytic leukemia)	ECO:0000269|PubMed:9573030	9573030		
Q13315	ATM	W2491R	Q13315/W2491R	ATM/W2491R	VARIANT	W -> R (in AT)	ECO:0000269|PubMed:9792410	9792410		
Q13315	ATM	A2524P	Q13315/A2524P	ATM/A2524P	VARIANT	A -> P (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	M2531T	Q13315/M2531T	ATM/M2531T	VARIANT	M -> T (found in patients with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	H2554D	Q13315/H2554D	ATM/H2554D	VARIANT	H -> D (in AT; lack of phosphorylation of target proteins)	ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314	194,311,889,463,314	loss	
Q13315	ATM	D2625E	Q13315/D2625E	ATM/D2625E	VARIANT	D -> E (in AT; unknown pathological significance; dbSNP:rs1196903858)	ECO:0000269|PubMed:10873394	10873394		
Q13315	ATM	D2625Q	Q13315/D2625Q	ATM/D2625Q	VARIANT	D -> Q (in AT; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:10817650	10817650		
Q13315	ATM	A2626P	Q13315/A2626P	ATM/A2626P	VARIANT	A -> P (in AT; unknown pathological significance; dbSNP:rs267606669)	ECO:0000269|PubMed:10873394	10873394		
Q13315	ATM	L2656P	Q13315/L2656P	ATM/L2656P	VARIANT	L -> P (in AT; dbSNP:rs121434218)	ECO:0000269|PubMed:9450874	9450874		
Q13315	ATM	T2666A	Q13315/T2666A	ATM/T2666A	VARIANT	T -> A (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs745775382)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	E2668G	Q13315/E2668G	ATM/E2668G	VARIANT	E -> G (in AT; unknown pathological significance; no effect on phosphorylation of target proteins)	ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314	194,311,889,463,314		
Q13315	ATM	G2695A	Q13315/G2695A	ATM/G2695A	VARIANT	G -> A (in T-prolymphocytic leukemia and B-cell chronic lymphocytic leukemia)	ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:9288106	100,239,479,288,106		
Q13315	ATM	I2702R	Q13315/I2702R	ATM/I2702R	VARIANT	I -> R (in AT; dbSNP:rs876659735)				
Q13315	ATM	R2719H	Q13315/R2719H	ATM/R2719H	VARIANT	R -> H (found in a patient with early-onset breast cancer; unknown pathological significance; dbSNP:rs55982963)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426	17344846,18384426		
Q13315	ATM	L2722R	Q13315/L2722R	ATM/L2722R	VARIANT	L -> R (in T-prolymphocytic leukemia)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	D2725G	Q13315/D2725G	ATM/D2725G	VARIANT	D -> G (found in T-prolymphocytic leukemia; unknown pathological significance; dbSNP:rs1555128314)	ECO:0000269|PubMed:9334731	9334731		
Q13315	ATM	D2725V	Q13315/D2725V	ATM/D2725V	VARIANT	D -> V (in T-prolymphocytic leukemia)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	A2726V	Q13315/A2726V	ATM/A2726V	VARIANT	A -> V (in AT; unknown pathological significance)	ECO:0000269|PubMed:10425038	10425038		
Q13315	ATM	F2732L	Q13315/F2732L	ATM/F2732L	VARIANT	F -> L (in T-prolymphocytic leukemia; dbSNP:rs876659619)	ECO:0000269|PubMed:9288106	9288106		
Q13315	ATM	G2765S	Q13315/G2765S	ATM/G2765S	VARIANT	G -> S (may contribute to breast cancer; lack of phosphorylation of target proteins; dbSNP:rs748634900)	ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:19431188	10534763,19431188	loss	
Q13315	ATM	K2810Q	Q13315/K2810Q	ATM/K2810Q	VARIANT	K -> Q (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	C2824Y	Q13315/C2824Y	ATM/C2824Y	VARIANT	C -> Y (in AT; dbSNP:rs876660927)	ECO:0000269|PubMed:9150358	9150358		
Q13315	ATM	P2829L	Q13315/P2829L	ATM/P2829L	VARIANT	P -> L (in AT; dbSNP:rs938431501)	ECO:0000269|PubMed:9711876	9711876		
Q13315	ATM	R2832C	Q13315/R2832C	ATM/R2832C	VARIANT	R -> C (in AT; also found in B-cell non-Hodgkin lymphoma; increases protein abundance; dbSNP:rs587779872)	ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9443866	10817650,10873394,9288106,9443866		
Q13315	ATM	R2832H	Q13315/R2832H	ATM/R2832H	VARIANT	R -> H (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	P2842R	Q13315/P2842R	ATM/P2842R	VARIANT	P -> R (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs879254065)	ECO:0000269|PubMed:17344846	17344846		
Q13315	ATM	R2849P	Q13315/R2849P	ATM/R2849P	VARIANT	R -> P (in AT; dbSNP:rs587782202)	ECO:0000269|PubMed:9887333	9887333		
Q13315	ATM	S2855R	Q13315/S2855R	ATM/S2855R	VARIANT	S -> R (in AT; unknown pathological significance; dbSNP:rs780905851)	ECO:0000269|PubMed:10425038	10425038		
Q13315	ATM	G2867R	Q13315/G2867R	ATM/G2867R	VARIANT	G -> R (in AT)	ECO:0000269|PubMed:8698354, ECO:0000269|PubMed:9887333	86,983,549,887,333		
Q13315	ATM	L2890V	Q13315/L2890V	ATM/L2890V	VARIANT	L -> V (in T-prolymphocytic leukemia; dbSNP:rs587779874)	ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9488043	92,881,069,488,043		
Q13315	ATM	E2904G	Q13315/E2904G	ATM/E2904G	VARIANT	E -> G (in AT; dbSNP:rs786202826)	ECO:0000269|PubMed:8845835	8845835		
Q13315	ATM	R2909G	Q13315/R2909G	ATM/R2909G	VARIANT	R -> G (in AT)	ECO:0000269|PubMed:9792410	9792410		
Q13315	ATM	P2974L	Q13315/P2974L	ATM/P2974L	VARIANT	P -> L (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	A3006P	Q13315/A3006P	ATM/A3006P	VARIANT	A -> P (found in T-prolymphocytic leukemia; unknown pathological significance; dbSNP:rs876658767)	ECO:0000269|PubMed:9334731	9334731		
Q13315	ATM	R3008C	Q13315/R3008C	ATM/R3008C	VARIANT	R -> C (in AT; also found in T-prolymphocytic leukemia and mantle cell lymphoma; lack of phosphorylation of target proteins; dbSNP:rs587782292)	ECO:0000269|PubMed:10706620, ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, ECO:0000269|PubMed:9872980	10706620,10817650,19431188,9334731,9488043,9872980	loss	
Q13315	ATM	R3008H	Q13315/R3008H	ATM/R3008H	VARIANT	R -> H (in B-cell chronic lymphocytic leukemia; dbSNP:rs587781894)	ECO:0000269|PubMed:10397742	10397742		
Q13315	ATM	K3018N	Q13315/K3018N	ATM/K3018N	VARIANT	K -> N (in B-cell chronic lymphocytic leukemia)	ECO:0000269|PubMed:10397742	10397742		
Q13315	ATM	G3029D	Q13315/G3029D	ATM/G3029D	VARIANT	G -> D (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	V3056L	Q13315/V3056L	ATM/V3056L	VARIANT	V -> L (found in a patient with familial pancreatic cancer; unknown pathological significance)	ECO:0000269|PubMed:28726808	28726808		
Q13315	ATM	S367A	Q13315/S367A	ATM/S367A	MUTAGEN	S->A: Loss of IR-induced S-367 autophosphorylation. Reduced correction of cell cycle checkpoint defects and DNA-repair activity. No effect on S-1893 nor S-1981 autophosphorylation.	ECO:0000269|PubMed:16858402	16858402	loss	
Q13315	ATM	S1893A	Q13315/S1893A	ATM/S1893A	MUTAGEN	S->A: Loss of IR-induced S-1893 autophosphorylation. Reduced correction of cell cycle checkpoint defects and DNA-repair activity. No effect on S-367 nor S-1981 autophosphorylation.	ECO:0000269|PubMed:16858402	16858402	loss	
Q13315	ATM	S1981A	Q13315/S1981A	ATM/S1981A	MUTAGEN	S->A: Loss of IR-induced S-1981 autophosphorylation. Reduced correction of cell cycle checkpoint defects and DNA-repair activity. No effect on S-367 nor S-1893 autophosphorylation. No dimer disruption.	ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16858402	12556884,16858402	loss	
Q13315	ATM	S1981D	Q13315/S1981D	ATM/S1981D	MUTAGEN	S->D,E: Disrupts the dimer.	ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16858402	12556884,16858402	activating	
Q13315	ATM	S1981E	Q13315/S1981E	ATM/S1981E	MUTAGEN	S->D,E: Disrupts the dimer.	ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16858402	12556884,16858402	activating	
Q13315	ATM	S2685T	Q13315/S2685T	ATM/S2685T	MUTAGEN	S->T: No effect on phosphorylation of target proteins.	ECO:0000269|PubMed:19431188	19431188		
Q13315	ATM	K3016Q	Q13315/K3016Q	ATM/K3016Q	MUTAGEN	K->Q: Mimics acetylation, preventing dephosphorylation and subsequent ATM deactivation during the late stage of DNA damage response.	ECO:0000269|PubMed:30944854	30944854	activating	
Q13315	ATM	K3018R	Q13315/K3018R	ATM/K3018R	MUTAGEN	K->R: Retains DNA damage-inducible acetylation and S-1981 autophosphorylation.	ECO:0000269|PubMed:17923702	17923702		
Q13418	ILK	A262V	Q13418/A262V	ILK/A262V	VARIANT	A -> V (found in a patient with severe dilated cardiomyopathy; unknown pathological significance; dbSNP:rs387907366)	ECO:0000269|PubMed:17646580	17646580		
Q13418	ILK	H99D	Q13418/H99D	ILK/H99D	MUTAGEN	H->D: Alters interaction with LIMS1.	ECO:0000269|PubMed:19074270	19074270		
Q13418	ILK	E359K	Q13418/E359K	ILK/E359K	MUTAGEN	E->K: Inactivation of ILK.	ECO:0000269|PubMed:9736715	9736715	loss	
Q13464	ROCK1	P1193S	Q13464/P1193S	ROCK1/P1193S	VARIANT	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs1057520015)	ECO:0000269|PubMed:17344846	17344846		
Q13464	ROCK1	D1113A	Q13464/D1113A	ROCK1/D1113A	MUTAGEN	D->A: Abolishes cleavage by caspase-3.	ECO:0000269|PubMed:11283607	11283607		
Q13470	TNK1	R339K	Q13470/R339K	TNK1/R339K	VARIANT	R -> K (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13523	PRPF4B	F658L	Q13523/F658L	PRPF4B/F658L	VARIANT	F -> L (in a breast cancer sample; somatic mutation; dbSNP:rs1230491406)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
Q13535	ATR	A1488P	Q13535/A1488P	ATR/A1488P	VARIANT	A -> P (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13535	ATR	A2002G	Q13535/A2002G	ATR/A2002G	VARIANT	A -> G (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13535	ATR	Q2144R	Q13535/Q2144R	ATR/Q2144R	VARIANT	Q -> R (in FCTCS; dbSNP:rs387906797)	ECO:0000269|PubMed:22341969	22341969		
Q13535	ATR	S2233I	Q13535/S2233I	ATR/S2233I	VARIANT	S -> I (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13535	ATR	E2438K	Q13535/E2438K	ATR/E2438K	VARIANT	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13535	ATR	E2537Q	Q13535/E2537Q	ATR/E2537Q	VARIANT	E -> Q (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13546	RIPK1	A64V	Q13546/A64V	RIPK1/A64V	VARIANT	A -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs774996232)	ECO:0000269|PubMed:17344846	17344846		
Q13546	RIPK1	V81I	Q13546/V81I	RIPK1/V81I	VARIANT	V -> I (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs758268804)	ECO:0000269|PubMed:17344846	17344846		
Q13546	RIPK1	A220V	Q13546/A220V	RIPK1/A220V	VARIANT	A -> V (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs759012409)	ECO:0000269|PubMed:17344846	17344846		
Q13546	RIPK1	D324N	Q13546/D324N	RIPK1/D324N	VARIANT	D -> N (in AIEFL; prevents cleavage by CASP8; changed inflammatory response; dbSNP:rs1760720617)	ECO:0000269|PubMed:31827281	31827281		
Q13546	RIPK1	D324Y	Q13546/D324Y	RIPK1/D324Y	VARIANT	D -> Y (in AIEFL; prevents cleavage by CASP8; changed inflammatory response)	ECO:0000269|PubMed:31827281	31827281		
Q13546	RIPK1	S161E	Q13546/S161E	RIPK1/S161E	MUTAGEN	S->E: No effect on RIPK1 autophosphorylation.	ECO:0000269|PubMed:18408713	18408713		
Q13546	RIPK1	D324K	Q13546/D324K	RIPK1/D324K	MUTAGEN	D->K: Abolishes cleavage by caspase-8.	ECO:0000269|PubMed:10521396	10521396		
Q13546	RIPK1	K377R	Q13546/K377R	RIPK1/K377R	MUTAGEN	K->R: Abolishes RIP-mediated NF-Kappa-B activation.	ECO:0000269|PubMed:16603398	16603398		
Q13546	RIPK1	S536C	Q13546/S536C	RIPK1/S536C	MUTAGEN	S->C: Strongly reduced homodimerization and interaction with RIPK3.	ECO:0000269|PubMed:29681455	29681455		
Q13546	RIPK1	K599R	Q13546/K599R	RIPK1/K599R	MUTAGEN	K->R: Blocks homodimerization, necroptosis and apoptosis.	ECO:0000269|PubMed:29440439	29440439		
Q13546	RIPK1	R603A	Q13546/R603A	RIPK1/R603A	MUTAGEN	R->A: Abolished GlcNAcylation by E.coli NleB1.	ECO:0000269|PubMed:30979585	30979585		
Q13554	CAMK2B	E110K	Q13554/E110K	CAMK2B/E110K	VARIANT	E -> K (in MRD54; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554402092)	ECO:0000269|PubMed:29100089	29100089	increase	
Q13554	CAMK2B	P139L	Q13554/P139L	CAMK2B/P139L	VARIANT	P -> L (in MRD54; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554389088)	ECO:0000269|PubMed:29100089	29100089	increase	
Q13554	CAMK2B	P213L	Q13554/P213L	CAMK2B/P213L	VARIANT	P -> L (in MRD54; dbSNP:rs1554387293)	ECO:0000269|PubMed:29560374	29560374		
Q13554	CAMK2B	E237K	Q13554/E237K	CAMK2B/E237K	VARIANT	E -> K (in MRD54; no effect on protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554386687)	ECO:0000269|PubMed:29100089	29100089	increase	
Q13554	CAMK2B	R284S	Q13554/R284S	CAMK2B/R284S	VARIANT	R -> S (in MRD54; dbSNP:rs1554385203)	ECO:0000269|PubMed:29560374	29560374		
Q13554	CAMK2B	K301E	Q13554/K301E	CAMK2B/K301E	VARIANT	K -> E (in MRD54; no effect on protein abundance; loss of autophosphorylation; changed function in neuronal migration; dbSNP:rs1554385111)	ECO:0000269|PubMed:29100089	29100089	loss	
Q13554	CAMK2B	P489L	Q13554/P489L	CAMK2B/P489L	VARIANT	P -> L (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs555460132)	ECO:0000269|PubMed:17344846	17344846		
Q13627	DYRK1A	Y415F	Q13627/Y415F	DYRK1A/Y415F	VARIANT	Y -> F	ECO:0000269|PubMed:10329007	10329007		
Q13627	DYRK1A	Q681H	Q13627/Q681H	DYRK1A/Q681H	VARIANT	Q -> H	ECO:0000269|PubMed:10329007	10329007		
Q13705	ACVR2B	R40H	Q13705/R40H	ACVR2B/R40H	VARIANT	R -> H (in HTX4; dbSNP:rs121434437)	ECO:0000269|PubMed:9916847	9916847		
Q13705	ACVR2B	V494I	Q13705/V494I	ACVR2B/V494I	VARIANT	V -> I (in HTX4; dbSNP:rs121434438)	ECO:0000269|PubMed:9916847	9916847		
Q13873	BMPR2	C60Y	Q13873/C60Y	BMPR2/C60Y	VARIANT	C -> Y (in PPH1; dbSNP:rs1085307172)	ECO:0000269|PubMed:11015450	11015450		
Q13873	BMPR2	S64R	Q13873/S64R	BMPR2/S64R	VARIANT	S -> R (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:28507310	28507310		
Q13873	BMPR2	Y67C	Q13873/Y67C	BMPR2/Y67C	VARIANT	Y -> C (in PPH1; significant decrease in nitric oxide synthesis by endothelial cells; dbSNP:rs1085307177)	ECO:0000269|PubMed:25187962	25187962		
Q13873	BMPR2	I77L	Q13873/I77L	BMPR2/I77L	VARIANT	I -> L (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	Q82H	Q13873/Q82H	BMPR2/Q82H	VARIANT	Q -> H (in PPH1; dbSNP:rs1085307185)	ECO:0000269|PubMed:12358323	12358323		
Q13873	BMPR2	C84F	Q13873/C84F	BMPR2/C84F	VARIANT	C -> F (in PPH1; alters alternative splicing of BMPR2; dbSNP:rs1085307197)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	H87Y	Q13873/H87Y	BMPR2/H87Y	VARIANT	H -> Y (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	Q92L	Q13873/Q92L	BMPR2/Q92L	VARIANT	Q -> L (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	Q109H	Q13873/Q109H	BMPR2/Q109H	VARIANT	Q -> H (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:28507310	28507310		
Q13873	BMPR2	C117Y	Q13873/C117Y	BMPR2/C117Y	VARIANT	C -> Y (in PPH1; dbSNP:rs1085307215)	ECO:0000269|PubMed:11015450	11015450		
Q13873	BMPR2	C118W	Q13873/C118W	BMPR2/C118W	VARIANT	C -> W (in PPH1; dbSNP:rs137852743)	ECO:0000269|PubMed:10973254	10973254		
Q13873	BMPR2	C123R	Q13873/C123R	BMPR2/C123R	VARIANT	C -> R (in PPH1; dbSNP:rs137852750)	ECO:0000269|PubMed:11115378	11115378		
Q13873	BMPR2	C123S	Q13873/C123S	BMPR2/C123S	VARIANT	C -> S (in PPH1; dbSNP:rs137852750)	ECO:0000269|PubMed:11115378	11115378		
Q13873	BMPR2	P138A	Q13873/P138A	BMPR2/P138A	VARIANT	P -> A (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:28507310	28507310		
Q13873	BMPR2	A162P	Q13873/A162P	BMPR2/A162P	VARIANT	A -> P (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	G182D	Q13873/G182D	BMPR2/G182D	VARIANT	G -> D (in PPH1; dbSNP:rs137852754)	ECO:0000269|PubMed:12358323	12358323		
Q13873	BMPR2	R248G	Q13873/R248G	BMPR2/R248G	VARIANT	R -> G (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:28507310	28507310		
Q13873	BMPR2	D264N	Q13873/D264N	BMPR2/D264N	VARIANT	D -> N (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	V341M	Q13873/V341M	BMPR2/V341M	VARIANT	V -> M (in PPH1; unknown pathological significance; unchanged subcellular localization; dbSNP:rs767882551)	ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	2,493,664,928,507,310		
Q13873	BMPR2	C347Y	Q13873/C347Y	BMPR2/C347Y	VARIANT	C -> Y (in PPH1; dbSNP:rs137852744)	ECO:0000269|PubMed:10973254	10973254		
Q13873	BMPR2	C420R	Q13873/C420R	BMPR2/C420R	VARIANT	C -> R (in PPH1; dbSNP:rs1085307324)	ECO:0000269|PubMed:11115378	11115378		
Q13873	BMPR2	K467R	Q13873/K467R	BMPR2/K467R	VARIANT	K -> R (in PPH1; unknown pathological significance; unchanged subcellular localization)	ECO:0000269|PubMed:28507310	28507310		
Q13873	BMPR2	C483R	Q13873/C483R	BMPR2/C483R	VARIANT	C -> R (in PPH1; sporadic; dbSNP:rs1085307354)	ECO:0000269|PubMed:11015450, ECO:0000269|PubMed:12358323	11015450,12358323		
Q13873	BMPR2	R491Q	Q13873/R491Q	BMPR2/R491Q	VARIANT	R -> Q (in PPH1; sporadic; dbSNP:rs137852749)	ECO:0000269|PubMed:10903931	10903931		
Q13873	BMPR2	R491W	Q13873/R491W	BMPR2/R491W	VARIANT	R -> W (in PPH1; dbSNP:rs137852746)	ECO:0000269|PubMed:10903931	10903931		
Q13873	BMPR2	K512T	Q13873/K512T	BMPR2/K512T	VARIANT	K -> T (in PPH1; dbSNP:rs1085307364)	ECO:0000269|PubMed:11115378	11115378		
Q13873	BMPR2	N519K	Q13873/N519K	BMPR2/N519K	VARIANT	N -> K (in PPH1; dbSNP:rs1085307365)				
Q13873	BMPR2	S775N	Q13873/S775N	BMPR2/S775N	VARIANT	S -> N (unchanged subcellular localization; dbSNP:rs2228545)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310	17344846,24936649,28507310		
Q13873	BMPR2	S863N	Q13873/S863N	BMPR2/S863N	VARIANT	S -> N (in PPH1; abnormal subcellular localization; significant increase in apoptosis of endothelial cells; significant decrease in proliferation of endothelial cells; significant decrease in nitric oxide synthesis by endothelial cells; significant increase in endothelin 1 synthesis by endothelial cells; dbSNP:rs1006246556)	ECO:0000269|PubMed:25187962	25187962		
Q13882	PTK6	L16F	Q13882/L16F	PTK6/L16F	VARIANT	L -> F (in a renal papillary sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q13882	PTK6	Y342A	Q13882/Y342A	PTK6/Y342A	MUTAGEN	Y->A: 3-fold lower specific kinase activity. Decreased, but still significant, autophosphorylation. Decreased, but still significant, autophosphorylation; when associated with A-447.	ECO:0000269|PubMed:12121988	12121988	decrease	
Q13882	PTK6	Y447F	Q13882/Y447F	PTK6/Y447F	MUTAGEN	Y->F: Decrease in transforming potential and increase in the kinase activity level. Decreased, but still significant, autophosphorylation; when associated with A-342.	ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083	12121988,15471878,8940083	increase	
Q13976	PRKG1	L12A	Q13976/L12A	PRKG1/L12A	MUTAGEN	L->A: Loss of binding to PPP1R12A.	ECO:0000269|PubMed:10567269	10567269		
Q13976	PRKG1	I19A	Q13976/I19A	PRKG1/I19A	MUTAGEN	I->A: Loss of binding to PPP1R12A.	ECO:0000269|PubMed:10567269	10567269		
Q13976	PRKG1	L26P	Q13976/L26P	PRKG1/L26P	MUTAGEN	L->P: Loss of binding to PPP1R12A.	ECO:0000269|PubMed:10567269	10567269		
Q13976	PRKG1	I33A	Q13976/I33A	PRKG1/I33A	MUTAGEN	I->A: Loss of binding to PPP1R12A.	ECO:0000269|PubMed:10567269	10567269		
Q13976	PRKG1	L40A	Q13976/L40A	PRKG1/L40A	MUTAGEN	L->A: Loss of binding to PPP1R12A.	ECO:0000269|PubMed:10567269	10567269		
Q13976	PRKG1	L281A	Q13976/L281A	PRKG1/L281A	MUTAGEN	L->A: Reduces cGMP binding affinity.	ECO:0000269|PubMed:24239458	24239458		
Q13976	PRKG1	R282A	Q13976/R282A	PRKG1/R282A	MUTAGEN	R->A: Reduces cGMP binding affinity.	ECO:0000269|PubMed:24239458	24239458		
Q13976	PRKG1	T302A	Q13976/T302A	PRKG1/T302A	MUTAGEN	T->A: Reduces cGMP binding affinity.	ECO:0000269|PubMed:24239458	24239458		
Q13976	PRKG1	Y336A	Q13976/Y336A	PRKG1/Y336A	MUTAGEN	Y->A: Reduces cGMP binding affinity.	ECO:0000269|PubMed:24239458	24239458		
Q14004	CDK13	Q103R	Q14004/Q103R	CDK13/Q103R	VARIANT	Q -> R (in RNA edited version)				
Q14004	CDK13	G714R	Q14004/G714R	CDK13/G714R	VARIANT	G -> R (in CHDFIDD; dbSNP:rs1057519633)	ECO:0000269|PubMed:27479907	27479907		
Q14004	CDK13	G717R	Q14004/G717R	CDK13/G717R	VARIANT	G -> R (in CHDFIDD; dbSNP:rs1057519632)	ECO:0000269|PubMed:27479907	27479907		
Q14004	CDK13	K734E	Q14004/K734E	CDK13/K734E	VARIANT	K -> E (in CHDFIDD; dbSNP:rs1064795731)	ECO:0000269|PubMed:28807008	28807008		
Q14004	CDK13	R751Q	Q14004/R751Q	CDK13/R751Q	VARIANT	R -> Q (in CHDFIDD; dbSNP:rs1057519634)	ECO:0000269|PubMed:27479907	27479907		
Q14004	CDK13	N842D	Q14004/N842D	CDK13/N842D	VARIANT	N -> D (in CHDFIDD; dbSNP:rs1554333853)	ECO:0000269|PubMed:28807008	28807008		
Q14004	CDK13	N842S	Q14004/N842S	CDK13/N842S	VARIANT	N -> S (in CHDFIDD; dbSNP:rs878853160)	ECO:0000269|PubMed:27479907, ECO:0000269|PubMed:28807008	27479907,28807008		
Q14012	CAMK1	P217S	Q14012/P217S	CAMK1/P217S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs907102077)	ECO:0000269|PubMed:17344846	17344846		
Q14012	CAMK1	K49A	Q14012/K49A	CAMK1/K49A	MUTAGEN	K->A: Catalytically inactive form; prevents CDK4 activation.	ECO:0000269|PubMed:14754892, ECO:0000269|PubMed:7641687	147,548,927,641,687	loss	
Q14012	CAMK1	T177D	Q14012/T177D	CAMK1/T177D	MUTAGEN	T->D: Partial activation in absence of CaMKK1.	ECO:0000269|PubMed:7641687	7641687	increase	
Q14164	IKBKE	K30A	Q14164/K30A	IKBKE/K30A	MUTAGEN	K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.	ECO:0000269|PubMed:23453969	23453969	decrease	
Q14164	IKBKE	K30R	Q14164/K30R	IKBKE/K30R	MUTAGEN	K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.	ECO:0000269|PubMed:23453969	23453969	decrease	
Q14164	IKBKE	K231R	Q14164/K231R	IKBKE/K231R	MUTAGEN	K->R: Loss of sumoylation and loss of targeting to nuclear bodies.	ECO:0000269|PubMed:20188669	20188669		
Q14164	IKBKE	K401A	Q14164/K401A	IKBKE/K401A	MUTAGEN	K->A: Loss of ubiquitination and decreased kinase activity. No effect on homodimerization.	ECO:0000269|PubMed:23453969	23453969	decrease	
Q14164	IKBKE	K401R	Q14164/K401R	IKBKE/K401R	MUTAGEN	K->R: Loss of ubiquitination and decreased kinase activity. Decreases interaction with IKBKB, IKBKG and MYD88. No effect on homodimerization.	ECO:0000269|PubMed:23453969	23453969	decrease	
Q14164	IKBKE	K416A	Q14164/K416A	IKBKE/K416A	MUTAGEN	K->A: No effect on ubiquitination.	ECO:0000269|PubMed:23453969	23453969		
Q14164	IKBKE	K416R	Q14164/K416R	IKBKE/K416R	MUTAGEN	K->R: No effect on ubiquitination.	ECO:0000269|PubMed:23453969	23453969		
Q14289	PTK2B	Y402F	Q14289/Y402F	PTK2B/Y402F	MUTAGEN	Y->F: Abolishes autophosphorylation. Abolishes interaction with SRC.	ECO:0000269|PubMed:8849729	8849729	loss	
Q14289	PTK2B	P859A	Q14289/P859A	PTK2B/P859A	MUTAGEN	P->A: Loss of interaction with NPHP1.	ECO:0000269|PubMed:11493697	11493697		
Q14296	FASTK	V424L	Q14296/V424L	FASTK/V424L	VARIANT	V -> L (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs758691941)	ECO:0000269|PubMed:17344846	17344846		
Q14296	FASTK	M35G	Q14296/M35G	FASTK/M35G	MUTAGEN	M->G: Abolishes isoform 4 expression.	ECO:0000269|PubMed:25704814	25704814		
Q14680	MELK	T460M	Q14680/T460M	MELK/T460M	VARIANT	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs144052967)	ECO:0000269|PubMed:17344846	17344846		
Q14680	MELK	C29V	Q14680/C29V	MELK/C29V	MUTAGEN	C->V: Abolishes dependence to reducing agents; when associated with V-70; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C70V	Q14680/C70V	MELK/C70V	MUTAGEN	C->V: Abolishes dependence to reducing agents; when associated with V-29; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C89A	Q14680/C89A	MELK/C89A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-154; A-168; A-169; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C154A	Q14680/C154A	MELK/C154A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-168; A-169; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	Y163F	Q14680/Y163F	MELK/Y163F	MUTAGEN	Y->F: Abolishes autophosphorylation on tyrosine but still active on exogenous substrates.	ECO:0000269|PubMed:16216881	16216881	decrease	
Q14680	MELK	T167E	Q14680/T167E	MELK/T167E	MUTAGEN	T->D,E: Phosphomimetic mutant that has similar kinase activity as wild-type.	ECO:0000269|PubMed:14976552	14976552	activating	
Q14680	MELK	C168A	Q14680/C168A	MELK/C168A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-169; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C169A	Q14680/C169A	MELK/C169A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-204; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	S171D	Q14680/S171D	MELK/S171D	MUTAGEN	S->D: Inactive.	ECO:0000269|PubMed:16216881	16216881	loss	
Q14680	MELK	C204A	Q14680/C204A	MELK/C204A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-286 and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C286A	Q14680/C286A	MELK/C286A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204; and A-339.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	C339A	Q14680/C339A	MELK/C339A	MUTAGEN	C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204 and A-286.	ECO:0000269|PubMed:16216881	16216881		
Q14680	MELK	T345A	Q14680/T345A	MELK/T345A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T387A	Q14680/T387A	MELK/T387A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T409A	Q14680/T409A	MELK/T409A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T415A	Q14680/T415A	MELK/T415A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T428A	Q14680/T428A	MELK/T428A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T446A	Q14680/T446A	MELK/T446A	MUTAGEN	T->A: Inhibits interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T460A	Q14680/T460A	MELK/T460A	MUTAGEN	T->A: Inhibits interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T466A	Q14680/T466A	MELK/T466A	MUTAGEN	T->A: Inhibits interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T478A	Q14680/T478A	MELK/T478A	MUTAGEN	T->A: Strongly inhibits interaction with PPP1R8. Enhances enzymatic activity.	ECO:0000269|PubMed:14699119	14699119		
Q14680	MELK	T518A	Q14680/T518A	MELK/T518A	MUTAGEN	T->A: No effect on interaction with PPP1R8.	ECO:0000269|PubMed:14699119	14699119		
Q15059	BRD3	T36N	Q15059/T36N	BRD3/T36N	VARIANT	T -> N (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15059	BRD3	A161T	Q15059/A161T	BRD3/A161T	VARIANT	A -> T (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15119	PDK2	G342R	Q15119/G342R	PDK2/G342R	VARIANT	G -> R (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs17855787)	ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846	15489334,17344846		
Q15120	PDK3	R158H	Q15120/R158H	PDK3/R158H	VARIANT	R -> H (in CMTX6; gain of function; results in a 5-fold increase in kinase activity, decreased sensitivity to pyruvate inhibition, reduced affinity for nucleotides and increased affinity for pyruvate dehydrogenase complex component E2 (PDC-E2), leading to PDC hyperphosphorylation and increased inactivation; dbSNP:rs397515323)	ECO:0000269|PubMed:23297365	23297365	activating	
Q15120	PDK3	E219A	Q15120/E219A	PDK3/E219A	VARIANT	E -> A (in a head & neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15120	PDK3	Y334S	Q15120/Y334S	PDK3/Y334S	VARIANT	Y -> S	ECO:0000269|PubMed:23297365	23297365		
Q15120	PDK3	N120H	Q15120/N120H	PDK3/N120H	MUTAGEN	N->H: No effect on kinase activity; when associated with N-121.	ECO:0000269|PubMed:23297365	23297365		
Q15120	PDK3	D121N	Q15120/D121N	PDK3/D121N	MUTAGEN	D->N: No effect on kinase activity; when associated with H-120.	ECO:0000269|PubMed:23297365	23297365		
Q15139	PRKD1	H152Y	Q15139/H152Y	PRKD1/H152Y	VARIANT	H -> Y (in a colorectal cancer sample; somatic mutation; dbSNP:rs1383618278)	ECO:0000269|PubMed:16959974	16959974		
Q15139	PRKD1	S225P	Q15139/S225P	PRKD1/S225P	VARIANT	S -> P	ECO:0000269|PubMed:17344846	17344846		
Q15139	PRKD1	L299W	Q15139/L299W	PRKD1/L299W	VARIANT	L -> W (in CHDED; dbSNP:rs1057519636)	ECO:0000269|PubMed:27479907	27479907		
Q15139	PRKD1	P585S	Q15139/P585S	PRKD1/P585S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15139	PRKD1	G592R	Q15139/G592R	PRKD1/G592R	VARIANT	G -> R (in CHDED; dbSNP:rs1057519635)	ECO:0000269|PubMed:27479907	27479907		
Q15139	PRKD1	R677M	Q15139/R677M	PRKD1/R677M	VARIANT	R -> M (in a lung bronchoalveolar carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15139	PRKD1	E857K	Q15139/E857K	PRKD1/E857K	VARIANT	E -> K (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q15139	PRKD1	P157G	Q15139/P157G	PRKD1/P157G	MUTAGEN	P->G: Increase in ability to bind phorbol ester, loss of ability to bind DAG.	ECO:0000269|PubMed:18076381	18076381		
Q15139	PRKD1	P281G	Q15139/P281G	PRKD1/P281G	MUTAGEN	P->G: No effect on ability to bind phorbol ester, slight increase in ability to bind DAG.	ECO:0000269|PubMed:18076381	18076381		
Q15139	PRKD1	Y432E	Q15139/Y432E	PRKD1/Y432E	MUTAGEN	Y->E: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL.	ECO:0000269|PubMed:12637538	12637538		
Q15139	PRKD1	Y432F	Q15139/Y432F	PRKD1/Y432F	MUTAGEN	Y->F: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL. Unaltered kinase activity. Decreased kinase activity; when associated with F-463 and F-502.	ECO:0000269|PubMed:12637538	12637538		
Q15139	PRKD1	Y463F	Q15139/Y463F	PRKD1/Y463F	MUTAGEN	Y->F: Decreased phosphorylation level when coexpressed with either SRC or ABL in HeLa cells. Decreased kinase activity.	ECO:0000269|PubMed:12637538	12637538	decrease	
Q15139	PRKD1	Y502F	Q15139/Y502F	PRKD1/Y502F	MUTAGEN	Y->F: Decreased phosphorylation level when coexpressed with SRC in HeLa cells. Unchanged phosphorylation level when coexpressed with ABL. Unaltered kinase activity. Decreased kinase activity; when associated with F-432 and F-502.	ECO:0000269|PubMed:12637538	12637538		
Q15208	STK38	E18K	Q15208/E18K	STK38/E18K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15303	ERBB4	T140I	Q15303/T140I	ERBB4/T140I	VARIANT	T -> I (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15303	ERBB4	S303Y	Q15303/S303Y	ERBB4/S303Y	VARIANT	S -> Y (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15303	ERBB4	V675A	Q15303/V675A	ERBB4/V675A	MUTAGEN	V->A: Abolishes proteolytic processing and nuclear localization.	ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:17638867	15746097,17638867		
Q15303	ERBB4	V721I	Q15303/V721I	ERBB4/V721I	MUTAGEN	V->I: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	A773S	Q15303/A773S	ERBB4/A773S	MUTAGEN	A->S: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	R782Q	Q15303/R782Q	ERBB4/R782Q	MUTAGEN	R->Q: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	E810K	Q15303/E810K	ERBB4/E810K	MUTAGEN	E->K: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	P854Q	Q15303/P854Q	ERBB4/P854Q	MUTAGEN	P->Q: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	E872K	Q15303/E872K	ERBB4/E872K	MUTAGEN	E->K: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	T926M	Q15303/T926M	ERBB4/T926M	MUTAGEN	T->M: No effect on kinase activity.	ECO:0000269|PubMed:19098003	19098003		
Q15303	ERBB4	R992A	Q15303/R992A	ERBB4/R992A	MUTAGEN	R->A: Abolishes APC/C-mediated degradation; when associated with A-995 and A-1000.	ECO:0000269|PubMed:17638867	17638867		
Q15303	ERBB4	L995A	Q15303/L995A	ERBB4/L995A	MUTAGEN	L->A: Abolishes APC/C-mediated degradation; when associated with A-992 and A-1000.	ECO:0000269|PubMed:17638867	17638867		
Q15303	ERBB4	D1000A	Q15303/D1000A	ERBB4/D1000A	MUTAGEN	D->A: Abolishes APC/C-mediated degradation; when associated with A-992 and A-995.	ECO:0000269|PubMed:17638867	17638867		
Q15303	ERBB4	Y1035A	Q15303/Y1035A	ERBB4/Y1035A	MUTAGEN	Y->A: No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1301.	ECO:0000269|PubMed:16061658	16061658		
Q15303	ERBB4	Y1056A	Q15303/Y1056A	ERBB4/Y1056A	MUTAGEN	Y->A: Abolishes interaction with NEDD4 and impairs ubiquitination. Promotes nuclear translocation of ERBB4 intracellular domain E4ICD1.	ECO:0000269|PubMed:19561640	19561640	loss	
Q15303	ERBB4	Y1056F	Q15303/Y1056F	ERBB4/Y1056F	MUTAGEN	Y->F: Abolishes interaction with WWP1; when associated with F-1301.	ECO:0000269|PubMed:19561640	19561640		
Q15303	ERBB4	Y1301A	Q15303/Y1301A	ERBB4/Y1301A	MUTAGEN	Y->A: No effect on interaction with WWOX. Abolishes interaction with WWOX; when associated with A-1035. Loss of interaction with YAP1 and stimulation of transcription.	ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640	12807903,16061658,19561640		
Q15303	ERBB4	Y1301F	Q15303/Y1301F	ERBB4/Y1301F	MUTAGEN	Y->F: Abolishes interaction with WWP1; when associated with F-1056.	ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640	12807903,16061658,19561640		
Q15349	RPS6KA2	E311K	Q15349/E311K	RPS6KA2/E311K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267600891)	ECO:0000269|PubMed:17344846	17344846		
Q15349	RPS6KA2	R732Q	Q15349/R732Q	RPS6KA2/R732Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs376029388)	ECO:0000269|PubMed:17344846	17344846		
Q15375	EPHA7	E170K	Q15375/E170K	EPHA7/E170K	VARIANT	E -> K (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15375	EPHA7	G232R	Q15375/G232R	EPHA7/G232R	VARIANT	G -> R (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15375	EPHA7	R371W	Q15375/R371W	EPHA7/R371W	VARIANT	R -> W (in a colorectal cancer sample; somatic mutation; dbSNP:rs371089003)	ECO:0000269|PubMed:16959974	16959974		
Q15375	EPHA7	P903S	Q15375/P903S	EPHA7/P903S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15569	TESK1	H539Y	Q15569/H539Y	TESK1/H539Y	VARIANT	H -> Y (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation; dbSNP:rs1373248755)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
Q15569	TESK1	D175A	Q15569/D175A	TESK1/D175A	MUTAGEN	D->A: Abolishes inhibition of SPRY4-mediated repression of cell spreading. No effect on interaction with SPRY4 or colocalization with SPRY4 at vesicular spots in the cytoplasm.	ECO:0000269|PubMed:15584898	15584898		
Q15746	MYLK	R607G	Q15746/R607G	MYLK/R607G	VARIANT	R -> G	ECO:0000269|PubMed:17344846	17344846		
Q15746	MYLK	V1213M	Q15746/V1213M	MYLK/V1213M	VARIANT	V -> M (in AAT7; unknown pathological significance; dbSNP:rs368390254)	ECO:0000269|PubMed:21055718	21055718		
Q15746	MYLK	P1588L	Q15746/P1588L	MYLK/P1588L	VARIANT	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1576401641)	ECO:0000269|PubMed:17344846	17344846		
Q15746	MYLK	S1759P	Q15746/S1759P	MYLK/S1759P	VARIANT	S -> P (in AAT7; 7-fold reduced affinity for calmodulin; 6-fold decreased Vmax; dbSNP:rs387906781)	ECO:0000269|PubMed:21055718	21055718		
Q15759	MAPK11	A221V	Q15759/A221V	MAPK11/A221V	VARIANT	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q15759	MAPK11	T180A	Q15759/T180A	MAPK11/T180A	MUTAGEN	T->A: Inactivation.	ECO:0000269|PubMed:15356147	15356147	loss	
Q15759	MAPK11	Y182F	Q15759/Y182F	MAPK11/Y182F	MUTAGEN	Y->F: Inactivation.	ECO:0000269|PubMed:15356147	15356147	loss	
Q15772	SPEG	E1178D	Q15772/E1178D	SPEG/E1178D	VARIANT	E -> D (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs757589345)	ECO:0000269|PubMed:17344846	17344846		
Q15772	SPEG	R1903W	Q15772/R1903W	SPEG/R1903W	VARIANT	R -> W (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs762000831)	ECO:0000269|PubMed:17344846	17344846		
Q15772	SPEG	V2742M	Q15772/V2742M	SPEG/V2742M	VARIANT	V -> M (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs566841339)	ECO:0000269|PubMed:17344846	17344846		
Q15772	SPEG	G2757V	Q15772/G2757V	SPEG/G2757V	VARIANT	G -> V (in CNM5; dbSNP:rs587777676)	ECO:0000269|PubMed:25087613	25087613		
Q15831	STK11	E14K	Q15831/E14K	STK11/E14K	VARIANT	E -> K (in cervical cancer; somatic mutation)	ECO:0000269|PubMed:12533684	12533684		
Q15831	STK11	E16G	Q15831/E16G	STK11/E16G	VARIANT	E -> G (in PJS)	ECO:0000269|PubMed:21411391	21411391		
Q15831	STK11	Y49D	Q15831/Y49D	STK11/Y49D	VARIANT	Y -> D (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs137853080)	ECO:0000269|PubMed:10201537	10201537		
Q15831	STK11	V66M	Q15831/V66M	STK11/V66M	VARIANT	V -> M (in cervical carcinoma; somatic mutation; dbSNP:rs1599915144)	ECO:0000269|PubMed:12533684, ECO:0000269|PubMed:19892943	12533684,19892943		
Q15831	STK11	R86G	Q15831/R86G	STK11/R86G	VARIANT	R -> G (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520039)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	R87K	Q15831/R87K	STK11/R87K	VARIANT	R -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1568690463)	ECO:0000269|PubMed:17344846	17344846		
Q15831	STK11	Q123R	Q15831/Q123R	STK11/Q123R	VARIANT	Q -> R (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs764449808)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	G135R	Q15831/G135R	STK11/G135R	VARIANT	G -> R (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs137853081)	ECO:0000269|PubMed:10201537	10201537		
Q15831	STK11	F157S	Q15831/F157S	STK11/F157S	VARIANT	F -> S (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	L160P	Q15831/L160P	STK11/L160P	VARIANT	L -> P (in cervical cancer; somatic mutation)	ECO:0000269|PubMed:12533684	12533684		
Q15831	STK11	G163D	Q15831/G163D	STK11/G163D	VARIANT	G -> D (in TGCT; a tumor with seminoma and teratoma components; associated with severely impaired but detectable kinase activity; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; predominantly nuclear localization; dbSNP:rs137853078)	ECO:0000269|PubMed:19892943, ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330	19892943,9605748,9887330	decrease	
Q15831	STK11	Q170P	Q15831/Q170P	STK11/Q170P	VARIANT	Q -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	G171S	Q15831/G171S	STK11/G171S	VARIANT	G -> S (in colorectal cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1599926499)	ECO:0000269|PubMed:19892943, ECO:0000269|PubMed:9731485	198,929,439,731,485	loss	
Q15831	STK11	H174R	Q15831/H174R	STK11/H174R	VARIANT	H -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	I177N	Q15831/I177N	STK11/I177N	VARIANT	I -> N (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520041)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	N181E	Q15831/N181E	STK11/N181E	VARIANT	N -> E (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; requires 2 nucleotide substitutions; dbSNP:rs1568707668)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	D194N	Q15831/D194N	STK11/D194N	VARIANT	D -> N (in PJS; dbSNP:rs121913315)	ECO:0000269|PubMed:10408777	10408777		DFG
Q15831	STK11	D194V	Q15831/D194V	STK11/D194V	VARIANT	D -> V (in lung cancer; somatic mutation; dbSNP:rs121913316)	ECO:0000269|PubMed:10079245	10079245		DFG
Q15831	STK11	D194Y	Q15831/D194Y	STK11/D194Y	VARIANT	D -> Y (in melanoma; sporadic malignant; somatic mutation; dbSNP:rs121913315)	ECO:0000269|PubMed:10208439	10208439		DFG
Q15831	STK11	E199Q	Q15831/E199Q	STK11/E199Q	VARIANT	E -> Q (in sporadic cancer; somatic mutation; does not affect kinase activity)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	A205T	Q15831/A205T	STK11/A205T	VARIANT	A -> T (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs730881981)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	D208N	Q15831/D208N	STK11/D208N	VARIANT	D -> N (in colorectal cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1555738372)	ECO:0000269|PubMed:9731485	9731485		
Q15831	STK11	G215D	Q15831/G215D	STK11/G215D	VARIANT	G -> D (in colorectal cancer; somatic mutation; dbSNP:rs1057520038)	ECO:0000269|PubMed:9731485	9731485		
Q15831	STK11	S216F	Q15831/S216F	STK11/S216F	VARIANT	S -> F (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs1057520017)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	E223V	Q15831/E223V	STK11/E223V	VARIANT	E -> V (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943	loss	
Q15831	STK11	T230P	Q15831/T230P	STK11/T230P	VARIANT	T -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	F231L	Q15831/F231L	STK11/F231L	VARIANT	F -> L (in cervical cancer; somatic mutation; dbSNP:rs929783669)	ECO:0000269|PubMed:12533684	12533684		
Q15831	STK11	S232P	Q15831/S232P	STK11/S232P	VARIANT	S -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	W239C	Q15831/W239C	STK11/W239C	VARIANT	W -> C (in PJS; late onset suggests reduced penetrance; dbSNP:rs137853082)	ECO:0000269|PubMed:12372054	12372054		
Q15831	STK11	L245R	Q15831/L245R	STK11/L245R	VARIANT	L -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	T250P	Q15831/T250P	STK11/T250P	VARIANT	T -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	Y272H	Q15831/Y272H	STK11/Y272H	VARIANT	Y -> H (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	D277Y	Q15831/D277Y	STK11/D277Y	VARIANT	D -> Y (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	P281L	Q15831/P281L	STK11/P281L	VARIANT	P -> L (in ovarian carcinoma; somatic mutation; dbSNP:rs121913322)	ECO:0000269|PubMed:10429654	10429654		
Q15831	STK11	L285Q	Q15831/L285Q	STK11/L285Q	VARIANT	L -> Q (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	R297K	Q15831/R297K	STK11/R297K	VARIANT	R -> K (in PJS; dbSNP:rs1568710381)	ECO:0000269|PubMed:10408777	10408777		
Q15831	STK11	P314H	Q15831/P314H	STK11/P314H	VARIANT	P -> H (in colorectal cancer; no effect heterotrimeric complex assembly with STRADA and CAB39)	ECO:0000269|PubMed:9809980	9809980		
Q15831	STK11	P315S	Q15831/P315S	STK11/P315S	VARIANT	P -> S (in PJS; pathogenicity uncertain; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs786202431)	ECO:0000269|PubMed:12372054, ECO:0000269|PubMed:19892943	12372054,19892943		
Q15831	STK11	P324L	Q15831/P324L	STK11/P324L	VARIANT	P -> L (in gastric carcinoma; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP:rs367807476)	ECO:0000269|PubMed:9683800	9683800		
Q15831	STK11	F354L	Q15831/F354L	STK11/F354L	VARIANT	F -> L (in colorectal cancer; somatic mutation; dbSNP:rs59912467)	ECO:0000269|PubMed:9731485	9731485		
Q15831	STK11	T367M	Q15831/T367M	STK11/T367M	VARIANT	T -> M (in colorectal cancer; somatic mutation; dbSNP:rs587782835)	ECO:0000269|PubMed:9731485	9731485		
Q15831	STK11	K44R	Q15831/K44R	STK11/K44R	MUTAGEN	K->R: No effect on kinase activity.	ECO:0000269|PubMed:18687677	18687677		
Q15831	STK11	K48Q	Q15831/K48Q	STK11/K48Q	MUTAGEN	K->Q: No effect on basal nucleocytoplasmic localization, but fails to translocate to the cytoplasm when coexpressed with SIRT1.	ECO:0000269|PubMed:18687677	18687677		
Q15831	STK11	R74A	Q15831/R74A	STK11/R74A	MUTAGEN	R->A: Impaired formation of a heterotrimeric complex with STRADA and CAB39; when associated with A-204.	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	K96R	Q15831/K96R	STK11/K96R	MUTAGEN	K->R: No effect on kinase activity.	ECO:0000269|PubMed:18687677	18687677		
Q15831	STK11	K97R	Q15831/K97R	STK11/K97R	MUTAGEN	K->R: No effect on kinase activity.	ECO:0000269|PubMed:18687677	18687677		
Q15831	STK11	F204A	Q15831/F204A	STK11/F204A	MUTAGEN	F->A: No effect. Impaired formation of a heterotrimeric complex with STRADA and CAB39; when associated with A-74.	ECO:0000269|PubMed:19892943	19892943		
Q15831	STK11	S428A	Q15831/S428A	STK11/S428A	MUTAGEN	S->A,E: No effect on kinase activity.	ECO:0000269|PubMed:18854309	18854309		
Q15831	STK11	S428E	Q15831/S428E	STK11/S428E	MUTAGEN	S->A,E: No effect on kinase activity.	ECO:0000269|PubMed:18854309	18854309		
Q15835	GRK1	V380D	Q15835/V380D	GRK1/V380D	VARIANT	V -> D (in CSNBO2; dbSNP:rs777094000)	ECO:0000269|PubMed:9020843	9020843		
Q15835	GRK1	P391H	Q15835/P391H	GRK1/P391H	VARIANT	P -> H (in CSNBO2; dbSNP:rs570621429)	ECO:0000269|PubMed:17070587	17070587		
Q15835	GRK1	S21E	Q15835/S21E	GRK1/S21E	MUTAGEN	S->E: Not phosphorylated by PKA.	ECO:0000269|PubMed:15946941	15946941		
Q16288	NTRK3	I71V	Q16288/I71V	NTRK3/I71V	VARIANT	I -> V (found in patients with CHD; unknown pathological significance; dbSNP:rs200923715)	ECO:0000269|PubMed:25196463	25196463		
Q16288	NTRK3	T93M	Q16288/T93M	NTRK3/T93M	VARIANT	T -> M (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; significantly reduced autophosphorylation; decreased NTRK3 signaling associated with decreased apoptosis in absence of NTF3; dbSNP:rs147992979)	ECO:0000269|PubMed:25196463	25196463	decrease	
Q16288	NTRK3	T149R	Q16288/T149R	NTRK3/T149R	VARIANT	T -> R (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs368222977)	ECO:0000269|PubMed:17344846	17344846		
Q16288	NTRK3	N163I	Q16288/N163I	NTRK3/N163I	VARIANT	N -> I (found in patients with CHD; unknown pathological significance; no change in autophosphorylation; no effect on NTRK3 signaling; dbSNP:rs547862658)	ECO:0000269|PubMed:25196463	25196463		
Q16288	NTRK3	V307L	Q16288/V307L	NTRK3/V307L	VARIANT	V -> L (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1388363572)	ECO:0000269|PubMed:17344846	17344846		
Q16288	NTRK3	L336Q	Q16288/L336Q	NTRK3/L336Q	VARIANT	L -> Q (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16288	NTRK3	I533F	Q16288/I533F	NTRK3/I533F	VARIANT	I -> F (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; no change in autophosphorylation; changed NTRK3 signaling with decreased apoptosis in absence of NTF3; dbSNP:rs869112057)	ECO:0000269|PubMed:25196463	25196463		
Q16288	NTRK3	A664S	Q16288/A664S	NTRK3/A664S	VARIANT	A -> S (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16288	NTRK3	H677Y	Q16288/H677Y	NTRK3/H677Y	VARIANT	H -> Y (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18293376	17344846,18293376		
Q16288	NTRK3	R735F	Q16288/R735F	NTRK3/R735F	VARIANT	R -> F (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)				
Q16288	NTRK3	W736C	Q16288/W736C	NTRK3/W736C	VARIANT	W -> C (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16288	NTRK3	R745P	Q16288/R745P	NTRK3/R745P	VARIANT	R -> P (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16288	NTRK3	Y766F	Q16288/Y766F	NTRK3/Y766F	VARIANT	Y -> F (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16288	NTRK3	I817M	Q16288/I817M	NTRK3/I817M	VARIANT	I -> M (probable disease-associated variant found in patients with CHD; associated with CHD susceptibility; no change in autophosphorylation; changed NTRK3 signaling with decreased apoptosis in absence of NTF3; dbSNP:rs869209165)	ECO:0000269|PubMed:25196463	25196463		
Q16512	PKN1	R185C	Q16512/R185C	PKN1/R185C	VARIANT	R -> C (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267605306)	ECO:0000269|PubMed:17344846	17344846		
Q16512	PKN1	F873L	Q16512/F873L	PKN1/F873L	VARIANT	F -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16512	PKN1	A921V	Q16512/A921V	PKN1/A921V	VARIANT	A -> V (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16512	PKN1	D108A	Q16512/D108A	PKN1/D108A	MUTAGEN	D->A: Abolishes cleavage by caspase-3 and formation of AF1 fragment.	ECO:0000269|PubMed:9751706	9751706		
Q16512	PKN1	R181A	Q16512/R181A	PKN1/R181A	MUTAGEN	R->A: Abolishes interaction with bacterial SspH1.	ECO:0000269|PubMed:24248594	24248594		
Q16512	PKN1	R181K	Q16512/R181K	PKN1/R181K	MUTAGEN	R->K: Decreases interaction with bacterial SspH1.	ECO:0000269|PubMed:24248594	24248594		
Q16512	PKN1	R185A	Q16512/R185A	PKN1/R185A	MUTAGEN	R->A: Abolishes interaction with bacterial SspH1.	ECO:0000269|PubMed:24248594	24248594		
Q16512	PKN1	D451A	Q16512/D451A	PKN1/D451A	MUTAGEN	D->A: Abolishes cleavage by caspase-3 and formation of 70 kDa fragment.	ECO:0000269|PubMed:9751706	9751706	loss	
Q16512	PKN1	D454A	Q16512/D454A	PKN1/D454A	MUTAGEN	D->A: Abolishes cleavage by caspase-3 and formation of 70 kDa fragment.	ECO:0000269|PubMed:9751706	9751706	loss	
Q16512	PKN1	D558A	Q16512/D558A	PKN1/D558A	MUTAGEN	D->A: Abolishes cleavage by caspase-3 and formation of AF3 fragment.	ECO:0000269|PubMed:9751706	9751706	loss	
Q16512	PKN1	D560A	Q16512/D560A	PKN1/D560A	MUTAGEN	D->A: Abolishes cleavage by caspase-3 and formation of AF3 fragment.	ECO:0000269|PubMed:9751706	9751706	loss	
Q16513	PKN2	D117A	Q16513/D117A	PKN2/D117A	MUTAGEN	D->A: Prevents proteolytic processing by caspase-3 during apoptosis. Diminishes pro-apoptotic function; when associated with E-700.	ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:9368003	109,269,259,368,003		
Q16513	PKN2	T121A	Q16513/T121A	PKN2/T121A	MUTAGEN	T->A: Does not suppress ciliogenesis; when associated with A-124.	ECO:0000269|PubMed:27104747	27104747		
Q16513	PKN2	T124A	Q16513/T124A	PKN2/T124A	MUTAGEN	T->A: Does not suppress ciliogenesis; when associated with A-121.	ECO:0000269|PubMed:27104747	27104747		
Q16513	PKN2	K686R	Q16513/K686R	PKN2/K686R	MUTAGEN	K->R: Does not inhibit interaction with PTPN13.	ECO:0000269|PubMed:11356191	11356191		
Q16513	PKN2	D700E	Q16513/D700E	PKN2/D700E	MUTAGEN	D->E: Prevents proteolytic processing by caspase-3 during apoptosis. Diminishes pro-apoptotic function; when associated with A-117.	ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:9368003	109,269,259,368,003		
Q16513	PKN2	F974A	Q16513/F974A	PKN2/F974A	MUTAGEN	F->A: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.	ECO:0000269|PubMed:10226025	10226025		
Q16513	PKN2	F977A	Q16513/F977A	PKN2/F977A	MUTAGEN	F->A,L: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241	decrease	
Q16513	PKN2	F977L	Q16513/F977L	PKN2/F977L	MUTAGEN	F->A,L: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241	decrease	
Q16513	PKN2	F977Y	Q16513/F977Y	PKN2/F977Y	MUTAGEN	F->W,Y: Reduces catalytic activity by 50%.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241	decrease	
Q16513	PKN2	D978A	Q16513/D978A	PKN2/D978A	MUTAGEN	D->A: Does not inhibit catalytic activity.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241		
Q16513	PKN2	D978S	Q16513/D978S	PKN2/D978S	MUTAGEN	D->A,S: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241		
Q16513	PKN2	Y979L	Q16513/Y979L	PKN2/Y979L	MUTAGEN	Y->F,L,W: Reduces catalytic activity by 25%.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241	decrease	
Q16513	PKN2	Y979W	Q16513/Y979W	PKN2/Y979W	MUTAGEN	Y->F,L,W: Reduces catalytic activity by 25%.	ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241	10226025,18835241	decrease	
Q16513	PKN2	C984S	Q16513/C984S	PKN2/C984S	MUTAGEN	C->S: Inhibits interaction with PTPN13.	ECO:0000269|PubMed:11356191	11356191		
Q16539	MAPK14	A51V	Q16539/A51V	MAPK14/A51V	VARIANT	A -> V (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16539	MAPK14	P322R	Q16539/P322R	MAPK14/P322R	VARIANT	P -> R (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16539	MAPK14	T175A	Q16539/T175A	MAPK14/T175A	MUTAGEN	T->A: No effect on either the kinase activity or tyrosine phosphorylation.	ECO:0000269|PubMed:7493921	7493921		
Q16539	MAPK14	D176A	Q16539/D176A	MAPK14/D176A	MUTAGEN	D->A: Emulation of the active state. Increase in activity; when associated with S-327 or L-327.	ECO:0000269|PubMed:15284239	15284239	increase	
Q16539	MAPK14	F327L	Q16539/F327L	MAPK14/F327L	MUTAGEN	F->L: Emulation of the active state. Increase in activity; when associated with A-176.	ECO:0000269|PubMed:15284239	15284239	increase	
Q16539	MAPK14	F327S	Q16539/F327S	MAPK14/F327S	MUTAGEN	F->S: Emulation of the active state. Increase in activity; when associated with A-176.	ECO:0000269|PubMed:15284239	15284239	increase	
Q16566	CAMK4	E150G	Q16566/E150G	CAMK4/E150G	VARIANT	E -> G (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16566	CAMK4	I469M	Q16566/I469M	CAMK4/I469M	VARIANT	I -> M (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs1239950009)	ECO:0000269|PubMed:17344846	17344846		
Q16566	CAMK4	S189A	Q16566/S189A	CAMK4/S189A	MUTAGEN	S->A: Increases phosphorylation of CREB1 2-fold. Decreases total O-linked glycosylation 2-fold. Increases ATP-binding affinity.	ECO:0000269|PubMed:19506079	19506079	increase	
Q16584	MAP3K11	T277E	Q16584/T277E	MAP3K11/T277E	MUTAGEN	T->E: No effect on SAPK activation.	ECO:0000269|PubMed:11053428	11053428		
Q16584	MAP3K11	T278A	Q16584/T278A	MAP3K11/T278A	MUTAGEN	T->A: No effect on autophosphorylation activity or activation of SAPK and MAPK14.	ECO:0000269|PubMed:11053428	11053428		
Q16584	MAP3K11	S281E	Q16584/S281E	MAP3K11/S281E	MUTAGEN	S->E: No effect on SAPK activation.	ECO:0000269|PubMed:11053428	11053428		
Q16620	NTRK2	L138F	Q16620/L138F	NTRK2/L138F	VARIANT	L -> F (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16620	NTRK2	G309R	Q16620/G309R	NTRK2/G309R	VARIANT	G -> R	ECO:0000269|Ref.5			
Q16620	NTRK2	Y434C	Q16620/Y434C	NTRK2/Y434C	VARIANT	Y -> C (in DEE58; unknown pathological significance; dbSNP:rs886041091)	ECO:0000269|PubMed:29100083	29100083		
Q16620	NTRK2	M697I	Q16620/M697I	NTRK2/M697I	VARIANT	M -> I (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16620	NTRK2	R699G	Q16620/R699G	NTRK2/R699G	VARIANT	R -> G (in a lung carcinoma sample; somatic mutation)	ECO:0000269|PubMed:18293376	18293376		
Q16620	NTRK2	T704I	Q16620/T704I	NTRK2/T704I	VARIANT	T -> I (in OBHD; unknown pathological significance; dbSNP:rs1554774973)	ECO:0000269|PubMed:29100083	29100083		
Q16620	NTRK2	R718C	Q16620/R718C	NTRK2/R718C	VARIANT	R -> C (in a lung carcinoma sample; somatic mutation; dbSNP:rs1324578301)	ECO:0000269|PubMed:18293376	18293376		
Q16644	MAPKAPK3	P28S	Q16644/P28S	MAPKAPK3/P28S	VARIANT	P -> S (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs375412266)	ECO:0000269|PubMed:17344846	17344846		
Q16644	MAPKAPK3	E105A	Q16644/E105A	MAPKAPK3/E105A	VARIANT	E -> A (in an ovarian endometrioid sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q16644	MAPKAPK3	L173P	Q16644/L173P	MAPKAPK3/L173P	VARIANT	L -> P (in MDPT3; decreased localization to the nucleus; dbSNP:rs886037913)	ECO:0000269|PubMed:26744326	26744326		
Q16654	PDK4	D394A	Q16654/D394A	PDK4/D394A	MUTAGEN	D->A: Loss of activity; when associated with A-395.	ECO:0000269|PubMed:18658136	18658136		
Q16654	PDK4	W395A	Q16654/W395A	PDK4/W395A	MUTAGEN	W->A: Loss of activity; when associated with A-394.	ECO:0000269|PubMed:18658136	18658136		
Q16671	AMHR2	R54C	Q16671/R54C	AMHR2/R54C	VARIANT	R -> C (in PMDS2; dbSNP:rs534999427)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	G142V	Q16671/G142V	AMHR2/G142V	VARIANT	G -> V (in PMDS2)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	H282Q	Q16671/H282Q	AMHR2/H282Q	VARIANT	H -> Q (in PMDS2; dbSNP:rs539695176)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	R406Q	Q16671/R406Q	AMHR2/R406Q	VARIANT	R -> Q (in PMDS2; dbSNP:rs137853104)	ECO:0000269|PubMed:11549681	11549681		
Q16671	AMHR2	D426G	Q16671/D426G	AMHR2/D426G	VARIANT	D -> G (in PMDS2)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	V458A	Q16671/V458A	AMHR2/V458A	VARIANT	V -> A (in PMDS2; dbSNP:rs775889926)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	D491H	Q16671/D491H	AMHR2/D491H	VARIANT	D -> H (in PMDS2; dbSNP:rs780680518)	ECO:0000269|PubMed:8872466	8872466		
Q16671	AMHR2	R504C	Q16671/R504C	AMHR2/R504C	VARIANT	R -> C (in PMDS2; dbSNP:rs772294564)	ECO:0000269|PubMed:8872466	8872466		
Q16816	PHKG1	V48M	Q16816/V48M	PHKG1/V48M	VARIANT	V -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs368370244)	ECO:0000269|PubMed:17344846	17344846		
Q16832	DDR2	R105S	Q16832/R105S	DDR2/R105S	VARIANT	R -> S (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:16140923, ECO:0000269|PubMed:17344846	16140923,17344846		
Q16832	DDR2	E113K	Q16832/E113K	DDR2/E113K	VARIANT	E -> K (in SEMD-SL; abolishes collagen binding; dbSNP:rs397514747)	ECO:0000269|PubMed:20223752	20223752		
Q16832	DDR2	R124W	Q16832/R124W	DDR2/R124W	VARIANT	R -> W (in SEMD-SL)	ECO:0000269|PubMed:26463668	26463668		
Q16832	DDR2	T713I	Q16832/T713I	DDR2/T713I	VARIANT	T -> I (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964865)	ECO:0000269|PubMed:19110212, ECO:0000269|PubMed:20223752	19110212,20223752		
Q16832	DDR2	I726R	Q16832/I726R	DDR2/I726R	VARIANT	I -> R (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964864)	ECO:0000269|PubMed:19110212, ECO:0000269|PubMed:20223752	19110212,20223752		
Q16832	DDR2	R752C	Q16832/R752C	DDR2/R752C	VARIANT	R -> C (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding; dbSNP:rs121964863)	ECO:0000269|PubMed:19110212, ECO:0000269|PubMed:20223752	19110212,20223752		
Q16832	DDR2	W52A	Q16832/W52A	DDR2/W52A	MUTAGEN	W->A: Abolishes collagen binding.	ECO:0000269|PubMed:20004161, ECO:0000269|PubMed:20223752	20004161,20223752		
Q16832	DDR2	Y736F	Q16832/Y736F	DDR2/Y736F	MUTAGEN	Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-740 and F-741.	ECO:0000269|PubMed:16186108	16186108	decrease	
Q16832	DDR2	Y740F	Q16832/Y740F	DDR2/Y740F	MUTAGEN	Y->F: Promotes autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-741.	ECO:0000269|PubMed:16186108	16186108	increase	
Q16832	DDR2	Y741F	Q16832/Y741F	DDR2/Y741F	MUTAGEN	Y->F: Reduces autophosphorylation. Abolishes phosphorylation by SRC; when associated with F-736 and F-740.	ECO:0000269|PubMed:16186108	16186108	decrease	
Q2M2I8	AAK1	G835D	Q2M2I8/G835D	AAK1/G835D	VARIANT	G -> D	ECO:0000269|PubMed:17344846	17344846		
Q2M2I8	AAK1	K74A	Q2M2I8/K74A	AAK1/K74A	MUTAGEN	K->A: Inhibits autophosphorylation and phosphorylation of AP2M1. Does not affect NUMB localization. Does not interact with monoubiquitinated NOTCH1.	ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:18657069, ECO:0000269|PubMed:21464124	12952931,18657069,21464124	loss	
Q2M2I8	AAK1	D176A	Q2M2I8/D176A	AAK1/D176A	MUTAGEN	D->A: Inhibits autophosphorylation and phosphorylation of AP2M1. Does not affect NUMB localization.	ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:18657069	12952931,18657069	loss	
Q32MK0	MYLK3	G390R	Q32MK0/G390R	MYLK3/G390R	VARIANT	G -> R (in a colorectal cancer sample; somatic mutation; dbSNP:rs141602742)	ECO:0000269|PubMed:16959974	16959974		
Q38SD2	LRRK1	A1803T	Q38SD2/A1803T	LRRK1/A1803T	VARIANT	A -> T	ECO:0000269|PubMed:17344846	17344846		
Q38SD2	LRRK1	L1824F	Q38SD2/L1824F	LRRK1/L1824F	VARIANT	L -> F	ECO:0000269|PubMed:17344846	17344846		
Q38SD2	LRRK1	S1847N	Q38SD2/S1847N	LRRK1/S1847N	VARIANT	S -> N	ECO:0000269|PubMed:17344846	17344846		
Q38SD2	LRRK1	D1927G	Q38SD2/D1927G	LRRK1/D1927G	VARIANT	D -> G	ECO:0000269|PubMed:17344846	17344846		
Q38SD2	LRRK1	K651A	Q38SD2/K651A	LRRK1/K651A	MUTAGEN	K->A: Loss of GTP/GDP-binding.	ECO:0000269|PubMed:16243488	16243488		
Q38SD2	LRRK1	K746G	Q38SD2/K746G	LRRK1/K746G	MUTAGEN	K->G: No effect on GTP-binding but reduction in subsequent stimulation of kinase activity.	ECO:0000269|PubMed:16243488	16243488	decrease	
Q38SD2	LRRK1	F1022C	Q38SD2/F1022C	LRRK1/F1022C	MUTAGEN	F->C: No effect on GTP-binding but loss of subsequent stimulation of kinase activity.	ECO:0000269|PubMed:16243488	16243488	loss	
Q38SD2	LRRK1	I1412T	Q38SD2/I1412T	LRRK1/I1412T	MUTAGEN	I->T: No effect on GTP-binding but reduction in subsequent stimulation of kinase activity.	ECO:0000269|PubMed:16243488	16243488	decrease	
Q52WX2	SBK1	K92E	Q52WX2/K92E	SBK1/K92E	VARIANT	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q52WX2	SBK1	A261S	Q52WX2/A261S	SBK1/A261S	VARIANT	A -> S	ECO:0000269|PubMed:17344846	17344846		
Q56UN5	MAP3K19	I500M	Q56UN5/I500M	MAP3K19/I500M	VARIANT	I -> M (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q58A45	PAN3	Y203A	Q58A45/Y203A	PAN3/Y203A	MUTAGEN	Y->A: Reduces interaction with polyadenylate-binding protein.	ECO:0000269|PubMed:18056425	18056425		
Q58A45	PAN3	F293A	Q58A45/F293A	PAN3/F293A	MUTAGEN	F->A: Reduces interaction with polyadenylate-binding protein.	ECO:0000269|PubMed:17595167, ECO:0000269|PubMed:18056425	17595167,18056425		
Q58F21	BRDT	A89V	Q58F21/A89V	BRDT/A89V	VARIANT	A -> V (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs781375003)	ECO:0000269|PubMed:17344846	17344846		
Q58F21	BRDT	H288Y	Q58F21/H288Y	BRDT/H288Y	VARIANT	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q58F21	BRDT	G928D	Q58F21/G928D	BRDT/G928D	VARIANT	G -> D (in SPGF21; no effect on protein expression; unknown pathological significance; dbSNP:rs754258809)	ECO:0000269|PubMed:28199965	28199965		
Q59H18	TNNI3K	F309L	Q59H18/F309L	TNNI3K/F309L	VARIANT	F -> L	ECO:0000269|PubMed:17344846	17344846		
Q59H18	TNNI3K	S430L	Q59H18/S430L	TNNI3K/S430L	VARIANT	S -> L (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q59H18	TNNI3K	R629G	Q59H18/R629G	TNNI3K/R629G	VARIANT	R -> G (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q59H18	TNNI3K	M798I	Q59H18/M798I	TNNI3K/M798I	VARIANT	M -> I (in a head & Neck squamous cell carcinoma sample; somatic mutation; dbSNP:rs201613442)	ECO:0000269|PubMed:17344846	17344846		
Q5JZY3	EPHA10	R150H	Q5JZY3/R150H	EPHA10/R150H	VARIANT	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs771803475)	ECO:0000269|PubMed:17344846	17344846		
Q5JZY3	EPHA10	L630P	Q5JZY3/L630P	EPHA10/L630P	VARIANT	L -> P	ECO:0000269|PubMed:17344846	17344846		
Q5JZY3	EPHA10	H775R	Q5JZY3/H775R	EPHA10/H775R	VARIANT	H -> R (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q5JZY3	EPHA10	A956T	Q5JZY3/A956T	EPHA10/A956T	VARIANT	A -> T	ECO:0000269|PubMed:17344846	17344846		
Q5S007	LRRK2	M712V	Q5S007/M712V	LRRK2/M712V	VARIANT	M -> V (in PARK8; dbSNP:rs199566791)	ECO:0000269|PubMed:18213618	18213618		
Q5S007	LRRK2	R793M	Q5S007/R793M	LRRK2/R793M	VARIANT	R -> M (in PARK8; unknown pathological significance; dbSNP:rs35173587)	ECO:0000269|PubMed:16157908, ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:16251215	16157908,16172858,16251215		
Q5S007	LRRK2	Q930R	Q5S007/Q930R	LRRK2/Q930R	VARIANT	Q -> R (in PARK8; unknown pathological significance; dbSNP:rs281865045)	ECO:0000269|PubMed:16251215	16251215		
Q5S007	LRRK2	R1067Q	Q5S007/R1067Q	LRRK2/R1067Q	VARIANT	R -> Q (in PARK8; dbSNP:rs111341148)	ECO:0000269|PubMed:16247070	16247070		
Q5S007	LRRK2	S1096C	Q5S007/S1096C	LRRK2/S1096C	VARIANT	S -> C (in PARK8; unknown pathological significance; dbSNP:rs76535406)				
Q5S007	LRRK2	I1122V	Q5S007/I1122V	LRRK2/I1122V	VARIANT	I -> V (in PARK8; dbSNP:rs34805604)	ECO:0000269|PubMed:15541309, ECO:0000269|PubMed:16172858	15541309,16172858		
Q5S007	LRRK2	S1228T	Q5S007/S1228T	LRRK2/S1228T	VARIANT	S -> T (in PARK8; dbSNP:rs60185966)	ECO:0000269|PubMed:16251215	16251215		
Q5S007	LRRK2	K1359I	Q5S007/K1359I	LRRK2/K1359I	VARIANT	K -> I (found in a renal cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:21248752	21248752		
Q5S007	LRRK2	I1371V	Q5S007/I1371V	LRRK2/I1371V	VARIANT	I -> V (in PARK8; unknown pathological significance; dbSNP:rs17466213)	ECO:0000269|PubMed:16157901, ECO:0000269|PubMed:16333314	16157901,16333314		
Q5S007	LRRK2	R1441C	Q5S007/R1441C	LRRK2/R1441C	VARIANT	R -> C (in PARK8; shows an increase in activity in both autophosphorylation and phosphorylation of a generic substrate; loss of interaction with SEC16A; shows an increase in activity in phosphorylation of RAB10; decreases phosphorylation-dependent binding to YWHAG; dbSNP:rs33939927)	ECO:0000269|PubMed:15541309, ECO:0000269|PubMed:16157909, ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:16269541, ECO:0000269|PubMed:16333314, ECO:0000269|PubMed:16533964, ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28202711, ECO:0000269|PubMed:29212815	15541309,16157909,16172858,16269541,16333314,16533964,25201882,26824392,28202711,29212815	increase	
Q5S007	LRRK2	R1441H	Q5S007/R1441H	LRRK2/R1441H	VARIANT	R -> H (in PARK8; shows an increase in activity in phosphorylation of RAB8A and RAB10; decreases phosphorylation-dependent binding to YWHAG; dbSNP:rs34995376)	ECO:0000269|PubMed:16157909, ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:29212815	16157909,16172858,26824392,29212815	increase	
Q5S007	LRRK2	R1514Q	Q5S007/R1514Q	LRRK2/R1514Q	VARIANT	R -> Q (in PARK8; unknown pathological significance; dbSNP:rs35507033)	ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22415848	16172858,17344846,22415848		
Q5S007	LRRK2	P1542S	Q5S007/P1542S	LRRK2/P1542S	VARIANT	P -> S (in PARK8; unknown pathological significance; dbSNP:rs33958906)	ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22415848	16172858,17344846,22415848		
Q5S007	LRRK2	R1550Q	Q5S007/R1550Q	LRRK2/R1550Q	VARIANT	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs200212150)	ECO:0000269|PubMed:17344846	17344846		
Q5S007	LRRK2	V1598E	Q5S007/V1598E	LRRK2/V1598E	VARIANT	V -> E (in PARK8; unknown pathological significance; dbSNP:rs721710)	ECO:0000269|PubMed:16172858	16172858		
Q5S007	LRRK2	R1628P	Q5S007/R1628P	LRRK2/R1628P	VARIANT	R -> P (may be associated with Parkinson disease in some populations; dbSNP:rs33949390)	ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:21641266, ECO:0000269|PubMed:22415848	16172858,21641266,22415848		
Q5S007	LRRK2	Y1699C	Q5S007/Y1699C	LRRK2/Y1699C	VARIANT	Y->C: Decreased membrane association when associated with D-727, D-728, or D-729. Inhibits autophosphorylation and RAB10 phosphorylation when associated with N-1348 or A-2017.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	R1723P	Q5S007/R1723P	LRRK2/R1723P	VARIANT	R -> P (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q5S007	LRRK2	R1728L	Q5S007/R1728L	LRRK2/R1728L	VARIANT	R -> L (in PARK8; dbSNP:rs145364431)	ECO:0000269|PubMed:18213618	18213618		
Q5S007	LRRK2	M1869T	Q5S007/M1869T	LRRK2/M1869T	VARIANT	M -> T (in PARK8; unknown pathological significance; dbSNP:rs35602796)	ECO:0000269|PubMed:16157908, ECO:0000269|PubMed:16172858	16157908,16172858		
Q5S007	LRRK2	K1906M	Q5S007/K1906M	LRRK2/K1906M	VARIANT	K -> M (does not inhibit interaction with RAB29; shows a progressive increase in neurite length and branching)	ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:23395371	17114044,23395371		
Q5S007	LRRK2	R1941H	Q5S007/R1941H	LRRK2/R1941H	VARIANT	R -> H (in PARK8; dbSNP:rs77428810)	ECO:0000269|PubMed:16272164	16272164		
Q5S007	LRRK2	I2012T	Q5S007/I2012T	LRRK2/I2012T	VARIANT	I -> T (in PARK8; unknown pathological significance; dbSNP:rs34015634)	ECO:0000269|PubMed:16172858	16172858		
Q5S007	LRRK2	G2019S	Q5S007/G2019S	LRRK2/G2019S	VARIANT	G->S: Decreased membrane association when associated with D-727, D-728, or D-729. Inhibits autophosphorylation and RAB10 phosphorylation when associated with N-1348 or A-2017.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	T2141M	Q5S007/T2141M	LRRK2/T2141M	VARIANT	T -> M (in PARK8; dbSNP:rs111691891)	ECO:0000269|PubMed:18213618	18213618		
Q5S007	LRRK2	R2143H	Q5S007/R2143H	LRRK2/R2143H	VARIANT	R -> H (in PARK8; dbSNP:rs201271001)	ECO:0000269|PubMed:18213618	18213618		
Q5S007	LRRK2	D2175H	Q5S007/D2175H	LRRK2/D2175H	VARIANT	D -> H (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs72547981)	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	Y2189C	Q5S007/Y2189C	LRRK2/Y2189C	VARIANT	Y -> C (in PARK8; no effect on WD domain homodimerization; no effect on kinase activity; dbSNP:rs35658131)	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	T2356I	Q5S007/T2356I	LRRK2/T2356I	VARIANT	T -> I (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs113511708)	ECO:0000269|PubMed:16272164, ECO:0000269|PubMed:30635421	16272164,30635421		
Q5S007	LRRK2	G2385R	Q5S007/G2385R	LRRK2/G2385R	VARIANT	G -> R (in PARK8; under conditions of oxidative stress the variant protein is more toxic and is associated with a higher rate of apoptosis; reduced binding to synaptic vesicles; no loss of interaction with SEC16A; shows an increase in activity in phosphorylation of RAB8A and RAB10; shows decreased WD domain homodimerization; reduced autophosphorylation at Ser-935; dbSNP:rs34778348)	ECO:0000269|PubMed:16172858, ECO:0000269|PubMed:17019612, ECO:0000269|PubMed:24687852, ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30635421	16172858,17019612,24687852,25201882,26824392,29212815,30635421		
Q5S007	LRRK2	V2390M	Q5S007/V2390M	LRRK2/V2390M	VARIANT	V -> M (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs79546190)	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	L2439I	Q5S007/L2439I	LRRK2/L2439I	VARIANT	L -> I (in PARK8; shows decreased WD domain homodimerization; no effect on kinase activity; dbSNP:rs72547983)	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	L2466H	Q5S007/L2466H	LRRK2/L2466H	VARIANT	L -> H (in PARK8; dbSNP:rs281865057)	ECO:0000269|PubMed:18213618	18213618		
Q5S007	LRRK2	C727D	Q5S007/C727D	LRRK2/C727D	MUTAGEN	C->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	ECO:0000269|PubMed:29212815	29212815	decrease	
Q5S007	LRRK2	L728D	Q5S007/L728D	LRRK2/L728D	MUTAGEN	L->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	ECO:0000269|PubMed:29212815	29212815	decrease	
Q5S007	LRRK2	L729D	Q5S007/L729D	LRRK2/L729D	MUTAGEN	L->D: Decreased kinase activity. Loss of RAB29-mediated activation and autophosphorylation of S-910, S-935, S-955, S-973 and S-1292. Decreased membrane association; when associated with G-1441, C-1699 and S-2019.	ECO:0000269|PubMed:29212815	29212815	decrease	
Q5S007	LRRK2	L789D	Q5S007/L789D	LRRK2/L789D	MUTAGEN	L->D: No effect on kinase activity and RAB29-mediated activation.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	L790D	Q5S007/L790D	LRRK2/L790D	MUTAGEN	L->D: No effect on kinase activity and RAB29-mediated activation.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	L791D	Q5S007/L791D	LRRK2/L791D	MUTAGEN	L->D: No effect on kinase activity and RAB29-mediated activation.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	T1343G	Q5S007/T1343G	LRRK2/T1343G	MUTAGEN	T->G: Decreased kinase activity; when associated with Q-1398.	ECO:0000269|PubMed:18230735	18230735		
Q5S007	LRRK2	K1347A	Q5S007/K1347A	LRRK2/K1347A	MUTAGEN	K->A: GTPase-dead mutant. Loss of interaction with SEC16A and impaired ability to recruit SEC16A to endoplasmic reticulum exit sites.	ECO:0000269|PubMed:25201882	25201882	loss	
Q5S007	LRRK2	T1348N	Q5S007/T1348N	LRRK2/T1348N	MUTAGEN	T->N: Loss of GTP binding. Inhibits autophosphorylation and RAB10 phosphorylation; when associated with G-1441, C-1699, or S-2019.	ECO:0000269|PubMed:29212815	29212815		
Q5S007	LRRK2	R1398Q	Q5S007/R1398Q	LRRK2/R1398Q	MUTAGEN	R->Q: Decreased kinase activity; when associated with G-1343.	ECO:0000269|PubMed:18230735	18230735		
Q5S007	LRRK2	K1906A	Q5S007/K1906A	LRRK2/K1906A	MUTAGEN	K->A: Loss of kinase activity. Decreases proteosomal degradation of MAPT; when associated with N-1994 and A-2017.	ECO:0000269|PubMed:26014385	26014385	loss	
Q5S007	LRRK2	D1994N	Q5S007/D1994N	LRRK2/D1994N	MUTAGEN	D->N: Loss of kinase activity. No loss of interaction with SEC16A and no loss of ability to recruit SEC16A to endoplasmic reticulum exit sites. Decreases proteosomal degradation of MAPT; when associated with A-1906 and A-2017.	ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:26824392	25201882,26014385,26824392	loss	
Q5S007	LRRK2	D2017A	Q5S007/D2017A	LRRK2/D2017A	MUTAGEN	D->A: Loss of kinase activity. Decreases proteosomal degradation of MAPT; when associated with A-1906 and N-1994. Loss of phosphorylation of RAB10; when associated with G-1441, C-1699, or S-2019.	ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30635421	26014385,29125462,29212815,30635421	loss	
Q5S007	LRRK2	L2343D	Q5S007/L2343D	LRRK2/L2343D	MUTAGEN	L->D: Decreases WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	F2344A	Q5S007/F2344A	LRRK2/F2344A	MUTAGEN	F->A: Decreases WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	S2345D	Q5S007/S2345D	LRRK2/S2345D	MUTAGEN	S->D: Decreases WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	Y2346A	Q5S007/Y2346A	LRRK2/Y2346A	MUTAGEN	Y->A: Decreases WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	E2395R	Q5S007/E2395R	LRRK2/E2395R	MUTAGEN	E->R: Decreases WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	M2408A	Q5S007/M2408A	LRRK2/M2408A	MUTAGEN	M->A,E: No effect on WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	M2408E	Q5S007/M2408E	LRRK2/M2408E	MUTAGEN	M->A,E: No effect on WD domain homodimerization. No effect on kinase activity.	ECO:0000269|PubMed:30635421	30635421		
Q5S007	LRRK2	S2409A	Q5S007/S2409A	LRRK2/S2409A	MUTAGEN	S->A: Decreases WD domain homodimerization.	ECO:0000269|PubMed:30635421	30635421		
Q5TCY1	TTBK1	S806F	Q5TCY1/S806F	TTBK1/S806F	VARIANT	S -> F (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q5TCY1	TTBK1	P855S	Q5TCY1/P855S	TTBK1/P855S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267601046)	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	G1121R	Q5VST9/G1121R	OBSCN/G1121R	VARIANT	G -> R	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	A1136V	Q5VST9/A1136V	OBSCN/A1136V	VARIANT	A -> V (in a colorectal cancer sample; somatic mutation; dbSNP:rs950055015)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
Q5VST9	OBSCN	H1156Q	Q5VST9/H1156Q	OBSCN/H1156Q	VARIANT	H -> Q	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	R1792H	Q5VST9/R1792H	OBSCN/R1792H	VARIANT	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs750681123)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	V1930M	Q5VST9/V1930M	OBSCN/V1930M	VARIANT	V -> M (in a colorectal cancer sample; somatic mutation; dbSNP:rs545316651)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	E2090K	Q5VST9/E2090K	OBSCN/E2090K	VARIANT	E -> K (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	S2314F	Q5VST9/S2314F	OBSCN/S2314F	VARIANT	S -> F (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	D3426E	Q5VST9/D3426E	OBSCN/D3426E	VARIANT	D -> E	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	R3834G	Q5VST9/R3834G	OBSCN/R3834G	VARIANT	R -> G	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	R3983Q	Q5VST9/R3983Q	OBSCN/R3983Q	VARIANT	R -> Q (in a colorectal cancer sample; somatic mutation; dbSNP:rs539154039)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	R4558H	Q5VST9/R4558H	OBSCN/R4558H	VARIANT	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs199865640)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	R4810Q	Q5VST9/R4810Q	OBSCN/R4810Q	VARIANT	R -> Q (in a breast cancer sample; somatic mutation; dbSNP:rs570805670)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	A4823S	Q5VST9/A4823S	OBSCN/A4823S	VARIANT	A -> S	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	A5071T	Q5VST9/A5071T	OBSCN/A5071T	VARIANT	A -> T (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q5VST9	OBSCN	E6473Q	Q5VST9/E6473Q	OBSCN/E6473Q	VARIANT	E -> Q	ECO:0000269|PubMed:17344846	17344846		
Q5VST9	OBSCN	R5975A	Q5VST9/R5975A	OBSCN/R5975A	MUTAGEN	R->A: Reduced binding to phosphatidylinositol 4,5-bisphosphate.	ECO:0000269|PubMed:28826662	28826662		
Q5VST9	OBSCN	R5980A	Q5VST9/R5980A	OBSCN/R5980A	MUTAGEN	R->A: Reduced binding to phosphatidylinositol 3,4-bisphosphate.	ECO:0000269|PubMed:28826662	28826662		
Q5VT25	CDC42BPA	E50K	Q5VT25/E50K	CDC42BPA/E50K	VARIANT	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q5VT25	CDC42BPA	I1418K	Q5VT25/I1418K	CDC42BPA/I1418K	VARIANT	I -> K	ECO:0000269|PubMed:17344846	17344846		
Q5VT25	CDC42BPA	D984A	Q5VT25/D984A	CDC42BPA/D984A	MUTAGEN	D->A: Prevents cleavage by CASP3.	ECO:0000269|PubMed:29162624	29162624		
Q5VT25	CDC42BPA	H1579A	Q5VT25/H1579A	CDC42BPA/H1579A	MUTAGEN	H->A: Loss of CDC42 binding; when associated with A-1582.	ECO:0000269|PubMed:9418861	9418861		
Q5VT25	CDC42BPA	H1582A	Q5VT25/H1582A	CDC42BPA/H1582A	MUTAGEN	H->A: Loss of CDC42 binding; when associated with A-1579.	ECO:0000269|PubMed:9418861	9418861		
Q6DT37	CDC42BPG	S280F	Q6DT37/S280F	CDC42BPG/S280F	VARIANT	S -> F (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs770462360)	ECO:0000269|PubMed:17344846	17344846		
Q6IQ55	TTBK2	D635G	Q6IQ55/D635G	TTBK2/D635G	VARIANT	D -> G (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6IQ55	TTBK2	E842G	Q6IQ55/E842G	TTBK2/E842G	VARIANT	E -> G (found in a patient with SCA11; unknown pathological significance; dbSNP:rs202004988)	ECO:0000269|PubMed:19533200	19533200		
Q6IQ55	TTBK2	R1110H	Q6IQ55/R1110H	TTBK2/R1110H	VARIANT	R -> H (found in a patient with SCA11; unknown pathological significance; dbSNP:rs146279300)	ECO:0000269|PubMed:19533200	19533200		
Q6IQ55	TTBK2	K50E	Q6IQ55/K50E	TTBK2/K50E	MUTAGEN	K->E,A: Leads to inactivation/destabilization of the protein.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6IQ55	TTBK2	K50A	Q6IQ55/K50A	TTBK2/K50A	MUTAGEN	K->E,A: Leads to inactivation/destabilization of the protein.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6IQ55	TTBK2	K143E	Q6IQ55/K143E	TTBK2/K143E	MUTAGEN	K->E,A: Leads to inactivation/destabilization of the protein.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6IQ55	TTBK2	K143A	Q6IQ55/K143A	TTBK2/K143A	MUTAGEN	K->E,A: Leads to inactivation/destabilization of the protein.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6IQ55	TTBK2	R181A	Q6IQ55/R181A	TTBK2/R181A	MUTAGEN	R->E,A: Impaired serine/threonine-protein kinase activity.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6IQ55	TTBK2	A184G	Q6IQ55/A184G	TTBK2/A184G	MUTAGEN	A->E,G: Impaired serine/threonine-protein kinase activity.	ECO:0000269|PubMed:21548880	21548880	loss	
Q6J9G0	STYK1	V395I	Q6J9G0/V395I	STYK1/V395I	VARIANT	V -> I (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6P0Q8	MAST2	K275E	Q6P0Q8/K275E	MAST2/K275E	VARIANT	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6P0Q8	MAST2	G655A	Q6P0Q8/G655A	MAST2/G655A	VARIANT	G -> A (in a breast mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6P0Q8	MAST2	G1703E	Q6P0Q8/G1703E	MAST2/G1703E	VARIANT	G -> E	ECO:0000269|PubMed:17344846	17344846		
Q6P3R8	NEK5	R290H	Q6P3R8/R290H	NEK5/R290H	VARIANT	R -> H	ECO:0000269|PubMed:17344846	17344846		
Q6P3R8	NEK5	C531R	Q6P3R8/C531R	NEK5/C531R	VARIANT	C -> R	ECO:0000269|PubMed:17344846	17344846		
Q6P3W7	SCYL2	Q863H	Q6P3W7/Q863H	SCYL2/Q863H	VARIANT	Q -> H (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6VAB6	KSR2	R676S	Q6VAB6/R676S	KSR2/R676S	VARIANT	R -> S (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6VAB6	KSR2	R718H	Q6VAB6/R718H	KSR2/R718H	MUTAGEN	R->H: Impairs formation of heterotetramers with MAP2K1, but not the formation of heterodimers.	ECO:0000269|PubMed:21441910	21441910		
Q6VAB6	KSR2	A879L	Q6VAB6/A879L	KSR2/A879L	MUTAGEN	A->L: Impairs MAP2K1 binding.	ECO:0000269|PubMed:21441910	21441910		
Q6XUX3	DSTYK	R29Q	Q6XUX3/R29Q	DSTYK/R29Q	VARIANT	R -> Q (in CAKUT1; unknown pathological significance; dbSNP:rs200780796)	ECO:0000269|PubMed:23862974	23862974		
Q6XUX3	DSTYK	D200G	Q6XUX3/D200G	DSTYK/D200G	VARIANT	D -> G (in CAKUT1)	ECO:0000269|PubMed:23862974	23862974		
Q6XUX3	DSTYK	S843L	Q6XUX3/S843L	DSTYK/S843L	VARIANT	S -> L (in CAKUT1; dbSNP:rs778586547)	ECO:0000269|PubMed:23862974	23862974		
Q6XUX3	DSTYK	K681Q	Q6XUX3/K681Q	DSTYK/K681Q	MUTAGEN	K->Q: No change.	ECO:0000269|PubMed:15178406	15178406		
Q6ZMQ8	AATK	S81F	Q6ZMQ8/S81F	AATK/S81F	VARIANT	S -> F (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZMQ8	AATK	L97V	Q6ZMQ8/L97V	AATK/L97V	VARIANT	L -> V (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZMQ8	AATK	M104V	Q6ZMQ8/M104V	AATK/M104V	VARIANT	M -> V (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1337040042)	ECO:0000269|PubMed:17344846	17344846		
Q6ZN16	MAP3K15	R255S	Q6ZN16/R255S	MAP3K15/R255S	VARIANT	R -> S (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZN16	MAP3K15	S562L	Q6ZN16/S562L	MAP3K15/S562L	VARIANT	S -> L (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZN16	MAP3K15	R677Q	Q6ZN16/R677Q	MAP3K15/R677Q	VARIANT	R -> Q (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZN16	MAP3K15	W1247R	Q6ZN16/W1247R	MAP3K15/W1247R	VARIANT	W -> R (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZWH5	NEK10	A66V	Q6ZWH5/A66V	NEK10/A66V	VARIANT	A -> V (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs201821707)	ECO:0000269|PubMed:17344846	17344846		
Q6ZWH5	NEK10	E379K	Q6ZWH5/E379K	NEK10/E379K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q6ZWH5	NEK10	P748L	Q6ZWH5/P748L	NEK10/P748L	VARIANT	P -> L (in CILD44; unknown pathological significance; dbSNP:rs1575215909)	ECO:0000269|PubMed:31959991	31959991		
Q6ZWH5	NEK10	R773C	Q6ZWH5/R773C	NEK10/R773C	VARIANT	R -> C (in CILD44; unknown pathological significance; dbSNP:rs766982731)	ECO:0000269|PubMed:31959991	31959991		
Q6ZWH5	NEK10	S684D	Q6ZWH5/S684D	NEK10/S684D	MUTAGEN	S->D: Increased mucociliary transport.	ECO:0000269|PubMed:31959991	31959991		
Q7KZI7	MARK2	T208A	Q7KZI7/T208A	MARK2/T208A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q7KZI7	MARK2	T596A	Q7KZI7/T596A	MARK2/T596A	MUTAGEN	T->A: Loss of membrane dissociation and binding to YWHAZ.	ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659	15084291,15324659		
Q7L7X3	TAOK1	E17G	Q7L7X3/E17G	TAOK1/E17G	VARIANT	E -> G (in DDIB)	ECO:0000269|PubMed:31230721	31230721		
Q7L7X3	TAOK1	S111F	Q7L7X3/S111F	TAOK1/S111F	VARIANT	S -> F (in DDIB; dbSNP:rs2030976698)	ECO:0000269|PubMed:31230721	31230721		
Q7L7X3	TAOK1	R150I	Q7L7X3/R150I	TAOK1/R150I	VARIANT	R -> I (in DDIB)	ECO:0000269|PubMed:33565190	33565190		
Q7L7X3	TAOK1	L167R	Q7L7X3/L167R	TAOK1/L167R	VARIANT	L -> R (in DDIB; affects neuron maturation and migration)	ECO:0000269|PubMed:33565190	33565190		
Q7L7X3	TAOK1	M231V	Q7L7X3/M231V	TAOK1/M231V	VARIANT	M -> V (in DDIB; unknown pathological significance)	ECO:0000269|PubMed:33565190	33565190		
Q7L7X3	TAOK1	K298E	Q7L7X3/K298E	TAOK1/K298E	VARIANT	K -> E (in DDIB)	ECO:0000269|PubMed:31230721	31230721		
Q7L7X3	TAOK1	D305A	Q7L7X3/D305A	TAOK1/D305A	VARIANT	D -> A (in DDIB)	ECO:0000269|PubMed:31230721	31230721		
Q7L7X3	TAOK1	L315F	Q7L7X3/L315F	TAOK1/L315F	VARIANT	L -> F (in DDIB; unknown pathological significance)	ECO:0000269|PubMed:33565190	33565190		
Q7L7X3	TAOK1	L548P	Q7L7X3/L548P	TAOK1/L548P	VARIANT	L -> P (in DDIB; affects neuron maturation and migration)	ECO:0000269|PubMed:33565190	33565190		
Q7L7X3	TAOK1	D376N	Q7L7X3/D376N	TAOK1/D376N	MUTAGEN	D->N: Does not abolish cleavage by caspase-3 (CASP3).	ECO:0000269|PubMed:16407310	16407310		
Q7L7X3	TAOK1	T643A	Q7L7X3/T643A	TAOK1/T643A	MUTAGEN	T->A: Abolishes phosphorylation by ATM; when associated with A-785 and A-990.	ECO:0000269|PubMed:17396146	17396146		
Q7L7X3	TAOK1	T785A	Q7L7X3/T785A	TAOK1/T785A	MUTAGEN	T->A: Abolishes phosphorylation by ATM; when associated with A-643 and A-990.	ECO:0000269|PubMed:17396146	17396146		
Q7L7X3	TAOK1	S990A	Q7L7X3/S990A	TAOK1/S990A	MUTAGEN	S->A: Abolishes phosphorylation by ATM; when associated with A-643 and A-785.	ECO:0000269|PubMed:17396146	17396146		
Q7RTN6	STRADA	Y185F	Q7RTN6/Y185F	STRADA/Y185F	MUTAGEN	Y->F: Suppresses STK11/LKB1 activation without affecting complex assembly.	ECO:0000269|PubMed:19892943	19892943		Domain inactive; pseudokinase
Q7RTN6	STRADA	H231A	Q7RTN6/H231A	STRADA/H231A	MUTAGEN	H->A: Inhibits interaction with STK11/LKB1; when associated with A-.	ECO:0000269|PubMed:19892943	19892943		Domain inactive; pseudokinase
Q7RTN6	STRADA	F233A	Q7RTN6/F233A	STRADA/F233A	MUTAGEN	F->A: Inhibits interaction with STK11/LKB1; when associated with A-.	ECO:0000269|PubMed:19892943	19892943		Domain inactive; pseudokinase
Q7RTN6	STRADA	L241A	Q7RTN6/L241A	STRADA/L241A	MUTAGEN	L->A: Inhibits interaction with STK11/LKB1.	ECO:0000269|PubMed:19892943	19892943		Domain inactive; pseudokinase
Q7RTN6	STRADA	Q251A	Q7RTN6/Q251A	STRADA/Q251A	MUTAGEN	Q->A: Inhibits interaction with STK11/LKB1.	ECO:0000269|PubMed:19892943	19892943		Domain inactive; pseudokinase
Q7Z2Y5	NRK	S424C	Q7Z2Y5/S424C	NRK/S424C	VARIANT	S -> C (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q7Z2Y5	NRK	I880L	Q7Z2Y5/I880L	NRK/I880L	VARIANT	I -> L (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs764355898)	ECO:0000269|PubMed:17344846	17344846		
Q7Z7A4	PXK	R54Q	Q7Z7A4/R54Q	PXK/R54Q	MUTAGEN	R->Q: No effect on subcellular location.	ECO:0000269|PubMed:16142408	16142408		
Q7Z7A4	PXK	Y56A	Q7Z7A4/Y56A	PXK/Y56A	MUTAGEN	Y->A: Results in redistribution of protein from cytoplasm throughout entire cell.	ECO:0000269|PubMed:16142408	16142408		
Q7Z7A4	PXK	R92L	Q7Z7A4/R92L	PXK/R92L	MUTAGEN	R->L: Results in redistribution of protein from cytoplasm throughout entire cell.	ECO:0000269|PubMed:16142408	16142408		
Q86SG6	NEK8	L330F	Q86SG6/L330F	NEK8/L330F	VARIANT	L -> F (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs199962228)	ECO:0000269|PubMed:18199800	18199800		
Q86SG6	NEK8	H425Y	Q86SG6/H425Y	NEK8/H425Y	VARIANT	H -> Y (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs118204032)	ECO:0000269|PubMed:18199800	18199800		
Q86SG6	NEK8	A497P	Q86SG6/A497P	NEK8/A497P	VARIANT	A -> P (in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP:rs146326420)	ECO:0000269|PubMed:18199800	18199800		
Q86TB3	ALPK2	E942K	Q86TB3/E942K	ALPK2/E942K	VARIANT	E -> K (in an ovarian undifferentiated carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q86TB3	ALPK2	K1476T	Q86TB3/K1476T	ALPK2/K1476T	VARIANT	K -> T (in a melanoma metastatic sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q86TB3	ALPK2	Q1853E	Q86TB3/Q1853E	ALPK2/Q1853E	VARIANT	Q -> E (rare variant found in East Asian patients; decreases luminal apoptosis, cell aggregation and basolateral membrane localization in colorectal cancer cells; dbSNP:rs55674018)	ECO:0000269|PubMed:28668886	28668886		
Q86TW2	ADCK1	A164G	Q86TW2/A164G	ADCK1/A164G	MUTAGEN	A->G: No effect on role in maintaining mitochondrial structure and function.	ECO:0000269|PubMed:31125351	31125351		
Q86TW2	ADCK1	K183I	Q86TW2/K183I	ADCK1/K183I	MUTAGEN	K->I: No effect on role in maintaining mitochondrial structure and function.	ECO:0000269|PubMed:31125351	31125351		
Q86TW2	ADCK1	D315A	Q86TW2/D315A	ADCK1/D315A	MUTAGEN	D->A: No effect on role in maintaining mitochondrial structure and function.	ECO:0000269|PubMed:31125351	31125351		
Q86UE8	TLK2	E54D	Q86UE8/E54D	TLK2/E54D	VARIANT	E -> D	ECO:0000269|PubMed:17344846	17344846		
Q86UE8	TLK2	A108G	Q86UE8/A108G	TLK2/A108G	VARIANT	A -> G	ECO:0000269|PubMed:17344846	17344846		
Q86UE8	TLK2	F173L	Q86UE8/F173L	TLK2/F173L	VARIANT	F -> L (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1331331651)	ECO:0000269|PubMed:17344846	17344846		
Q86UE8	TLK2	G297D	Q86UE8/G297D	TLK2/G297D	VARIANT	G -> D (in MRD57; unknown pathological significance; dbSNP:rs1555639254)	ECO:0000269|PubMed:29861108	29861108		
Q86UE8	TLK2	R339Q	Q86UE8/R339Q	TLK2/R339Q	VARIANT	R -> Q (in MRD57; unknown pathological significance; dbSNP:rs1567948287)	ECO:0000269|PubMed:29861108	29861108		
Q86UE8	TLK2	R339W	Q86UE8/R339W	TLK2/R339W	VARIANT	R -> W (in MRD57; unknown pathological significance; dbSNP:rs1567948262)	ECO:0000269|PubMed:29861108	29861108		
Q86UE8	TLK2	E447K	Q86UE8/E447K	TLK2/E447K	VARIANT	E -> K (in MRD57; unknown pathological significance; dbSNP:rs1567959483)	ECO:0000269|PubMed:29861108	29861108		
Q86UE8	TLK2	D551G	Q86UE8/D551G	TLK2/D551G	VARIANT	D -> G (in MRD57; unknown pathological significance; exhibits abnormal perinuclear localization instead of diffuse nuclear localization; mildly impairs kinase activity; reduced phosphorylation of ASF1A; dbSNP:rs2082811958)	ECO:0000269|PubMed:33323470	33323470	decrease	
Q86UE8	TLK2	R568W	Q86UE8/R568W	TLK2/R568W	VARIANT	R -> W (in MRD57; dbSNP:rs1283838287)	ECO:0000269|PubMed:29861108	29861108		
Q86UE8	TLK2	P680R	Q86UE8/P680R	TLK2/P680R	VARIANT	P -> R (in MRD57; dbSNP:rs1568018905)	ECO:0000269|PubMed:29861108	29861108		
Q86UX6	STK32C	V151L	Q86UX6/V151L	STK32C/V151L	VARIANT	V -> L (found in a patient with global developmental delay; unknown pathological significance)	ECO:0000269|PubMed:28940097	28940097		
Q86UX6	STK32C	R376H	Q86UX6/R376H	STK32C/R376H	VARIANT	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs764558009)	ECO:0000269|PubMed:16959974	16959974		
Q86YV5	PRAG1	L955A	Q86YV5/L955A	PRAG1/L955A	MUTAGEN	L->A: Decreases homodimerization. Abolished interaction with PEAK1. No effect on cell migration.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	L966A	Q86YV5/L966A	PRAG1/L966A	MUTAGEN	L->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	I1243A	Q86YV5/I1243A	PRAG1/I1243A	MUTAGEN	I->A: No effect on homodimerization. Decreases oligomerization. Decreases interaction with PEAK1.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	F1271A	Q86YV5/F1271A	PRAG1/F1271A	MUTAGEN	F->A: Decreases homodimerization. Decreases interaction with PEAK1.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	R1278A	Q86YV5/R1278A	PRAG1/R1278A	MUTAGEN	R->A: Decreases homodimerization.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	Y1282A	Q86YV5/Y1282A	PRAG1/Y1282A	MUTAGEN	Y->A: No effect on homodimerization. Decreases oligomerization. Decreases interaction with PEAK1. No effect on cell migration.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	F1366A	Q86YV5/F1366A	PRAG1/F1366A	MUTAGEN	F->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86YV5	PRAG1	W1382A	Q86YV5/W1382A	PRAG1/W1382A	MUTAGEN	W->A: Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q86Z02	HIPK1	L1165V	Q86Z02/L1165V	HIPK1/L1165V	VARIANT	L -> V	ECO:0000269|PubMed:17344846	17344846		
Q86Z02	HIPK1	K25R	Q86Z02/K25R	HIPK1/K25R	MUTAGEN	K->R: Reduced sumoylation and cytoplasmic subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-317; R-440; R-556 and R-1203.	ECO:0000269|PubMed:15701637	15701637		
Q86Z02	HIPK1	K317R	Q86Z02/K317R	HIPK1/K317R	MUTAGEN	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-440; R-556 and R-1203.	ECO:0000269|PubMed:15701637	15701637		
Q86Z02	HIPK1	K440R	Q86Z02/K440R	HIPK1/K440R	MUTAGEN	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-556 and R-1203.	ECO:0000269|PubMed:15701637	15701637		
Q86Z02	HIPK1	K556R	Q86Z02/K556R	HIPK1/K556R	MUTAGEN	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-440 and R-1203.	ECO:0000269|PubMed:15701637	15701637		
Q86Z02	HIPK1	K1203R	Q86Z02/K1203R	HIPK1/K1203R	MUTAGEN	K->R: Nuclear subcellular location. Impaired sumoylation and cytoplasmic subcellular location; when associated with R-25; R-317; R-440 and R-556.	ECO:0000269|PubMed:15701637	15701637		
Q8IU85	CAMK1D	K52A	Q8IU85/K52A	CAMK1D/K52A	MUTAGEN	K->A: Catalytically inactive form.	ECO:0000269|PubMed:16324104	16324104	loss	
Q8IVH8	MAP4K3	T669S	Q8IVH8/T669S	MAP4K3/T669S	VARIANT	T -> S (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IVH8	MAP4K3	K45E	Q8IVH8/K45E	MAP4K3/K45E	MUTAGEN	K->E: Loss of kinase activity and ability to activate JNK family.	ECO:0000269|PubMed:9275185	9275185	loss	
Q8IVT5	KSR1	S227P	Q8IVT5/S227P	KSR1/S227P	VARIANT	S -> P	ECO:0000269|PubMed:17344846	17344846		
Q8IVT5	KSR1	V359A	Q8IVT5/V359A	KSR1/V359A	VARIANT	V -> A	ECO:0000269|PubMed:17344846	17344846		
Q8IVT5	KSR1	Q663H	Q8IVT5/Q663H	KSR1/Q663H	VARIANT	Q -> H	ECO:0000269|PubMed:17344846	17344846		
Q8IVT5	KSR1	L47D	Q8IVT5/L47D	KSR1/L47D	MUTAGEN	L->D: Reduces interaction with BRAF and MAP2K1 and thus phosphorylation of MAP2K1.	ECO:0000269|PubMed:29433126	29433126		
Q8IVT5	KSR1	C62D	Q8IVT5/C62D	KSR1/C62D	MUTAGEN	C->D: Reduces interaction with BRAF and MAP2K1 and thus phosphorylation of MAP2K1.	ECO:0000269|PubMed:29433126	29433126		
Q8IVT5	KSR1	A637F	Q8IVT5/A637F	KSR1/A637F	MUTAGEN	A->F: No effect on MAP2K1 or MAP2K2 mediated-BRAF-KSR1 dimerization and BRAF activation.	ECO:0000269|PubMed:29433126	29433126		
Q8IVT5	KSR1	R639M	Q8IVT5/R639M	KSR1/R639M	MUTAGEN	R->M: No effect on MAP2K1 mediated-BRAF-KSR1 dimerization and BRAF activation.	ECO:0000269|PubMed:29433126	29433126		
Q8IVT5	KSR1	R665H	Q8IVT5/R665H	KSR1/R665H	MUTAGEN	R->H: Loss of MAP2K1 mediated-BRAF-KSR1 dimerization.	ECO:0000269|PubMed:29433126	29433126		
Q8IVT5	KSR1	W831R	Q8IVT5/W831R	KSR1/W831R	MUTAGEN	W->R: Loss of the interaction with MAP2K1 resulting in loss of BRAF-KSR1 dimerization and BRAF activation. No effect on ATP binding or interaction with HSP90AA1, 14-3-3 and CDC37.	ECO:0000269|PubMed:29433126	29433126		
Q8IW41	MAPKAPK5	T182A	Q8IW41/T182A	MAPKAPK5/T182A	MUTAGEN	T->A: No p38-beta/MAPK11-induced activation.	ECO:0000269|PubMed:12808055, ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:9628874	12808055,21329882,9628874		
Q8IWB6	TEX14	K321E	Q8IWB6/K321E	TEX14/K321E	VARIANT	K -> E (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IWB6	TEX14	S443C	Q8IWB6/S443C	TEX14/S443C	VARIANT	S -> C	ECO:0000269|PubMed:17344846	17344846		
Q8IWB6	TEX14	I559M	Q8IWB6/I559M	TEX14/I559M	VARIANT	I -> M	ECO:0000269|PubMed:17344846	17344846		
Q8IWQ3	BRSK2	T174A	Q8IWQ3/T174A	BRSK2/T174A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068	14976552,18339622,22798068	loss	
Q8IWU2	LMTK2	D484H	Q8IWU2/D484H	LMTK2/D484H	VARIANT	D -> H (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs147940573)	ECO:0000269|PubMed:17344846	17344846		
Q8IY84	NIM1K	P333S	Q8IY84/P333S	NIM1K/P333S	VARIANT	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs866026698)	ECO:0000269|PubMed:17344846	17344846		
Q8IY84	NIM1K	P411T	Q8IY84/P411T	NIM1K/P411T	VARIANT	P -> T (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IY84	NIM1K	T229E	Q8IY84/T229E	NIM1K/T229E	MUTAGEN	T->E: Constitutively active.	ECO:0000269|PubMed:15733851	15733851	activating	
Q8IYT8	ULK2	G627E	Q8IYT8/G627E	ULK2/G627E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IYT8	ULK2	A662V	Q8IYT8/A662V	ULK2/A662V	VARIANT	A -> V (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	G47A	Q8IZX4/G47A	TAF1L/G47A	VARIANT	G -> A (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	L750F	Q8IZX4/L750F	TAF1L/L750F	VARIANT	L -> F (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	L762I	Q8IZX4/L762I	TAF1L/L762I	VARIANT	L -> I (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	E794D	Q8IZX4/E794D	TAF1L/E794D	VARIANT	E -> D (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	H1549Y	Q8IZX4/H1549Y	TAF1L/H1549Y	VARIANT	H -> Y (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1587670372)	ECO:0000269|PubMed:17344846	17344846		
Q8IZX4	TAF1L	H1824Q	Q8IZX4/H1824Q	TAF1L/H1824Q	VARIANT	H -> Q (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8N2I9	STK40	M133T	Q8N2I9/M133T	STK40/M133T	VARIANT	M -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs755089893)	ECO:0000269|PubMed:17344846	17344846		
Q8N2I9	STK40	R211Q	Q8N2I9/R211Q	STK40/R211Q	VARIANT	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs539738963)	ECO:0000269|PubMed:17344846	17344846		
Q8N4C8	MINK1	E1010V	Q8N4C8/E1010V	MINK1/E1010V	VARIANT	E -> V (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8N4C8	MINK1	I1200V	Q8N4C8/I1200V	MINK1/I1200V	VARIANT	I -> V	ECO:0000269|PubMed:17344846	17344846		
Q8N568	DCLK2	V212M	Q8N568/V212M	DCLK2/V212M	VARIANT	V -> M (found in a patient with hereditary motor and sensory neuropathy; unknown pathological significance; dbSNP:rs759398144)	ECO:0000269|PubMed:25512093	25512093		
Q8N752	CSNK1A1L	R21Q	Q8N752/R21Q	CSNK1A1L/R21Q	VARIANT	R -> Q (in a colorectal cancer sample; somatic mutation; dbSNP:rs373362769)	ECO:0000269|PubMed:16959974	16959974		
Q8NB16	MLKL	L291P	Q8NB16/L291P	MLKL/L291P	VARIANT	L -> P (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1313508921)	ECO:0000269|PubMed:17344846	17344846		
Q8NB16	MLKL	F398I	Q8NB16/F398I	MLKL/F398I	VARIANT	F -> I (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NB16	MLKL	L58G	Q8NB16/L58G	MLKL/L58G	MUTAGEN	L->G: Does not affect formation of homotrimers, while translocation to the plasma membrane on necroptosis induction is impaired; when associated with G-76.	ECO:0000269|PubMed:24316671	24316671		
Q8NB16	MLKL	I76G	Q8NB16/I76G	MLKL/I76G	MUTAGEN	I->G: Does not affect formation of homotrimers, while translocation to the plasma membrane on necroptosis induction is impaired; when associated with G-58.	ECO:0000269|PubMed:24316671	24316671		
Q8NB16	MLKL	C86S	Q8NB16/C86S	MLKL/C86S	MUTAGEN	C->S: Abolishes binding to necrosulfonamide inhibitor.	ECO:0000269|PubMed:22265413	22265413		
Q8NB16	MLKL	L162G	Q8NB16/L162G	MLKL/L162G	MUTAGEN	L->G: Impairs formation of homotrimers and translocation to the plasma membrane on necroptosis induction; when associated with G-165.	ECO:0000269|PubMed:24316671	24316671		
Q8NB16	MLKL	L165G	Q8NB16/L165G	MLKL/L165G	MUTAGEN	L->G: Impairs formation of homotrimers and translocation to the plasma membrane on necroptosis induction; when associated with G-162.	ECO:0000269|PubMed:24316671	24316671		
Q8NB16	MLKL	K230M	Q8NB16/K230M	MLKL/K230M	MUTAGEN	K->M: Abolishes ATP-binding.	ECO:0000269|PubMed:24219132	24219132	loss	
Q8NB16	MLKL	K331N	Q8NB16/K331N	MLKL/K331N	MUTAGEN	K->N: Impairs ATP-binding.	ECO:0000269|PubMed:24219132	24219132	loss	
Q8NB16	MLKL	E351K	Q8NB16/E351K	MLKL/E351K	MUTAGEN	E->K: Binds ATP with an enhanced affinity.	ECO:0000269|PubMed:24219132	24219132	increase	
Q8NB16	MLKL	T357A	Q8NB16/T357A	MLKL/T357A	MUTAGEN	T->A: No effect. Abolishes ability to mediate necroptosis; when associated with A-358.	ECO:0000269|PubMed:22265413	22265413		
Q8NB16	MLKL	S358A	Q8NB16/S358A	MLKL/S358A	MUTAGEN	S->A: No effect. Abolishes ability to mediate necroptosis; when associated with A-357.	ECO:0000269|PubMed:22265413	22265413		
Q8NCB2	CAMKV	R40W	Q8NCB2/R40W	CAMKV/R40W	VARIANT	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1407808379)	ECO:0000269|PubMed:17344846	17344846		
Q8NCB2	CAMKV	G60S	Q8NCB2/G60S	CAMKV/G60S	VARIANT	G -> S (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NCB2	CAMKV	R274W	Q8NCB2/R274W	CAMKV/R274W	VARIANT	R -> W (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NE28	STKLD1	G139D	Q8NE28/G139D	STKLD1/G139D	VARIANT	G -> D (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NER5	ACVR1C	W267R	Q8NER5/W267R	ACVR1C/W267R	VARIANT	W -> R (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NER5	ACVR1C	T194D	Q8NER5/T194D	ACVR1C/T194D	MUTAGEN	T->D: Pro-apoptotic.	ECO:0000269|PubMed:15531507	15531507		
Q8NEV4	MYO3A	N525K	Q8NEV4/N525K	MYO3A/N525K	VARIANT	N -> K (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs1423134583)	ECO:0000269|PubMed:17344846	17344846		
Q8NEV4	MYO3A	S956R	Q8NEV4/S956R	MYO3A/S956R	VARIANT	S -> R (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NEV4	MYO3A	D1347H	Q8NEV4/D1347H	MYO3A/D1347H	VARIANT	D -> H (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NFD2	ANKK1	K347T	Q8NFD2/K347T	ANKK1/K347T	VARIANT	K -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NFD2	ANKK1	Q717L	Q8NFD2/Q717L	ANKK1/Q717L	VARIANT	Q -> L (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NFD2	ANKK1	R736L	Q8NFD2/R736L	ANKK1/R736L	VARIANT	R -> L (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NFD2	ANKK1	E764K	Q8NFD2/E764K	ANKK1/E764K	VARIANT	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8NG66	NEK11	T108M	Q8NG66/T108M	NEK11/T108M	VARIANT	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs200709914)	ECO:0000269|PubMed:17344846	17344846		
Q8NG66	NEK11	E492K	Q8NG66/E492K	NEK11/E492K	VARIANT	E -> K (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs140599545)	ECO:0000269|PubMed:17344846	17344846		
Q8NG66	NEK11	D617N	Q8NG66/D617N	NEK11/D617N	VARIANT	D -> N (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs765563230)	ECO:0000269|PubMed:17344846	17344846		
Q8NG66	NEK11	K61R	Q8NG66/K61R	NEK11/K61R	MUTAGEN	K->R: Loss of kinase activity.	ECO:0000269|PubMed:12154088	12154088	loss	
Q8NI60	COQ8A	R213W	Q8NI60/R213W	COQ8A/R213W	VARIANT	R -> W (in COQ10D4; dbSNP:rs119468005)	ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:22036850	1,831,907,222,036,850		
Q8NI60	COQ8A	R271C	Q8NI60/R271C	COQ8A/R271C	VARIANT	R -> C (in COQ10D4; dbSNP:rs145034527)	ECO:0000269|PubMed:22036850	22036850		
Q8NI60	COQ8A	G272D	Q8NI60/G272D	COQ8A/G272D	VARIANT	G -> D (in COQ10D4; dbSNP:rs119468006)	ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:22036850	1,831,907,222,036,850		
Q8NI60	COQ8A	G272V	Q8NI60/G272V	COQ8A/G272V	VARIANT	G -> V (in COQ10D4; dbSNP:rs119468006)	ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:22036850	1,831,907,222,036,850		
Q8NI60	COQ8A	R299W	Q8NI60/R299W	COQ8A/R299W	VARIANT	R -> W (in COQ10D4; decreased stability; dbSNP:rs201908721)	ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27106809	22036850,25498144,27106809		
Q8NI60	COQ8A	A304T	Q8NI60/A304T	COQ8A/A304T	VARIANT	A -> T (in COQ10D4; dbSNP:rs778798354)	ECO:0000269|PubMed:22036850	22036850		
Q8NI60	COQ8A	A304V	Q8NI60/A304V	COQ8A/A304V	VARIANT	A -> V (in COQ10D4; dbSNP:rs748118737)	ECO:0000269|PubMed:22036850	22036850		
Q8NI60	COQ8A	Y429C	Q8NI60/Y429C	COQ8A/Y429C	VARIANT	Y -> C (in COQ10D4; decreased stability; dbSNP:rs144147839)	ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144	22036850,25498144		
Q8NI60	COQ8A	Y514C	Q8NI60/Y514C	COQ8A/Y514C	VARIANT	Y -> C (in COQ10D4; dbSNP:rs119468008)	ECO:0000269|PubMed:18319074	18319074		
Q8NI60	COQ8A	G549S	Q8NI60/G549S	COQ8A/G549S	VARIANT	G -> S (in COQ10D4; decreased stability; dbSNP:rs119468009)	ECO:0000269|PubMed:18319074, ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144	18319074,22036850,25498144		
Q8NI60	COQ8A	E551K	Q8NI60/E551K	COQ8A/E551K	VARIANT	E -> K (in COQ10D4; decreased stability; dbSNP:rs119468004)	ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144	18319072,22036850,25498144		
Q8NI60	COQ8A	F578V	Q8NI60/F578V	COQ8A/F578V	VARIANT	F -> V (in COQ10D4; unknown pathological significance)	ECO:0000269|PubMed:27106809	27106809		
Q8NI60	COQ8A	P602R	Q8NI60/P602R	COQ8A/P602R	VARIANT	P -> R (in COQ10D4; dbSNP:rs61995958)	ECO:0000269|PubMed:24048965	24048965		
Q8NI60	COQ8A	L214A	Q8NI60/L214A	COQ8A/L214A	MUTAGEN	L->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L214I	Q8NI60/L214I	COQ8A/L214I	MUTAGEN	L->I,F,G,V: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L214L	Q8NI60/L214L	COQ8A/L214L	MUTAGEN	L->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L214F	Q8NI60/L214F	COQ8A/L214F	MUTAGEN	L->I,F,G,V: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L214G	Q8NI60/L214G	COQ8A/L214G	MUTAGEN	L->I,F,G,V: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L214V	Q8NI60/L214V	COQ8A/L214V	MUTAGEN	L->I,F,G,V: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A215I	Q8NI60/A215I	COQ8A/A215I	MUTAGEN	A->I,L,G: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A215L	Q8NI60/A215L	COQ8A/A215L	MUTAGEN	A->I,L,G: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A215G	Q8NI60/A215G	COQ8A/A215G	MUTAGEN	A->I,L,G: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	N216A	Q8NI60/N216A	COQ8A/N216A	MUTAGEN	N->A,L,F,M: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	N216L	Q8NI60/N216L	COQ8A/N216L	MUTAGEN	N->A,L,F,M: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	N216F	Q8NI60/N216F	COQ8A/N216F	MUTAGEN	N->A,L,F,M: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	N216M	Q8NI60/N216M	COQ8A/N216M	MUTAGEN	N->A,L,F,M: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	F217A	Q8NI60/F217A	COQ8A/F217A	MUTAGEN	F->A: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G218I	Q8NI60/G218I	COQ8A/G218I	MUTAGEN	G->I,L,F: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G218L	Q8NI60/G218L	COQ8A/G218L	MUTAGEN	G->I,L,F: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G218F	Q8NI60/G218F	COQ8A/G218F	MUTAGEN	G->I,L,F: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G219A	Q8NI60/G219A	COQ8A/G219A	MUTAGEN	G->A,F: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G219F	Q8NI60/G219F	COQ8A/G219F	MUTAGEN	G->A,F: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G219I	Q8NI60/G219I	COQ8A/G219I	MUTAGEN	G->I: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L220G	Q8NI60/L220G	COQ8A/L220G	MUTAGEN	L->G: Impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A221L	Q8NI60/A221L	COQ8A/A221L	MUTAGEN	A->L: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	V222A	Q8NI60/V222A	COQ8A/V222A	MUTAGEN	V->A: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G223A	Q8NI60/G223A	COQ8A/G223A	MUTAGEN	G->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G223I	Q8NI60/G223I	COQ8A/G223I	MUTAGEN	G->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G223L	Q8NI60/G223L	COQ8A/G223L	MUTAGEN	G->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G223F	Q8NI60/G223F	COQ8A/G223F	MUTAGEN	G->A,I,L,F: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L224V	Q8NI60/L224V	COQ8A/L224V	MUTAGEN	L->V: Impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G225L	Q8NI60/G225L	COQ8A/G225L	MUTAGEN	G->L: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	F226A	Q8NI60/F226A	COQ8A/F226A	MUTAGEN	F->A: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G227V	Q8NI60/G227V	COQ8A/G227V	MUTAGEN	G->V,F,L,I: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G227F	Q8NI60/G227F	COQ8A/G227F	MUTAGEN	G->V,F,L,I: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G227L	Q8NI60/G227L	COQ8A/G227L	MUTAGEN	G->V,F,L,I: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	G227I	Q8NI60/G227I	COQ8A/G227I	MUTAGEN	G->V,F,L,I: Strongly impairs homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A228I	Q8NI60/A228I	COQ8A/A228I	MUTAGEN	A->I,L,F: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A228L	Q8NI60/A228L	COQ8A/A228L	MUTAGEN	A->I,L,F: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A228F	Q8NI60/A228F	COQ8A/A228F	MUTAGEN	A->I,L,F: Does not impair homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	L229A	Q8NI60/L229A	COQ8A/L229A	MUTAGEN	L->A: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	A230I	Q8NI60/A230I	COQ8A/A230I	MUTAGEN	A->I: Slightly impaired homodimerization.	ECO:0000269|PubMed:25216398	25216398		
Q8NI60	COQ8A	K276R	Q8NI60/K276R	COQ8A/K276R	MUTAGEN	K->R,H: Does not affect selectivity for binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294	25498144,27499294		
Q8NI60	COQ8A	K276H	Q8NI60/K276H	COQ8A/K276H	MUTAGEN	K->R,H: Does not affect selectivity for binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294	25498144,27499294		
Q8NI60	COQ8A	Q279R	Q8NI60/Q279R	COQ8A/Q279R	MUTAGEN	Q->R,H: Does not affect selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	Q279H	Q8NI60/Q279H	COQ8A/Q279H	MUTAGEN	Q->R,H: Does not affect selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	A339G	Q8NI60/A339G	COQ8A/A339G	MUTAGEN	A->G: Enables autophosphorylation but inhibits coenzyme Q biosynthesis in vivo.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	K358R	Q8NI60/K358R	COQ8A/K358R	MUTAGEN	K->R: Abolishes binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	E405A	Q8NI60/E405A	COQ8A/E405A	MUTAGEN	E->A,Q: Slightly affects selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	E405Q	Q8NI60/E405Q	COQ8A/E405Q	MUTAGEN	E->A,Q: Slightly affects selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	E411Q	Q8NI60/E411Q	COQ8A/E411Q	MUTAGEN	E->Q: Impaired binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	D488N	Q8NI60/D488N	COQ8A/D488N	MUTAGEN	D->N: Impaired binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	N493A	Q8NI60/N493A	COQ8A/N493A	MUTAGEN	N->A: Impaired binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	D507N	Q8NI60/D507N	COQ8A/D507N	MUTAGEN	D->N: Strongly impairs binding ADP or ATP. Impaired multi-subunit COQ enzyme complex.	ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294	25498144,27499294		
Q8NI60	COQ8A	R611A	Q8NI60/R611A	COQ8A/R611A	MUTAGEN	R->A,Q: Does not affect selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8NI60	COQ8A	R611Q	Q8NI60/R611Q	COQ8A/R611Q	MUTAGEN	R->A,Q: Does not affect selectivity for binding ADP or ATP.	ECO:0000269|PubMed:25498144	25498144		
Q8TAS1	UHMK1	K54A	Q8TAS1/K54A	UHMK1/K54A	MUTAGEN	K->A: Loss of kinase activity.	ECO:0000269|PubMed:12093740	12093740	loss	
Q8TD08	MAPK15	K42A	Q8TD08/K42A	MAPK15/K42A	MUTAGEN	K->A: Not phosphorylated at Thr-175 and Tyr-177.	ECO:0000269|PubMed:16336213	16336213		
Q8TD08	MAPK15	D155A	Q8TD08/D155A	MAPK15/D155A	MUTAGEN	D->A: Unable to induce the formation of autophagosomal structures. Is able to bind to MAP1LC3B and to colocalize with this protein to autophagosomal structures. Does not induce phosphorylation by methyl methanesulfonate. Loas of phosphorylation. Dominant negative mutant. Not phosphorylated at Thr-175 and Tyr-177.	ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:19166846, ECO:0000269|PubMed:22948227	16336213,19166846,22948227	loss	
Q8TD08	MAPK15	T175A	Q8TD08/T175A	MAPK15/T175A	MUTAGEN	T->A: Loss of autophosphorylation and activity. Still heavily phosphorylated at Tyr-177. Does not rescues inhibition of O-glycosylation in MAPK15-depleted cells; when associated with F-177.	ECO:0000269|PubMed:11875070, ECO:0000269|PubMed:16336213, ECO:0000269|PubMed:24618899	11875070,16336213,24618899	loss	
Q8TD08	MAPK15	Y177F	Q8TD08/Y177F	MAPK15/Y177F	MUTAGEN	Y->F: Does not rescue inhibition of O-glycosylation in MAPK15-depleted cells; when associated with A-175.	ECO:0000269|PubMed:24618899	24618899		
Q8TD08	MAPK15	Q300A	Q8TD08/Q300A	MAPK15/Q300A	MUTAGEN	Q->A: Impairs interaction with PCNA. Associates with chromatin.	ECO:0000269|PubMed:20733054	20733054		
Q8TD08	MAPK15	P390A	Q8TD08/P390A	MAPK15/P390A	MUTAGEN	P->A: Impairs chromatin binding; when associated with A-398. Increases kinase activity; when associated with A-398.	ECO:0000269|PubMed:20733054	20733054		
Q8TD08	MAPK15	P398A	Q8TD08/P398A	MAPK15/P398A	MUTAGEN	P->A: Impairs chromatin binding; when associated with A-390. Increases kinase activity; when associated with A-390.	ECO:0000269|PubMed:20733054	20733054		
Q8TD19	NEK9	R681H	Q8TD19/R681H	NEK9/R681H	VARIANT	R -> H (in APUG; dbSNP:rs142859694)	ECO:0000269|PubMed:26633546	26633546		
Q8TD19	NEK9	P870S	Q8TD19/P870S	NEK9/P870S	VARIANT	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8TD19	NEK9	T214A	Q8TD19/T214A	NEK9/T214A	MUTAGEN	T->A: No effect on autophosphorylation.	ECO:0000269|PubMed:11864968	11864968		
Q8TDC3	BRSK1	R303W	Q8TDC3/R303W	BRSK1/R303W	VARIANT	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs144130246)	ECO:0000269|PubMed:17344846	17344846		
Q8TDC3	BRSK1	V319I	Q8TDC3/V319I	BRSK1/V319I	VARIANT	V -> I (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8TDC3	BRSK1	G391E	Q8TDC3/G391E	BRSK1/G391E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8TDC3	BRSK1	T189A	Q8TDC3/T189A	BRSK1/T189A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q8TDR2	STK35	K231M	Q8TDR2/K231M	STK35/K231M	MUTAGEN	K->M: No autophosphorylation.	ECO:0000269|PubMed:11973348	11973348	loss	
Q8TDX7	NEK7	I275M	Q8TDX7/I275M	NEK7/I275M	VARIANT	I -> M (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8TDX7	NEK7	Y28A	Q8TDX7/Y28A	NEK7/Y28A	MUTAGEN	Y->A: Significant decrease in catalytic activity; when associated with A-31.	ECO:0000269|PubMed:19941817	19941817	decrease	
Q8TDX7	NEK7	L31A	Q8TDX7/L31A	NEK7/L31A	MUTAGEN	L->A: Significant decrease in catalytic activity; when associated with A-28.	ECO:0000269|PubMed:19941817	19941817	decrease	
Q8TDX7	NEK7	N90A	Q8TDX7/N90A	NEK7/N90A	MUTAGEN	N->A: Reduced protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	N90R	Q8TDX7/N90R	NEK7/N90R	MUTAGEN	N->R,K: Strongly reduced protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	N90K	Q8TDX7/N90K	NEK7/N90K	MUTAGEN	N->R,K: Strongly reduced protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	K96E	Q8TDX7/K96E	NEK7/K96E	MUTAGEN	K->E: Strongly increased protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	increase	
Q8TDX7	NEK7	Y97L	Q8TDX7/Y97L	NEK7/Y97L	MUTAGEN	Y->F,L: Moderate increase in catalytic activity.	ECO:0000269|PubMed:19941817	19941817	increase	
Q8TDX7	NEK7	M122A	Q8TDX7/M122A	NEK7/M122A	MUTAGEN	M->A,R: Decreased interaction with NEK9 and subsequent activation of NEK7 kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	M122R	Q8TDX7/M122R	NEK7/M122R	MUTAGEN	M->A,R: Decreased interaction with NEK9 and subsequent activation of NEK7 kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	H125A	Q8TDX7/H125A	NEK7/H125A	MUTAGEN	H->A: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	K128E	Q8TDX7/K128E	NEK7/K128E	MUTAGEN	K->E: Does not affect interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	Q129R	Q8TDX7/Q129R	NEK7/Q129R	MUTAGEN	Q->R: Decreased interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	K130A	Q8TDX7/K130A	NEK7/K130A	MUTAGEN	K->A,E: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	K130E	Q8TDX7/K130E	NEK7/K130E	MUTAGEN	K->A,E: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	R131A	Q8TDX7/R131A	NEK7/R131A	MUTAGEN	R->A,D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	ECO:0000269|PubMed:26522158	26522158	loss	
Q8TDX7	NEK7	R131D	Q8TDX7/R131D	NEK7/R131D	MUTAGEN	R->A,D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	ECO:0000269|PubMed:26522158	26522158	loss	
Q8TDX7	NEK7	R131E	Q8TDX7/R131E	NEK7/R131E	MUTAGEN	R->E: Decreased interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	L132D	Q8TDX7/L132D	NEK7/L132D	MUTAGEN	L->D: Abolished interaction with NEK9 and subsequent activation of NEK7 kinase activity.	ECO:0000269|PubMed:26522158	26522158	loss	
Q8TDX7	NEK7	L132W	Q8TDX7/L132W	NEK7/L132W	MUTAGEN	L->W: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	R136E	Q8TDX7/R136E	NEK7/R136E	MUTAGEN	R->E: Decreased interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	R155E	Q8TDX7/R155E	NEK7/R155E	MUTAGEN	R->E: Strongly reduced protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	decrease	
Q8TDX7	NEK7	I169F	Q8TDX7/I169F	NEK7/I169F	MUTAGEN	I->F: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	T172A	Q8TDX7/T172A	NEK7/T172A	MUTAGEN	T->A: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	S195A	Q8TDX7/S195A	NEK7/S195A	MUTAGEN	S->A: Abolished phosphorylation with NEK9 and protein kinase activity.	ECO:0000269|PubMed:26522158	26522158	loss	
Q8TDX7	NEK7	D261A	Q8TDX7/D261A	NEK7/D261A	MUTAGEN	D->A: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	H262A	Q8TDX7/H262A	NEK7/H262A	MUTAGEN	H->A: Does not affect interaction with NEK9.	ECO:0000269|PubMed:26522158	26522158		
Q8TDX7	NEK7	E280V	Q8TDX7/E280V	NEK7/E280V	MUTAGEN	E->V,R: Does not affect interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	E280R	Q8TDX7/E280R	NEK7/E280R	MUTAGEN	E->V,R: Does not affect interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	D290R	Q8TDX7/D290R	NEK7/D290R	MUTAGEN	D->R: Does not affect interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TDX7	NEK7	R294E	Q8TDX7/R294E	NEK7/R294E	MUTAGEN	R->E: Does not affect interaction with NLRP3.	ECO:0000269|PubMed:31189953	31189953		
Q8TEA7	TBCK	R503I	Q8TEA7/R503I	TBCK/R503I	VARIANT	R -> I (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8TEA7	TBCK	R511H	Q8TEA7/R511H	TBCK/R511H	VARIANT	R -> H (in IHPRF3; dbSNP:rs869320711)	ECO:0000269|PubMed:27040692	27040692		
Q8TEA7	TBCK	L551P	Q8TEA7/L551P	TBCK/L551P	VARIANT	L -> P (in IHPRF3)	ECO:0000269|PubMed:27040691	27040691		
Q8TEA7	TBCK	I806V	Q8TEA7/I806V	TBCK/I806V	VARIANT	I -> V (in a head & Neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WTQ7	GRK7	S253F	Q8WTQ7/S253F	GRK7/S253F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WTQ7	GRK7	S23A	Q8WTQ7/S23A	GRK7/S23A	MUTAGEN	S->A: No effect on kinase activity. Increase kinase activity; when associated with A-36.	ECO:0000269|PubMed:15946941	15946941		
Q8WTQ7	GRK7	S36A	Q8WTQ7/S36A	GRK7/S36A	MUTAGEN	S->A: No effect on kinase activity. Increase kinase activity; when associated with A-23.	ECO:0000269|PubMed:15946941	15946941		
Q8WU08	STK32A	S89F	Q8WU08/S89F	STK32A/S89F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WU08	STK32A	M316I	Q8WU08/M316I	STK32A/M316I	VARIANT	M -> I (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WU08	STK32A	G2A	Q8WU08/G2A	STK32A/G2A	MUTAGEN	G->A: Localizes to cytoplasm.	ECO:0000269|PubMed:25043870	25043870		
Q8WZ42	TTN	V54M	Q8WZ42/V54M	TTN/V54M	VARIANT	V -> M (in CMD1G; affects interaction with TCAP/telethonin; dbSNP:rs139517732)	ECO:0000269|PubMed:11846417	11846417		
Q8WZ42	TTN	V115M	Q8WZ42/V115M	TTN/V115M	VARIANT	V -> M (in a metastatic melanoma sample; somatic mutation; dbSNP:rs564777385)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R279W	Q8WZ42/R279W	TTN/R279W	VARIANT	R -> W (in MFM9; disrupts NBR1-binding; dbSNP:rs138060032)	ECO:0000269|PubMed:15802564	15802564		
Q8WZ42	TTN	R740L	Q8WZ42/R740L	TTN/R740L	VARIANT	R -> L (in CMH9; dbSNP:rs28933405)	ECO:0000269|PubMed:10462489	10462489		
Q8WZ42	TTN	A743V	Q8WZ42/A743V	TTN/A743V	VARIANT	A -> V (in CMD1G; affects interaction with TCAP/telethonin; dbSNP:rs267607157)	ECO:0000269|PubMed:11846417	11846417		
Q8WZ42	TTN	T799M	Q8WZ42/T799M	TTN/T799M	VARIANT	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs149061352)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E937D	Q8WZ42/E937D	TTN/E937D	VARIANT	E -> D (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	W976R	Q8WZ42/W976R	TTN/W976R	VARIANT	W -> R (in CMD1G; dbSNP:rs267607155)	ECO:0000269|PubMed:11788824	11788824		
Q8WZ42	TTN	A1347T	Q8WZ42/A1347T	TTN/A1347T	VARIANT	A -> T (in a metastatic melanoma sample; somatic mutation; dbSNP:rs267599092)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R1350H	Q8WZ42/R1350H	TTN/R1350H	VARIANT	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs539470256)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R1664Q	Q8WZ42/R1664Q	TTN/R1664Q	VARIANT	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs375029799)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	G1692D	Q8WZ42/G1692D	TTN/G1692D	VARIANT	G -> D (in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs370004591)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	T1907I	Q8WZ42/T1907I	TTN/T1907I	VARIANT	T -> I (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	P2107L	Q8WZ42/P2107L	TTN/P2107L	VARIANT	P -> L (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	D2240Y	Q8WZ42/D2240Y	TTN/D2240Y	VARIANT	D -> Y	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L2432F	Q8WZ42/L2432F	TTN/L2432F	VARIANT	L -> F (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs571572592)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	I2771M	Q8WZ42/I2771M	TTN/I2771M	VARIANT	I -> M (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs576644663)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	P3238L	Q8WZ42/P3238L	TTN/P3238L	VARIANT	P -> L (in a bladder carcinoma sample; somatic mutation; dbSNP:rs397517792)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E3482K	Q8WZ42/E3482K	TTN/E3482K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E3570K	Q8WZ42/E3570K	TTN/E3570K	VARIANT	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	S3799Y	Q8WZ42/S3799Y	TTN/S3799Y	VARIANT	S -> Y (in CMD1G)	ECO:0000269|PubMed:11846417	11846417		
Q8WZ42	TTN	I4291T	Q8WZ42/I4291T	TTN/I4291T	VARIANT	I -> T (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	S4465N	Q8WZ42/S4465N	TTN/S4465N	VARIANT	S -> N (in CMD1G; dbSNP:rs281864908)	ECO:0000269|PubMed:11846417	11846417		
Q8WZ42	TTN	R12642C	Q8WZ42/R12642C	TTN/R12642C	VARIANT	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs199684560)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E12657K	Q8WZ42/E12657K	TTN/E12657K	VARIANT	E -> K (in a Wilms tumor; somatic mutation; dbSNP:rs778634417)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	S12720F	Q8WZ42/S12720F	TTN/S12720F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E13049G	Q8WZ42/E13049G	TTN/E13049G	VARIANT	E -> G	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E13083K	Q8WZ42/E13083K	TTN/E13083K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1458591077)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	Q13099R	Q8WZ42/Q13099R	TTN/Q13099R	VARIANT	Q -> R (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R13434K	Q8WZ42/R13434K	TTN/R13434K	VARIANT	R -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	N13785S	Q8WZ42/N13785S	TTN/N13785S	VARIANT	N -> S (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	Q13870H	Q8WZ42/Q13870H	TTN/Q13870H	VARIANT	Q -> H (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L14728V	Q8WZ42/L14728V	TTN/L14728V	VARIANT	L -> V (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R15555I	Q8WZ42/R15555I	TTN/R15555I	VARIANT	R -> I (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs751398376)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	Y15635C	Q8WZ42/Y15635C	TTN/Y15635C	VARIANT	Y -> C (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R16195H	Q8WZ42/R16195H	TTN/R16195H	VARIANT	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs373526624)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R16424P	Q8WZ42/R16424P	TTN/R16424P	VARIANT	R -> P	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	D17866N	Q8WZ42/D17866N	TTN/D17866N	VARIANT	D -> N	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	G17906E	Q8WZ42/G17906E	TTN/G17906E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation; dbSNP:rs374713701)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R18164T	Q8WZ42/R18164T	TTN/R18164T	VARIANT	R -> T (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	A18222T	Q8WZ42/A18222T	TTN/A18222T	VARIANT	A -> T	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	V18835A	Q8WZ42/V18835A	TTN/V18835A	VARIANT	V -> A (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1336054298)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R18881K	Q8WZ42/R18881K	TTN/R18881K	VARIANT	R -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1204056923)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L19060Q	Q8WZ42/L19060Q	TTN/L19060Q	VARIANT	L -> Q (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs1383995916)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R19091K	Q8WZ42/R19091K	TTN/R19091K	VARIANT	R -> K (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	P19224S	Q8WZ42/P19224S	TTN/P19224S	VARIANT	P -> S (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E19392K	Q8WZ42/E19392K	TTN/E19392K	VARIANT	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	A19480S	Q8WZ42/A19480S	TTN/A19480S	VARIANT	A -> S (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	T20179K	Q8WZ42/T20179K	TTN/T20179K	VARIANT	T -> K	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	A20408T	Q8WZ42/A20408T	TTN/A20408T	VARIANT	A -> T (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	T20892N	Q8WZ42/T20892N	TTN/T20892N	VARIANT	T -> N	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	C21851R	Q8WZ42/C21851R	TTN/C21851R	VARIANT	C -> R (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs55713867)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	Q22537H	Q8WZ42/Q22537H	TTN/Q22537H	VARIANT	Q -> H (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L22646P	Q8WZ42/L22646P	TTN/L22646P	VARIANT	L -> P (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	A22801T	Q8WZ42/A22801T	TTN/A22801T	VARIANT	A -> T (in a metastatic melanoma sample; somatic mutation; dbSNP:rs764005465)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R22823W	Q8WZ42/R22823W	TTN/R22823W	VARIANT	R -> W (in a metastatic melanoma sample; somatic mutation; dbSNP:rs369098292)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L23079F	Q8WZ42/L23079F	TTN/L23079F	VARIANT	L -> F (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	D23282N	Q8WZ42/D23282N	TTN/D23282N	VARIANT	D -> N (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	H23303Y	Q8WZ42/H23303Y	TTN/H23303Y	VARIANT	H -> Y (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	A23515S	Q8WZ42/A23515S	TTN/A23515S	VARIANT	A -> S (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E23551Q	Q8WZ42/E23551Q	TTN/E23551Q	VARIANT	E -> Q (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	D23872N	Q8WZ42/D23872N	TTN/D23872N	VARIANT	D -> N (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	F23952L	Q8WZ42/F23952L	TTN/F23952L	VARIANT	F -> L (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	V24159A	Q8WZ42/V24159A	TTN/V24159A	VARIANT	V -> A (in a head and neck squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	E25859K	Q8WZ42/E25859K	TTN/E25859K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs375422359)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	K26059E	Q8WZ42/K26059E	TTN/K26059E	VARIANT	K -> E (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	S29880L	Q8WZ42/S29880L	TTN/S29880L	VARIANT	S -> L (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	T30617S	Q8WZ42/T30617S	TTN/T30617S	VARIANT	T -> S (in a renal chromophobe cancer sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	V30809I	Q8WZ42/V30809I	TTN/V30809I	VARIANT	V -> I (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs397517769)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	T32171N	Q8WZ42/T32171N	TTN/T32171N	VARIANT	T -> N (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R32411W	Q8WZ42/R32411W	TTN/R32411W	VARIANT	R -> W (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs756924372)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L32943R	Q8WZ42/L32943R	TTN/L32943R	VARIANT	L -> R (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	R32996Q	Q8WZ42/R32996Q	TTN/R32996Q	VARIANT	R -> Q (in CMD1G; dbSNP:rs199642423)	ECO:0000269|PubMed:16465475	16465475		
Q8WZ42	TTN	R33242C	Q8WZ42/R33242C	TTN/R33242C	VARIANT	R -> C (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs1003158162)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	L33904P	Q8WZ42/L33904P	TTN/L33904P	VARIANT	L -> P (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q8WZ42	TTN	I34306N	Q8WZ42/I34306N	TTN/I34306N	VARIANT	I -> N (in TMD; dbSNP:rs281864928)	ECO:0000269|PubMed:12891679	12891679		
Q8WZ42	TTN	L34315P	Q8WZ42/L34315P	TTN/L34315P	VARIANT	L -> P (in TMD; dbSNP:rs267607156)	ECO:0000269|PubMed:12145747	12145747		
Q8WZ42	TTN	K32207A	Q8WZ42/K32207A	TTN/K32207A	MUTAGEN	K->A: Disrupts catalytic activity.	ECO:0000269|PubMed:9804419	9804419	loss	
Q8WZ42	TTN	Y32341E	Q8WZ42/Y32341E	TTN/Y32341E	MUTAGEN	Y->E: No phosphorylation on tyrosine.	ECO:0000269|PubMed:9804419	9804419		
Q92630	DYRK2	P198L	Q92630/P198L	DYRK2/P198L	VARIANT	P -> L (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1384093596)	ECO:0000269|PubMed:17344846	17344846		
Q92772	CDKL2	L98I	Q92772/L98I	CDKL2/L98I	VARIANT	L -> I (in an ovarian papillary serous adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q92772	CDKL2	R149Q	Q92772/R149Q	CDKL2/R149Q	VARIANT	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs755711267)	ECO:0000269|PubMed:17344846	17344846		
Q92918	MAP4K1	S737F	Q92918/S737F	MAP4K1/S737F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1238066548)	ECO:0000269|PubMed:17344846	17344846		
Q96BR1	SGK3	A92V	Q96BR1/A92V	SGK3/A92V	VARIANT	A -> V (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q96BR1	SGK3	R90A	Q96BR1/R90A	SGK3/R90A	MUTAGEN	R->A: Partially localized to the membrane.	ECO:0000269|PubMed:16790420	16790420		
Q96D53	COQ8B	L98R	Q96D53/L98R	COQ8B/L98R	VARIANT	L -> R (in NPHS9)	ECO:0000269|PubMed:25967120	25967120		
Q96D53	COQ8B	R178W	Q96D53/R178W	COQ8B/R178W	VARIANT	R -> W (in NPHS9; dbSNP:rs398122978)	ECO:0000269|PubMed:24270420, ECO:0000269|PubMed:25967120	2,427,042,025,967,120		
Q96D53	COQ8B	D286G	Q96D53/D286G	COQ8B/D286G	VARIANT	D -> G (in NPHS9; dbSNP:rs398122979)	ECO:0000269|PubMed:24270420	24270420		
Q96D53	COQ8B	P310L	Q96D53/P310L	COQ8B/P310L	VARIANT	P -> L (in NPHS9)	ECO:0000269|PubMed:25967120	25967120		
Q96D53	COQ8B	R320W	Q96D53/R320W	COQ8B/R320W	VARIANT	R -> W (in NPHS9; dbSNP:rs369573693)	ECO:0000269|PubMed:24270420	24270420		
Q96D53	COQ8B	R343W	Q96D53/R343W	COQ8B/R343W	VARIANT	R -> W (in NPHS9; dbSNP:rs398122981)	ECO:0000269|PubMed:24270420	24270420		
Q96D53	COQ8B	R477Q	Q96D53/R477Q	COQ8B/R477Q	VARIANT	R -> Q (in NPHS9; dbSNP:rs1057519347)	ECO:0000269|PubMed:24270420	24270420		
Q96D53	COQ8B	A498E	Q96D53/A498E	COQ8B/A498E	VARIANT	A -> E (in NPHS9)	ECO:0000269|PubMed:25967120	25967120		
Q96GD4	AURKB	K215Q	Q96GD4/K215Q	AURKB/K215Q	MUTAGEN	K->Q: Mimics acetylation, promoting accurate chromosome segregation.	ECO:0000269|PubMed:26829474	26829474	activating	
Q96GD4	AURKB	K215R	Q96GD4/K215R	AURKB/K215R	MUTAGEN	K->R: Abolished acetylation by KAT5, leading to impaired chromosome segregation.	ECO:0000269|PubMed:26829474	26829474	loss	
Q96GX5	MASTL	E167D	Q96GX5/E167D	MASTL/E167D	VARIANT	E -> D (found in a large family with autosomal dominant thrombocytopenia; unknown pathological significance; no effect on nuclear localization; dbSNP:rs28941470)	ECO:0000269|PubMed:12890928, ECO:0000269|PubMed:19460416	12890928,19460416		
Q96J92	WNK4	E434D	Q96J92/E434D	WNK4/E434D	VARIANT	E -> D (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96J92	WNK4	E562K	Q96J92/E562K	WNK4/E562K	VARIANT	E -> K (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853093)	ECO:0000269|PubMed:11498583, ECO:0000269|PubMed:23387299, ECO:0000269|PubMed:23576762	11498583,23387299,23576762		
Q96J92	WNK4	D564A	Q96J92/D564A	WNK4/D564A	VARIANT	D -> A (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853094)	ECO:0000269|PubMed:11498583, ECO:0000269|PubMed:23453970	1,149,858,323,453,970		
Q96J92	WNK4	Q565E	Q96J92/Q565E	WNK4/Q565E	VARIANT	Q -> E (in PHA2B; impaired interaction with KLHL3; dbSNP:rs137853092)	ECO:0000269|PubMed:11498583, ECO:0000269|PubMed:23387299, ECO:0000269|PubMed:23576762	11498583,23387299,23576762		
Q96J92	WNK4	P813L	Q96J92/P813L	WNK4/P813L	VARIANT	P -> L	ECO:0000269|PubMed:17344846	17344846		
Q96J92	WNK4	P992S	Q96J92/P992S	WNK4/P992S	VARIANT	P -> S (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96J92	WNK4	L1013P	Q96J92/L1013P	WNK4/L1013P	VARIANT	L -> P	ECO:0000269|PubMed:17344846	17344846		
Q96J92	WNK4	R1185C	Q96J92/R1185C	WNK4/R1185C	VARIANT	R -> C (in PHA2B; dbSNP:rs137853095)	ECO:0000269|PubMed:11498583	11498583		
Q96KB5	PBK	T9E	Q96KB5/T9E	PBK/T9E	MUTAGEN	T->E: TP53-binding.	ECO:0000269|PubMed:17482142	17482142		
Q96KB5	PBK	T320A	Q96KB5/T320A	PBK/T320A	MUTAGEN	T->A: Decrease in the binding to DLG1.	ECO:0000269|PubMed:10779557	10779557		
Q96KB5	PBK	V322A	Q96KB5/V322A	PBK/V322A	MUTAGEN	V->A: Decrease in the binding to DLG1.	ECO:0000269|PubMed:10779557	10779557		
Q96KG9	SCYL1	H495Y	Q96KG9/H495Y	SCYL1/H495Y	VARIANT	H -> Y (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96L34	MARK4	R418C	Q96L34/R418C	MARK4/R418C	VARIANT	R -> C (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs780763668)	ECO:0000269|PubMed:17344846	17344846		
Q96L34	MARK4	T214A	Q96L34/T214A	MARK4/T214A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q96L96	ALPK3	Q433E	Q96L96/Q433E	ALPK3/Q433E	VARIANT	Q -> E (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96L96	ALPK3	G1364E	Q96L96/G1364E	ALPK3/G1364E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96NX5	CAMK1G	A443T	Q96NX5/A443T	CAMK1G/A443T	VARIANT	A -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1228276529)	ECO:0000269|PubMed:17344846	17344846		
Q96PF2	TSSK2	K27R	Q96PF2/K27R	TSSK2/K27R	VARIANT	K -> R (may be associated with infertility; dbSNP:rs3747052)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19926886	17344846,19926886		
Q96PY6	NEK1	E25K	Q96PY6/E25K	NEK1/E25K	VARIANT	E -> K (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96PY6	NEK1	G145R	Q96PY6/G145R	NEK1/G145R	VARIANT	G -> R (in SRTD6; dbSNP:rs431905508)	ECO:0000269|PubMed:22499340	22499340		
Q96PY6	NEK1	L253S	Q96PY6/L253S	NEK1/L253S	VARIANT	L -> S (in SRTD6)	ECO:0000269|PubMed:22499340	22499340		
Q96PY6	NEK1	R261H	Q96PY6/R261H	NEK1/R261H	VARIANT	R -> H (in ALS24; associated with disease susceptibility; dbSNP:rs200161705)	ECO:0000269|PubMed:27455347	27455347		
Q96PY6	NEK1	A294P	Q96PY6/A294P	NEK1/A294P	VARIANT	A -> P (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96PY6	NEK1	K745N	Q96PY6/K745N	NEK1/K745N	VARIANT	K -> N	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	D160N	Q96Q15/D160N	SMG1/D160N	VARIANT	D -> N	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	D320G	Q96Q15/D320G	SMG1/D320G	VARIANT	D -> G	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	V829I	Q96Q15/V829I	SMG1/V829I	VARIANT	V -> I	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	R1029Q	Q96Q15/R1029Q	SMG1/R1029Q	VARIANT	R -> Q	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	P1275R	Q96Q15/P1275R	SMG1/P1275R	VARIANT	P -> R	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	S1358P	Q96Q15/S1358P	SMG1/S1358P	VARIANT	S -> P	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	S2171C	Q96Q15/S2171C	SMG1/S2171C	VARIANT	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	I3239T	Q96Q15/I3239T	SMG1/I3239T	VARIANT	I -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96Q15	SMG1	K3583Q	Q96Q15/K3583Q	SMG1/K3583Q	VARIANT	K -> Q (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96Q40	CDK15	K93E	Q96Q40/K93E	CDK15/K93E	VARIANT	K -> E (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96Q40	CDK15	E276D	Q96Q40/E276D	CDK15/E276D	VARIANT	E -> D (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1490814436)	ECO:0000269|PubMed:17344846	17344846		
Q96QP1	ALPK1	T237M	Q96QP1/T237M	ALPK1/T237M	VARIANT	T -> M (in ROSAH)	ECO:0000269|PubMed:30967659, ECO:0000269|PubMed:31939038	30967659,31939038		
Q96QP1	ALPK1	K339E	Q96QP1/K339E	ALPK1/K339E	VARIANT	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96QP1	ALPK1	Q67A	Q96QP1/Q67A	ALPK1/Q67A	MUTAGEN	Q->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with A-231.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	R116A	Q96QP1/R116A	ALPK1/R116A	MUTAGEN	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	R150A	Q96QP1/R150A	ALPK1/R150A	MUTAGEN	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	R153A	Q96QP1/R153A	ALPK1/R153A	MUTAGEN	R->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	D231A	Q96QP1/D231A	ALPK1/D231A	MUTAGEN	D->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with A-67.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	K233A	Q96QP1/K233A	ALPK1/K233A	MUTAGEN	K->A: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	T237E	Q96QP1/T237E	ALPK1/T237E	MUTAGEN	T->E: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with K-295.	ECO:0000269|PubMed:30111836	30111836		
Q96QP1	ALPK1	F295K	Q96QP1/F295K	ALPK1/F295K	MUTAGEN	F->K: Impaired ADP-D-glycero-beta-D-manno-heptose-binding and ability to activate the serine/threonine-protein kinase activity; when associated with E-237.	ECO:0000269|PubMed:30111836	30111836		
Q96QS6	PSKH2	S116I	Q96QS6/S116I	PSKH2/S116I	VARIANT	S -> I (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96QS6	PSKH2	K212I	Q96QS6/K212I	PSKH2/K212I	VARIANT	K -> I (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs778066815)	ECO:0000269|PubMed:17344846	17344846		
Q96QT4	TRPM7	S406C	Q96QT4/S406C	TRPM7/S406C	VARIANT	S -> C (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96QT4	TRPM7	T720S	Q96QT4/T720S	TRPM7/T720S	VARIANT	T -> S (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1040254222)	ECO:0000269|PubMed:17344846	17344846		
Q96QT4	TRPM7	M830V	Q96QT4/M830V	TRPM7/M830V	VARIANT	M -> V (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96QT4	TRPM7	G1046D	Q96QT4/G1046D	TRPM7/G1046D	VARIANT	G -> D (probable disease-associated variant found in a patient with hypomagnesemia and secondary hypocalcemia; de novo variant; causes severely reduced Mg(2+) uptake in transfected cells; dbSNP:rs2059709974)	ECO:0000269|PubMed:35561741	35561741		
Q96QT4	TRPM7	T1482I	Q96QT4/T1482I	TRPM7/T1482I	VARIANT	T -> I (mutant channels are functional but show increased susceptibility to inhibition by intracellular magnesium concentrations compared to wild-type channels; dbSNP:rs8042919)	ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846	14702039,16051700,17344846		
Q96RG2	PASK	E11K	Q96RG2/E11K	PASK/E11K	VARIANT	E -> K (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1277219458)	ECO:0000269|PubMed:17344846	17344846		
Q96RG2	PASK	P1301S	Q96RG2/P1301S	PASK/P1301S	VARIANT	P -> S	ECO:0000269|PubMed:17344846	17344846		
Q96RG2	PASK	R1058K	Q96RG2/R1058K	PASK/R1058K	MUTAGEN	R->K: Does not affect protein kinase activity.	ECO:0000269|PubMed:20943661	20943661		
Q96RR4	CAMKK2	P127L	Q96RR4/P127L	CAMKK2/P127L	VARIANT	P -> L (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96RR4	CAMKK2	A182T	Q96RR4/A182T	CAMKK2/A182T	VARIANT	A -> T (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1207121718)	ECO:0000269|PubMed:17344846	17344846		
Q96RU7	TRIB3	T60I	Q96RU7/T60I	TRIB3/T60I	VARIANT	T -> I (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs757496714)	ECO:0000269|PubMed:17344846	17344846		
Q96RU8	TRIB1	E360A	Q96RU8/E360A	TRIB1/E360A	VARIANT	E->A: Decreased interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	F371L	Q96RU8/F371L	TRIB1/F371L	VARIANT	F -> L (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96RU8	TRIB1	D355A	Q96RU8/D355A	TRIB1/D355A	MUTAGEN	D->A: Decreased interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	Q356A	Q96RU8/Q356A	TRIB1/Q356A	MUTAGEN	Q->A: Decreased interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	I357A	Q96RU8/I357A	TRIB1/I357A	MUTAGEN	I->A: Decreased interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	V358I	Q96RU8/V358I	TRIB1/V358I	MUTAGEN	V->I,A: Loss of interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	V358A	Q96RU8/V358A	TRIB1/V358A	MUTAGEN	V->I,A: Loss of interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	P359A	Q96RU8/P359A	TRIB1/P359A	MUTAGEN	P->A: Strongly decreased interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96RU8	TRIB1	Y361A	Q96RU8/Y361A	TRIB1/Y361A	MUTAGEN	Y->A: No effect on interaction with COP1.	ECO:0000269|PubMed:27041596	27041596		
Q96S38	RPS6KC1	L554I	Q96S38/L554I	RPS6KC1/L554I	VARIANT	L -> I (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96S38	RPS6KC1	G663A	Q96S38/G663A	RPS6KC1/G663A	VARIANT	G -> A (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96S38	RPS6KC1	C1003Y	Q96S38/C1003Y	RPS6KC1/C1003Y	VARIANT	C -> Y (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96S38	RPS6KC1	E1022K	Q96S38/E1022K	RPS6KC1/E1022K	VARIANT	E -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q96S44	TP53RK	A25T	Q96S44/A25T	TP53RK/A25T	VARIANT	A -> T	ECO:0000269|Ref.2			
Q96S44	TP53RK	G42D	Q96S44/G42D	TP53RK/G42D	VARIANT	G -> D (in GAMOS4; dbSNP:rs773814837)	ECO:0000269|PubMed:28805828	28805828		
Q96S44	TP53RK	T81R	Q96S44/T81R	TP53RK/T81R	VARIANT	T -> R (in GAMOS4; abolished interaction with TPRKB; dbSNP:rs1432218739)	ECO:0000269|PubMed:28805828	28805828		
Q96S44	TP53RK	R243L	Q96S44/R243L	TP53RK/R243L	VARIANT	R -> L (in GAMOS4; dbSNP:rs776588426)	ECO:0000269|PubMed:28805828	28805828		
Q96S53	TESK2	G11A	Q96S53/G11A	TESK2/G11A	VARIANT	G -> A (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1428512439)	ECO:0000269|PubMed:17344846	17344846		
Q96SB4	SRPK1	S37A	Q96SB4/S37A	SRPK1/S37A	MUTAGEN	S->A: No effect on protein phosphorylation.	ECO:0000269|PubMed:12565829	12565829		
Q96SB4	SRPK1	S222A	Q96SB4/S222A	SRPK1/S222A	MUTAGEN	S->A: No effect on protein phosphorylation.	ECO:0000269|PubMed:12565829	12565829		
Q96SB4	SRPK1	S311G	Q96SB4/S311G	SRPK1/S311G	MUTAGEN	S->G: No effect on protein phosphorylation.	ECO:0000269|PubMed:12565829	12565829		
Q96SB4	SRPK1	S436G	Q96SB4/S436G	SRPK1/S436G	MUTAGEN	S->G: No effect on protein phosphorylation.	ECO:0000269|PubMed:12565829	12565829		
Q96SB4	SRPK1	S619A	Q96SB4/S619A	SRPK1/S619A	MUTAGEN	S->A: No effect on protein phosphorylation.	ECO:0000269|PubMed:12565829	12565829		
Q99558	MAP3K14	G514K	Q99558/G514K	MAP3K14/G514K	VARIANT	G -> K (in a lung neuroendocrine carcinoma sample; somatic mutation; requires 2 nucleotide substitutions)	ECO:0000269|PubMed:17344846	17344846		
Q99558	MAP3K14	T852I	Q99558/T852I	MAP3K14/T852I	VARIANT	T -> I (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q99558	MAP3K14	T559A	Q99558/T559A	MAP3K14/T559A	MUTAGEN	T->A: Abolishes 'Lys-63'-linked ubiquitination.	ECO:0000269|PubMed:20682767	20682767		
Q99570	PIK3R4	R936Q	Q99570/R936Q	PIK3R4/R936Q	VARIANT	R -> Q (in a breast cancer sample; somatic mutation; dbSNP:rs181132426)	ECO:0000269|PubMed:16959974	16959974		
Q99683	MAP3K5	R32K	Q99683/R32K	MAP3K5/R32K	MUTAGEN	R->K: No effect on methylation by PRMT1.	ECO:0000269|PubMed:22095282	22095282		
Q99683	MAP3K5	R78K	Q99683/R78K	MAP3K5/R78K	MUTAGEN	R->K: Reduced methylation by PRMT1. Abolishes methylation by PRMT1 and PRMT1-mediated inhibition of MAPK35 activation; when associated with K-80.	ECO:0000269|PubMed:22095282	22095282		
Q99683	MAP3K5	R80K	Q99683/R80K	MAP3K5/R80K	MUTAGEN	R->K: Reduced methylation by PRMT1. Abolishes methylation by PRMT1 and PRMT1-mediated inhibition of MAPK35 activation; when associated with K-78.	ECO:0000269|PubMed:22095282	22095282		
Q99683	MAP3K5	T838A	Q99683/T838A	MAP3K5/T838A	MUTAGEN	T->A: Does not affect interaction with TRIM48.	ECO:0000269|PubMed:29186683	29186683		
Q99683	MAP3K5	S966A	Q99683/S966A	MAP3K5/S966A	MUTAGEN	S->A: Enhanced induction of apoptosis, increased kinase activity, and loss of YWHAG binding.	ECO:0000269|PubMed:10411906, ECO:0000269|PubMed:15094778	10411906,15094778	increase	
Q99986	VRK1	S14A	Q99986/S14A	VRK1/S14A	MUTAGEN	S->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	T102A	Q99986/T102A	VRK1/T102A	MUTAGEN	T->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	S125A	Q99986/S125A	VRK1/S125A	MUTAGEN	S->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	S150A	Q99986/S150A	VRK1/S150A	MUTAGEN	S->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	S158A	Q99986/S158A	VRK1/S158A	MUTAGEN	S->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	K179A	Q99986/K179A	VRK1/K179A	MUTAGEN	K->A: Does not affect phosphorylation at S-342.	ECO:0000269|PubMed:19103756	19103756		
Q99986	VRK1	S239A	Q99986/S239A	VRK1/S239A	MUTAGEN	S->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	T305A	Q99986/T305A	VRK1/T305A	MUTAGEN	T->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	T312A	Q99986/T312A	VRK1/T312A	MUTAGEN	T->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	T355A	Q99986/T355A	VRK1/T355A	MUTAGEN	T->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q99986	VRK1	T390A	Q99986/T390A	VRK1/T390A	MUTAGEN	T->A: Does not abolish autophosphorylation.	ECO:0000269|PubMed:10951572	10951572		
Q9BQI3	EIF2AK1	G202S	Q9BQI3/G202S	EIF2AK1/G202S	VARIANT	G -> S (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1216460058)	ECO:0000269|PubMed:17344846	17344846		
Q9BQI3	EIF2AK1	I448V	Q9BQI3/I448V	EIF2AK1/I448V	VARIANT	I -> V (in LEMSPAD; unknown pathological significance; mildly reduced phosphorylation of eukaryotic translation initiation factor 2-alpha; dbSNP:rs1583476115)	ECO:0000269|PubMed:32197074	32197074	decrease	
Q9BRS2	RIOK1	D324A	Q9BRS2/D324A	RIOK1/D324A	MUTAGEN	D->A: Abolishes autophosphorylation activity; enhances association with pre-40S ribosomal subunits; inhibits processing of 18S-E pre-rRNA to the mature 18S rRNA.	ECO:0000269|PubMed:22072790	22072790	loss	
Q9BUB5	MKNK1	K78M	Q9BUB5/K78M	MKNK1/K78M	MUTAGEN	K->M: Loss of kinase activity; when associated with D-232.	ECO:0000269|PubMed:11463832	11463832		
Q9BUB5	MKNK1	D232A	Q9BUB5/D232A	MKNK1/D232A	MUTAGEN	D->A: Loss of kinase activity; when associated with K-78.	ECO:0000269|PubMed:11463832	11463832		
Q9BUB5	MKNK1	T250A	Q9BUB5/T250A	MKNK1/T250A	MUTAGEN	T->A: Loss of kinase activity; when associated with T-255.	ECO:0000269|PubMed:11463832	11463832		
Q9BUB5	MKNK1	T255A	Q9BUB5/T255A	MKNK1/T255A	MUTAGEN	T->A: Loss of kinase activity; when associated with T-250.	ECO:0000269|PubMed:11463832	11463832		
Q9BVS4	RIOK2	I216T	Q9BVS4/I216T	RIOK2/I216T	VARIANT	I -> T (in a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs147608663)	ECO:0000269|PubMed:17344846	17344846		
Q9BVS4	RIOK2	K123A	Q9BVS4/K123A	RIOK2/K123A	MUTAGEN	K->A: Abolishes autophosphorylation; impairs release of pre-40S trans-acting factors and rRNA processing; when associated with A-246.	ECO:0000269|PubMed:19564402	19564402	loss	
Q9BVS4	RIOK2	D246A	Q9BVS4/D246A	RIOK2/D246A	MUTAGEN	D->A: Abolishes autophosphorylation; impairs release of pre-40S trans-acting factors and rRNA processing; when associated with A-123.	ECO:0000269|PubMed:19564402	19564402	loss	
Q9BVS4	RIOK2	S335A	Q9BVS4/S335A	RIOK2/S335A	MUTAGEN	S->A: Does not affect autophosphorylation activity; when associated with A-380 and A-548. Does not affect the timing of metaphase-anaphase transition; when associated with A-380 and A-548.	ECO:0000269|PubMed:21880710	21880710		
Q9BVS4	RIOK2	S335D	Q9BVS4/S335D	RIOK2/S335D	MUTAGEN	S->D: Increases time spent in metaphase; when associated with D-380 and D-548.	ECO:0000269|PubMed:21880710	21880710		
Q9BVS4	RIOK2	S380A	Q9BVS4/S380A	RIOK2/S380A	MUTAGEN	S->A: Does not affect autophosphorylation activity; when associated with A-335 and A-548. Does not affect the timing of metaphase-anaphase transition; when associated with A-335 and A-548.	ECO:0000269|PubMed:21880710	21880710		
Q9BVS4	RIOK2	S380D	Q9BVS4/S380D	RIOK2/S380D	MUTAGEN	S->D: Increases time spent in metaphase; when associated with D-335 and D-548.	ECO:0000269|PubMed:21880710	21880710		
Q9BVS4	RIOK2	L400A	Q9BVS4/L400A	RIOK2/L400A	MUTAGEN	L->A: Nuclear relocalization; when associated with A-403.	ECO:0000269|PubMed:19564402	19564402		
Q9BVS4	RIOK2	I403A	Q9BVS4/I403A	RIOK2/I403A	MUTAGEN	I->A: Nuclear relocalization; when associated with A-400.	ECO:0000269|PubMed:19564402	19564402		
Q9BVS4	RIOK2	S548A	Q9BVS4/S548A	RIOK2/S548A	MUTAGEN	S->A: Does not affect autophosphorylation activity; when associated with A-335 and A-380. Does not affect the timing of metaphase-anaphase transition; when associated with A-335 and A-380.	ECO:0000269|PubMed:21880710	21880710		
Q9BVS4	RIOK2	S548D	Q9BVS4/S548D	RIOK2/S548D	MUTAGEN	S->D: Increases time spent in metaphase; when associated with D-335 and D-380.	ECO:0000269|PubMed:21880710	21880710		
Q9BWU1	CDK19	G28A	Q9BWU1/G28A	CDK19/G28A	VARIANT	G -> A (in DEE87; dbSNP:rs1783518890)	ECO:0000269|PubMed:33495529	33495529		
Q9BWU1	CDK19	Y32C	Q9BWU1/Y32C	CDK19/Y32C	VARIANT	Y -> C (in DEE87; dbSNP:rs1783517622)	ECO:0000269|PubMed:33495529	33495529		
Q9BWU1	CDK19	T196A	Q9BWU1/T196A	CDK19/T196A	VARIANT	T -> A (in DEE87; fails to rescue neurologic phenotypes in a Drosophila model system; dbSNP:rs1779473650)	ECO:0000269|PubMed:32330417	32330417		
Q9BWU1	CDK19	F197L	Q9BWU1/F197L	CDK19/F197L	VARIANT	F -> L (in DEE87; dbSNP:rs1779473436)	ECO:0000269|PubMed:33495529	33495529		
Q9BWU1	CDK19	W198C	Q9BWU1/W198C	CDK19/W198C	VARIANT	W -> C (in DEE87; dbSNP:rs1779473213)	ECO:0000269|PubMed:33495529	33495529		
Q9BWU1	CDK19	R200W	Q9BWU1/R200W	CDK19/R200W	VARIANT	R -> W (in DEE87; dbSNP:rs1779472995)	ECO:0000269|PubMed:33495529	33495529		
Q9BX84	TRPM6	G75V	Q9BX84/G75V	TRPM6/G75V	VARIANT	G -> V (in a lung adenocarcinoma sample; somatic mutation; dbSNP:rs1193127627)	ECO:0000269|PubMed:17344846	17344846		
Q9BX84	TRPM6	S141L	Q9BX84/S141L	TRPM6/S141L	VARIANT	S -> L (in HOMG1; impairs heterodimer formation resulting in intracellular retention; dbSNP:rs121912625)	ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260	1,203,256,814,976,260	decrease	
Q9BX84	TRPM6	L708P	Q9BX84/L708P	TRPM6/L708P	VARIANT	L -> P (in HOMG1; loss of function; no effect on cell membrane localization)	ECO:0000269|PubMed:23942199	23942199	loss	
Q9BX84	TRPM6	E872G	Q9BX84/E872G	TRPM6/E872G	VARIANT	E -> G (in HOMG1; loss of function; no effect on cell membrane localization)	ECO:0000269|PubMed:23942199	23942199	loss	
Q9BX84	TRPM6	W1007C	Q9BX84/W1007C	TRPM6/W1007C	VARIANT	W -> C (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BX84	TRPM6	Y1053C	Q9BX84/Y1053C	TRPM6/Y1053C	VARIANT	Y -> C (in HOMG1; loss of function; no effect on cell membrane localization)	ECO:0000269|PubMed:23942199	23942199	loss	
Q9BX84	TRPM6	L1143P	Q9BX84/L1143P	TRPM6/L1143P	VARIANT	L -> P (in HOMG1; loss of function; no effect on cell membrane localization)	ECO:0000269|PubMed:23942199	23942199	loss	
Q9BX84	TRPM6	Q1663R	Q9BX84/Q1663R	TRPM6/Q1663R	VARIANT	Q -> R (no effect on function or cell membrane localization; dbSNP:rs55679040)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:23942199	17344846,23942199		
Q9BX84	TRPM6	S1754N	Q9BX84/S1754N	TRPM6/S1754N	VARIANT	S -> N (in HOMG1; loss of function; no effect on cell membrane localization)	ECO:0000269|PubMed:23942199	23942199	loss	
Q9BX84	TRPM6	T1851D	Q9BX84/T1851D	TRPM6/T1851D	MUTAGEN	T->D: Significantly decreases autophosphorylation. Does not alter binding to RACK1 or inhibition by RACK1.	ECO:0000269|PubMed:18258429	18258429	loss	
Q9BXA6	TSSK6	D135N	Q9BXA6/D135N	TSSK6/D135N	MUTAGEN	D->N: Loss of kinase activity. No effect of binding to TSACC.	ECO:0000269|PubMed:15870294, ECO:0000269|PubMed:20829357	15870294,20829357	loss	
Q9BXM7	PINK1	C92F	Q9BXM7/C92F	PINK1/C92F	VARIANT	C -> F (in PARK6; dbSNP:rs1553145550)	ECO:0000269|PubMed:15349860	15349860		
Q9BXM7	PINK1	C125G	Q9BXM7/C125G	PINK1/C125G	VARIANT	C -> G (in PARK6)	ECO:0000269|PubMed:16401616	16401616		
Q9BXM7	PINK1	Q126P	Q9BXM7/Q126P	PINK1/Q126P	VARIANT	Q -> P (in PARK6; strongly reduces interaction with PRKN; dbSNP:rs775809722)	ECO:0000269|PubMed:18286320, ECO:0000269|PubMed:20798600	1,828,632,020,798,600		
Q9BXM7	PINK1	R147H	Q9BXM7/R147H	PINK1/R147H	VARIANT	R -> H (in PARK6; unknown pathological significance; dbSNP:rs138050841)	ECO:0000269|PubMed:15505171	15505171		
Q9BXM7	PINK1	A168P	Q9BXM7/A168P	PINK1/A168P	VARIANT	A -> P (in PARK6; no effect on autophosphorylation; localizes to the mitochondria and immunogold experiments reveal that both wild-type and mutant proteins face the mitochondrial intermembrane space; dbSNP:rs768091663)	ECO:0000269|PubMed:15349860, ECO:0000269|PubMed:16009891, ECO:0000269|PubMed:16207731, ECO:0000269|PubMed:24784582	15349860,16009891,16207731,24784582		
Q9BXM7	PINK1	V170G	Q9BXM7/V170G	PINK1/V170G	VARIANT	V -> G (in PARK6; dbSNP:rs1553145929)	ECO:0000269|PubMed:24652937	24652937		
Q9BXM7	PINK1	P196L	Q9BXM7/P196L	PINK1/P196L	VARIANT	P -> L (in PARK6; dbSNP:rs138302371)	ECO:0000269|PubMed:16009891	16009891		
Q9BXM7	PINK1	P215L	Q9BXM7/P215L	PINK1/P215L	VARIANT	P -> L (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs371854396)	ECO:0000269|PubMed:17344846	17344846		
Q9BXM7	PINK1	A217D	Q9BXM7/A217D	PINK1/A217D	VARIANT	A -> D (in PARK6; dbSNP:rs74315360)	ECO:0000269|PubMed:16966503	16966503		
Q9BXM7	PINK1	E240K	Q9BXM7/E240K	PINK1/E240K	VARIANT	E -> K (in PARK6; dbSNP:rs573931674)	ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:16401616	15596610,16401616		
Q9BXM7	PINK1	L268V	Q9BXM7/L268V	PINK1/L268V	VARIANT	L -> V (in PARK6; dbSNP:rs372280083)	ECO:0000269|PubMed:16207217, ECO:0000269|PubMed:18330912	16207217,18330912		
Q9BXM7	PINK1	H271Q	Q9BXM7/H271Q	PINK1/H271Q	VARIANT	H -> Q (in PARK6; dbSNP:rs28940284)	ECO:0000269|PubMed:15349870	15349870		
Q9BXM7	PINK1	R279H	Q9BXM7/R279H	PINK1/R279H	VARIANT	R -> H (in PARK6; dbSNP:rs74315358)	ECO:0000269|PubMed:15970950	15970950		
Q9BXM7	PINK1	A280T	Q9BXM7/A280T	PINK1/A280T	VARIANT	A -> T (in PARK6; early-onset; dbSNP:rs772510148)	ECO:0000269|PubMed:16482571	16482571		
Q9BXM7	PINK1	G309D	Q9BXM7/G309D	PINK1/G309D	VARIANT	G -> D (in PARK6; fails to maintain mitochondrial membrane potential; full-length mutant has no effect on autophosphorylation; strongly reduces interaction with PRKN; decreases PRKN and SNCAIP ubiquitination and degradation; decreases Drp1 phosphorylation; dbSNP:rs74315355)	ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:16207731, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:32484300	15087508,16207731,19229105,20798600,32484300	decrease	
Q9BXM7	PINK1	L347P	Q9BXM7/L347P	PINK1/L347P	VARIANT	L -> P (in PARK6; strongly reduces interaction with PRKN; reduced ubiquitination of MIRO1; dbSNP:rs28940285)	ECO:0000269|PubMed:15349870, ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:22396657, ECO:0000269|PubMed:22956510	15349870,15596610,20798600,22396657,22956510	decrease	
Q9BXM7	PINK1	D362H	Q9BXM7/D362H	PINK1/D362H	VARIANT	D -> H	ECO:0000269|PubMed:15596610	15596610		
Q9BXM7	PINK1	L369P	Q9BXM7/L369P	PINK1/L369P	VARIANT	L -> P (in PARK6; dbSNP:rs1195888869)	ECO:0000269|PubMed:16401616	16401616		
Q9BXM7	PINK1	C388R	Q9BXM7/C388R	PINK1/C388R	VARIANT	C -> R (in PARK6; dbSNP:rs1553146806)	ECO:0000269|PubMed:15955953	15955953		
Q9BXM7	PINK1	P399L	Q9BXM7/P399L	PINK1/P399L	VARIANT	P -> L (probable disease-associated variant found in early-onset Parkinson disease with digenic inheritance; found in a patient also carrying mutation S-39 in PARK7; decreases PRKN and SNCAIP ubiquitination and degradation; dbSNP:rs119451946)	ECO:0000269|PubMed:16632486, ECO:0000269|PubMed:19229105	16632486,19229105	decrease	
Q9BXM7	PINK1	R407Q	Q9BXM7/R407Q	PINK1/R407Q	VARIANT	R -> Q (in PARK6; early-onset; dbSNP:rs556540177)	ECO:0000269|PubMed:16257123	16257123		
Q9BXM7	PINK1	G409V	Q9BXM7/G409V	PINK1/G409V	VARIANT	G -> V (in PARK6; dbSNP:rs1553146818)	ECO:0000269|PubMed:16401616	16401616		
Q9BXM7	PINK1	E417G	Q9BXM7/E417G	PINK1/E417G	VARIANT	E -> G (in PARK6; dbSNP:rs1553146822)	ECO:0000269|PubMed:15349870	15349870		
Q9BXM7	PINK1	Y431H	Q9BXM7/Y431H	PINK1/Y431H	VARIANT	Y -> H (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs74315361)	ECO:0000269|PubMed:16969854	16969854		
Q9BXM7	PINK1	N451S	Q9BXM7/N451S	PINK1/N451S	VARIANT	N -> S (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs747400197)	ECO:0000269|PubMed:16969854	16969854		
Q9BXM7	PINK1	L461S	Q9BXM7/L461S	PINK1/L461S	VARIANT	L -> S	ECO:0000269|PubMed:16969854	16969854		
Q9BXM7	PINK1	R464H	Q9BXM7/R464H	PINK1/R464H	VARIANT	R -> H (in PARK6; dbSNP:rs764328076)	ECO:0000269|PubMed:15349860	15349860		
Q9BXM7	PINK1	E476K	Q9BXM7/E476K	PINK1/E476K	VARIANT	E -> K (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs115477764)	ECO:0000269|PubMed:15349860, ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:16009891, ECO:0000269|PubMed:16969854, ECO:0000269|PubMed:18330912	15349860,15596610,16009891,16969854,18330912		
Q9BXM7	PINK1	L489P	Q9BXM7/L489P	PINK1/L489P	VARIANT	L -> P (in PARK6; dbSNP:rs1553146903)	ECO:0000269|PubMed:15596610	15596610		
Q9BXM7	PINK1	R501P	Q9BXM7/R501P	PINK1/R501P	VARIANT	R -> P (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs61744200)	ECO:0000269|PubMed:16969854	16969854		
Q9BXM7	PINK1	Q534QQ	Q9BXM7/Q534QQ	PINK1/Q534QQ	VARIANT	Q -> QQ (in PARK6)	ECO:0000269|PubMed:15970950	15970950		
Q9BXM7	PINK1	C575R	Q9BXM7/C575R	PINK1/C575R	VARIANT	C -> R (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions; dbSNP:rs1553147052)	ECO:0000269|PubMed:16969854	16969854		
Q9BXM7	PINK1	K219A	Q9BXM7/K219A	PINK1/K219A	MUTAGEN	K->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with Ala-362 and Ala-384.	ECO:0000269|PubMed:23620051	23620051		
Q9BXM7	PINK1	K219M	Q9BXM7/K219M	PINK1/K219M	MUTAGEN	K->M: Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with A-362 and A-384.	ECO:0000269|PubMed:18957282, ECO:0000269|PubMed:32047033	18957282,32047033		
Q9BXM7	PINK1	D362A	Q9BXM7/D362A	PINK1/D362A	MUTAGEN	D->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with A-219 and A-384. Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with M-219 and A-384.	ECO:0000269|PubMed:18957282, ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:32047033	18957282,23620051,32047033		
Q9BXM7	PINK1	D384A	Q9BXM7/D384A	PINK1/D384A	MUTAGEN	D->A: Abolishes MFN2 phosphorylation and interaction with PRKN; when associated with A-219 and A-362. Loss of enzyme activity and impaired localization of PRKN to mitochondria; when associated with M-219 and A-362.	ECO:0000269|PubMed:18957282, ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:32047033	18957282,23620051,32047033		
Q9BXM7	PINK1	D384N	Q9BXM7/D384N	PINK1/D384N	MUTAGEN	D->N: Loss of activity. Abolishes Drp1 phosphorylation. No effect on localization to mitochondria.	ECO:0000269|PubMed:32484300	32484300	loss	
Q9BXU1	STK31	H684Y	Q9BXU1/H684Y	STK31/H684Y	VARIANT	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BXU1	STK31	V860L	Q9BXU1/V860L	STK31/V860L	VARIANT	V -> L (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BYP7	WNK3	S854C	Q9BYP7/S854C	WNK3/S854C	VARIANT	S -> C (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BYP7	WNK3	L1533F	Q9BYP7/L1533F	WNK3/L1533F	VARIANT	L -> F (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BYP7	WNK3	S1634P	Q9BYP7/S1634P	WNK3/S1634P	VARIANT	S -> P (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BYP7	WNK3	D294A	Q9BYP7/D294A	WNK3/D294A	MUTAGEN	D->A: Catalytically inactive form. Inhibits sodium-coupled chloride cotransporters and activates potassium-coupled chloride cotransporters.	ECO:0000269|PubMed:16275913, ECO:0000269|PubMed:21613606	16275913,21613606	loss	
Q9BYT3	STK33	L160V	Q9BYT3/L160V	STK33/L160V	VARIANT	L -> V (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BZL6	PRKD2	G848E	Q9BZL6/G848E	PRKD2/G848E	VARIANT	G -> E (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BZL6	PRKD2	G870E	Q9BZL6/G870E	PRKD2/G870E	VARIANT	G -> E (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9BZL6	PRKD2	Y87F	Q9BZL6/Y87F	PRKD2/Y87F	MUTAGEN	Y->F: Loss of phosphorylation. No effect on the interaction with PRKCD. No effect on Ser-706 or/and Ser-710 phosphorylation.	ECO:0000269|PubMed:28428613	28428613		
Q9BZL6	PRKD2	S244E	Q9BZL6/S244E	PRKD2/S244E	MUTAGEN	S->E: Constitutive kinase activity; when associated with E-706 and E-710.	ECO:0000269|PubMed:23503467	23503467		
Q9BZL6	PRKD2	P275G	Q9BZL6/P275G	PRKD2/P275G	MUTAGEN	P->G: Increase in ability to bind phorbol ester, slight increase in ability to bind DAG.	ECO:0000269|PubMed:18076381	18076381		
Q9BZL6	PRKD2	Y438D	Q9BZL6/Y438D	PRKD2/Y438D	MUTAGEN	Y->D: Slight increase in Tyr-717 phosphorylation. No effect on Ser-706 or/and Ser-710 phosphorylation. Increase in Tyr-717 phosphorylation; when associated with E-706 and E-710.	ECO:0000269|PubMed:28428613	28428613	increase	
Q9BZL6	PRKD2	Y438F	Q9BZL6/Y438F	PRKD2/Y438F	MUTAGEN	Y->F: Loss of phosphorylation. No effect on phosphorylation of Tyr-717 and on Ser-706 or/and Ser-710 phosphorylation.	ECO:0000269|PubMed:15604256, ECO:0000269|PubMed:28428613	15604256,28428613	decrease	
Q9BZL6	PRKD2	S706A	Q9BZL6/S706A	PRKD2/S706A	MUTAGEN	S->A: Abolishes phosphorylation. Loss of Tyr-717 phosphorylation and any other tyrosine phosphorylation, and increases NF-kappa-B activation in response to oxidative stress; when associated with A-710.	ECO:0000269|PubMed:28428613	28428613		
Q9BZL6	PRKD2	S706E	Q9BZL6/S706E	PRKD2/S706E	MUTAGEN	S->E: Constitutive kinase activity; when associated with E-710 or with E-244 and E-710. Increases Tyr-717 phosphorylation; when associated with E-710 or with E-710 and D-438.	ECO:0000269|PubMed:23503467, ECO:0000269|PubMed:28428613	23503467,28428613		
Q9BZL6	PRKD2	S710A	Q9BZL6/S710A	PRKD2/S710A	MUTAGEN	S->A: Abolishes phosphorylation. Loss of Tyr-717 phosphorylation and any other tyrosine phosphorylation, and increases NF-kappa-B activation in response to oxidative stress; when associated with A-706.	ECO:0000269|PubMed:28428613	28428613		
Q9BZL6	PRKD2	S710E	Q9BZL6/S710E	PRKD2/S710E	MUTAGEN	S->E: Constitutive kinase activity; when associated with E-706 or with E-244 and E-706. when associated with E-710 or with E-244 and E-710. Increases Tyr-717 phosphorylation; when associated with E-710 or with E-710 and D-438.	ECO:0000269|PubMed:23503467, ECO:0000269|PubMed:28428613	23503467,28428613		
Q9C098	DCLK3	P108L	Q9C098/P108L	DCLK3/P108L	VARIANT	P -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9C098	DCLK3	E422K	Q9C098/E422K	DCLK3/E422K	VARIANT	E -> K (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs373605259)	ECO:0000269|PubMed:17344846	17344846		
Q9C098	DCLK3	S472N	Q9C098/S472N	DCLK3/S472N	VARIANT	S -> N (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9C098	DCLK3	R554C	Q9C098/R554C	DCLK3/R554C	VARIANT	R -> C (in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs374711533)	ECO:0000269|PubMed:17344846	17344846		
Q9C098	DCLK3	G570R	Q9C098/G570R	DCLK3/G570R	VARIANT	G -> R (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9C098	DCLK3	V596A	Q9C098/V596A	DCLK3/V596A	VARIANT	V -> A (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9C0K7	STRADB	G155E	Q9C0K7/G155E	STRADB/G155E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H093	NUAK2	K503R	Q9H093/K503R	NUAK2/K503R	VARIANT	K -> R (in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP:rs1271546767)	ECO:0000269|PubMed:17344846	17344846		
Q9H093	NUAK2	G541E	Q9H093/G541E	NUAK2/G541E	VARIANT	G -> E (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H093	NUAK2	T208A	Q9H093/T208A	NUAK2/T208A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q9H0K1	SIK2	T175A	Q9H0K1/T175A	SIK2/T175A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q9H1R3	MYLK2	A87V	Q9H1R3/A87V	MYLK2/A87V	VARIANT	A -> V (in CMH; dbSNP:rs121908107)	ECO:0000269|PubMed:11733062	11733062		
Q9H1R3	MYLK2	A95E	Q9H1R3/A95E	MYLK2/A95E	VARIANT	A -> E (in CMH; dbSNP:rs121908108)	ECO:0000269|PubMed:11733062	11733062		
Q9H1R3	MYLK2	A117V	Q9H1R3/A117V	MYLK2/A117V	VARIANT	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP:rs1229709568)	ECO:0000269|PubMed:17344846	17344846		
Q9H2G2	SLK	Q405K	Q9H2G2/Q405K	SLK/Q405K	VARIANT	Q -> K (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H2G2	SLK	E604Q	Q9H2G2/E604Q	SLK/E604Q	VARIANT	E -> Q (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs190220654)	ECO:0000269|PubMed:17344846	17344846		
Q9H2K8	TAOK3	P20T	Q9H2K8/P20T	TAOK3/P20T	VARIANT	P -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H2K8	TAOK3	S392Y	Q9H2K8/S392Y	TAOK3/S392Y	VARIANT	S -> Y (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H2K8	TAOK3	T181A	Q9H2K8/T181A	TAOK3/T181A	MUTAGEN	T->A: No autophosphorylation and no kinase activity; when associated with F-183.	ECO:0000269|PubMed:10559204	10559204		
Q9H2K8	TAOK3	Y183F	Q9H2K8/Y183F	TAOK3/Y183F	MUTAGEN	Y->F: No autophosphorylation and no kinase activity; when associated with A-181.	ECO:0000269|PubMed:10559204	10559204		
Q9H2K8	TAOK3	S324A	Q9H2K8/S324A	TAOK3/S324A	MUTAGEN	S->A: Inhibits activation of the p38/MAPK14 stress-activated MAPK cascade in response to DNA damage.	ECO:0000269|PubMed:17396146	17396146		
Q9H2X6	HIPK2	K228A	Q9H2X6/K228A	HIPK2/K228A	MUTAGEN	K->A: Locates in the nucleoplasm, no effect on interaction with RANBP9, but loss of kinase activity toward PML, RUNX1, EP300 and DAZAP2.	ECO:0000269|PubMed:11267674, ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12220523, ECO:0000269|PubMed:12874272, ECO:0000269|PubMed:12907596, ECO:0000269|PubMed:14678985, ECO:0000269|PubMed:18695000, ECO:0000269|PubMed:19015637, ECO:0000269|PubMed:33591310	11267674,11740489,11925430,12220523,12874272,12907596,14678985,18695000,19015637,33591310	loss	
Q9H2X6	HIPK2	K228R	Q9H2X6/K228R	HIPK2/K228R	MUTAGEN	K->R: Abolishes enzymatic activity, no effect on interaction with TP53 and TP73 or on BMP-induced transcriptional activation. Enhances BMP-induced transcriptional activation; when associated with 359-AAF-361.	ECO:0000269|PubMed:11267674, ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12220523, ECO:0000269|PubMed:12874272, ECO:0000269|PubMed:12907596, ECO:0000269|PubMed:14678985, ECO:0000269|PubMed:18695000, ECO:0000269|PubMed:19015637	11267674,11740489,11925430,12220523,12874272,12907596,14678985,18695000,19015637	loss	
Q9H2X6	HIPK2	K803A	Q9H2X6/K803A	HIPK2/K803A	MUTAGEN	K->A: Impaired nuclear localization; when associated with A-805.	ECO:0000269|PubMed:21145359	21145359		
Q9H2X6	HIPK2	K805A	Q9H2X6/K805A	HIPK2/K805A	MUTAGEN	K->A: Impaired nuclear localization; when associated with A-803.	ECO:0000269|PubMed:21145359	21145359		
Q9H2X6	HIPK2	R833A	Q9H2X6/R833A	HIPK2/R833A	MUTAGEN	R->A: Impaired nuclear localization.	ECO:0000269|PubMed:21145359	21145359		
Q9H2X6	HIPK2	K835E	Q9H2X6/K835E	HIPK2/K835E	MUTAGEN	K->E: Impaired nuclear localization.	ECO:0000269|PubMed:21145359	21145359		
Q9H3Y6	SRMS	K258M	Q9H3Y6/K258M	SRMS/K258M	MUTAGEN	K->M: Loss of kinase activity. Exhibits a diffused cytoplasmic localization. No effect on interaction with KHDRBS1 or VIM but abolishes tyrosine phosphorylation of both substrates.	ECO:0000269|PubMed:23822091, ECO:0000269|PubMed:29496907	23822091,29496907	loss	
Q9H3Y6	SRMS	Y380F	Q9H3Y6/Y380F	SRMS/Y380F	MUTAGEN	Y->F: Significant reduction in phosphorylation.	ECO:0000269|PubMed:23822091	23822091	decrease	
Q9H4A3	WNK1	E419Q	Q9H4A3/E419Q	WNK1/E419Q	VARIANT	E -> Q (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H4A3	WNK1	E1199G	Q9H4A3/E1199G	WNK1/E1199G	VARIANT	E -> G (in a colorectal cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q9H4A3	WNK1	Q1799E	Q9H4A3/Q1799E	WNK1/Q1799E	VARIANT	Q -> E (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation)	ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846	16959974,17344846		
Q9H4A3	WNK1	S2190C	Q9H4A3/S2190C	WNK1/S2190C	VARIANT	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H4A3	WNK1	F2362L	Q9H4A3/F2362L	WNK1/F2362L	VARIANT	F -> L (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H4B4	PLK3	T219E	Q9H4B4/T219E	PLK3/T219E	MUTAGEN	T->E: Kinase-defective mutant.	ECO:0000269|PubMed:16478733	16478733	loss	
Q9H5K3	POMK	Q258R	Q9H5K3/Q258R	POMK/Q258R	VARIANT	Q -> R (in MDDGA12; dbSNP:rs397509386)	ECO:0000269|PubMed:23519211	23519211		
Q9H5K3	POMK	V302D	Q9H5K3/V302D	POMK/V302D	VARIANT	V -> D (in MDDGA12; dbSNP:rs199756983)	ECO:0000269|PubMed:24925318	24925318		
Q9H5K3	POMK	M342I	Q9H5K3/M342I	POMK/M342I	VARIANT	M -> I (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9H792	PEAK1	H611Q	Q9H792/H611Q	PEAK1/H611Q	VARIANT	H -> Q (in a bladder carcinoma NOS sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		Inactive kinase
Q9H792	PEAK1	S1035F	Q9H792/S1035F	PEAK1/S1035F	VARIANT	S -> F (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		Inactive kinase
Q9H792	PEAK1	P1145L	Q9H792/P1145L	PEAK1/P1145L	VARIANT	P -> L (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		Inactive kinase
Q9H792	PEAK1	Y635E	Q9H792/Y635E	PEAK1/Y635E	MUTAGEN	Y->E: 50% reduction in interaction with GRB2. No effect on interaction with SHC1.				Inactive kinase
Q9H792	PEAK1	Y635F	Q9H792/Y635F	PEAK1/Y635F	MUTAGEN	Y->F: Impairs interaction with tensin TNS3 and association with integrin ITGB1. 50% reduction in interaction with GRB2. No effect on interaction with unphosphorylated SHC1 but reduces interaction with tyrosine-phosphorylated SHC1. Reduces focal adhesion localization. Reduces cell migration.	ECO:0000269|PubMed:35687021	35687021		Inactive kinase
Q9H792	PEAK1	Y665E	Q9H792/Y665E	PEAK1/Y665E	MUTAGEN	Y->E: No effect on localization with actin. Decreases localization in focal adhesion. Fails to regulate focal adhesion dynamics. Decreases cell migration.	ECO:0000269|PubMed:23105102	23105102		Inactive kinase
Q9H792	PEAK1	Y665F	Q9H792/Y665F	PEAK1/Y665F	MUTAGEN	Y->F: No effect on focal adhesion subcellular localization. Does not affect colocalization with F-actin.	ECO:0000269|PubMed:23105102	23105102		Inactive kinase
Q9H792	PEAK1	Y1188F	Q9H792/Y1188F	PEAK1/Y1188F	MUTAGEN	Y->F: Fails to bind SHC1. Reduced recruitment of SHC1 to focal adhesions. Slightly reduces interaction with GRB2. Does not affect interaction with RASAL2. Does not affect association with integrin ITGB1.	ECO:0000269|PubMed:23846654, ECO:0000269|PubMed:35687021	23846654,35687021		Inactive kinase
Q9H792	PEAK1	F1609A	Q9H792/F1609A	PEAK1/F1609A	MUTAGEN	F->A: No effect on interaction with PRAG1.	ECO:0000269|PubMed:29079850	29079850		Inactive kinase
Q9H792	PEAK1	A1707D	Q9H792/A1707D	PEAK1/A1707D	MUTAGEN	A->D: Disrupts homodimerization.	ECO:0000269|PubMed:29212708	29212708		Inactive kinase
Q9HBH9	MKNK2	T244A	Q9HBH9/T244A	MKNK2/T244A	MUTAGEN	T->A: Loss of kinase activity; when associated with T-249.	ECO:0000269|PubMed:11463832	11463832		
Q9HBH9	MKNK2	T249A	Q9HBH9/T249A	MKNK2/T249A	MUTAGEN	T->A: Loss of kinase activity; when associated with T-244.	ECO:0000269|PubMed:11463832	11463832		
Q9HBY8	SGK2	E199K	Q9HBY8/E199K	SGK2/E199K	VARIANT	E -> K (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9HC98	NEK6	K74M	Q9HC98/K74M	NEK6/K74M	MUTAGEN	K->M: Loss of autophosphorylation and of kinase activity and induction of apoptosis; when associated with M-75.	ECO:0000269|PubMed:14563848, ECO:0000269|PubMed:19001501	14563848,19001501		
Q9HC98	NEK6	K75M	Q9HC98/K75M	NEK6/K75M	MUTAGEN	K->M: Loss of autophosphorylation and of kinase activity and induction of apoptosis; when associated with M-74.	ECO:0000269|PubMed:14563848, ECO:0000269|PubMed:19001501	14563848,19001501		
Q9HCP0	CSNK1G1	R230W	Q9HCP0/R230W	CSNK1G1/R230W	VARIANT	R -> W (probable disease-associated variant found in a patient with non-syndromic early-onset epilepsy associated with severe developmental delay and microcephaly; dbSNP:rs587777544)	ECO:0000269|PubMed:24463883	24463883		
Q9NQU5	PAK6	R3H	Q9NQU5/R3H	PAK6/R3H	VARIANT	R -> H (in a colorectal cancer sample; somatic mutation; dbSNP:rs201346085)	ECO:0000269|PubMed:16959974	16959974		
Q9NQU5	PAK6	L514R	Q9NQU5/L514R	PAK6/L514R	VARIANT	L -> R (in a lung small cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NQU5	PAK6	S165A	Q9NQU5/S165A	PAK6/S165A	MUTAGEN	S->A: Almost complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with F-566.	ECO:0000269|PubMed:15550393	15550393		
Q9NQU5	PAK6	S560A	Q9NQU5/S560A	PAK6/S560A	MUTAGEN	S->A: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.	ECO:0000269|PubMed:15550393	15550393		
Q9NQU5	PAK6	Y566F	Q9NQU5/Y566F	PAK6/Y566F	MUTAGEN	Y->F: Complete loss of PAK6 activation by MAP2K6/MAPKK6; when associated with A-165.	ECO:0000269|PubMed:15550393	15550393		
Q9NR20	DYRK4	A70S	Q9NR20/A70S	DYRK4/A70S	VARIANT	A -> S	ECO:0000269|PubMed:17344846	17344846		
Q9NRH2	SNRK	G611S	Q9NRH2/G611S	SNRK/G611S	VARIANT	G -> S (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs368877591)	ECO:0000269|PubMed:17344846	17344846		
Q9NRH2	SNRK	P748L	Q9NRH2/P748L	SNRK/P748L	VARIANT	P -> L (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRH2	SNRK	I765M	Q9NRH2/I765M	SNRK/I765M	VARIANT	I -> M (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRH2	SNRK	T173A	Q9NRH2/T173A	SNRK/T173A	MUTAGEN	T->A,E: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:15733851	15733851	loss	
Q9NRH2	SNRK	T173E	Q9NRH2/T173E	SNRK/T173E	MUTAGEN	T->A,E: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:15733851	15733851	loss	
Q9NRM7	LATS2	G40E	Q9NRM7/G40E	LATS2/G40E	VARIANT	G -> E (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRM7	LATS2	S83C	Q9NRM7/S83C	LATS2/S83C	MUTAGEN	S->C: Fails to localize at the centromere during interphase.	ECO:0000269|PubMed:15147269	15147269		
Q9NRM7	LATS2	S83E	Q9NRM7/S83E	LATS2/S83E	MUTAGEN	S->E: Fails to localize at the centromere during interphase.	ECO:0000269|PubMed:15147269	15147269		
Q9NRP7	STK36	S660C	Q9NRP7/S660C	STK36/S660C	VARIANT	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation; dbSNP:rs1244829273)	ECO:0000269|PubMed:17344846	17344846		
Q9NRP7	STK36	S767Y	Q9NRP7/S767Y	STK36/S767Y	VARIANT	S -> Y (in an ovarian papillary serous adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRP7	STK36	Q1138K	Q9NRP7/Q1138K	STK36/Q1138K	VARIANT	Q -> K (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRP7	STK36	P1185S	Q9NRP7/P1185S	STK36/P1185S	VARIANT	P -> S (in an ovarian endometrioid sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NRP7	STK36	H1313P	Q9NRP7/H1313P	STK36/H1313P	VARIANT	H -> P	ECO:0000269|PubMed:17344846	17344846		
Q9NRP7	STK36	K33R	Q9NRP7/K33R	STK36/K33R	MUTAGEN	K->R: No effect on nuclear localization of GLI1 or GLI2 or on GLI-mediated transcription.	ECO:0000269|PubMed:10806483	10806483		
Q9NSY1	BMP2K	V68M	Q9NSY1/V68M	BMP2K/V68M	VARIANT	V -> M (in a lung squamous cell carcinoma sample; somatic mutation; dbSNP:rs770167074)	ECO:0000269|PubMed:17344846	17344846		
Q9NWZ3	IRAK4	I5V	Q9NWZ3/I5V	IRAK4/I5V	VARIANT	I -> V (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs56312115)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:24316379	17344846,24316379		
Q9NWZ3	IRAK4	R12C	Q9NWZ3/R12C	IRAK4/R12C	VARIANT	R -> C (in IMD67; no effect on inhibition of NF-kappa-B complex activation; loss of interaction with MYD88; decreases protein stability; dbSNP:rs377584435)	ECO:0000269|PubMed:17878374, ECO:0000269|PubMed:24316379	17878374,24316379		
Q9NWZ3	IRAK4	R20W	Q9NWZ3/R20W	IRAK4/R20W	VARIANT	R -> W (increases inhibition of NF-kappa-B complex activation; decreases interaction with MYD88; decreases protein stability; dbSNP:rs143625818)	ECO:0000269|PubMed:24316379	24316379		
Q9NWZ3	IRAK4	I26T	Q9NWZ3/I26T	IRAK4/I26T	VARIANT	I -> T (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs138116867)	ECO:0000269|PubMed:24316379	24316379		
Q9NWZ3	IRAK4	I39V	Q9NWZ3/I39V	IRAK4/I39V	VARIANT	I -> V (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs113588409)	ECO:0000269|PubMed:24316379	24316379		
Q9NWZ3	IRAK4	S98R	Q9NWZ3/S98R	IRAK4/S98R	VARIANT	S -> R (no effect on inhibition of NF-kappa-B activation; no effect on interaction with MYD88; dbSNP:rs4251469)	ECO:0000269|PubMed:24316379, ECO:0000269|Ref.5	24316379		
Q9NWZ3	IRAK4	G298D	Q9NWZ3/G298D	IRAK4/G298D	VARIANT	G -> D (in IMD67; decreases inhibition of NF-kappa-B complex activation; impairs neutrophil migration and phagocytosis; dbSNP:rs568782766)	ECO:0000269|PubMed:19663824, ECO:0000269|PubMed:21057262, ECO:0000269|PubMed:24316379	19663824,21057262,24316379	decrease	
Q9NY57	STK32B	G35E	Q9NY57/G35E	STK32B/G35E	VARIANT	G -> E (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NYL2	MAP3K20	R250W	Q9NYL2/R250W	MAP3K20/R250W	VARIANT	R -> W (in CNM6; unknown pathological significance; dbSNP:rs763481300)	ECO:0000269|PubMed:30237576	30237576		
Q9NYL2	MAP3K20	A281T	Q9NYL2/A281T	MAP3K20/A281T	VARIANT	A -> T (in an ovarian endometrioid sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NYL2	MAP3K20	F368C	Q9NYL2/F368C	MAP3K20/F368C	VARIANT	F -> C (in SFMMP; produces protein aggregation; dbSNP:rs863225437)	ECO:0000269|PubMed:26755636	26755636		
Q9NYL2	MAP3K20	A505S	Q9NYL2/A505S	MAP3K20/A505S	VARIANT	A -> S (in SFMMP; mild destabilization of the protein)	ECO:0000269|PubMed:32266845	32266845		
Q9NYL2	MAP3K20	S657A	Q9NYL2/S657A	MAP3K20/S657A	MUTAGEN	S->A: Abolished association with BTRC without affecting protein stability.	ECO:0000269|PubMed:32289254	32289254		
Q9NYV4	CDK12	R912H	Q9NYV4/R912H	CDK12/R912H	VARIANT	R -> H (in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NYY3	PLK2	S14T	Q9NYY3/S14T	PLK2/S14T	VARIANT	S -> T (in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP:rs1404394734)	ECO:0000269|PubMed:17344846	17344846		
Q9NYY3	PLK2	G92S	Q9NYY3/G92S	PLK2/G92S	VARIANT	G -> S (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9NYY3	PLK2	W503F	Q9NYY3/W503F	PLK2/W503F	MUTAGEN	W->F: Impairs localization to the centrosome and centriole duplication; when associated with A-629 and M-631.	ECO:0000269|PubMed:19001868	19001868		
Q9NYY3	PLK2	H629A	Q9NYY3/H629A	PLK2/H629A	MUTAGEN	H->A: Impairs localization to the centrosome and centriole duplication; when associated with F-503 and M-631.	ECO:0000269|PubMed:19001868	19001868		
Q9NYY3	PLK2	K631M	Q9NYY3/K631M	PLK2/K631M	MUTAGEN	K->M: Impairs localization to the centrosome and centriole duplication; when associated with F-503 and A-631.	ECO:0000269|PubMed:19001868	19001868		
Q9NZJ5	EIF2AK3	R588Q	Q9NZJ5/R588Q	EIF2AK3/R588Q	VARIANT	R -> Q (in WRS; dbSNP:rs121908569)	ECO:0000269|PubMed:10932183	10932183		
Q9P0L2	MARK1	Y233C	Q9P0L2/Y233C	MARK1/Y233C	VARIANT	Y -> C (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9P0L2	MARK1	N355T	Q9P0L2/N355T	MARK1/N355T	VARIANT	N -> T (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9P0L2	MARK1	T215A	Q9P0L2/T215A	MARK1/T215A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q9P0L2	MARK1	R698S	Q9P0L2/R698S	MARK1/R698S	MUTAGEN	R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-701.	ECO:0000269|PubMed:21145462	21145462		
Q9P0L2	MARK1	R701S	Q9P0L2/R701S	MARK1/R701S	MUTAGEN	R->S: Impairs phospholipid-binding, targeting to membrane and vesicle-binding; when associated with S-698.	ECO:0000269|PubMed:21145462	21145462		
Q9P286	PAK5	S312P	Q9P286/S312P	PAK5/S312P	VARIANT	S -> P (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs952665081)	ECO:0000269|PubMed:17344846	17344846		
Q9P286	PAK5	T538N	Q9P286/T538N	PAK5/T538N	VARIANT	T -> N (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9P286	PAK5	V604I	Q9P286/V604I	PAK5/V604I	VARIANT	V -> I (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9P286	PAK5	G704S	Q9P286/G704S	PAK5/G704S	VARIANT	G -> S (in a metastatic melanoma sample; somatic mutation; dbSNP:rs1484691555)	ECO:0000269|PubMed:17344846	17344846		
Q9P289	STK26	G36W	Q9P289/G36W	STK26/G36W	VARIANT	G -> W (in a gastric adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9P2K8	EIF2AK4	R585Q	Q9P2K8/R585Q	EIF2AK4/R585Q	VARIANT	R -> Q (in PVOD2; dbSNP:rs587777106)	ECO:0000269|PubMed:24292273	24292273		
Q9P2K8	EIF2AK4	L643R	Q9P2K8/L643R	EIF2AK4/L643R	VARIANT	L -> R (in PVOD2; dbSNP:rs757852728)	ECO:0000269|PubMed:24292273	24292273		
Q9P2K8	EIF2AK4	H939Y	Q9P2K8/H939Y	EIF2AK4/H939Y	VARIANT	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UBE8	NLK	A343T	Q9UBE8/A343T	NLK/A343T	VARIANT	A -> T (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UBE8	NLK	K167N	Q9UBE8/K167N	NLK/K167N	MUTAGEN	K->N: Abrogates kinase activity.	ECO:0000269|PubMed:20061393	20061393	loss	
Q9UBS0	RPS6KB2	T443M	Q9UBS0/T443M	RPS6KB2/T443M	VARIANT	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs374535834)	ECO:0000269|PubMed:17344846	17344846		
Q9UF33	EPHA6	F704S	Q9UF33/F704S	EPHA6/F704S	VARIANT	F -> S	ECO:0000269|PubMed:17344846	17344846		
Q9UHD2	TBK1	F24S	Q9UHD2/F24S	TBK1/F24S	VARIANT	F -> S (loss of IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	D50A	Q9UHD2/D50A	TBK1/D50A	VARIANT	D -> A (in IIAE8; decreased expression levels; dbSNP:rs1010930015)	ECO:0000269|PubMed:22851595	22851595		
Q9UHD2	TBK1	Y105C	Q9UHD2/Y105C	TBK1/Y105C	VARIANT	Y -> C (in FTDALS4; dbSNP:rs1366668789)	ECO:0000269|PubMed:25803835	25803835		
Q9UHD2	TBK1	V152L	Q9UHD2/V152L	TBK1/V152L	VARIANT	V -> L (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	I207V	Q9UHD2/I207V	TBK1/I207V	VARIANT	I -> V (in IIAE8; unknown pathological significance; dbSNP:rs1555203557)	ECO:0000269|PubMed:26513235	26513235		
Q9UHD2	TBK1	D296H	Q9UHD2/D296H	TBK1/D296H	VARIANT	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UHD2	TBK1	I305T	Q9UHD2/I305T	TBK1/I305T	VARIANT	I -> T (in FTDALS4; dbSNP:rs770942184)	ECO:0000269|PubMed:25803835	25803835		
Q9UHD2	TBK1	L306I	Q9UHD2/L306I	TBK1/L306I	VARIANT	L -> I (in FTDALS4; unknown pathological significance; dbSNP:rs201970436)	ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:25943890	2,144,760,025,943,890		
Q9UHD2	TBK1	R384Q	Q9UHD2/R384Q	TBK1/R384Q	VARIANT	R -> Q (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	N388S	Q9UHD2/N388S	TBK1/N388S	VARIANT	N -> S (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	I397T	Q9UHD2/I397T	TBK1/I397T	VARIANT	I -> T (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	K401E	Q9UHD2/K401E	TBK1/K401E	VARIANT	K -> E (in FTDALS4; dbSNP:rs756751089)	ECO:0000269|PubMed:25943890	25943890		
Q9UHD2	TBK1	G410R	Q9UHD2/G410R	TBK1/G410R	VARIANT	G -> R (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1262765773)	ECO:0000269|PubMed:17344846	17344846		
Q9UHD2	TBK1	L508I	Q9UHD2/L508I	TBK1/L508I	VARIANT	L -> I (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	I522M	Q9UHD2/I522M	TBK1/I522M	VARIANT	I -> M (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	A533T	Q9UHD2/A533T	TBK1/A533T	VARIANT	A -> T (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	A571V	Q9UHD2/A571V	TBK1/A571V	VARIANT	A -> V (in FTDALS4; dbSNP:rs765035140)	ECO:0000269|PubMed:25803835	25803835		
Q9UHD2	TBK1	M598V	Q9UHD2/M598V	TBK1/M598V	VARIANT	M -> V (in FTDALS4; dbSNP:rs899858451)	ECO:0000269|PubMed:25803835	25803835		
Q9UHD2	TBK1	E653Q	Q9UHD2/E653Q	TBK1/E653Q	VARIANT	E -> Q (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	P659S	Q9UHD2/P659S	TBK1/P659S	VARIANT	P -> S (no effect on IFNB induction)	ECO:0000269|PubMed:32972995	32972995		
Q9UHD2	TBK1	K30R	Q9UHD2/K30R	TBK1/K30R	MUTAGEN	K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-401.	ECO:0000269|PubMed:23453971	23453971		
Q9UHD2	TBK1	S172A	Q9UHD2/S172A	TBK1/S172A	MUTAGEN	S->A: Loss of kinase activity. No effect on dimerization. Loss of localization to cytoplasmic spherical structures.	ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:36640307	11839743,23453972,36640307	loss	
Q9UHD2	TBK1	Y179A	Q9UHD2/Y179A	TBK1/Y179A	MUTAGEN	Y->A: Loss of localization to cytoplasmic spherical structures.	ECO:0000269|PubMed:36640307	36640307		
Q9UHD2	TBK1	L316E	Q9UHD2/L316E	TBK1/L316E	MUTAGEN	L->E: Decreases kinase activity. No effect on phosphorylation.	ECO:0000269|PubMed:23453972	23453972	decrease	
Q9UHD2	TBK1	E355R	Q9UHD2/E355R	TBK1/E355R	MUTAGEN	E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with A-357 or R-448.	ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972	23453971,23453972		
Q9UHD2	TBK1	R357A	Q9UHD2/R357A	TBK1/R357A	MUTAGEN	R->A: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.	ECO:0000269|PubMed:23453971	23453971		
Q9UHD2	TBK1	K401R	Q9UHD2/K401R	TBK1/K401R	MUTAGEN	K->R: Decreases ubiquitination. Abolishes ubiquitination, phosphorylation and kinase activity; when associated with R-30.	ECO:0000269|PubMed:23453971	23453971		
Q9UHD2	TBK1	E448R	Q9UHD2/E448R	TBK1/E448R	MUTAGEN	E->R: Decreases phosphorylation and kinase activity. Abolishes dimerization; when associated with R-355.	ECO:0000269|PubMed:23453972	23453972		
Q9UHD2	TBK1	H459E	Q9UHD2/H459E	TBK1/H459E	MUTAGEN	H->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-466 and E-470.	ECO:0000269|PubMed:23453972	23453972		
Q9UHD2	TBK1	I466E	Q9UHD2/I466E	TBK1/I466E	MUTAGEN	I->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-470.	ECO:0000269|PubMed:23453972	23453972		
Q9UHD2	TBK1	F470E	Q9UHD2/F470E	TBK1/F470E	MUTAGEN	F->E: Abolishes dimerization and decreases kinase activity but no effect on phosphorylation; when associated with E-459 and E-466.	ECO:0000269|PubMed:23453972	23453972		
Q9UHD2	TBK1	M690A	Q9UHD2/M690A	TBK1/M690A	MUTAGEN	M->A: Decreases interaction with TANK.	ECO:0000269|PubMed:21931631	21931631		
Q9UHD2	TBK1	L693A	Q9UHD2/L693A	TBK1/L693A	MUTAGEN	L->A: Almost abolishes interaction with TANK.	ECO:0000269|PubMed:21931631	21931631		
Q9UHD2	TBK1	K694E	Q9UHD2/K694E	TBK1/K694E	MUTAGEN	K->E: Strongly decreases interaction with TANK and TBKBP1. No effect on phosphorylation.	ECO:0000269|PubMed:21931631	21931631		
Q9UHD2	TBK1	L704A	Q9UHD2/L704A	TBK1/L704A	MUTAGEN	L->A: Strongly decreases interaction with AZI2, TANK and TBKBP1. No effect on phosphorylation.	ECO:0000269|PubMed:21931631	21931631		
Q9UHD2	TBK1	N708A	Q9UHD2/N708A	TBK1/N708A	MUTAGEN	N->A: Decreases interaction with TANK.	ECO:0000269|PubMed:21931631	21931631		
Q9UHD2	TBK1	L711A	Q9UHD2/L711A	TBK1/L711A	MUTAGEN	L->A: Almost abolishes interaction with TANK.	ECO:0000269|PubMed:21931631	21931631		
Q9UHY1	NRBP1	P432L	Q9UHY1/P432L	NRBP1/P432L	VARIANT	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP:rs753734841)	ECO:0000269|PubMed:17344846	17344846		
Q9UIK4	DAPK2	S299A	Q9UIK4/S299A	DAPK2/S299A	MUTAGEN	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	ECO:0000269|PubMed:11230133	11230133		
Q9UIK4	DAPK2	S318D	Q9UIK4/S318D	DAPK2/S318D	MUTAGEN	S->D: Abolishes apoptotic activity.	ECO:0000269|PubMed:11230133	11230133		
Q9UIK4	DAPK2	S320A	Q9UIK4/S320A	DAPK2/S320A	MUTAGEN	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	ECO:0000269|PubMed:11230133	11230133		
Q9UIK4	DAPK2	S323A	Q9UIK4/S323A	DAPK2/S323A	MUTAGEN	S->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	ECO:0000269|PubMed:11230133	11230133		
Q9UIK4	DAPK2	T329A	Q9UIK4/T329A	DAPK2/T329A	MUTAGEN	T->A: No effect on Ca(2+)-calmodulin independent phosphorylation or apoptotic activity.	ECO:0000269|PubMed:11230133	11230133		
Q9UIK4	DAPK2	S367A	Q9UIK4/S367A	DAPK2/S367A	MUTAGEN	S->A: No effect on interaction with YWHAE.	ECO:0000269|PubMed:26047703	26047703		
Q9UIK4	DAPK2	S368A	Q9UIK4/S368A	DAPK2/S368A	MUTAGEN	S->A: No effect on interaction with YWHAE.	ECO:0000269|PubMed:26047703	26047703		
Q9UIK4	DAPK2	T369A	Q9UIK4/T369A	DAPK2/T369A	MUTAGEN	T->A: Interaction with YWHAE is reduced.	ECO:0000269|PubMed:26047703	26047703		
Q9UIK4	DAPK2	S370A	Q9UIK4/S370A	DAPK2/S370A	MUTAGEN	S->A: Interaction with YWHAE is increased.	ECO:0000269|PubMed:26047703	26047703		
Q9UK32	RPS6KA6	Y140C	Q9UK32/Y140C	RPS6KA6/Y140C	VARIANT	Y -> C (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UK32	RPS6KA6	S258T	Q9UK32/S258T	RPS6KA6/S258T	VARIANT	S -> T (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UK32	RPS6KA6	S372A	Q9UK32/S372A	RPS6KA6/S372A	MUTAGEN	S->A: No effect on activity.	ECO:0000269|PubMed:15632195	15632195		
Q9UK32	RPS6KA6	T581A	Q9UK32/T581A	RPS6KA6/T581A	MUTAGEN	T->A: No effect on activity.	ECO:0000269|PubMed:15632195	15632195		
Q9UKI8	TLK1	R121C	Q9UKI8/R121C	TLK1/R121C	VARIANT	R -> C	ECO:0000269|PubMed:17344846	17344846		
Q9UL54	TAOK2	K57A	Q9UL54/K57A	TAOK2/K57A	MUTAGEN	K->A: Loss of kinase activity. In isoform 1, excluded from the nucleus. No effect on microtubule-binding.	ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:12639963, ECO:0000269|PubMed:16893890, ECO:0000269|PubMed:17158878	10660600,12639963,16893890,17158878	loss	
Q9UL54	TAOK2	D169A	Q9UL54/D169A	TAOK2/D169A	MUTAGEN	D->A: Loss of kinase activity; No effect on MAP3K7-mediated activation of NF-kappa-B.	ECO:0000269|PubMed:16893890	16893890	loss	
Q9UL54	TAOK2	D919N	Q9UL54/D919N	TAOK2/D919N	MUTAGEN	D->N: No effect on kinase activity, nor on JNK activation, but severe reduction in nuclear localization and apoptotic membrane blebbing.	ECO:0000269|PubMed:17158878	17158878		
Q9UM73	ALK	L560F	Q9UM73/L560F	ALK/L560F	VARIANT	L -> F (in a breast pleomorphic lobular carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UM73	ALK	A877S	Q9UM73/A877S	ALK/A877S	VARIANT	A -> S (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs746442213)	ECO:0000269|PubMed:17344846	17344846		
Q9UM73	ALK	D1091N	Q9UM73/D1091N	ALK/D1091N	VARIANT	D -> N (in NBLST3; somatic mutation; dbSNP:rs864309584)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	G1128A	Q9UM73/G1128A	ALK/G1128A	VARIANT	G -> A (in NBLST3; dbSNP:rs113994088)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	T1151M	Q9UM73/T1151M	ALK/T1151M	VARIANT	T -> M (in NBLST3; dbSNP:rs113994091)	ECO:0000269|PubMed:18923525	18923525		
Q9UM73	ALK	M1166R	Q9UM73/M1166R	ALK/M1166R	VARIANT	M -> R (in NBLST3; somatic mutation; dbSNP:rs1057520019)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	I1171N	Q9UM73/I1171N	ALK/I1171N	VARIANT	I -> N (in NBLST3; somatic mutation; dbSNP:rs1057519698)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	F1174C	Q9UM73/F1174C	ALK/F1174C	VARIANT	F -> C (in NBLST3; dbSNP:rs1057519697)	ECO:0000269|PubMed:18923523	18923523		
Q9UM73	ALK	F1174I	Q9UM73/F1174I	ALK/F1174I	VARIANT	F -> I (in NBLST3; somatic mutation; dbSNP:rs281864719)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	R1192P	Q9UM73/R1192P	ALK/R1192P	VARIANT	R -> P (in NBLST3; dbSNP:rs113994089)	ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923523	18724359,18923523		
Q9UM73	ALK	A1234T	Q9UM73/A1234T	ALK/A1234T	VARIANT	A -> T (in NBLST3; somatic mutation)	ECO:0000269|PubMed:18923525	18923525		
Q9UM73	ALK	F1245C	Q9UM73/F1245C	ALK/F1245C	VARIANT	F -> C (in NBLST3; somatic mutation; dbSNP:rs863225283)	ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923525	18724359,18923525		
Q9UM73	ALK	F1245V	Q9UM73/F1245V	ALK/F1245V	VARIANT	F -> V (in NBLST3; somatic mutation; dbSNP:rs281864720)				
Q9UM73	ALK	I1250T	Q9UM73/I1250T	ALK/I1250T	VARIANT	I -> T (in NBLST3; somatic mutation; dbSNP:rs113994092)	ECO:0000269|PubMed:18724359	18724359		
Q9UM73	ALK	R1275L	Q9UM73/R1275L	ALK/R1275L	VARIANT	R -> L (observed in neuroblastoma; dbSNP:rs113994087)	ECO:0000269|PubMed:18923523	18923523		
Q9UM73	ALK	Y1278S	Q9UM73/Y1278S	ALK/Y1278S	VARIANT	Y -> S (in NBLST3; somatic mutation; dbSNP:rs863225285)	ECO:0000269|PubMed:18923523	18923523		
Q9UM73	ALK	E859A	Q9UM73/E859A	ALK/E859A	MUTAGEN	E->A: Slightly decreased autophosphorylation. Decreased autophosphorylation and subsequent activation; when associated with A-974.	ECO:0000269|PubMed:34819673	34819673		
Q9UM73	ALK	Y966A	Q9UM73/Y966A	ALK/Y966A	MUTAGEN	Y->A: Slightly decreased autophosphorylation. Strongly reduced autophosphorylation and subsequent activation; when associated with A-994.	ECO:0000269|PubMed:34819673	34819673		
Q9UM73	ALK	E974A	Q9UM73/E974A	ALK/E974A	MUTAGEN	E->A: Slightly decreased autophosphorylation. Decreased autophosphorylation and subsequent activation; when associated with A-859.	ECO:0000269|PubMed:34819673	34819673		
Q9UM73	ALK	E994A	Q9UM73/E994A	ALK/E994A	MUTAGEN	E->A: SlStrongly reduced autophosphorylation and subsequent activation; when associated with A-966.	ECO:0000269|PubMed:34819673	34819673		
Q9UM73	ALK	Y1507F	Q9UM73/Y1507F	ALK/Y1507F	MUTAGEN	Y->F: Impairs interaction with SHC1.	ECO:0000269|PubMed:17274988	17274988		
Q9UPN9	TRIM33	M580I	Q9UPN9/M580I	TRIM33/M580I	VARIANT	M -> I (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UPN9	TRIM33	E811K	Q9UPN9/E811K	TRIM33/E811K	VARIANT	E -> K (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UPN9	TRIM33	P885S	Q9UPN9/P885S	TRIM33/P885S	VARIANT	P -> S (in a glioblastoma multiforme sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UPN9	TRIM33	C125A	Q9UPN9/C125A	TRIM33/C125A	MUTAGEN	C->A: Abolishes E3 activity but does not affect interaction with SMAD4; when associated with A-128.	ECO:0000269|PubMed:15820681	15820681		
Q9UPN9	TRIM33	C128A	Q9UPN9/C128A	TRIM33/C128A	MUTAGEN	C->A: Abolishes E3 activity but does not affect interaction with SMAD4; when associated with A-125.	ECO:0000269|PubMed:15820681	15820681		
Q9UPZ9	CILK1	I102L	Q9UPZ9/I102L	CILK1/I102L	VARIANT	I -> L (in EJM10; unknown pathological significance; dbSNP:rs748539319)	ECO:0000269|PubMed:29539279	29539279		
Q9UPZ9	CILK1	F115Y	Q9UPZ9/F115Y	CILK1/F115Y	VARIANT	F -> Y (in a renal clear cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UPZ9	CILK1	K220E	Q9UPZ9/K220E	CILK1/K220E	VARIANT	K -> E (in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system)	ECO:0000269|PubMed:29539279	29539279		
Q9UPZ9	CILK1	K305T	Q9UPZ9/K305T	CILK1/K305T	VARIANT	K -> T (in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP:rs765078446)	ECO:0000269|PubMed:29539279	29539279		
Q9UPZ9	CILK1	A615T	Q9UPZ9/A615T	CILK1/A615T	VARIANT	A -> T (in EJM10; unknown pathological significance; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP:rs55932059)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:29539279	17344846,29539279		
Q9UPZ9	CILK1	K33R	Q9UPZ9/K33R	CILK1/K33R	MUTAGEN	K->R: Loss of activity and autophosphorylation; when associated with R-34; R-36 and R-38.	ECO:0000269|PubMed:10699974	10699974		
Q9UPZ9	CILK1	K34R	Q9UPZ9/K34R	CILK1/K34R	MUTAGEN	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-36 and R-38.	ECO:0000269|PubMed:10699974	10699974		
Q9UPZ9	CILK1	K36R	Q9UPZ9/K36R	CILK1/K36R	MUTAGEN	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-34 and R-38.	ECO:0000269|PubMed:10699974	10699974		
Q9UPZ9	CILK1	K38R	Q9UPZ9/K38R	CILK1/K38R	MUTAGEN	K->R: Loss of activity and autophosphorylation; when associated with R-33; R-34 and R-36.	ECO:0000269|PubMed:10699974	10699974		
Q9UPZ9	CILK1	T157A	Q9UPZ9/T157A	CILK1/T157A	MUTAGEN	T->A: Reduction of activity and loss of autophosphorylation. Loss of activity and autophosphorylation; when associated with F-159.	ECO:0000269|PubMed:10699974	10699974	decrease	
Q9UPZ9	CILK1	Y159F	Q9UPZ9/Y159F	CILK1/Y159F	MUTAGEN	Y->F: Reduction of activity and loss of autophosphorylation. Loss of activity and autophosphorylation; when associated with A-157.	ECO:0000269|PubMed:10699974	10699974	decrease	
Q9UQ07	MOK	E272D	Q9UQ07/E272D	MOK/E272D	VARIANT	E -> D (in a breast pleomorphic lobular carcinoma sample; somatic mutation; dbSNP:rs1567133856)	ECO:0000269|PubMed:17344846	17344846		
Q9UQB9	AURKC	G52E	Q9UQB9/G52E	AURKC/G52E	VARIANT	G -> E (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UQB9	AURKC	E148Q	Q9UQB9/E148Q	AURKC/E148Q	VARIANT	E -> Q (in a lung squamous cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UQB9	AURKC	H244Q	Q9UQB9/H244Q	AURKC/H244Q	VARIANT	H -> Q (in a lung adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9UQM7	CAMK2A	F98S	Q9UQM7/F98S	CAMK2A/F98S	VARIANT	F -> S (in MRD53; no effect on protein abundance; decreased autophosphorylation; decreased neuronal migration; dbSNP:rs1554122526)	ECO:0000269|PubMed:29100089	29100089	decrease	
Q9UQM7	CAMK2A	E109D	Q9UQM7/E109D	CAMK2A/E109D	VARIANT	E -> D (in MRD53; no effect on protein abundance; increased autophosphorylation; decreased neuronal migration)	ECO:0000269|PubMed:29100089	29100089	increase	
Q9UQM7	CAMK2A	A112V	Q9UQM7/A112V	CAMK2A/A112V	VARIANT	A -> V (in MRD53; unknown pathological significance)	ECO:0000269|PubMed:29100089	29100089		
Q9UQM7	CAMK2A	P138A	Q9UQM7/P138A	CAMK2A/P138A	VARIANT	P -> A (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration)	ECO:0000269|PubMed:25533962, ECO:0000269|PubMed:29100089	25533962,29100089		
Q9UQM7	CAMK2A	E183V	Q9UQM7/E183V	CAMK2A/E183V	VARIANT	E -> V (in MRD53; increased ubiquitin-mediated proteasomal degradation with a dominant negative effect on wild-type protein; decreased localization to dendritic spines; no effect on holoenzyme assembly; loss of interaction with SHANK3; loss of interaction with GRIN2B; loss of interaction with CACNB2; loss of interaction with LRRC7; loss of interaction with GRM5; decreased protein serine/threonine kinase activity with a dominant negative effect on wild-type protein; decreased autophosphorylation; changed dendritic spine development; decreased neuronal migration; dbSNP:rs1554122129)	ECO:0000269|PubMed:28130356, ECO:0000269|PubMed:29100089	28130356,29100089	decrease	
Q9UQM7	CAMK2A	P212L	Q9UQM7/P212L	CAMK2A/P212L	VARIANT	P -> L (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration; dbSNP:rs926027867)	ECO:0000269|PubMed:29100089	29100089		
Q9UQM7	CAMK2A	P235L	Q9UQM7/P235L	CAMK2A/P235L	VARIANT	P -> L (in MRD53; unknown pathological significance; no effect on protein abundance; no effect on autophosphorylation; no effect on neuronal migration; dbSNP:rs864309606)	ECO:0000269|PubMed:29100089, ECO:0000269|PubMed:29560374	29100089,29560374		
Q9UQM7	CAMK2A	H282R	Q9UQM7/H282R	CAMK2A/H282R	VARIANT	H -> R (in MRD53; decreased protein abundance; increased autophosphorylation; decreased neuronal migration; dbSNP:rs1554121875)	ECO:0000269|PubMed:29100089	29100089	increase	
Q9UQM7	CAMK2A	T286P	Q9UQM7/T286P	CAMK2A/T286P	VARIANT	T->P: No effect on neuronal migration; when associated with R-42.	ECO:0000269|PubMed:29100089	29100089		
Q9UQM7	CAMK2A	H466Y	Q9UQM7/H466Y	CAMK2A/H466Y	VARIANT	H -> Y (in MRT63; decreased oligomerization; dbSNP:rs1554119274)	ECO:0000269|PubMed:29784083	29784083		
Q9UQM7	CAMK2A	K42R	Q9UQM7/K42R	CAMK2A/K42R	MUTAGEN	K->R: No effect on protein stability or degradation. No effect on neuronal migration; when associated with P-286.	ECO:0000269|PubMed:29100089	29100089		
Q9UQM7	CAMK2A	T286A	Q9UQM7/T286A	CAMK2A/T286A	MUTAGEN	T->A: No effect on neuronal migration.	ECO:0000269|PubMed:29100089	29100089		
Q9UQM7	CAMK2A	T286D	Q9UQM7/T286D	CAMK2A/T286D	MUTAGEN	T->D: Loss of neuronal migration.	ECO:0000269|PubMed:29100089	29100089		
Q9Y243	AKT3	G171R	Q9Y243/G171R	AKT3/G171R	VARIANT	G -> R (in a glioblastoma multiforme sample; somatic mutation; dbSNP:rs1402272180)	ECO:0000269|PubMed:17344846	17344846		
Q9Y243	AKT3	N229S	Q9Y243/N229S	AKT3/N229S	VARIANT	N -> S (in MPPH2; dbSNP:rs397514605)	ECO:0000269|PubMed:22729224, ECO:0000269|PubMed:23745724	22729224,23745724		
Q9Y243	AKT3	R465W	Q9Y243/R465W	AKT3/R465W	VARIANT	R -> W (in MPPH2; disease phenotype overlaps with megalencephaly-capillary malformation syndrome; dbSNP:rs587776935)	ECO:0000269|PubMed:22729224	22729224		
Q9Y243	AKT3	T305A	Q9Y243/T305A	AKT3/T305A	MUTAGEN	T->A: No activation after pervanadate treatment.	ECO:0000269|PubMed:11387345	11387345		
Q9Y243	AKT3	T305D	Q9Y243/T305D	AKT3/T305D	MUTAGEN	T->D: 2-fold increase of phosphorylation steady state level, no activation after pervanadate treatment.	ECO:0000269|PubMed:11387345	11387345	increase	
Q9Y243	AKT3	T447A	Q9Y243/T447A	AKT3/T447A	MUTAGEN	T->A: No effect.	ECO:0000269|PubMed:11387345	11387345		
Q9Y243	AKT3	T447D	Q9Y243/T447D	AKT3/T447D	MUTAGEN	T->D: No effect.	ECO:0000269|PubMed:11387345	11387345		
Q9Y243	AKT3	S472D	Q9Y243/S472D	AKT3/S472D	MUTAGEN	S->D: 1.4-fold increase of phosphorylation steady state level, 50% decrease of activity after pervanadate treatment.	ECO:0000269|PubMed:10092583	10092583	increase	
Q9Y2H1	STK38L	G99A	Q9Y2H1/G99A	STK38L/G99A	VARIANT	G -> A (in a aLLTEL/AML1+ sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y2H9	MAST1	S93L	Q9Y2H9/S93L	MAST1/S93L	VARIANT	S -> L (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance; dbSNP:rs878853165)	ECO:0000269|PubMed:30449657	30449657		
Q9Y2H9	MAST1	G98V	Q9Y2H9/G98V	MAST1/G98V	VARIANT	G -> V (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	ECO:0000269|PubMed:30449657	30449657		
Q9Y2H9	MAST1	A269T	Q9Y2H9/A269T	MAST1/A269T	VARIANT	A -> T (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y2H9	MAST1	G517S	Q9Y2H9/G517S	MAST1/G517S	VARIANT	G -> S (in MCCCHCM; dbSNP:rs1568413207)	ECO:0000269|PubMed:30449657	30449657		
Q9Y2H9	MAST1	A915T	Q9Y2H9/A915T	MAST1/A915T	VARIANT	A -> T (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	ECO:0000269|PubMed:30449657	30449657		
Q9Y2H9	MAST1	P1177R	Q9Y2H9/P1177R	MAST1/P1177R	VARIANT	P -> R (in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance)	ECO:0000269|PubMed:30449657	30449657		
Q9Y2H9	MAST1	H1240Y	Q9Y2H9/H1240Y	MAST1/H1240Y	VARIANT	H -> Y (in an ovarian serous carcinoma sample; somatic mutation; dbSNP:rs1411105125)	ECO:0000269|PubMed:17344846	17344846		
Q9Y2K2	SIK3	R187C	Q9Y2K2/R187C	SIK3/R187C	VARIANT	R -> C (in SEMDK; decreased protein expression; decreased kinase activity; no effect on the interaction with DEPTOR, MLST8/GbetaL, RICTOR and RPTOR; dbSNP:rs1565460853)	ECO:0000269|PubMed:30232230	30232230	decrease	
Q9Y2K2	SIK3	H389L	Q9Y2K2/H389L	SIK3/H389L	VARIANT	H -> L (in a breast cancer sample; somatic mutation; dbSNP:rs376144593)	ECO:0000269|PubMed:16959974	16959974		
Q9Y2K2	SIK3	A1161V	Q9Y2K2/A1161V	SIK3/A1161V	VARIANT	A -> V (in a breast cancer sample; somatic mutation)	ECO:0000269|PubMed:16959974	16959974		
Q9Y2K2	SIK3	T221A	Q9Y2K2/T221A	SIK3/T221A	MUTAGEN	T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	ECO:0000269|PubMed:14976552	14976552	loss	
Q9Y2K2	SIK3	S626A	Q9Y2K2/S626A	SIK3/S626A	MUTAGEN	S->A: No effect on interaction with 14-3-3 proteins, nor on cAMP signaling.	ECO:0000269|PubMed:29211348	29211348		
Q9Y2K2	SIK3	S626E	Q9Y2K2/S626E	SIK3/S626E	MUTAGEN	S->E: No effect on cAMP signaling.	ECO:0000269|PubMed:29211348	29211348		
Q9Y2U5	MAP3K2	M112I	Q9Y2U5/M112I	MAP3K2/M112I	VARIANT	M -> I (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y463	DYRK1B	R102C	Q9Y463/R102C	DYRK1B/R102C	VARIANT	R -> C (in AOMS3; accumulation of intracellular lipid is significantly greater than with wild-type protein; cells expressing the variant are able to transform into mature adipocytes without requiring adipogenic medium; expression levels of CEBPA, PPARG forms 1 and 2 and PPARGC1A are higher and those of GLI1 and CDKN1B are lower in cells transfected with the mutant protein compared to wild-type; WNT1 signaling activity is lower in mutant cells compared to wild-type; dbSNP:rs367643250)	ECO:0000269|PubMed:24827035	24827035	decrease	
Q9Y463	DYRK1B	Q275R	Q9Y463/Q275R	DYRK1B/Q275R	VARIANT	Q -> R (in a metastatic melanoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y463	DYRK1B	Y271F	Q9Y463/Y271F	DYRK1B/Y271F	MUTAGEN	Y->F: Abolishes kinase activity; when associated with F-273.	ECO:0000269|PubMed:10910078	10910078		
Q9Y463	DYRK1B	Y273F	Q9Y463/Y273F	DYRK1B/Y273F	MUTAGEN	Y->F: Abolishes kinase activity; when associated with F-271.	ECO:0000269|PubMed:10910078	10910078		
Q9Y4A5	TRRAP	R171C	Q9Y4A5/R171C	TRRAP/R171C	VARIANT	R -> C (in DFNA75; unknown pathological significance; dbSNP:rs200157211)	ECO:0000269|PubMed:31231791	31231791		
Q9Y4A5	TRRAP	D394N	Q9Y4A5/D394N	TRRAP/D394N	VARIANT	D -> N (in DFNA75; unknown pathological significance; dbSNP:rs1554407965)	ECO:0000269|PubMed:31231791	31231791		
Q9Y4A5	TRRAP	S722F	Q9Y4A5/S722F	TRRAP/S722F	VARIANT	S -> F (found in a cutaneous malignant melanoma sample; somatic mutation; induces cell transformation and confers resistance to apoptosis; dbSNP:rs147405090)	ECO:0000269|PubMed:21499247	21499247		
Q9Y4A5	TRRAP	L805F	Q9Y4A5/L805F	TRRAP/L805F	VARIANT	L -> F (in DEDDFA; unknown pathological significance; dbSNP:rs1562940289)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	F860L	Q9Y4A5/F860L	TRRAP/F860L	VARIANT	F -> L (in DEDDFA; unknown pathological significance)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	R893C	Q9Y4A5/R893C	TRRAP/R893C	VARIANT	R -> C (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	R893L	Q9Y4A5/R893L	TRRAP/R893L	VARIANT	R -> L (in DEDDFA; unknown pathological significance)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	I1031M	Q9Y4A5/I1031M	TRRAP/I1031M	VARIANT	I -> M (in DEDDFA)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	R1035Q	Q9Y4A5/R1035Q	TRRAP/R1035Q	VARIANT	R -> Q (in DEDDFA; unknown pathological significance)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	S1037R	Q9Y4A5/S1037R	TRRAP/S1037R	VARIANT	S -> R (in DEDDFA; unknown pathological significance)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	A1043T	Q9Y4A5/A1043T	TRRAP/A1043T	VARIANT	A -> T (in DEDDFA; dbSNP:rs1562945106)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	E1104G	Q9Y4A5/E1104G	TRRAP/E1104G	VARIANT	E -> G (in DEDDFA; dbSNP:rs1790257064)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	E1106K	Q9Y4A5/E1106K	TRRAP/E1106K	VARIANT	E -> K (in DEDDFA; dbSNP:rs1584324956)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	G1111W	Q9Y4A5/G1111W	TRRAP/G1111W	VARIANT	G -> W (in DEDDFA; unknown pathological significance)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	G1159R	Q9Y4A5/G1159R	TRRAP/G1159R	VARIANT	G -> R (in DEDDFA; dbSNP:rs1790288810)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	R1669H	Q9Y4A5/R1669H	TRRAP/R1669H	VARIANT	R -> H (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs373632999)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	R1724H	Q9Y4A5/R1724H	TRRAP/R1724H	VARIANT	R -> H (in a gastric adenocarcinoma sample; somatic mutation; dbSNP:rs782203759)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	R1859C	Q9Y4A5/R1859C	TRRAP/R1859C	VARIANT	R -> C (in DEDDFA; dbSNP:rs1791432323)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	W1866C	Q9Y4A5/W1866C	TRRAP/W1866C	VARIANT	W -> C (in DEDDFA; unknown pathological significance; dbSNP:rs1562957576)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	W1866R	Q9Y4A5/W1866R	TRRAP/W1866R	VARIANT	W -> R (in DEDDFA; dbSNP:rs1562957569)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	G1883R	Q9Y4A5/G1883R	TRRAP/G1883R	VARIANT	G -> R (in DEDDFA)	ECO:0000269|PubMed:30827496	30827496		
Q9Y4A5	TRRAP	P1932L	Q9Y4A5/P1932L	TRRAP/P1932L	VARIANT	P -> L (in DEDDFA; unknown pathological significance; also found in a colorectal adenocarcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:30827496	17344846,30827496		
Q9Y4A5	TRRAP	R1947L	Q9Y4A5/R1947L	TRRAP/R1947L	VARIANT	R -> L (in an ovarian mucinous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	R2004Q	Q9Y4A5/R2004Q	TRRAP/R2004Q	VARIANT	R -> Q (in DEDDFA; unknown pathological significance; dbSNP:rs1562959030)	ECO:0000269|PubMed:30424743	30424743		
Q9Y4A5	TRRAP	R2302W	Q9Y4A5/R2302W	TRRAP/R2302W	VARIANT	R -> W (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs528967912)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	P2690L	Q9Y4A5/P2690L	TRRAP/P2690L	VARIANT	P -> L (in a lung large cell carcinoma sample; somatic mutation; dbSNP:rs753661271)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	T2931M	Q9Y4A5/T2931M	TRRAP/T2931M	VARIANT	T -> M (in a colorectal adenocarcinoma sample; somatic mutation; dbSNP:rs1294404368)	ECO:0000269|PubMed:17344846	17344846		
Q9Y4A5	TRRAP	R3757Q	Q9Y4A5/R3757Q	TRRAP/R3757Q	VARIANT	R -> Q (in DEDDFA; unknown pathological significance; dbSNP:rs987263983)	ECO:0000269|PubMed:30827496	30827496		
Q9Y572	RIPK3	K50A	Q9Y572/K50A	RIPK3/K50A	MUTAGEN	K->A: Abolishes kinase activity. Loss of PGAM5- and MLKL-binding. No effect on RIPK1-binding. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of STUB1-mediated ubiquitination.	ECO:0000269|PubMed:10339433, ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:29883609	10339433,10358032,22265414,29883609	loss	
Q9Y572	RIPK3	T182A	Q9Y572/T182A	RIPK3/T182A	MUTAGEN	T->A: Abolishes kinase activity. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with STUB1 and STUB1-mediated ubiquitination. No loss of interaction with RIPK1. Loss of ability to mediate TNF-induced necroptosis. Loss of autophosphorylation at Ser-227.	ECO:0000269|PubMed:29883609	29883609	loss	
Q9Y572	RIPK3	T182S	Q9Y572/T182S	RIPK3/T182S	MUTAGEN	T->S: No loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with RIPK1 and MLKL.	ECO:0000269|PubMed:29883609	29883609		
Q9Y572	RIPK3	Y185A	Q9Y572/Y185A	RIPK3/Y185A	MUTAGEN	Y->A,F: Loss of interaction with PELI1 and PELI1-mediated ubiquitination.	ECO:0000269|PubMed:29883609	29883609		
Q9Y572	RIPK3	Y185F	Q9Y572/Y185F	RIPK3/Y185F	MUTAGEN	Y->A,F: Loss of interaction with PELI1 and PELI1-mediated ubiquitination.	ECO:0000269|PubMed:29883609	29883609		
Q9Y572	RIPK3	S227A	Q9Y572/S227A	RIPK3/S227A	MUTAGEN	S->A: Abolishes ability to mediate necroptosis. Partial loss of kinase activity. No loss of PELI1-mediated degradation.	ECO:0000269|PubMed:22265413, ECO:0000269|PubMed:29883609	22265413,29883609	decrease	
Q9Y572	RIPK3	S227D	Q9Y572/S227D	RIPK3/S227D	MUTAGEN	S->D: No loss of PELI1-mediated degradation.	ECO:0000269|PubMed:29883609	29883609		
Q9Y572	RIPK3	K363R	Q9Y572/K363R	RIPK3/K363R	MUTAGEN	K->R: Loss of PELI1-mediated ubiquitination. No loss of interaction with PELI1.	ECO:0000269|PubMed:29883609	29883609		
Q9Y5P4	CERT1	S132L	Q9Y5P4/S132L	CERT1/S132L	VARIANT	S -> L (in MRD34; dbSNP:rs1064794019)	ECO:0000269|PubMed:25533962	25533962		
Q9Y5P4	CERT1	S138C	Q9Y5P4/S138C	CERT1/S138C	VARIANT	S -> C (found in a patient with intellectual disability)	ECO:0000269|PubMed:23033978	23033978		
Q9Y5P4	CERT1	G243R	Q9Y5P4/G243R	CERT1/G243R	VARIANT	G -> R (in MRD34; associated with authism and epilepsy)	ECO:0000269|PubMed:25356899	25356899		
Q9Y5P4	CERT1	D324A	Q9Y5P4/D324A	CERT1/D324A	MUTAGEN	D->A: Impairs the endoplasmic reticulum-to-Golgi ceramide trafficking and abolishes the interaction with				
Q9Y5P4	CERT1	E472A	Q9Y5P4/E472A	CERT1/E472A	MUTAGEN	E->A: Reduces ceramide transfer.	ECO:0000269|PubMed:18184806	18184806		
Q9Y5P4	CERT1	Q493A	Q9Y5P4/Q493A	CERT1/Q493A	MUTAGEN	Q->A: No effect on ceramide transfer activity.	ECO:0000269|PubMed:18184806	18184806		
Q9Y5P4	CERT1	W499A	Q9Y5P4/W499A	CERT1/W499A	MUTAGEN	W->A: Reduces affinity for membranes. Abolishes ceramide transfer; when associated with A-588.	ECO:0000269|PubMed:20036255	20036255		
Q9Y5P4	CERT1	N530A	Q9Y5P4/N530A	CERT1/N530A	MUTAGEN	N->A: Reduces ceramide transfer.	ECO:0000269|PubMed:18184806	18184806		
Q9Y5P4	CERT1	W588A	Q9Y5P4/W588A	CERT1/W588A	MUTAGEN	W->A: Abolishes ceramide transfer; when associated with A-499.				
Q9Y5S2	CDC42BPB	A142T	Q9Y5S2/A142T	CDC42BPB/A142T	VARIANT	A -> T (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	D175Y	Q9Y5S2/D175Y	CDC42BPB/D175Y	VARIANT	D -> Y (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	I293M	Q9Y5S2/I293M	CDC42BPB/I293M	VARIANT	I -> M (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	K500E	Q9Y5S2/K500E	CDC42BPB/K500E	VARIANT	K -> E (in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP:rs1158962067)	ECO:0000269|PubMed:17344846	17344846		
Q9Y5S2	CDC42BPB	R867C	Q9Y5S2/R867C	CDC42BPB/R867C	VARIANT	R -> C (in CHOCNS)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	L871P	Q9Y5S2/L871P	CDC42BPB/L871P	VARIANT	L -> P (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	R876P	Q9Y5S2/R876P	CDC42BPB/R876P	VARIANT	R -> P (in CHOCNS)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	R876W	Q9Y5S2/R876W	CDC42BPB/R876W	VARIANT	R -> W (in a colorectal adenocarcinoma sample and CHOCNS; somatic mutation; dbSNP:rs1595472741)	ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:32031333	17344846,32031333		
Q9Y5S2	CDC42BPB	R1299Q	Q9Y5S2/R1299Q	CDC42BPB/R1299Q	VARIANT	R -> Q (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y5S2	CDC42BPB	E1315K	Q9Y5S2/E1315K	CDC42BPB/E1315K	VARIANT	E -> K (in a lung large cell carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		
Q9Y5S2	CDC42BPB	R1350P	Q9Y5S2/R1350P	CDC42BPB/R1350P	VARIANT	R -> P (in CHOCNS; unknown pathological significance)	ECO:0000269|PubMed:32031333	32031333		
Q9Y616	IRAK3	P22L	Q9Y616/P22L	IRAK3/P22L	VARIANT	P -> L (may be associated with ASRT5; dbSNP:rs536546109)	ECO:0000269|PubMed:17503328	17503328		
Q9Y616	IRAK3	P111A	Q9Y616/P111A	IRAK3/P111A	VARIANT	P -> A (may be associated with ASRT5; abolishes phosphorylation of Ser-110; abolishes interaction with PIN1; no effect on cytoplasmic localization; reduces protein stability; dbSNP:rs373806603)	ECO:0000269|PubMed:17503328, ECO:0000269|PubMed:29686383	17503328,29686383		
Q9Y616	IRAK3	V134M	Q9Y616/V134M	IRAK3/V134M	VARIANT	V -> M (may be associated with ASRT5; dbSNP:rs138559915)	ECO:0000269|PubMed:17503328	17503328		
Q9Y616	IRAK3	L400V	Q9Y616/L400V	IRAK3/L400V	VARIANT	L -> V (may be associated with ASRT5; dbSNP:rs146120640)	ECO:0000269|PubMed:17503328	17503328		
Q9Y616	IRAK3	R429Q	Q9Y616/R429Q	IRAK3/R429Q	VARIANT	R -> Q (may be associated with ASRT5; dbSNP:rs140671957)	ECO:0000269|PubMed:17503328	17503328		
Q9Y616	IRAK3	S110A	Q9Y616/S110A	IRAK3/S110A	MUTAGEN	S->A: Abolishes phosphorylation. Abolishes interaction with PIN1. Reduces protein stability.	ECO:0000269|PubMed:29686383	29686383		
Q9Y616	IRAK3	S110E	Q9Y616/S110E	IRAK3/S110E	MUTAGEN	S->E: Phosphomimic. Slight decrease in the interaction with PIN1. Weak interaction with PIN1 in absence of IL33-mediated dendritic cell stimulation. Increases resistant to degradation. Localizes to the nucleus in absence of stimulus. Does not affect isomerization of Pro-111 peptide bond.	ECO:0000269|PubMed:29686383	29686383		
Q9Y616	IRAK3	L210E	Q9Y616/L210E	IRAK3/L210E	MUTAGEN	L->E: Abolishes dimerization.	ECO:0000269|PubMed:33238146	33238146		
Q9Y616	IRAK3	E214L	Q9Y616/E214L	IRAK3/E214L	MUTAGEN	E->L: Enhances dimerization.	ECO:0000269|PubMed:33238146	33238146		
Q9Y616	IRAK3	S467A	Q9Y616/S467A	IRAK3/S467A	MUTAGEN	S->A: No effect on the interaction with PIN1.	ECO:0000269|PubMed:29686383	29686383		
Q9Y6E0	STK24	D321N	Q9Y6E0/D321N	STK24/D321N	MUTAGEN	D->N: Loss of proteolytic cleavage by caspases.	ECO:0000269|PubMed:12107159	12107159		
Q9Y6R4	MAP3K4	E1413Q	Q9Y6R4/E1413Q	MAP3K4/E1413Q	VARIANT	E -> Q (in an ovarian serous carcinoma sample; somatic mutation)	ECO:0000269|PubMed:17344846	17344846		